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Alkaptonuria (AKU) is a rare inherited disorder of tyrosine metabolism caused 
by lack of the enzyme homogentisate 1,2-dioxygenase (HGD). The primary 
biochemical consequence of HGD deficiency is increased circulating 
concentration of homogentisic acid (HGA); this is the central cause of the 
devastating multi-systemic damage observed in AKU. One of the most striking 
pathophysiological features of AKU is accumulation of ochronotic pigment 
derived from HGA in tissues throughout the body. HGA has an affinity for 
cartilaginous tissue. Presence of ochronotic pigment in cartilage of load-
bearing joints causes severe early-onset osteoarthropathy; the greatest cause 
of morbidity in AKU.  
This thesis addresses two major unanswered questions in AKU. First is the 
wider metabolic consequences both of HGD deficiency and those observed 
following treatment with the promising HGA-lowering agent nitisinone. A 
metabolomics approach was employed to address these questions, with the 
aim of discovering biomarkers with potential clinical value in monitoring 
disease in AKU and in assessing the wider metabolic consequences of 
nitisinone treatment. Second, this thesis explores the nature of ochronotic 
pigment derived from HGA. The chemical structure of ochronotic pigment is 
not known, nor are the mechanisms by which HGA interacts with and binds 
into the cartilage extracellular matrix. Various analytical chemistry techniques 
were employed to study the chemical properties of ochronotic pigment and 
pigmented cartilage in patients and mice with AKU. 
The data from chemical analyses presented in this thesis provide new insights 
into the nature of ochronotic pigment. The chemical structure of ochronotic 
pigment remains unknown, but the pigment had long been widely cited as a 
polymer in the literature.  First, these data fundamentally challenge the idea 
that ochronotic pigment is a polymeric species. Through study of ochronotic 
tissue samples, the data also indicate for the first time a specific alteration to 
the cartilage matrix that enables binding of HGA-derived species. 
An LC-QTOF-MS metabolic phenotyping strategy was developed, enabling 
identification of hundreds of metabolites simultaneously, based on chemical 
properties of accurate mass and chromatographic retention time. Application 
of this technique to AKU showed that the biochemical alterations following a) 
targeted deletion of the HGD gene in mice to cause AKU, and b) nitisinone 
treatment, reflect a complex, interconnected network of metabolite changes. 
The data not only stimulate myriad further lines of research into AKU 
pathophysiology but also reveal previously uncharacterised association 
between metabolites at a network level. These studies provide a prime 
example of how rare diseases such as inborn errors of metabolism can offer 
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1.1 Alkaptonuria (AKU) 
1.1.1  AKU is an historic disease 
AKU is an iconic disease. It holds a unique place in medical history as the first 
disease shown to follow Mendelian inheritance. Archibald Garrod (1857-
1936), an English physician widely regarded as the father of inborn errors of 
metabolism, studied four disorders: AKU, pentosuria, cystinuria and albinism. 
Pentosuria (OMIM #260800) is a defect in L-xylulose reductase, necessary for 
xylitol metabolism, leading to overproduction of pentose sugars and 
pentosuria, but is otherwise harmless as it does not accumulate in the body or 
produce a disease process of its own (1). This is unlike AKU (OMIM #203500), 
in which disease is attributable to accumulation of the metabolite homogentisic 
acid (HGA) in tissues throughout the body (2–4). 
Garrod’s close study of families with AKU led to his observation that AKU was 
more likely to occur in the children of first cousins. Working with William 
Bateson, the chief proponent of Mendel’s principles of heredity at the time, 
Garrod established that AKU followed a characteristic pattern of inheritance in 
families that is now referred to as autosomal-recessive. In Garrod’s seminal 
1902 paper on AKU, he refers to the disease as a “study of chemical 
individuality” (2). In this regard, Garrod alluded to the notion that inherited 
diseases are attributable to specific biochemical causes, despite the absence 
of knowledge at that time about particular molecules such as DNA and the 
concept of genes. Garrod’s pioneering work on AKU paved the way for 




1.1.2  The genetic basis of AKU 
It is now known that the specific genetic cause of AKU is bi-allelic mutations in 
HGD. The HGD gene encodes the enzyme homogentisate 1,2-dioxygenase 
(HGD; E.C.1.12.11.5.), an enzyme of phenylalanine and tyrosine metabolism 
(5). HGD is located on chromosome 3 (region: 3q21-q23), comprises 14 exons 
and encodes a protein of 445 amino acids (6). The HGD enzyme is responsible 
for metabolising ingested phenylalanine and tyrosine that is surplus to daily 
needs. For tyrosine, a non-essential amino acid, this also includes that 
produced during protein turnover. In humans without AKU, significant HGD 
enzyme expression has only been shown in the liver and kidney 
(https://www.proteinatlas.org/ENSG00000113924-HGD/tissue) (7).  
As of January 2020, 213 unique human HGD mutations have been identified 
(8) (http://hgddatabase.cvtisr.sk/). The general worldwide prevalence of AKU 
is estimated to be 1 in 100,000-250,000. AKU hotspots have been identified in 
Dominican Republic, India, Jordan and Slovakia, with the greatest incidence 
in North West Slovakia; estimated to be 1 in 19,000. These hotspots are 
attributed to limited gene pools associated with isolated communities. 
Increased incidence in Dominican Republic is thought to be a classic founder 
effect, whereas the high incidence in Slovakia is a surprising and somewhat 
unexplained result of at least 12 different mutations (6). The discovery of AKU 
hotspots in recent years reflects heightened interest in the disease through the 
Findacure (www.findacure.org.uk) and DevelopAKUre 
(www.developakure.eu/) consortia. It is likely that there is a large worldwide 
pool of undiagnosed AKU, and further hotspots could be identified particularly 
with heightened awareness of the disease in developing countries (9).  
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1.1.3  AKU is a disease of tyrosine metabolism 
The metabolic defect in AKU, as a result of HGD mutations, is a lack of the 
HGD enzyme. This results in over-production of HGA (2,5-
dihydroxyphenylacetic acid or homogentisic acid) (10), the hallmark 
biochemical feature of the disease (Figure 1.1A). In AKU the increased HGA 
is excreted in the urine in daily gram quantities, and HGA concentration in the 
urine is 1000-fold greater than that in the circulation (11). Despite such efficient 
renal excretion of HGA, the circulating concentration of HGA remains elevated; 
mean HGA serum concentration in untreated AKU is 30 µmol/L (range 11.9-
75.2 µmol/L) (12), compared with <1.5 µmol/L in healthy subjects (13,14). The 
elevated HGA directly causes a disease process referred to as ochronosis, 
whereby a striking black-yellow ‘ochronotic’ pigment accumulates in tissues 
throughout the body (3,10). It is proposed that ochronotic pigment is formed 
by the oxidative polymerisation of HGA. In the classic scheme, HGA is 
oxidised to form the intermediary benzoquinone acetic acid (BQA), which 
subsequently polymerises to result in the final pigment product (15) (Figure 
1.01B). 
The most debilitating feature of AKU is a severe, early-onset osteoarthropathy 
which is directly attributable to ochronosis. Connective tissues, and especially 
cartilage, are particularly susceptible to ochronotic pigmentation (Figure 1.02). 
In joint cartilage this leads to a form of osteoarthritis (OA) due to presence of 





Figure 1.01. AKU, the tyrosine pathway and ochronosis. A: the 
phenylalanine-tyrosine metabolic pathway and its defect in AKU. In AKU, lack 
of the enzyme homogentisate 1,2-dioxygenase causes an increase in 
homogentisic acid (HGA) in the circulation, which accumulates in connective 
tissue as ochronotic pigment. Nitisinone is used for reduction of HGA 
concentration in AKU due to its inhibition of the enzyme 4-
hydroxyphenylpyruvic acid dioxygenase. The tyrosine pathway in full is only 
present in liver and kidney. B: the classic scheme of ochronotic pigment 
formation in AKU. HGA oxidises to benzoquinone (BQA) intermediate, which 
undergoes subsequent self-polymerisation to form ochronotic pigment (10).  
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1.1.4  Clinical presentation of AKU 
An interesting feature of AKU is the slowly progressive nature of the disease. 
The genetic defect is present from birth, but often the only sign of the disease 
in the first decades of life is darkening of urine when left to stand, due to high 
HGA concentrations (Figure 1.03A). Besides this, the overt clinical 
manifestations of the disease do not usually appear until the third-fourth 
decades of life (11).  
Ochronosis is central to the pathophysiological features of AKU, which are 
multisystemic (16). In addition to the aforementioned early-onset 
osteoarthropathy, the debilitating features of the disease include renal and 
prostate stones, cardiac valve disease, osteopenia, fractures and rupture of 
muscle, tendon and ligament (3,17,18).  
Ochronosis becomes apparent from the 3rd decade onwards; this is with joint 
involvement but with ochronotic pigment visible externally such as in the pinna 
of the ear (Figure 1.03B), followed by the sclera of the eye (Figure 1.03C). 
Rate of ochronosis and disease progression rapidly increases in the 5th and 
6th decades of life (19). The worsening of symptoms with age is potentially due 
to a number of factors, including decrease in urinary excretion of HGA due to 
age-related impairment in kidney function (18,20), the cumulative effect of 
HGA exposure to tissues over time, and degradation of joint cartilage occurring 
as part of the natural ageing process (9). Renal failure markedly accelerates 
ochronosis and morbidity in AKU (21,22). Interestingly, there is no correlation 




Ochronotic osteoarthropathy predominantly affects axial and load-bearing 
joints; particularly the spinal column, hips and knees (Figure 1.02) (23). Often 
lower back pain is one of the earliest presenting clinical symptoms (24). Spinal 
symptoms worsen from the fourth decade onwards, leading to progressive 
kyphoscoliosis and impaired spinal and thoracic mobility (25). Ochronotic 
osteoarthropathy is generally degenerative as opposed to inflammatory, and 
the consequential chronic joint pain almost inevitably requires multiple joint 
replacement surgeries over the course of lifespan.  
In terms of the non-joint features of AKU, cardiovascular manifestations are 
common (Figure 1.03D-F). Aortic valve disease is a particularly frequent 
feature, with 40% prevalence by the fifth decade of life (26). Aortic valve 
stenosis and sclerosis is attributable to the deposition of ochronotic pigment in 
connective tissue, which leads to dystrophic calcification. Increased 
prevalence of kidney stones in AKU has been attributed to the extremely high 
levels of urinary HGA excretion (18); a recent study estimated kidney HGA 
clearance rates by glomerular filtration and net renal tubular secretion to 
exceed the theoretical maximum renal plasma flow of 600 mL/min (20).   
Aside from the physical features of the disease, psychopathological features 
such as depression and sleep disturbance are also common in AKU (17). 
These features are likely to relate to living with a chronic disease and its 





Figure 1.02. Features of ochronosis in human joint tissue. A: unstained 
cut section of femur condyle showing little pigment on left side progressing to 
full pigmentation on the right side. B: dark pigmentation seen in arthroscopy 
of knee joint showing fibrillar blackened cartilage. C: head of femur showing 
uniform pigmentation. D: hip joint showing rim of cartilage and marked 
cartilage loss with exposure of underlying bone. E: spine seen from posterior 
or dorsal aspect showing marked ochronosis of cartilaginous intervertebral 






Figure 1.03. Features of ochronosis in human non-joint tissue. A: dark 
AKU urine (right) compared with non-AKU urine (left). B: external ear cartilage 
pigmentation. C: dark pigmentation of temporal aspect of sclera in right eye. 
D: longitudinal cut section of abdominal aorta and common iliac bifurcation, 
showing more pigment at bifurcation and branch point orifices. E: low-pressure 
pulmonary trunk and valve showing little pigment. F: high-pressure aortic root 
and valve with marked pigmentation. G: pigment at junction of palmer and 




1.1.5  Distribution of ochronosis is not uniform 
At post-mortem, pigment is patchy and present in areas of stress/damage in 
non-cartilaginous tissues, suggesting that damaged tissue undergoes 
pigmentation whereas undamaged tissue is resistant to pigmentation. 
Cartilage is highly pigmented, but this is also uneven across the cartilage (23). 
Possible factors involved in damaging tissues and producing pigment are 
shown in Table 1.01. Despite the constant exposure of all body tissues to HGA 
in AKU, most tissues are resistant to pigmentation.  
 
Table 1.01. Factors influencing tissue ochronotic pigmentation. 
Tissue Damaging factor 
Spinal intervertebral disks Weight-bearing stress 
Joints 
Weight-bearing stress, movement 
damage 
Tendons Tensile stresses 
Ligaments Tensile stresses 
Aortic valve 
Systemic blood pressure, expansile 
stress 
Aortic root 
Systemic blood pressure, expansile 
stress 
Arterial tree branch points Shear stress, Bernoulli effect 
Cartilage of airways Expansion, lengthening and 
contracting 
Ear cartilage Pressure on ears during sleep 





Cartilage especially susceptible to ochronosis includes highly loaded tissues 
such as articular cartilage, fibrocartilage (intervertebral discs, pubic 
symphysis), costochondral, as well as less-stressed cartilage in the pinna and 
nose, and the trachea-bronchial system (23). Highly stressed tissues such as 
joints, spine, tendons and ligament are pigmented. Ochronotic pigment has 
been noted in the skin, especially at the interface of the palmar and dorsal skin 
of the hands (Figure 1.03G); possibly sites of greater stress (27). Pigmentation 
of the nails of the hands and feet has been described. Secretory glands in the 
axilla, groin and eyelids pigment (28). Ocular tissues also pigment, including 
the conjunctivum, cornea and sclera. Ochronosis has been observed in the 
tympanic membrane and ear wax. Cardiac valves are affected by ochronotic 
pigment more in left side of heart, and aortic more than mitral valve (23); the 
pulmonary vascular system and the right side of the heart is much less 
pigmented. Pigmentation can be observed in the arterial system, mostly 
around branch points and tributaries; areas of greater stress (23). There is 
currently no information on pigmentation in the venous system. Renal 
parenchyma, especially the medulla and pyramidal tissues, show ochronosis. 
The periosteum has been shown to pigment but not the bone itself, raising the 
possibility of bone mineral binding to collagen preventing binding of HGA-
derived molecules. Teeth enamel has been said to pigment, but needs more 
evidence given that bone does not pigment (29). It is generally held that 
muscle, liver, lung (excluding the bronchial system) and brain are not affected 
by ochronotic pigment. There is no convincing description of gastrointestinal 
and genital pigmentation. There is no description of pigment in pancreas, an 
organ where alkaline secretions are produced unlike the salivary glands. It is 
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not known if there is biliary excretion of HGA, even though pigmented gall 
stones make this likely. Paucicellular tissues such as cartilage, tendon and 
ligament appear to pigment easily compared to highly cellular tissues such as 
liver. 
It is likely that HGA is increased in the cerebrospinal fluid (CSF), tears and 
saliva although direct evidence is lacking. Circulating HGA is well 
characterised but tissue HGA, i.e. intracellular HGA, has not been directly 
assessed. It is likely HGA (and other metabolite acids) is protein-bound but 
this requires characterisation.  
1.1.6  Effect of ochronosis  
The effect of ochronosis on affected tissues is summarised in Table 1.02. The 
deposition of ochronotic in tissue including cartilage alters its material 
properties leading to the tissue becoming hard and brittle. The Young’s 
modulus, a mechanical measure of the stiffness of a solid material, is altered 
depending upon the degree of pigmentation in AKU. Our group has proposed 
a model of joint failure based on initiation of ochronosis in calcified cartilage 
before progressing to involve the entire cartilage and spiralling into joint failure, 
requiring joint replacement (30).  
This process of ochronotic stiffening also compromises intervertebral discs 
and adjoining bone. Ochronosis of intervertebral disks leads to severe spinal 
disease characterised by severe pain as well as kyphosis and scoliosis; spinal 
cord compression by involved discs can require decompressive spinal surgery. 
Spinal fusion can ensue in the latter stages resulting in loss of mobility and 
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flexibility in all parts of the spine, but especially in the cervical and lumbar 
regions.  
Although all cardiac valves can show ochronosis, it is the aortic valve and the 
aortic root that are subject to more pigmentation resulting in severe aortic 
stenosis requiring valve replacement surgery. Valve replacement surgery is 
often hazardous due to the friable ochronotic aortic root and valve. 
Scleral ochronosis can distort the corneal curvature and result in astigmatism 
(31,32). Ochronotic ear cartilage may be associated with pain in pinna of the 
ear (31). Hearing loss especially to high frequency is a feature of AKU 
(33,34). Rigid articular cartilage can lead to subchondral osteopenia. 
Generalised osteoporosis is also noted in AKU and associated with 
increased fracture (35). The failure of ochronotic connective tissue results in 
tendon ruptures, especially of the Achilles tendon, but other tendon ruptures 
have also been observed such as flexor and extensor foot, patellar, bicipital 
and gluteal regions (36,37). Similarly ruptures of ochronotic ligaments have 
been described. Muscle rupture has also been reported more frequently in 
AKU. Stone formation featuring ochronotic pigment has been found in 
kidney, prostate, gall bladder and salivary glands, resulting in symptomatic 
obstruction of these organs (38). Renal failure can ensue both due to 
obstruction and renal parenchymal ochronosis, sometimes leading to fatal 




Table 1.02. Effect of ochronosis on affected tissues. 
Tissue with ochronosis Effect 
Articular cartilage 
Resorption of calcified articular cartilage and 
subchondral bone and joint failure 
Articular cartilage 
Osteopenia due to resorption activated by stiff 
pigment 
Intervertebral discs 
Spondylosis, fracture, osteopenia, scoliosis, 
kyphosis, cord compression, radiculopathy 
Ligaments Rupture 
Aortic valve and root Aortic stenosis and aortic rigidity 
Tendons (e.g. Achilles, foot 
flexor and extensor, 
patellar, gluteal, biceps) 
Rupture 
Sclera Distortion in corneal curvature; astigmatism, 
glaucoma 
Ear cartilage Possible pain in ear 
Middle/inner ear Hearing loss, ear ossicles disorder leading to 




1.1.7   Treatment of AKU  
It is reasonable to assume that antioxidant therapy should be efficacious in 
treating AKU by preventing oxidation of HGA to BQA, the proposed initial step 
in ochronotic pigment formation. For reasons that are unclear, antioxidant 
ascorbic acid therapy has no clear benefit in AKU, a condition with a proposed 
oxidant-damage hypothesis in terms of ochronosis formation (41,42). This is 
analogous to the lack of efficacy of antioxidant strategies in coronary artery 




Reduced protein intake should decrease flux down the tyrosine catabolic 
pathway and, in theory, reduce ochronosis and lower morbidity in AKU. 
However, except for occasional case reports in childhood, there is no evidence 
that restricting dietary protein decreases ochronosis. Anecdotally, vegetarians 
and vegans are noted to have less ochronosis and lower morbidity but no 
systematic evidence exists to support low protein diet in AKU (31). All other 
approved therapies used in clinical practice are supportive and palliative and 
do not address the elevated HGA and its effects (17). 
A more promising treatment strategy in AKU is pharmacological inhibition of 
4-hydroxyphenylpyruvic acid dioxygenase (HPPD), the enzyme responsible 
for formation of HGA and its downstream metabolites (Figure 1.01A). 
Nitisinone (2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione), a 
reversible competitive inhibitor of HPPD, has revolutionised the treatment of 
hereditary tyrosinaemia type-1 (HT-1; OMIM #276700) (43,44). HT-1 is 
another rare inherited disorder of tyrosine metabolism, in which defective 
activity of the enzyme fumarylacetoacetate hydrolase causes accumulation of 
toxic metabolites that are downstream of HGA in the tyrosine pathway (Figure 
1.01A). Increased fumaryl- and maleyl-acetoacetic acid results in hepatorenal 
damage and increases in derivatives of succinylacetone leads to a porphyria-
like neurological crisis. These severe symptoms are present from birth if 
untreated, therefore nitisinone, a licensed drug in HT-1, is routinely 
administered as soon as HT-1 diagnosis is confirmed or suspected.  In HT-1, 
nitisinone’s inhibition of HPPD controls liver failure in >90% of cases, improves 




Nitisinone was first suggested as a treatment for HGA in AKU in 1998 (48), 
and is now shown to be highly effective in reducing HGA despite not being 
approved in AKU (49). Nitisinone not only decreases HGA but also arrests 
ochronosis in mice (50). A recent publication shows photographic evidence of 
partial reversal of ochronosis in sclera and ear cartilage in AKU patients (49). 
The National Institutes of Health (NIH) carried out a nitisinone interventional 
study in AKU between 2005 and 2009 and showed a sustained and marked 
decrease in urine HGA over the 3-year duration of the study (51). However, 
their agreement with the regulatory agency, the U.S. Food and Drug 
Administration (FDA), to approve nitisinone for AKU, required them to show a 
difference in range of motion at the hip between the nitisinone-treated and 
untreated groups. Statistical significance was not found for the range of motion 
comparison and the study reported inconclusive. 
Since 2012, nitisinone has been used off-label to treat patients attending the 
United Kingdom National AKU Centre (NAC) in Liverpool, funded by NHS 
England Highly Specialised Services; 2 mg nitisinone daily, which is the same 
dose given in the NIH study. The data from the NAC patient cohort were 
recently reported (49); these data confirmed the biochemical efficacy of 
nitisinone in AKU in terms of urinary HGA, but also showed slower progression 
of morbidity. Furthermore, the NAC data showed overt partial reversal of 
ochronosis, the primary pathogenetic event in AKU. 
It is important to note that nitisinone, while shown to be a highly effective 
therapy for preventing ochronosis, is not a perfect therapy in AKU. It is well-
recognised that nitisinone treatment results in significant hyper-tyrosinaemia 
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in AKU (18) and HT-I (43,44); tyrosine is upstream of HGA and HPPD, the 
enzyme inhibited by nitisinone (Figure 1.01A). The consequences of hyper-
tyrosinaemia are not fully understood in AKU, but concerns have been raised 
that it may contribute to the neurodevelopmental delay observed in infants with 
HT-I on nitisinone therapy (44). Recent analyses did not find changes to 
monoamine neurotransmitters in brain tissue from nitisinone-treated mice (52), 
although more data are required to fully ascertain the impact of hyper-
tyrosinaemia on central nervous system (CNS) homoeostasis. Other potential 
future therapies for AKU may employ approaches to directly restore HGD 
activity, for example by enzyme replacement therapy and gene therapy. 
However, research into these approaches is still in its very early stages, and 
they are also not without their own concerns and challenges, for example 
potential off-target effects.  
1.1.8  Model systems of AKU 
Model systems have been developed for investigating various effects of HGA 
exposure under controlled conditions in vitro, in vivo and ex vivo. In vitro 
models include human serum (53,54) and osteoblastic (cell line) and 
chondrocytic (cell line and isolated from human cartilage) cell cultures (55–
62). Incubation of cell cultures with HGA leads to ochronotic pigment formation 
by four weeks. The amount of ochronotic pigment formed is proportionate to 
the concentrations of HGA in the medium (62). Ex vivo organotypic 
approaches have modelled AKU by studying the effect of HGA on human 
cartilage explants (55,63,64). In these studies, pericellular pigmentation of 
cartilage explants is visible after two months of incubation with HGA (63). 
Development of these model systems has not only been useful in studying the 
18 
 
development of ochronotic pigment under controlled conditions, but also a 
number of other pathophysiological events closely associated with ochronosis 
including secondary amyloidosis (55,60,61), perturbed redox homeostasis 
(53,54,56,57,59,60,65) and disorder of the cartilage extracellular matrix, 
including proteoglycan loss and collagen fibril re-arrangement (59,61,64). 
Several HGD-knockout mouse models of AKU have also been developed. 
These mice were previously only considered to be models of AKU 
biochemistry as they present with confounding pathology. Despite a marked 
elevation in plasma and urinary HGA, mice do not develop the striking 
macroscopic ochronosis observed in adult humans, except in the kidneys after 
around 13 months (66). Several potential explanations for the lack of 
widespread macroscopic pigmentation in AKU mice are: a) reduced joint-
loading of quadrupedal mice, b) faster cellular turnover for removal of pigment 
and c) that the shorter lifespan of mice compared with humans might be 
insufficient for gross pigment deposition (50).  
Closer observations revealed that AKU mice do show pigment in cartilage in a 
way that mirrors the early stages of human ochronosis (50,66). Ochronotic 
pigment can be observed microscopically in chondrocytes within the articular 
cartilage at around 15 weeks (50) and this pigmentation increases 
progressively over the lifespan. This pattern of pigmentation is similar to early 
human AKU, in which pigment deposition begins within single chondrocytes of 
the calcified cartilage and eventually results in widespread extracellular 
pigmentation (30). An exact serum HGA concentration threshold at which 
ochronotic pigment develops is not known, but a threshold range of 40-60 
µmol/L has been reported in mice (67).   
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Nitisinone is also shown to be an efficacious therapy in AKU mice, as it 
decreases plasma and urine HGA concentrations, as with patients. Marked 
hyper-tyrosinaemia also occurs in AKU mice treated with nitisinone (50,68–
70). These factors support the use of HGD-knockout mice as a model of 
biochemistry in both untreated and nitisinone-treated AKU. Studies in mice 
have also enabled the important observation that nitisinone completely arrests 
the process of ochronosis. Lifetime treatment with nitisinone also completely 
prevented the deposition of ochronotic pigment in cartilage. Nitisinone 
treatment could not, however, reverse ochronosis by eliminating existing 
pigmentation (50,69). 
More recently, a mouse model of AKU has been developed in our laboratory 
by targeted knockout-first disruption of the HGD gene (70); the AKU mouse 
data described in previous studies (50,66–69) was from mice with HGD 
disruption by N-ethyl-N-nitrosurea (ENU) mutagenesis.  In this regard, the 
targeted HGD-knockout mouse is a preferred model of AKU, as ENU 
mutagenesis causes a high frequency of genomic mutations, which can be 
potentially confounding (71). However, the AKU phenotypes of these mice, 
which were both studied as part of this thesis, are almost identical (70).  
Additional data from the recent report of the new targeted HGD-knockout 
mouse also further support the indispensable contribution of the liver to 
clearance of HGA. Conditional liver-specific deletion of HGD (20% of liver 
HGD mRNA remaining), but not kidney, in non-AKU mice resulted in elevated 




1.2.1  The metabolome and metabolomics 
Metabolomics is the comprehensive qualitative or quantitative study of the 
metabolome, defined as the entire complement of metabolites within a 
biological system, which includes a cell,  tissue, biofluid, organ or organism 
(72). Metabolites are small molecules, typically <1500 Da, which comprise the 
precursors, intermediates and products of cellular processes. Metabolites are 
part of a complex, inter-connected and regulated metabolic network which also 
includes enzymes and cofactors (73). Metabolic networks are dynamic; they 
are subject to constant activity, or flux, as a result of the complex interplay 
between genome and environment (74). The collective metabolite profile or 
‘fingerprint’ is therefore  considered to provide a snapshot of metabolism, or a 
direct readout of the physiological state of an organism at a given point in time 
(75–77). 
Metabolomics is a relatively new field compared with more established ‘omics 
approaches, such as genomics, transcriptomics and proteomics. However the 
basic notion of metabolomics, in that biological fluids convey key information 
about the phenotype, can be traced back to ancient China (2000-1500 BC), 
where sweet-tasting urine was used as an indication of a disease now 
recognised as diabetes mellitus (78). The idea that a metabolite profile can 
describe the makeup of a biological fluid for different individuals was first 
formally recorded in the work of Roger Williams in the 1940’s, in which he 
coined the term ‘biochemical individuality’ (79). Williams and colleagues 
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showed that characteristic metabolic profiles in saliva and urine were 
associated with pathologies such as alcoholism and schizophrenia.  
Metabolomics is complementary to the other omics fields noted above but can 
be considered to confer some advantages as a biomarker discovery approach. 
Metabolites are downstream of genes, transcripts and proteins and therefore 
changes in them are amplified relative to the transcriptome or proteome. 
Second, as metabolites are the end-products of biochemical interactions, the 
metabolome can be thought of as the closest biochemical representation of 
the phenotype (76).  
The past 20 years has seen a burgeoning of interest in metabolomics, with 
myriad applications in diverse research fields including medical science, 
pharmacology, plant biology, synthetic biology, food and environmental 
analysis and microbiology (80).  Metabolomics is also becoming a major part 
of systems biology approaches (81–83), which aim to understand biological 
systems as a whole by means of integrating data from different omics 
modalities. 
1.2.2 Non-targeted metabolomics: opportunities and challenges 
Metabolomics experiments can be performed using targeted or non-targeted 
approaches (75). In targeted experiments, a pre-defined list of metabolites is 
measured. The specified metabolites of interest are usually from a specific 
biochemical hypothesis or part of a common metabolite network or pathway. 
The advantage of targeted approaches is increased specificity and the ability 
to absolutely quantify metabolite concentrations. Early metabolomics studies 
employed targeted metabolic profiling of biofluids using GC-MS; gas 
22 
 
chromatography (GC) coupled with mass spectrometry (MS). These 
pioneering studies led to the discovery of numerous diseases caused by single 
gene defects (84,85).   
The appeal of non-targeted analyses is the global nature of their scope, as the 
data acquisition is not limited to a pre-specified set of metabolites. Non-
targeted analyses therefore enable less-biased characterisation of the 
metabolome and comprehensive tracking of the biochemical reactions in a 
system. The rapid growth in metabolomics in the past two decades is largely 
attributable to advances in instrumentation and technology which support a 
non-targeted approach. Improvements in MS and chromatographic techniques 
(86–90), but also informatics have particularly driven this development, making 
it possible to separate and measure thousands of metabolites simultaneously 
from minimal biological material.  
While the value of non-targeted metabolomic analyses continues to be borne 
out (83), the interpretation of the resulting datasets remains a challenge. 
Metabolite structure identification and data interpretation are two particular 
challenges and are discussed in the following sections. 
1.2.2.1 Metabolite identification 
Chemical structure identification still represents a well-documented bottleneck 
in metabolomics workflows (91,92). There is far greater variation in the 
chemical configuration of metabolites compared to genes and proteins. Genes 
and proteins comprise linear combinations of nucleotides (4-letter codes) and 
amino acids (20-letter codes) respectively, meaning that they can now be 
identified in a comparatively simple way by sequencing. It should be 
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acknowledged, however, that chemical identification of post-translationally 
modified proteins is considerably more challenging. For metabolites, the 
number of possible atomic and chemical sub-structure arrangements is vast, 
therefore alternative identification strategies are required which are more 
complex than sequencing (93). The metabolite identification challenges 
specific to MS, the analytical platform primarily used for metabolomic analyses 
presented in this thesis, are described by Dunn et al. (94). As MS-based 
compound identification is based on accurate mass (AM), discrimination 
between species with the same monoisotopic mass but different chemical 
structures, such as isomers and chiral molecules, presents a particular 
challenge. These compounds have the same empirical formula but differ in the 
structural arrangement of their atoms. Another challenge is the multiplicity 
observed in mass spectra, whereby more than one ion relates to the parent 
compound; for example isotopes and adducts formed during the ionisation 
process. This multiplicity adds complexity to the task of assigning the ions 
observed to a given structure.  
Generally, metabolites can be identified by reference to spectral 
databases/libraries or by a de novo approach (94). Spectral libraries are 
indispensable tools for metabolite identification amongst metabolomics 
researchers (83), as discussed in Chapter 2. De novo compound identification 
procedures are usually employed when no candidate compound match is 
obtained in established databases. Commonly-employed de novo structural 
identification approaches in metabolomics include collision-induced 
compound fragmentation, also known as MS/MS or MS2 in mass-spectrometry 
(see section 1.4), and two-dimensional NMR (see section 1.52).  
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1.2.2.2 Data interpretation 
A second challenge relates to extracting meaningful information from the vast 
datasets generated from metabolomics experiments. As discussed further in 
Chapter 3, the high-throughput nature of these experiments means that in the 
resulting datasets, there are usually more metabolites detected than the 
number of samples analysed. It is therefore not feasible to interrogate the 
datasets by traditional univariate approaches based on reviewing the 
observed values of each variable, or metabolite, on an individual basis. 
Instead, multivariate chemometric statistical techniques are employed, which 
consider the values of multiple metabolites across the samples simultaneously 
(95–97). The overall aim in metabolomics is to extract from a complex 
background of signals the most relevant features of the data that relate to the 
biological question at hand (95). Generally, multivariate analyses frequently 
applied to metabolomic datasets fall under two categories; unsupervised and 
supervised techniques. These two approaches have the same aim of 
visualising and identifying the metabolites that discriminate between different 
sample classes, for example patients with a particular condition versus 
unaffected controls.  
Unsupervised approaches are used to visualise the structure of the data in a 
non-biased way, as the generated models do not consider sample class 
membership. Principal components analysis (PCA) is one of the most-
employed unsupervised method in metabolomics (see Chapter 3, section 
3.6.1). PCA can be employed to assess the overall structure of the dataset 
with the aim of identifying the metabolites that have the greatest contribution 
to the overall variation present in the data. Supervised approaches are often 
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used to confirm the unsupervised analyses and to further interrogate the 
differences in the data for the purposes of biomarker discovery. Supervised 
methods aim to identify the variables with the greatest contribution to the 
separation between the pre-specified groupings within the data. In other 
words, this approach aims to identify the metabolites that predict sample group 
classification. Data modelling techniques based on partial least squares (PLS) 
methods are some of the most-widely employed supervised approaches in 
metabolomics (98), although new techniques are constantly emerging, such 
as predictive models based on advanced machine-learning algorithms (99). 
The plethora of computational tools and multivariate statistical approaches for 
analysis of metabolomics data reflects the ever-increasing interest in the field, 
but consequently, selection of the most appropriate is not trivial. Although the 
field has reached some consensus on favoured tools (e.g. multivariate 
approaches using techniques such as PCA, PLS), the need for harmonisation 
in data analysis strategies employed across the community has been 
highlighted (100). There is also recognition that some approaches might be 
favoured out of convenience rather than for being the best suited to the 
analysis (101).  
1.2.2.2 Standards in metabolomics research 
Compared with established omics fields, metabolomics is still relatively in its 
infancy. Despite the rapid advancements in the field in recent years, 
consensus guidelines for performing metabolomics experiments are still 
evolving (102). In 2007, the Metabolomics Standards Initiative published a 
series of guidelines covering all stages of a metabolomics experiment (103–
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107). With reference to the challenges discussed above, these guidelines 
included minimum reporting standards for analysis of metabolomics data (106) 
and metabolite identification (107).  
In the minimum reporting standards guidelines, 4 levels of metabolite 
identification were described (107) (Table 1.03). Level 1, the highest level of 
metabolite identification confidence, requires two matched orthogonal 
chemical properties against an authentic chemical standard analysed under 
identical analytical conditions. In LC-MS data, orthogonal chemical properties 
could refer to measured AM plus isotope pattern, chromatographic retention 
time (RT) or MS/MS fragmentation spectra. ‘Putative’ annotation (levels 2 and 
3) refer to one or two matched properties only against data that were not 
acquired under identical analytical conditions; these often include databases 
or spectral libraries generated in other laboratories using different analytical 
parameters. Level 4 identification refers to unknown metabolites for which no 
data currently exists. 
Encouraging recent trends in metabolomics are the drive for freely-available, 
open source computational tools (108), public repositories of metabolomics 
data (109,110) and open data analysis platforms in which the methods and 






Table 1.03. Levels of metabolite identification in metabolomics. The 4 
levels of metabolite identification are from the 2007 proposed minimum 
reporting standards of the Chemical Analysis Working Group, as part of the 









Comparison of two or more orthogonal 
properties with an authentic chemical standard 





Based upon physicochemical properties and/or 
spectral similarity with public/commercial 







Based upon characteristic physicochemical 
properties of a chemical class of compounds, 
or by spectral similarity to known compounds of 
a chemical class 
4 Unknown 
Although unidentified and unclassified, these 
metabolites can still be differentiated and 
quantified based upon spectral data 
 
1.2.3  LC-QTOF-MS: application to metabolomics 
The wide range of analytical techniques employed in metabolomics reflects 
the diversity of applications within the field. Analytical platforms include MS 
coupled to chromatographic techniques such as liquid chromatography (LC) 
and GC, nuclear magnetic resonance (NMR) spectroscopy and vibrational 
spectroscopy (e.g. infrared spectroscopy, Fourier transform-infrared (FTIR) 
spectroscopy and Raman spectroscopy) (112). Along with NMR, LC-MS is one 
of the most widely employed techniques in metabolomics (see Table 1.04 
28 
 
which compares the attributes of LC-MS and NMR for metabolomics), owing 
to its  high throughput, soft ionisation and broad coverage of metabolites (113). 
Developments in MS and chromatographic techniques have been key factors 
in the rise in popularity of metabolomics over recent years (86–90). Such 
advances include the development of mass analysers with improved mass 
resolution. High-resolution instruments have the ability to separate closely-
spaced masses in complex mixtures, for example compounds with the same 
nominal mass (i.e. mass expressed in integer Da units) but with different 
elemental compositions, and therefore different monoisotopic AM (i.e. mass 
expressed in mDa) (114). Mass analysers such as time-of-flight (TOF), Fourier 
transform ion cyclotron resonance (FTICR) and Orbitrap are the highest 
resolution instruments currently available (mass resolution >10,000). Other 
advances include improvement to electronic components of the hardware, 
such as the detector, supporting increased signal sensitivity and attenuation 
of signal saturation. Development of improved software programs has also 






Table 1.04 Comparison of NMR and MS analytical platforms for 
metabolomics. Information from (116). 
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Polarity bias +ve/-ve  
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Liquid-chromatography quadrupole time-of-flight mass spectrometry (LC-
QTOF-MS) is the analytical platform employed in the metabolomics 
experiments described in this thesis. First introduced in 1948 (117), TOF mass 
analysers were originally used for de novo peptide sequencing (118). LC-
QTOF-MS is a powerful analytical tool which enables rapid measurements 
with high sensitivity and resolution. TOFs have a theoretically infinite mass 
range which enables analysis of a wide range of small and large molecules; 
mass-to-charge ratio (m/z), not mass, is detected, and ion species can acquire 
multiple charges. 
The basic principle of TOF is the separation of ionised molecules over a given 
path by time-of-flight. The ‘flight’ is the time between the application of a high 
voltage pulse to the back plate of an ion pulser and when the ion strikes the 
detector. The flight time for each mass is unique; determined by the energy of 
its acceleration, distance to travel and its m/z. For a given energy and distance, 
mass equals the square of the ion’s time-of-flight (t). As TOF analysers are 
specifically designed to keep the values for energy and distance constant, 
accurate measurement of time of flight enables the accurate calculation of 
mass (m) by the following formula, in which A refers to energy and distance 
combined:   
m = At2 
With distance and energy held constant in the TOF flight tube, the result is that 
ions with lower mass arrive at the detector earlier. This is because ions with 
smaller mass have increased velocity (119).  
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Figure 1.04 demonstrates the time-of-flight principle in a schematic 
representation of the 6550 QTOF-MS (Agilent), the specific instrument used 
in the metabolomics studies described in this thesis. In this instrument, ions 
from the sample are drawn into the MS via a hexabore capillary. The ions are 
focused into a beam by passing through 2 funnels followed by an octupole ion 
guide. A quadrupole mass filter provides the option to select for specific ions 
for targeted analyses (see MS/MS analysis, section 1.4). The ions are 
accelerated to high kinetic energy into the collision cell (left open in the 
metabolomics experiments here; no collision energy applied). Upon exiting the 
collision cell, the ions are focused into an optimally focused beam and then 
pass through a pair of slits into the final vacuum stage. The parallel beam of 
ions then enters the ion pulser. A high voltage pulse is applied to the backplate, 
which accelerates the ions through the stack of pulser plates into the flight 
tube. Once at the top of the flight tube, the direction of the ions is reversed 
back down the flight tube towards the detector by a two-stage electrostatic 
mirror. Ions arriving at the detector strike a microchannel plate, causing the 
release of electrons. Each channel serves as an electron multiplier. The 
electronic signal results in the emission of photons, which are focused onto a 
photomultiplier. The photomultiplier amplifies the number of photons, 
converting to an electrical signal proportional to the number of photons. 
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Figure 1.04. Schematic representation of a QTOF mass spectrometer. 
Model shown here is an Agilent 6550 QTOF. Numbering corresponds to the 
following hardware features. 1) ion source, 2) capillary inlet to mass 
spectrometer, 3) iFunnel (x2), 4) octapole ion guide, 5) quadrupole mass filter, 
6) collision cell, 7) ion transfer region (ion optics), 8) flight tube comprising ion 
pulser, two-stage ion mirror, microchannel plate detector connected to 
photomultiplier. Flight tube (2 m in total), showing schematic representation of 
molecules separated by time-of-flight according to mass-to-charge ratio (m/z). 
Adapted from (120). 
 
MS is particularly powerful due to the interfacing with ionisation techniques 
such as electrospray ionisation (ESI) (121) and matrix assisted laser 
desorption ionisation (MALDI) (122). ESI has become one of the most 
important techniques used in the coupling of MS to LC. ESI facilitates 
ionisation of a wide range of molecules (small molecules to polymers and 
proteins), operates at atmospheric pressure and moderate temperatures and 
is considered a soft ionisation technique (123). The basic principle of ESI is 
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that solutes in a solution are transformed into gas phase ions before their 
introduction to the MS. Figure 1.05A shows a representation of an ESI source 
attached to an MS inlet. The LC eluent is sprayed, or nebulised, into a chamber 
at atmospheric pressure. Within the chamber, the droplets are subject to a 
high-voltage electrostatic field, which results in the ions of one polarity 
migrating to the surface of the droplet. Consequently, the sample is then 
simultaneously charged and dispersed into smaller charged droplets (Figure 
1.05B) (120). The mechanism of ESI is not fully understood but this ‘ion 
evaporation model’ is the most widely accepted for small molecules (124). The 
ions formed by ESI can be positively charged by addition of hydrogen (or other 
cations such as sodium or ammonium from mobile phase modifiers), 
expressed as [M+H]+, where (M) is the molecular ion. Alternatively, ions can 
be negatively charge by removal of a hydrogen nucleus, expressed as [M-H]-, 
or possible adduction of other anions (e.g. formate from mobile phase 
modifiers). Efficiency of the generation of gas phase ions by ESI depends on 
a number of factors, including chemical structure, solvent type and parameters 
applied to the source (125). Modifiers such as formic acid are often added to 
solvents to enhance ionisation. These decrease the initial droplet size (by 






Figure 1.05. Electrospray ionisation (ESI). A: electrospray ionisation 
source. Note that dual ESI was the method employed in the following studies; 
a second nebuliser is used to introduce reference mass ions for accurate mass 
calibration. B:  desorption of ions from solution in ESI. Adapted from (120). 
 
ESI ionises molecules in the liquid phase, which makes it compatible with LC. 
Liquid-phase separations have become indispensable to a wide range of MS-
based applications in metabolomics. LC enables separation of many 
components in complex mixtures by RT, the time taken for a given analyte to 
elute from the LC column. LC separation considerably increases the number 




LC separation of sample analytes prior to ionisation & MS detection is 
important for a number of reasons. First, in analysis of complex mixtures, or 
matrices, presence of other non-volatile or less volatile molecules can interfere 
with analyte ionisation, a phenomenon known as ion suppression (126). 
Second, LC offers a second orthogonal dimension of separation to that 
observed in the MS (based on time-of-flight or m/z in a TOF analyser). The 
TOF separation occurs over the time-frame of milliseconds (i.e. faster than the 
acquisition rate of mass spectra). Without separation by chromatographic RT, 
which occurs over the course of seconds-minutes, all mass peaks obtained 
from the sample ions would appear in the same crowded spectrum, presenting 
a significant challenge in downstream data processing. 
 
Separation in LC is based on the chemical properties of analytes; their 
differential affinities for the mobile phase, a liquid solvent passed through the 
column, compared with the column stationary phase, the material within the 
LC column referred to as the packing. The relative affinity of a given analyte 
for the mobile versus stationary phase is determined by the analyte’s charge 
and polarity. These properties result in the formation of bands for different 
analytes within the column which elute at different times (Figure 1.06A).  There 
is a vast array of LC column specifications available which are designed to 
selectively retain and separate different groups of compounds. Broadly 
speaking, there are two main types of LC; normal-phase and reversed-phase 
(Figure 1.06B). Reversed-phase LC is more suited to separation of non-polar 
analytes, which are more strongly retained by the non-polar stationary phase 
compared with the polar mobile phase. Conversely, normal-phase LC 
36 
 
combines a column that has a polar stationary phase with a non-polar mobile 
phase, resulting in retention and separation of polar metabolites. 
Peak capacity is the term used to define efficiency of the separation in gradient 
elution LC, defined as the number of theoretical peaks that can be separated 
within a given column under specified analytical conditions. A number of 
factors affect peak capacity in LC, including column length, mobile phase flow 
rate, temperature, make-up of the stationary phase (composition and particle 







Figure 1.06. Analyte separation by liquid chromatography. A: at time zero 
the black band represents the injected sample. At 10 min separation of the 
sample has occurred into different analyte bands, represented by the different 
coloured dyes. Note that the yellow band is the earliest eluting analyte; it 
moves the fastest and has a broader band moving faster in the column. The 
blue band is more strongly retained; it has a narrower, focused analyte band 
and moves slowest in the column. B: differential chromatographic retention of 
analytes by normal-phase and reversed-phase chromatography. Yellow, red 
and blue bands represent polar, moderately polar and non-polar analytes 
respectively. In normal-phase chromatography polar analytes are more 
strongly retained. In reversed-phase chromatography non-polar analytes are 
more strongly retained. Gradient elution is commonly employed to overcome 
the phenomenon whereby well-retained peaks are adequately separated 
(narrow, focused bands) but less well-retained analytes are subject to band 
broadening in the column, resulting in broader chromatographic peaks with 
poor separation. In gradient elution, the solvent composition (water versus 
organic solvent) is altered systematically over time. Adapted from (129). 
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1.2.4 Metabolomics in the clinical laboratory and its potential in AKU 
One application of metabolomics in which its vast potential is becoming more 
widely recognised is in the medical field. Recent years have seen major 
interest in metabolomics as an approach to discover new biomarkers for a 
range of clinical purposes, including those that can predict drug efficacy, 
disease progression (prognosis) and drug toxicity (77,130–133). In coming 
years, metabolomics is expected to become a major component of a new 
strategy to provide precision medicine approaches which aim to tailor medical 
care based on individual patient metabolome profiles (134).  
Metabolomics has clear potential in the clinical management of inborn errors 
of metabolism (135,136). Despite significant advances in the diagnosis and 
treatment of some inherited metabolic diseases over recent years, monitoring 
of disease progression and susceptibility is challenging. Routine clinical 
biochemistry assays for monitoring inborn errors of metabolism are generally 
based on the measurement of individual metabolites. With reference to AKU, 
our laboratory has developed assays using triple-quadrupole MS for 
measuring key metabolites of the tyrosine metabolic pathway, including HGA 
and tyrosine, in serum (137) and urine (138) with high quantitative accuracy 
and precision. The assays have been employed in various clinical trials of 
nitisinone in AKU (11,139) and continue to be indispensable for monitoring 
disease progression and response to nitisinone (i.e. monitoring concentration 
of the consequently increased tyrosine) in patients attending the NAC 
(12,140). A limitation of these methods is that they are limited to specific 
metabolites within the tyrosine pathway. Metabolomics can offer a wider 
assessment of metabolism in AKU. This approach will enable investigation of 
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the wider metabolic consequences of the disease process, including 
ochronosis, and response to nitisinone.  
Metabolomics in AKU has the potential to assess the biochemical impact of 
ochronosis. Given the early-onset and inevitable OA in AKU, there is a clear 
opportunity to identify novel metabolite markers of ochronotic 
osteoarthropathy (see section 1.3.3), for example early markers of cartilage 
matrix degradation breakdown that could be detected in urine as with bone 
resorption products. Currently there are no biomarkers that accurately predict 
onset of OA.  
Metabolomic analysis also enables wider assessment of the metabolic impact 
of nitisinone. This is important for several reasons. First is that the wider 
consequences of hyper-tyrosinaemia following nitisinone treatment are not 
known (141). There are several reports of AKU patients on nitisinone 
presenting with dermal toxicity and ocular dendritiform corneal keratopathy 
attributable to tyrosine deposition (14,142–144). In these cases, nitisinone 
treatment had to be withdrawn. The factors leading to corneal keratopathy are 
unknown, and it is important to identify which patients are particularly at risk of 
this side effect of nitisinone. Second, metabolomics enables assessment of 
potential ‘off-target’ effects of nitisinone treatment beyond its desired ‘targeted’ 
effect of inhibiting HGD. The potential for nitisinone to act on other enzymes is 
not known, and the off-target effects of any drug are essential when 





Table 1.04. Rationale for metabolomics in AKU. 
Paradigm Aim of metabolomic analyses 
Untreated AKU Reveal mechanisms of disease 
Correlation with other clinical phenotyping data 
Detect early biomarker of OA 
Wider biochemical consequences of HGD deficiency 
Discovery of AKU sub-phenotypes 
Nitisinone-treated 
AKU 
Wider consequences of hyper-tyrosinaemia  
Potential off-target effects of nitisinone 
Biomarker for predicting corneal keratopathy 
 
1.3 The nature of ochronotic pigment in AKU 
1.3.1  Structure of ochronotic pigment: classical view 
A fundamental question in understanding the process of ochronosis and the 
development of therapeutic interventions aimed at its prevention or potential 
reversal concerns the structure of ochronotic pigment itself. The prevailing 
view on the mechanism by which HGA produces ochronotic pigment largely 
comes from work carried out by Zannoni and colleagues in the 1960’s. These 
authors stated that guinea pig cartilage and skin contain enzymes, namely 
HGA polyphenol oxidases, which were shown to catalyse the in vitro oxidation 
of HGA, which is colourless, into a dark, ochronotic-like pigment (146). BQA 
was demonstrated as an intermediate in the in vitro enzymatic oxidation of 
HGA, and it was proposed that polymerisation of BQA forms ochronotic 
41 
 
pigment (Figure 1.01B) (146,147). However, it is important to note the lack of 
evidence that polyphenol oxidase enzymes are expressed in human or other 
mammals (148). Enzymes that can oxidise HGA, HGA-oxidases, are observed 
in various species of bacteria known to produce pyomelanin pigment derived 
from HGA (42,149). In these species, HGA-derived pyomelanin is thought to 
serve various adaptive functions including resistance to environmental stress 
such as UV light and oxidising agents.  
Subsequent research showed that HGA oxidation can occur non-
enzymatically between pH 6.8 and 9.5 in the presence of oxygen (150). This 
phenomenon is observed in the classic sign of AKU; slow, spontaneous 
darkening of urine. Adding alkali to urine instantly turns urine black, and 
subsequent acidification does not alter the colour, suggesting a potentially 
irreversible change. The presence of BQA in oxidized HGA solutions has been 
confirmed by chromatography (151) and UV-vis spectroscopy (152).  
It is still widely-stated in the literature that oxidation of HGA to benzoquinone 
intermediates occurs spontaneously in AKU and results in a polymeric pigment 
structure.  
1.3.2  Structure of ochronotic pigment: emerging view 
Given the general assumption in the literature that ochronotic pigment is a 
product of HGA oxidative polymerisation, it seems pertinent here to define the 
term ‘polymer’. The accepted definition of a polymer is a large molecule, or 
macromolecule, composed of multiple repeating subunits of a relatively lower 
molecular weight monomer (153). The classic concept of a polymer is that the 
monomer subunits are covalently bound (154). 
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Roberts et al. (42) question the widely-held assumption that ochronotic 
pigment is polymeric. These authors cite the lack of conclusive evidence for 
this in the literature and make the point that a polymeric structure is not 
necessarily required to produce the visual properties of a dark pigment, as 
there are numerous examples of low-molecular weight biological pigments. 
More recent analysis of synthetically-derived ochronotic pigment solutions 
using size exclusion chromatography suggested a molecular weight greater 
than HGA, as indicated by a peak at shorter RT. However, visually pigmented 
solutions could be formed from HGA (over a shorter period of time; 10 days as 
opposed to 2 years) without evidence of the peak corresponding to ochronotic 
pigment and no observed decrease in the HGA peak (155). This suggests that 
the visual darkening of the solution due to increased pH could be due to 
presence of the low-molecular weight oxidised form of HGA over a relatively 
shorter period. 
Ochronotic pigment has been referred to as ‘melanin-like’ in the literature (42); 
largely because melanin is another dark biological pigment derived from 
tyrosine and classically considered to be formed by polymerisation. However, 
there is a growing body of evidence that melanin and ochronotic pigment are 
not covalently bound structures, and that their macromolecules do not 
comprise regularly repeating monomers. A recent study reported data from 
physicochemical analyses on the pyomelanin pigment produced in the 
bacteria Rubrivivax benzoatilyticus (strain JA2) (156). This bacteria mirrors the 
conditions of ochronotic pigment production in AKU; absence of the HGD gene 
causes accumulation of HGA, resulting in a brown pigment under aerobic 
conditions and in the presence of phenylalanine (157). FTIR spectroscopy 
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showed a range of band stretching vibrations indicating various chemical 
groups (aromatic and aliphatic C-H stretches, phenolic C-O stretches, 
aromatic ring C=C bonds, and C=O stretches due to –COOH groups) 
characteristic of a pigment structure derived from HGA. X-ray diffraction 
spectra of the pigment showed similar characteristics to that of melanin, with 
broad diffraction indicating an amorphous compound structure. The 
absorbance spectra showed a broad band at wavelengths 280-350 nm, with 
increased general absorbance across the UV-visual range without distinct 
peaks. Similar absorbance properties have been reported previously for 
ochronotic pigment (42,155) and also melanin (eumelanin derived from 5,6,-
dihydroxyindole-2-carboxylic acid); (158), and are thought to reflect a 
chemically heterogeneous structure of oligomers formed by a range of 
different bonding mechanisms, also referred to as chemical disorder (159). 
These absorbance properties might also account for the physical appearance 
of some pigmented substances, which in the case of melanin is thought to 
provide its physiologically important optical characteristics, i.e. its ability to 
absorb UV light (42,160). In contrast, specific, well-defined chemical 
signatures have been obtained for BQA, the proposed low molecular weight 
oxidation product of HGA. Specific visual-range absorbance peaks 
corresponding to BQA have been reported in a series of publications by 
Tokuhara and colleagues. These peaks were observed at 406 and 430 nm 
from analysis of solutions of HGA or AKU urine following alkalinisation 
(161,162), although other researchers have been unable to replicate these 
findings (42). Specific BQA signals were also recently reported by Tokuhara 
et al. (162) from LC-QTOF-MS and NMR analyses. 
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Computational analyses of eumelanin support a structure formed by stacked 
eumelanin protomolecules with random-like arrangement; in other words 
loosely-bound aggregates as opposed to a covalent polymer (160). This 
aggregate structure of melanin is further supported by mass spectrometric and 
spectrophotometric analyses indicating a possible formation mechanism by 
self-aggregation of L-dopa by a combination of non-covalent mechanisms 
including hydrogen bonds, π- π stacking and ionic bonds (163). The same 
aggregation was observed for other structurally similar catecholamines which, 
like HGA, are derived from tyrosine. Together, these more recent data are 
inconsistent with the idea that ochronotic pigment and melanin are polymeric 
structures comprised of regularly repeating units with distinct chemical 
signatures. The term polymer therefore does not appear to accurately describe 
the chemical nature of ochronotic pigment or melanin, as currently understood.  
1.3.3  Molecular interaction of ochronotic pigment with cartilage matrix  
Aside from the chemical structure of ochronotic pigment itself, the molecular 
mechanism through which HGA interacts with the cartilage matrix is also 
unknown. It is also not known, for example, whether the initial binding occurs 
as HGA, the oxidised intermediate BQA or ochronotic pigment, or if there is a 
specific binding site within individual proteins or the extracellular matrix. HGA 
is an inherently water-soluble substance, and should in principle be easily 
removed from body tissues simply by circulation, unless it is specifically 
retained by the tissue. It is currently believed that existing tissue ochronosis is 
not fully reversible. There are indications of partial reversal of pigment 
following long-term nitisinone therapy (140), but the mechanism of such 
reversal is currently unknown. It is not known if the ochronotic process is 
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dynamic (i.e. formation and removal of pigment co-existing), although 
macrophages with pigment has been described in case reports (164–166). 
Collagen, specifically type-II, the predominant protein in cartilage, is known to 
have a highly hierarchical fibrillar structure. First, three chains of type-II 
collagen form a staggered, hydrogen-bonded homotrimer; the characteristic 
collagen triple helix. After secretion into the extracellular space, the triple 
helices self-assemble and crosslink with the aid of other extracellular matrix 
components (167,168) to give fibrils with a distinctive 67-nm banding pattern. 
In cartilage, these fibrils further twist together to form aligned fibres.  
Ultrastructural examination of pigmented cartilage showed that initial 
pigmentation is closely associated with the periodicity of collagen fibres. A 
periodic banding pattern of ochronotic pigment was observed on individual 
collagen fibres, with very early pigmentation appearing as small granules on 
the surface of fibres (Figure 1.07A) (169). These findings suggest that a 
nucleation-like event underlies ochronosis, where initial granular deposits on 
individual collagen fibres is followed by further rapid pigment deposition (9). 
The data also suggest that collagen fibrils provide specific binding sites for 
pigment.  
Close observation of tissues obtained from AKU patients (30,66) and mice 
(50,66) and in vitro (62) models of AKU show that cartilage is initially resistant 
to pigmentation. It is proposed that biomechanical and biochemical changes, 
such as those that occur in cartilage as part of the natural ageing process, 
render tissues susceptible to ochronosis. The exposed collagen hypothesis 
theorises that binding sites become available for HGA following the loss of 
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protective molecules such as proteoglycans and glycosaminoglycans (GAGs), 
as illustrated in Figure 1.07B (9). Consistent with this hypothesis, AKU 
cartilage is shown to have lower levels of extractable GAGs and oligomeric 
matrix protein than osteoarthritic and non-osteoarthritic cartilage (170). There 
is also evidence that the structure and maturity of the collagen matrix can 
influence pigment deposition. Newly-synthesised aberrant matrix proteins in 
scar tissue also appear to pigment rapidly, as reported in the case of a 
mediastinal mass from an AKU patient (171). Solid-state NMR (ssNMR) 
analysis of AKU articular joint cartilage also observed spectra indicative of 
marked collagen disorder at the atomic level (172), further supporting the idea 
that disruption to the collagen matrix supports ochronotic deposition. In 
support of this idea, wider structural damage of collagen organisation has been 
observed in cartilage collagen, in OA, for example the aligned fibres of type-II 
collagen have been shown to split apart into smaller diameters in osteoarthritic 






Figure 1.07. Interaction between ochronotic pigment and cartilage 
collagen. A: transmission electron microscopy image of ochronotic 
ligamentous capsule. Collagen fibres in longitudinal section show a distinct 
electron-dense pigment on their surface. Numerous pigment shards can be 
seen on single fibres. Not all fibres present with pigment deposition. Gradient 
of pigmentation can be seen running left (no pigment on fibres) to right (large 
electron-dense shards replacing fibres). Arrows indicate a distinct periodic 
binding pattern associated with pigment granules on a single fibre. Source: 
(16). B: schematic representation of the exposed collagen hypothesis of 
ochronosis. Initially, collagen fibrils are resistant to binding of homogentisic 
acid (HGA) or its derivatives. Following loss or breakdown of specific 
protective matrix constituents including proteoglycans (PG), binding sites 
become available for HGA-associated compounds. It is proposed that the 
initial binding event initiates ochronosis and that the process of widespread 





In terms of the exact HGA-associated species that initially binds to cartilage, it 
is thought that the oxidised BQA intermediate is more reactive than HGA (174). 
Coloured solutions of oxidised HGA are known to show more irreversible 
binding to hide powder collagen compared to colourless solutions of non-
oxidised HGA (175,176). Chemical investigations of BQA using 
spectrophotometric methods has shown that it binds irreversibly with free 
amino groups (177,178). Additionally, irreversible binding of BQA occurs with 
albumin and homogenates of skin and cartilage (179). The current hypotheses 
of the binding of collagen to HGA or derived species therefore involve BQA to 
a large degree, though it has been shown that oxidized (coloured) and fresh 
(colourless) HGA solutions show highly similar infrared spectra (180), 
suggesting strongly that the conversion of HGA to BQA is incomplete, and that 
the HGA hydroquinone functionality remains substantial even in coloured 
solutions of oxidized HGA. While HGA is colourless, the air oxidation of urine 
from AKU patients and the joint cartilage degradation are both accompanied 
by a striking colour change from colourless/white to brownish black. The 
presence of BQA or related oxidised species is inferred from the colour of 
ochronotic cartilage, though whether the degree of conversion is complete in 
these solutions and in vivo is currently unknown. 
1.3.4  Detection of ochronosis 
Gross ochronosis is easily visible as dark pigment in tissues such as the 
cartilage of the ears and sclera of the eyes. Photographs of the eyes and ears 
have been used to follow the pigmentation process, both in terms of 
understanding the natural history of AKU as well as to study the effect of 
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reducing HGA concentrations on ochronotic pigment. This may be the most 
efficacious way to follow pigment change (140). 
However, to detect small amounts of pigment, more sensitive techniques are 
required. Such techniques can employ the property of HGA as a reducing 
agent and can be used in tissues in vitro and ex vivo; one such approach 
employs Schmorl’s stain, a ferricyanide reduction method (Figure 1.08) to 
detect microscopic ochronotic pigment (62); this supports the idea that 
ochronotic pigment originates from HGA. Biopsy of tissues such as ear 
cartilage reveals ochronotic pigment even when it is not visible externally 
visually through the intact skin (27). 
Investigations such as arthroscopy and bronchoscopy can reveal ochronosis 
and suggest diagnosis of AKU for the first time. Diagnosis has also been made 
following the observation of black aorta at open heart surgery for aortic valve 
replacement (181). Direct detection of ochronotic pigment in vivo is possible 
by Raman spectroscopy. Such a technique has been validated in ex vivo 
tissue (182) and is being adapted as an in vivo technique using ear cartilage 





Figure 1.08. Histological detection of ochronotic pigment. A: ochronotic 
pigment in the joint capsule of the knee of a patient with AKU. Pigment 
deposits are seen as brown granules in the cartilage extracellular matrix and 
within individual fibroblasts. Section stained with nuclear fast red. B: near 
serial section of the joint capsule with Schmorl’s stain. Ochronotic deposits are 
stained green. Bar: 50 μm. Source:  
 
Ochronosis can be observed in ex vivo samples, especially from joints, and 
these can vary in the extent and degree of pigmentation. The earliest pigment 
is articular cartilage is seen in calcified cartilage cells at the junction between 
the calcified cartilage and subchondral bone (184). Similarly, ochronotic 
pigment is found in intervertebral discs and adjacent articular cartilage (23).  
It would be an advantage to quantify ochronotic pigment in vivo but such a 
technique is not available at present. Availability of techniques to monitor 
changes in whole body pigment, increase or decrease or no change over time, 
would be highly informative.  
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1.4  Analytical techniques for studying ochronotic pigment: mass 
spectrometry 
In addition to metabolomics, MS platforms such as LC-QTOF-MS can be 
applied for identifying the chemical structures of unknown molecules such as 
ochronotic pigment. Aside from the more general attributes of the technology 
that are discussed above (i.e. high sensitivity, high-resolution mass accuracy, 
non-targeted data acquisition), this technique provides additional structural 
information on compounds by generation of compound fragments, or ‘product’ 
ions from the precursor ion which are recorded and combined into a spectrum 
(MS/MS or MS2). In MS/MS analyses, a specified collision energy is applied to 
ions. ‘Collision-induced dissociation’ (CID) of compounds (this occurs in the 
collision cell component of a QTOF; Figure 1.04) in this way enables the 
chemical structure to be deciphered based on the compound fragments or 
sub-structures generated. MS/MS can be performed by a targeted (Figure 
1.09) or non-targeted approach. In targeted MS/MS analyses a specific 
precursor ion (or ions) is selected for fragmentation (based on AM with/without 
RT specified – selection by quadrupole filter in QTOF; Figure 1.04), whereas 
in non-targeted analyses fragmentation can be performed on any precursor 
ion that exceeds a given abundance threshold within a specified time frame. 
Compound identification in MS/MS analyses is often performed by matching 
the observed fragmentation spectra with data from compound spectral libraries 
(92,107,185). When there are no data for compounds in spectral databases or 
libraries, as is most likely the case for ochronotic pigment, this approach has 
to be performed de novo. The de novo approach is more challenging, but 
important clues to the compound’s sub-structure can still be gained from the 
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fragment ions generated. Furthermore, a range of computational tools is 




Figure 1.09. MS/MS for chemical structure elucidation. A: selection of 
precursor ion by accurate mass and RT; dipeptide hydroxyprolyl-leucine (hyp-
leu) in this example of targeted MS/MS. B: spectrum acquired from collision 
induced dissociation (CID) at 40 V. Blue diamond represents the fragmented 
precursor ion. Generation of the product fragment ions confirms identification 
of this compound as hyp-leu. The annotated product ions are hyp (dissociated 
from the dipeptide and known fragments of hyp and leu). Source: unpublished 
data acquired by LC-QTOF-MS analysis of culture media from an in vitro 
osteoclast bone resorption assay. The hyp-leu dipeptide is a previously 




1.5  Analytical techniques for studying ochronotic pigment: NMR 
spectroscopy 
NMR spectroscopy is an analytical technique widely used in chemistry, 
structural biology and material science to study structure at the molecular 
level, by observing local magnetic fields around atomic nuclei.  Not all nuclei 
can be observed by NMR; in biological applications, frequently observed NMR-
sensitive nuclei are 1H, 13C, 15N, 19F and 31P.  While 1H, 19F and 31P are all 
highly abundant (>99%) on earth, 13C and 15N are only present at 
approximately 1% and 0.4% (188), respectively. In the NMR experiments 
employed to study ochronotic pigment and cartilage samples here, analyses 
were based on 1H and 13C nuclei (Chapters 6 and 7). 1H is also referred to as 
a proton NMR as the hydrogen nucleus consists of one proton only. 
1.5.1  The vector model 
The vector model is useful for explaining the basic concepts of NMR. The 
fundamental idea of this model is the net alignment of NMR-sensitive nuclei in 
a given direction, referred to as the magnetisation vector. The magnetisation 
vector is zero when the sample is not subject to an external magnetic field, but 
aligned with the applied field in an external magnetic field, such as that 
generated by the NMR spectrometer magnet (represented by the z-axis in 
Figure 1.10A). In NMR experiments, the magnetisation vector generally needs 
to be tipped away from the applied magnetic field. Such tipping is generally 
achieved by applying a resonant radiofrequency (RF) pulse perpendicular to 
the external magnetic field. Figure 1.10B shows how applying an RF pulse 
along the x-axis moves the alignment of the magnetisation vector away from 
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the direction of the magnetic field (z-axis). As a result, the magnetisation vector 
rotates, or precesses, around the direction of the magnetic field at an angle (β) 
in a cone-like motion (189). 
The precession frequency is characteristic of a given nucleus and fundamental 
to the final NMR spectrum obtained. For example, at a field strength of 9.4 T, 
13C precesses at 100 MHz while 1H precesses at 400 MHz. At a higher field 
strength of 18.8 T, 13C precesses at 200 MHz while 1H precesses at 800 MHz.   
NMR data detection is enabled by placing a coil of wire around the sample, as 
shown in the direction of the x axis in Figure 1.10C. The magnetisation vector 
cuts the coil and induces a current which is then amplified and recorded as 
NMR data. The precession of the magnetisation results in a current that 
oscillates at the Larmor frequency over time; this voltage-vs-time NMR data is 
the free induction decay (FID). Application of a mathematical process known 
as Fourier transformation results in the conversion of the FID data from the 
time domain into the frequency domain (189). Plotting the transformed output 







Figure 1.10. Fundamental concepts of NMR spectroscopy according to 
the vector model. A: at equilibrium a sample has net magnetisation aligned 
in the direction of an external magnetic field; here the magnetisation vector is 
aligned with the z-axis. B: upon application of a radiofrequency (RF) pulse, the 
magnetisation vector is tilted away from the z-axis and precesses around the 
external magnetic field at an angle in a cone-like motion. The precessional 
frequency is characteristic of a given NMR-sensitive nuclei. C: the precessing 
magnetisation is detected by a coil, shown here along the x-axis. D: the free 
induction decay (FID) NMR signal is converted from the time domain to the 
frequency domain by Fourier transformation, resulting in the final NMR 





The resulting NMR spectrum is a series of chemical shift signals, 
conventionally plotted in parts per million (ppm). 1H and 13C chemical shift 
values are indicative of particular chemical structures, therefore the NMR 
spectra can be used for structural determination of a molecule. This is 
illustrated in Figures 1.11A and 1.11B, for 1H and 13C chemical shifts, 
respectively.   
 
 
Figure 1.11. Typical 1H (A) and 13C (B) NMR chemical shift values for 
various chemical structures. Note that these are typical values only; exact 
values depend on experimental parameters such as solvent composition, 
temperature and presence of other functional groups. Note that TMS 
(trimethylsilane) has 1H and 13C chemical shift values of 0; all other chemical 
shifts are determined relative to it. Figures adapted from (190).  
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1.5.2  Two-dimensional NMR 
Two-dimensional (2D) NMR is an approach used to probe molecular structures 
in greater detail. One-dimensional spectra show one frequency dimension and 
determine the intensity of one type of nuclei in the sample. 2D NMR provides 
a second frequency dimension, which enables different nuclei to be correlated 
to each other.  The resulting signals in the final 2D spectra represent intensity 
values, not for single nuclei as in 1D NMR, but for pairs of frequency variables 
arising from nuclei whose spins are in some way related to each other. 2D 
NMR spectra are conventionally plotted in the form of contour plots, in which 
intensity is indicated by contour lines, analogous to the indication of height 
relief in a topographical map (Figure 1.12). The advantage of the second 
frequency dimension is that it can make it possible to separate signals that 
overlap in conventional 1D NMR; see peaks indicated in green in Figure 1.12 
(189).  
HETCOR (HETeronuclear CORrelation coupling) is a specific 2D NMR 
experiment discussed in Chapter 7. This experiment is used to detect carbons 
that are in close proximity (within 5 Å) of hydrogens. These 13C – 1H couplings 
are represented by the peaks plotted on a 2D spectrum in which the 13C and 
1H chemical shifts are plotted against each other, as shown by the schematic 
representation in Figure 1.12. In ssNMR, the strong 1H – 1H couplings can be 
mitigated with the frequency-switched Lee-Goldburg (FSLG) sequence to 




Figure 1.12. Two-dimensional (2D) NMR. Schematic representation of an 
NMR spectrum obtained from a 2D HETCOR (HETeronuclear CORrelation 
coupling) experiment. Signals are plotted as a function of two frequency 
domains, the 13C and 1H chemical shifts (δ), and represent the coupling 
between the spins of carbons and proximal hydrogens within a molecule. 
Highlighted in green are two peaks that would overlap in the 13C dimension 
but are resolved in the 1H dimension, indicating 1H coupling to different 13C 




1.5.3  Solid-state NMR and magic angle spinning 
In contrast to conventional NMR in which samples are analysed in the solution 
state, ssNMR deals with the analysis of samples in the solid state. This NMR 
approach is particularly attractive for chemical analysis of ochronotic tissues 
in their native, intact form. However, in ssNMR additional measures are 
required to achieve high-resolution spectra. In solution-state NMR, the many 
random orientations interconvert rapidly due to ‘tumbling’. In ssNMR, the 
random orientations of the molecular system remain unchanged throughout 
the NMR experiment in the static state. These random molecular orientations 
give different spectral frequencies, resulting in much broader lines in the final 
NMR spectra (“chemical shift anisotropy”) and many overlapping signals. 
Moreover, heteronuclear dipolar couplings (1H-13C) are often several orders of 
magnitude larger in the solid-state compared to the solution-state, again due 
to the absence of tumbling and averaging. Magic angle spinning (MAS) is a 
technique routinely employed in ssNMR to improve spectral resolution by 
alleviating and even removing the effects of line broadening attributable to 
chemical shift anisotropy and heteronuclear dipolar coupling (192). In MAS, 
the sample is spun rapidly in a cylindrical rotor at the ‘magic angle’ (54.74°) 
relative to the direction of the applied magnetic field. The rapid rotation enables 
the undesirable interactions to be averaged out, giving rise to higher resolution 
ssNMR signals. 
1.5.4  Cross polarisation 
Cross polarisation (CP) is another useful technique in ssNMR spectroscopy. 
CP can be employed to enhance the signal of relatively low-abundance nuclei 
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such as 13C. This approach is particularly applicable in NMR analyses of non-
isotopically enriched material, as the natural abundance of 13C is 1.1%. CP is 
achieved by a specific pulse sequence designed to transfer the larger 
magnetisation of 1H to 13C (1H has greater magnetic sensitivity). Another 
advantage of this experiment is that it can be repeated more frequently 
(usually every few seconds) within a given time frame, which is important for 
signal enhancement. 13C has low abundance, and in non-CP NMR 
experiments it is necessary to wait potentially minutes for the 13C spin 
magnetisation to recover before the experiment can be repeated. 1H has high 
abundance and is highly coupled to other 1H nuclei, which means that their 
spin relaxes more efficiently. Using 1H to generate the magnetisation means 
that the relaxation of 1H dominates over that of 13C and the delay times 
between experiments can be reduced (192). 
1.5.5  Dynamic nuclear polarisation 
Dynamic nuclear polarisation (DNP) can be used to enhance sensitivity of non-
isotopically enriched organic and biological samples in MAS ssNMR 
experiments (193). In DNP, signal enhancement of one to two orders of 
magnitude can be achieved by transfer of the much larger polarisation of 
electron spins to 1H within the sample. The electrons come from a radical 
solution which is applied to the sample. Transfer of magnetisation by DNP 
requires microwave irradiation, which is generated by a gyrotron. To ensure 
efficient transfer, DNP experiments are carried out at low temperature (i.e. 100 
K in the experiments detailed in Chapter 7). 
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1.6  Aims and objectives 
This thesis aims to explore two major gaps in the current understanding of 
AKU. First are the consequences that treatment with nitisinone have on the 
disease in terms of wider metabolism, and how these relate to the metabolic 
profile of untreated AKU. Second is the chemical nature of ochronotic pigment; 
its chemical structure and how its incorporation into cartilage results in severe 
early-onset osteoarthropathy. The specific objectives are as follows: 
1. Establishment of a comprehensive strategy for metabolomic analysis 
by LC-QTOF-MS 
2. Employment of the metabolomic analytical technique developed to 
explore: 
a) the consequences of nitisinone treatment on wider metabolism in 
patients and mice with AKU 
b) the consequences of HGD deficiency on wider metabolism in 
untreated mice from a newly-established model of AKU 
3. Structural analyses of ochronotic pigment formed in vitro (derived from 
HGA standard) and in vivo (ochronotic cartilage) using a range of 





2.0  DEVELOPMENT OF A COMPREHENSIVE LC-QTOF-MS 








Published work resulting from content included in this chapter (see Supporting 
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Chem. 2019;65(4):530–9. 
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Metabolite Library of Standards by LC-QTOF-MS analysis. figshare. 
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The above works report the metabolic profiling strategy developed and 
validated by BPN, and described in this chapter, in addition to the resulting 
AMRT databases. BPN was the main contributor to the laboratory analyses 




Davison AS, Norman BP, Ross GA, Hughes AT, Khedr M, Milan AM, 
Gallagher JA, Ranganath LR. Evaluation of the serum metabolome of 
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nitisinone using LC‐QTOF‐MS. JIMD Rep. 2019;48(1):67–74. 
 
The above works resulted from the application of the metabolic profiling 
strategy developed by BPN and reported in this chapter. BPN contributed to 






One strategy for identification of unknown chemical entities generated by LC-
MS is by reference to publicly available spectral libraries, which have become 
generally accepted as indispensable resources to researchers in the field of 
metabolomics (194–198). Although the human metabolome, for example, is 
not yet fully characterised, significant efforts are underway to catalogue 
analytical data acquired from tens of thousands of biologically relevant 
chemical standards according to mass spectra and MS/MS spectral 
fragmentation patterns in addition to data from coupled techniques such as RT 
(LC), retention indexes (GC) and collisional cross sections (ion mobility). For 
example, the recently updated 2018 version of the Human Metabolome 
Database (199) now contains entries for more than 115,000 compounds, 
containing information on human metabolites including their biological 
function, tissue and biospecimen location, physiological concentration, 
disease associations, metabolic pathways, experimental spectra and 
predicted MS/MS spectra. A range of other mass spectral libraries of small 
molecule metabolites is commonly employed by researchers in metabolomics; 
as of 2016 the most widely used spectral libraries were METLIN, MassBank, 
KEGG, NIST MS, ChemSpider, LipidMaps and PubChem (200). Together, 
these databases cover a broad range of volatile and non-volatile low molecular 
weight compounds from different chemical classes including both those of 
endogenous and exogenous origin.  
A major limitation of compound identification using publicly available 
compound databases is that the data were acquired by different laboratories 
employing different analytical parameters and techniques. These include 
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different MS ionisation techniques [e.g. ESI, MALDI, atmospheric-pressure 
chemical ionisation (APCI)] and different analytical parameters applied to 
coupled techniques such as liquid and GC, capillary electrophoresis etc. To 
resolve this issue, an in-house AM / RT (AMRT) database was generated from 
the analysis of 619 small molecule metabolite standards with LC-QTOF-MS 
for the purpose of predicting the identity of unknown entities acquired under 
identical analytical conditions based on orthogonal chemical properties (i.e. 
AM and RT). It is shown that coupling three separate but complementary LC 
techniques to MS maximised coverage of the metabolite standards, which 
spanned a range in molecular weight (45-1354 Da) and chemical classes 
including carboxylic acids, amino acids, biogenic amines, nucleotides, 
carbohydrates, fatty acids, lipids, steroids and hormones; overall covering a 
broad range of primary metabolism. 
It is then shown that the targeted LC-QTOF-MS strategy can be applied to 
identify unknown compounds present in complex biological matrices such as 
urine.  
2.2 LC-QTOF-MS analysis of metabolite standards from the Sigma 
IROA MSMLS suite 
2.2.1  Metabolite standards library preparation 
619 metabolite standards (molecular weight range: 45-1354 Da) were from the 
IROA MS metabolite library of standards (MSMLS: Sigma Aldrich, UK) 
contained in seven 1.2 ml polypropylene deepwell plates, with each individual 
compound at 5 µg in an individual well (>95% purity). Plates were stored at  
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-80°C. MSMLS compounds are accessible via the following link: 
https://www.sigmaaldrich.com/catalog/product/sigma/msmls. 
Prior to analysis, plates were thawed at room temperature and compounds 
reconstituted in 15 µL methanol (LC/MS grade, Sigma Aldrich) followed by 285 
µL deionised water (purified in-house via DIRECT-Q 3UV Millipore water 
purification system). Plates 1-5 were left to stand for at least 1 h at room 
temperature following addition of water and methanol. Plates 6 and 7, which 
contained primarily lipid-like compounds, were left to stand for 2 h at room 
temperature following addition of methanol to ensure solubilisation; water was 
then added after this period. Plates were then agitated on a plate shaker (MTS 
2/4m IKA, Germany) at 600 rpm for 10 minutes. Compounds were pooled 
across the rows of each plate (12 wells per row). 20 µL was taken from each 
well and pooled into one well so that 12 compounds were analysed per 
injection. Fifty-six injections were performed in positive and negative ionisation 
polarity across all plates; in total 112 injections for each LC-QTOF-MS method 
(Figure 2.01). Each pool had a total volume of 240 µL with each compound at 
0.14 mg/mL (1-31 µmol/L). 
It was noted that some rows contained isobaric metabolites; these compounds 
were added to new pools containing 3-6 compounds of different molecular 
weight. D-frucotse, D-galactose, L-sorbose, alpha-D-glucose, melibiose and 
palatinose were injected individually; re-pooling was impractical as they share 






Figure 2.01. Summary of experiment workflow for preparation and LC-QTOF-MS analysis of the 619 metabolite standards. 
Compounds were pooled across rows (A1-A12, B1-12 etc.) in each of seven 96-well plates. Analysis comprised 112 injections of 
compound pools incorporating positive and negative electrospray ionisation (ESI) polarity for methods 1, 2 and 3. 
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2.2.2 Analytical conditions 
Chemicals 
Water for mobiles phases was purified in-house as above. Methanol, 
acetonitrile, isopropanol (Sigma Aldrich), formic acid (Biosolve, Netherlands) 
and ammonium formate (Fisher Scientific, Germany) were LC/MS grade. 
Equipment 
Sample analysis was performed on an Agilent 1290 Infinity UHPLC system 
coupled to an Agilent 6550 QTOF-MS equipped with a dual AJS ESI source 
(Agilent Technologies UK Ltd., Cheadle, UK). 
Chromatographic conditions 
Three chromatographic methods were designed to separate different 
compound classes. Method 1: non-polar compounds. Method 2: a range of 
polar and non-polar compounds. Method 3: polar compounds. 
Method 1 
A Zorbax Eclipse Plus C18 column (2.1 x 100 mm, 1.8µm, Agilent) was 
maintained at 60°C with a flow rate of 0.4 mL/minute. Mobile phases were (A) 
water and (B) methanol both containing 5 mmol/L ammonium formate and 
0.1% formic acid. The elution gradient started at 5% mobile phase B at 0-1 
minutes increasing linearly to 100% B by 12 minutes, held at 100% B until 14 





Method 2 employed the same conditions and elution gradient as method A, 
but with an Atlantis dC18 column (3.0 x 100 mm, 3 µm, Waters, UK). 
Method 3 
A BEH Amide column (3.0 x 150 mm, 1.7 µm, Waters) was maintained at 40°C 
with a flow rate 0.6 mL/minute. Mobile phases were (A) water and (B) 
acetonitrile (both contained 0.1% formic acid). The elution gradient started at 
99% mobile phase B decreasing linearly to 30% from 1-12 minutes, held at 
30% mobile phase B until 12.6 minutes, returning to 99% mobile phase B for 
3.4 minutes to recondition the column. 
For all methods, sample injection volume was 1 µL for metabolite standards. 
The autosampler was maintained at 4°C and the autosampler needle was 
washed with a solution of methanol:isopropanol:water (45:45:10 v/v) between 
sampling. 
QTOF-MS conditions 
The mass spectrometer was tuned and calibrated according to protocols 
recommended by the manufacturer. Acquisition was performed in 2 GHz 
mode, positive and negative ionisation polarity and mass range 50-1700. The 
capillary voltage was 4000 V and fragmentor voltage 380 V. The desolvation 
gas temperature was 200°C with flow rate at 15 L/min. The sheath gas 
temperature was 300°C with flow rate at 12 L/min. The nebulizer pressure was 
40 psig and nozzle voltage 1000 V (± for positive and negative ionisation 
modes). The acquisition rate was 3 spectra/second. 
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A reference mass correction solution was prepared in 95:5 methanol:water 
containing 5 mmol/L purine (C5H4N4, CAS No.: 120-73-0), 100 mmol/L 
trifluoroacetic acid ammonium salt (TFA; CF3CO2NH4, CAS No.: 3336-58-1) 
and 2.5 mmol/L hexakis(1H, 1H, 3H-tetrafluoropropoxy)phosphazine (HP-
0921; C18H18F24N3O6P3, CAS No.: 58943-98-9) (Agilent). The solution was 
continually infused at a flow rate of 0.5 mL/min by a separate isocratic pump 
for constant mass correction [positive ionisation: purine (m/z 121.0509), HP-
0921 (m/z 922.0098); negative ionisation: TFA (m/z 112.9856), purine (m/z 
119.0363), HP-0921 (HP-0921 + formate adduct: m/z 966.0007)]. 
2.2.3 Acquisition and processing of data from metabolite standards 
Data were acquired and processed using the following software from the 
MassHunter package (Agilent). Data were acquired with Data Acquisition 
(build 06.00). Quality checks and processing of raw data files (Agilent ‘.d’ files) 
were performed with Qualitative Analysis (build 07.00). Extracted ion 
chromatograms (EICs) of reference masses were performed to check mass 
accuracy remained <5 ppm throughout the run. Binary pump pressure curves 
for injections across each analytical sequence were overlaid to check 
chromatographic reproducibility. 
From data acquired from analysis of metabolite standards, compound signals 
were extracted in Qualitative Analysis (build 07.00) based on the molecular 
formulae of compounds in each injection using the find by formula algorithm; 
with a mass window of theoretical AM (calculated from molecular formula)  ±5 
ppm (Figure 2.02). Allowed species for positive ionisation mode were: H+ and 
Na+, with the addition of NH4+ for methods 1 and 2 (mobile phases contained 
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ammonium formate); and for negative ionisation mode H- with the addition of 
CHO2- for methods 1 and 2. Dimers were allowed for both ionisation polarities. 
Charge state range was 1-2. 
 
 
Figure 2.02. Representative example of the data processing output from 
extraction of signals for metabolite standards. A: combined 
chromatograms representing the signals for ten standards successfully 
extracted from the data. The data displayed is from one injection of twelve 
metabolite standards pooled and analysed by method 2 in positive polarity. B: 
example individual extracted ion chromatogram for urate. C: example cleaned 
mass spectrum for urate; the displayed ions represent the +H (m/z 169.0364, 
170.0391 and 171.0411, corresponding to 12C, 13C and 2x 13C isotopologues 




2.2.4 Data from LC-QTOF-MS analysis of metabolite standards 
Compound signals were extracted as described above. Only standards with 
RT >0.3 min after the initial column void were considered. Of the 619 
standards analysed, 519 (83.8%) were retained sufficiently to be detected by 
at least one of the three LC-QTOF-MS methods. 177/619 (28.6%) of 
compounds were detected by all three methods. A considerable proportion of 
compounds were retained and detected by one (116/619 [18.7%]) or two 
(226/619 [36.5%]) methods only, demonstrating the utility of combining data 
from the three chromatographic methods to increase coverage of the 
metabolome (Figure 2.03A). Figure 2.03 (B-D) shows the distribution in mass 
and RT for compounds detected by the three methods. AM, RT and charge 
state of detected compounds were entered into an in-house AMRT metabolite 
database for each method for matching unknowns against. The databases 
could then be used to identify unknown peaks in data from experimental 
analyses. 
Figure 2.03 (B-D) also highlights the differences in selectivity between the 
methods for three chemical groups: carbohydrates, amino acids and lipids. 
Method 3 retains and separates highly polar, water-soluble compounds such 
as carbohydrates (20/26 detected, RT range: 5-9.5 minutes). In methods 1 and 
2, the same carbohydrates were weakly retained; for method 1 all 
carbohydrates detected eluted within the column void volume (24/26 detected, 
RT range: 0.58-0.68 minutes) and for method 2 all carbohydrates detected 
eluted close to the void volume (23/26 detected, RT range: 1.32-1.44 minutes). 
Method 1 showed enhanced suitability for analysis of lipid-like compounds 
(11/11 detected, RT range: 7.69-13.72 minutes) compared to methods 2 (8/11 
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detected, RT range: 9.27-14.3 minutes) and 3 (7/11 detected, RT range: 1.5-
8.26 minutes) which detected fewer of these compounds within a narrower RT 
range overall. All three methods showed detection and a degree of 
chromatographic separation for the amino acids, with method 3 appearing to 
show the most useful chromatographic resolution and retention (19/21 
detected, RT range: 5.42-8.1 minutes) compared to methods 1 (21/21 
detected, RT range: 0.55-2.82 minutes) and 2 (21/21 detected, RT range: 
1.07-4.6 minutes).  
Separate AMRT databases were created for methods 1-3, detailing the 
theoretical AM and RT of each detected metabolite standard, as described 
below. The databases have been made publicly available to the metabolomics 








Figure 2.03. Summary of data acquired from analysis of metabolite 
standards. A: Venn diagram summarising the number of compounds retained 
and detected by methods 1-3. 177 compounds were retained and detected by 
all methods. Non-overlapping sections show that an additional 118 
compounds were only detected by one method. This shows that coverage of 
the metabolome can be enhanced by combining data from acquired using 
methods 1-3. (B-D) Mass vs RT scatter plots for metabolite standards detected 
with the three analytical methods. B: Method 1 is more suited for separation 
of non-polar lipid-like compounds. C: Method 2 provided separation of both 
amino acids and lipids and D: Method 3 is optimal for chromatographic 
separation of polar compounds such as carbohydrates. Squares, triangles and 
diamonds represent amino acids, selected carbohydrates and selected lipids 
respectively. Red markers indicate compounds eluting within the column void 
volume (defined here as the earliest eluting compound for each method +0.3 
minutes). Methods 1 and 2 employed reversed-phase chromatography with 
Zorbax Eclipse Plus C18 (2.1 x 100 mm, 1.8 µm, Agilent Technologies, UK) 
and Atlantis dC18 (3 x 100 mm, 3 µm, Waters, UK) columns respectively. 
Method 3 employed normal-phase chromatography with a BEH amide column 
(3.0 x 150 mm, 1.7 µm, Waters, UK). 
 
2.2.5 Generation of AMRT databases from metabolite standards 
Three separate AMRT databases were created for the metabolite standards 
analysed by methods 1-3 using PCDL Manager (build 08.00, Agilent). The 
MassHunter METLIN metabolites PCD/PCDL accurate mass database 
(Agilent, build 07.00) was used as the basis for the AMRT databases. The 
version of the METLIN metabolites database employed here contains entries 
for 30,232 small molecules, including information such as chemical name, 
empirical formula, monoisotopic AM and deposited spectral and collisional 
cross section (ion mobility) data. Unique chemical identifiers are also provided 
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for each compound, including CAS, ChemSpider, METLIN, KEGG and HMDB 
unique accession numbers. Attaching such accession numbers is important 
not only for providing an unambiguous chemical identifier, and therefore 
avoiding potential confusion arising from the use of many different synonyms, 
which is common for metabolites, but also to enable mapping of metabolites 
of interest to pathways using tools such as Agilent Pathways Architect; the use 
of which is described in subsequent chapters. Once each metabolite from the 
Sigma IROA MSMLS library had been matched with an entry from the METLIN 
database, all of the selected entries, together with their METLIN information 
and data, were appended to separate blank PCDL databases for analytical 
methods 1-3. The Sigma compound name (i.e. the synonym used by Sigma), 
and RT, as provided from the present analysis, of each detected compound 





Figure 2.04. An example of compound entries from the AMRT databases created from analysis of metabolite standards and 
fully integrated with compound information from the METLIN database. The screenshot shows compound entries in PCDL 
Manager for the AMRT database created for method 2. From left-to-right, column headings refer to: 1) Name - the name used in the 
METLIN database, 2) Synonyms - the name used by Sigma-Aldrich, 3) Formula - empirical formula, 4) Mass - theoretical accurate 
mass, 5) RT – RT measured by the analytical method described above, 6) - 9) chemical database accession numbers, 10) 
NumSpectra - number of deposited experimental spectra (including positive and negative ionisation and different collision energies), 
11) CCS Count - collisional cross section data from ion mobility MS analysis.  
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2.2.6 Discussion of LC-QTOF-MS analysis of metabolite standards and 
generation of AMRT libraries 
The data from analysis of metabolite standards demonstrate the enhanced 
coverage achieved from combining the three complementary LC-QTOF-MS 
techniques as detailed above for non-targeted metabolic profiling. Of the 619 
standards, 118 additional compounds were detected by combining data from 
all three methods. The mass vs RT distributions of compounds that were 
sufficiently retained to be detected (Figure 2.03) highlight the complementary 
selectivities of the three methods for chromatographically resolving 
metabolites from different biochemical groups. Methods 1 and 2 were more 
successful in resolving non-polar, lipid-like compounds. Method 3 was more 
successful in resolving highly polar compounds such as polar amino acids and 
carbohydrates. Method 2 was also selected because the chromatographic 
column (Atlantis dC18 3.0 x 100 mm, 3 µm, Waters, UK) continues to be used 
for LC-MS/MS quantitation of nitisinone, HGA and other tyrosine-related 
metabolites in serum (137) and urine (138) at the NAC . 
AM, charge state, RT and MS/MS fragmentation spectra were entered into in-
house compound databases to provide unique method-specific chemical 
signatures of the compounds under study. The following sections detail the 
application of the databases for identification of unknown compounds acquired 
from LC-QTOF-MS analysis of human biofluid samples (urine). 
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2.3 Application of developed AMRT databases for targeted metabolite 
identification in urine 
Generation of the AMRT databases from analysis of metabolite standards, as 
described above, formed the basis of a targeted data extraction and metabolite 
identification strategy which was applied to biological samples such as urine. 
It is important to clarify that the datasets discussed in the following sections 
were acquired using a non-targeted analytical method, as no precursor ion 
selection was performed during sample analysis. The targeted aspect of this 
approach refers to the data analysis only, in which AMRT databases for each 
of methods 1-3 provided the targets for compound signals to extract from the 
data by matched AMRT. Further details on this targeted extraction approach 
and complementary non-targeted extraction are provided in Chapter 3 (section 
3.3.1). 
2.3.1 Urine used to evaluate targeted LC-QTOF-MS strategy 
24-h urine was obtained from 25 AKU patients attending the NAC in Liverpool 
(12 male, 13 female, mean age (±SD) 51(±15) years) as part of a wider 
metabolic profiling experiment (see Chapter 4). Samples were collected from 
the same patients before commencement of nitisinone therapy then at 3 (2 mg 
every other day), 12 and 24 months (2 mg daily) on nitisinone. An overall 
pooled sample was created by pooling 20 µL of each individual urine sample. 
Pooled urine samples were diluted 1:3 urine:deionised water prior to analysis. 
Data from this pooled sample was used to evaluate the number of AMRT 
matches obtained using methods 1-3. 
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2.3.2   AKU-relevant compounds spiked into water and urine matrices 
HGA, phenylalanine, metadrenaline (MA), normetadrenaline (NMA), 3-
methoxytyramine (3-MT) and tyrosine standards were purchased from Sigma 
Aldrich, UK. Nitisinone was purchased from APL, Sweden. All dilutions and 
sample preparation were performed in glass. 
Stock solutions of standards were prepared to concentrations of 10 mmol/L. 
Tyrosine was dissolved in 1 mL sulfuric acid before addition of 9 mL deionised 
water. HGA and phenylalanine were dissolved in 10 mL deionised water. 
Nitisinone was dissolved in 5 mL acetonitrile before addition of 5 mL deionised 
water. MA, NMA and 3-MT were prepared in 10 mL (0.1 mmol/L) hydrochloric 
acid. 
Stock solutions were stored at -80°C. Combined standard solutions of HGA, 
phenylalanine, tyrosine and nitisinone were prepared in water and urine 
matrices to 0.1-500 µmol/L via serial dilution with human urine (non-AKU) 
diluted 1:3 urine: deionised water.  
Combined MA, NMA and 3-MT standard solutions were prepared in deionised 
water to 0.1-25 µmol/L. MA, NMA and 3-MT were focused on in the urine 
matrix as these are direct metabolites of the parent catecholamine compounds 
(adrenaline, noradrenaline and dopamine analysed in Sigma library) and are 
present at higher concentrations in urine. Commercial urine calibration 
standards (Chromsystems, Munich) were prepared at concentrations of 0-24.8 
µmol/L for MA; 0-46.8 µmol/L for NMA; and 0-27.7 µmol/L for 3-MT. These 




2.3.3   Acquisition and processing of data from analysis of urine by LC-
QTOF-MS 
Urine samples for assessment of the LC-QTOF-MS strategy were analysed 
under identical analytical conditions as detailed above for metabolite 
standards. Pooled urine samples from AKU patients were analysed by all three 
LC-QTOF-MS methods in positive and negative ionisation, mass range 50-
1700. Unknown chemical entities from these analyses were matched against 
the respective AMRT database with mass and RT matches required; 
theoretical AM ± 10ppm and database RT ± 0.3 minutes. This RT tolerance 
was chosen in order to allow for a reasonable degree of RT shift for 
metabolites present in urine matrix compared to the measured RT of their 
corresponding chemical standards, which were analysed in blank solvent 
matrix. Allowed ion species were the same as described above for metabolite 
standards (section 2.2.3). This data processing was performed in Profinder 
(build 08.00). 
For AKU-relevant standards spiked into water and urine, HGA, nitisinone, 
phenylalanine and tyrosine were analysed by method 2; MA, NMA and 3-MT 
were analysed by method 3. These methods were selected as they gave the 
most optimal chromatographic separation of the compounds under study. HGA 
and nitisinone were analysed in negative ionisation mode as this showed the 
greatest signal. Tyrosine, phenylalanine, MA, NMA and 3-MT were analysed 
in positive ionisation mode. Signals for these compounds were quantified 
using MassHunter Q-TOF Quantitative Analysis (build 06.00), based on total 
peak area.  
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2.3.4  Identification of unknown urinary metabolites by AMRT 
Unknown chemical entities detected from analysis of pooled urine from AKU 
patients in positive or negative ionisation polarity were matched against the 
respective AMRT database generated for each method. Here, urine analysis 
comprised two replicate injections of the pooled sample from the AKU urine 
metabolomics experiment; i.e. the first (post-equilibration) and last injection of 
an entire urine profiling experiment comprising 205 injections in total. Only 
matches obtained from both replicate injections in positive or negative 
ionisation polarity were analysed further, and only unknowns with single AMRT 
compound matches were considered identified in this analysis. Several 
additional QC filters were then applied to AMRT matches to ensure 
reproducibility across the analytical run; CV <25% for peak area and RT 
between the two replicate injections. Table 2.01 summarises the number of 
matches retained for each method following each of these filtering steps. 
Importantly, no compounds were filtered out due to RT CV >25%; the 
maximum RT CV% change between replicate injections of the overall pooled 
QC across all analytical runs was 4.1%. 
Figure 2.05 (A) shows that 203 unique compound matches were obtained from 
urine in at least one polarity by at least one method (see Supporting materials, 
Appendix 1 for details of the matches obtained by methods 1-3). Fourteen 
AMRT matches were obtained by all three methods. An additional 61 AMRT 
matches were obtained by two methods, and 128 matches by only one of the 
methods, further supporting the increased coverage achieved by the three 
methods in combination. Scatter plots in Figure 2.05 (B-D) show the mass and 
RT distribution of the AMRT matches.  
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Table 2.01 shows the number of AMRT matches obtained when narrower 
AMRT matching windows were applied. For each method, >50% of matches 
obtained at ±10 ppm and ±0.3 min post-QC remained when the window was 





Figure 2.05. Summary of compounds identified from analysis of urine by 
AMRT. A: Venn diagram summarising the number of urine AMRT matches 
obtained for methods 1-3. Combining data across the three analytical methods 
increased the number of AMRT matches, again demonstrating the enhanced 
coverage of the metabolome achieved by the strategy. B-D: mass vs RT 
scatter plots for AMRT compound matches obtained from LC-QTOF-MS 
analysis of urine by (B) Method 1, (C) Method 2 and (D) Method 3. These data 
were obtained from analysis of a pooled human urine sample consisting of 




Table 2.01. Number of AMRT matches obtained by the three methods and retained following quality control filtering and 
decreasing AMRT window size during feature extraction. (+) and (-) refer to positive and negative polarity respectively. 
Feature extraction 
window 
Filtering step Number of urine AMRT matches 
    Method 1    Method 2    Method 3    
    
(+) (-) (+) (-) (+) (-) 
 
Accurate mass 10ppm,                  
RT 0.3min 
None 274 153 248 105 111 74 
  
(1) Unique AMRTs only, manual 
curation 
80 38 121 43 70 37 
  
(2) Abundance QC: peak area CV 
<25% between replicates 
75 36 107 35 59 30 
  
(3) RT shift QC: RT CV <25% 
between replicates   
75 36 107 35 59 30 
 
Accurate mass 5ppm, RT 
0.15min 
Steps (1) - (3) 44 31 65 25 38 22 
 
Accurate mass 2.5ppm,                 
RT 0.075min 
Steps (1) - (3) 17 21 22 12 14 13 
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2.3.5  Data from analysis of AKU-relevant compounds spiked into water and 
urine matrices  
Sensitivity and response linearity  
HGA, NTBC, phenylalanine and tyrosine were analysed by method 1. 3-MT, MA 
and NMA were analysed by method 3 (methods described in section 2.2.2). Both 
LC-QTOF-MS methods successfully resolved the compounds under study. R2 
values for HGA, nitisinone, phenylalanine and tyrosine showed linearity in the 
spiked concentration ranges tested in water and urine matrices (0.1–500 µmol/L 
for HGA and nitisinone, 0.1 –100 µmol/L for phenylalanine and tyrosine) (Table 
2.02). As shown by lower limit of detection (LLOD) values in Table 2.02, a 
response was recorded for the lowest concentration standard of each compound. 
LLOD values did not account for HGA, tyrosine and phenylalanine native to the 
urine sample, however there was no base nitisinone in the urine sample; the 
donor was not on nitisinone therapy. MA, NMA and 3-MT eluted between 3.7-4.4 






Table 2.02. m/z, retention times (RTs), lower limits of detection (LLOD) and 
linearity of response for standard compounds across the concentration 
range. R2 values for spiked concentration ranges 0.1-500 µmol/L for HGA and 
NTBC; 0.5-100 µmol/L for tyrosine and phenylalanine (phe); 0.1-25 µmol/L for 
NMA, MA and 3-MT. HGA, NTBC, phenylalanine and tyrosine were analysed by 
method 1. 3-MT, MA and NMA were analysed by method 3 (methods described 
in section 2.2.2). 
























































4.4  0.1 0.98  0.1 0.97 
*LLOD is not strictly valid for tyrosine and phenylalanine in urine here as these 
compounds are native to the urine sample used. The NMA, MA and 3-MT values were 






Analysis of matrix effects 
Potential matrix effects of ion suppression were assessed by monitoring the signal 
of isocratically-delivered reference ions throughout the chromatographic run. 
Components of complex matrices such as serum and urine can prevent ionisation 
of sample constituents (126), which should be reflected by loss of ionisation of 
compounds from the reference mass solution given the close proximity of the 
sample and reference ion sources. As shown in Figure 2.06, low molecular weight 
reference ions of m/z 119.036 (negative ionisation mode) and 121.0509 (positive 
ionisation mode) showed a relatively consistent signal across the run for both 
chromatographic methods for urine matrix compared with blank water or methanol 
injections (remaining within the 10 ppm extraction window). There was some 
limited evidence of dropout in reference ion signal, particularly in urine spiked to 
the highest concentrations at regions of greatest elution. Despite this drop-out, 






Figure 2.06. Analysis of matrix effects on ion suppression through 
monitoring signal for reference ions. A: reference ion for negative polarity; m/z 
119.036, B: reference ion for positive polarity; m/z 121.0509. Traces represent 
the signal for these reference ions during analysis of difference matrices; water 
(blue), methanol (green) and urine diluted 1 in 4 (orange) blank matrix (upper 
trace) and matrix spiked with HGA, nitisinone, phenylalanine and tyrosine, 
standards at the highest concentration analysed (lower trace). Data extraction 
was performed with 10 ppm error. Reference ions were detected within 10 ppm 
for all sample types. There was some evidence of reference ion drop-out for urine 
matrices compared with injections of blank water or methanol, but this was 






As compound identification remains a major challenge to the interpretation of 
metabolomic data, a strategy for comprehensive LC-QTOF-MS metabolic 
profiling was developed, with compound structure identification by three AMRT 
databases generated from analysis of 619 metabolite standards. The standards 
span a range in molecular weight (45-1354 Da) and chemical classes including 
carboxylic acids, amino acids, biogenic amines, nucleotides, carbohydrates, fatty 
acids, lipids, steroids and hormones, representing a broad range of primary 
metabolism. Application of this strategy enabled: a) enhanced coverage of the 
metabolite standards; b) identification of unknown chemical entities in complex 
biological matrix (urine) using the appropriate AMRT database; c) 
chromatographic separation, sub-micromolar detection and linearity across the 
concentration range for tyrosine-related metabolites of established relevance to 
AKU when spiked into urine.  
It is widely recognised in the literature that different analytical techniques are 
required according to different metabolite properties (86,112). The distribution in 
mass and RT of compounds detected by each of the three methods in this study 
shows their different suitabilities for separating different classes of biological 
molecules. Method 1 was most successful in resolving non-polar, lipid-like 
compounds. Method 3 was more successful in resolving highly polar compounds 
such as polar amino acids and carbohydrates. Method 2 provided the best overall 
chromatographic separation across the entire suite of standards.  
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Methods 1 and 2 showed some similarity in analyte retention (Figure 2.03 B-D). 
Method 2 was selected as the Atlantis dC18 column was used to 
chromatographically resolve metabolites of the tyrosine pathway for the 
quantitative analysis of serum  (137) and urine (138) from AKU patients. This 
column also provides greater overall retention of polar metabolites over a regular 
C18 column due to endcapping of bi-functionally bonded C18 stationary phase 
material. Method 1 was included here to improve peak capacity owing to the 
greater number of theoretical plates provided by the smaller particle size of this 
column (2.1 µm) versus the column for method 2 (3.0 µm). Moreover, methods 1 
and 2 yielded 39 and 57 (Figure 2.05 A) AMRT matches respectively that were 
exclusive to each technique. Although it is demonstrated here that use of three 
separate chromatographic techniques improves coverage of the metabolome, 
this may not always be feasible. For large-scale studies, for example, it may be 
pragmatic to use two of the methods to reduce analytical and processing time. 
Detection of compounds of known relevance to AKU and/or its treatment with 
nitisinone spiked into urine at sub-micromolar concentrations shows that the LC-
QTOF-MS methods reported are highly sensitive even when applied to low-
abundance metabolites within complex biological matrices. Ion suppression is a 
major concern in MS, particularly using ESI (202), caused by the presence of 
other compounds that interfere with the ionisation of analytes of interest 
(126,203,204) and therefore particularly problematic for complex biological 
matrices such as biofluids which typically contain hundreds of different 
compounds at high concentrations, ranging from small, simple inorganic salts to 
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large proteins. Ion suppression can potentially occur in the solution phase or gas 
phase during the ESI ionisation process and studies on biological sample extracts 
suggests that a major cause is the presence of non-volatile or less volatile matrix 
compounds. The exact mechanism by which the matrix interferes with ionisation 
of a given analyte of interest is not fully understood, but could be attributable to 
decreased efficiency of either spray droplet formation or evaporation, thereby 
decreasing the amount of charged ion in the gas phase for a given compound 
and therefore final MS signal recorded by the detector (202). Various measures 
can be taken to address ion suppression, for example extensive sample clean-up 
(e.g. solid-phase extraction), signal correction using internal standards and 
modification of coupled chromatographic separations (126). The lower limits of 
detection reported here for analysis of AKU-relevant standards supports that ion 
suppression was not a major concern for the standards analysed using the 
chromatographic and mass spectrometric conditions applied. Moreover, the 
monitoring of signal for reference ions for methods 1-3 (see Figure 2.06) showed 
minimal ion suppression by the introduction of urine sample matrix. Reference ion 
signal is a useful indicator of ion suppression, as reference ions of a known mass 
were continually delivered to the ion source throughout the analytical run from a 
separate probe adjacent to the sample probe, and they therefore compete for 
ionisation with compounds originating from the sample. Figure 2.06 shows some 
limited evidence of ion suppression for urine compared to blank solvent matrix, 
as the reference ion signal decreased at times of high co-elution; i.e. around at or 
close to the initial void for each method, as a number of non-retained compounds 
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elute together and enter the mass spectrometer together (see Figure 2.03B-D; 
compounds eluting in initial void highlighted in red). The development of three 
complementary chromatographic techniques however, means that a particular 
compound of interest will most likely be retained, and therefore subject to more 
limited ion suppression, by at least one of methods 1-3. 
A major advantage of compound identification by an in-house LC-MS compound 
database compared to public databases (185,199,200,205,206) is that the data 
were acquired under identical analytical conditions. Data from public databases 
are typically acquired by different laboratories using different analytical 
parameters and techniques. Theoretical AM can be calculated for a given 
compound given the molecular formula, however compound data from public 
databases such as spectral data and particularly chromatographic RT are largely 
determined by the technologies and analytical parameters applied. The 
Metabolomics Standards Initiative has established levels of confidence for 
metabolite identification (94,107). Only identification strategies, such as the one 
reported here, that compare two or more orthogonal chemical properties (e.g. 
AMRT) with an authentic chemical standard under identical analytical conditions, 
achieve the highest level of identification confidence. Identifications by reference 
to public databases in which data were acquired under different analytical 
conditions can only achieve the second level of confidence, designated ‘putative 





In conclusion, an LC-QTOF-MS strategy was developed for enhanced coverage 
of the metabolome with targeted compound structure identification by reference 
to three AMRT databases, which have been made publicly available as a 
resource to the metabolomics community. The strategy and databases developed 
will support metabolic profiling experiments to address important questions 
relating to wider metabolism in AKU beyond the tyrosine pathway, and as a 
metabolic phenotyping strategy more generally. More specifically, this approach 
will help to streamline and simplify data processing and metabolite identification, 
which remain the major challenges in metabolomic analyses. 
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3.0  DEVELOPMENT OF A WORKFLOW FOR ANALYSIS OF LC-QTOF-





In metabolomics, as with other ‘omics approaches, the number of observations or 
chemical entities present in the data often greatly exceeds the number of samples 
analysed. The high-throughput nature of these experiments is integral to their 
appeal, but the resulting challenge of extracting meaningful information from the 
data is substantial (81,207).  
First, there is a considerable proportion of redundant data. This redundancy partly 
reflects background signals from compounds not native to the sample, for 
example contaminants introduced throughout the various stages of sample 
collection and preparation that do not convey biologically meaningful information. 
Data redundancy also refers to the high degree of correlated signals within the 
data (208); in raw, unprocessed LC-MS metabolomics data, signals present as 
m/z-RT pairs, and there are typically multiple signals representing the same 
metabolite, for example associated isotopes, adducts and multimers. 
Furthermore, where the aim of a metabolomics study is typically to discover a 
biomarker that can reliably discriminate between different groups of samples (e.g. 
cases versus controls in a classic clinical metabolomics study), there is a high 
likelihood of obtaining false-positives, or spurious associations between a given 
entity and a particular sample group (209). The high tendency for false positives 
is a reflection of the complexity of metabolomics datasets and may be attributable 
to a host of potential factors throughout the experimental workflow, including 
those related to experiment design, sample analysis or from data processing 
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artefacts introduced during feature extraction, for example false alignment of 
features across samples. 
These challenges and potential pitfalls highlight the need for robust and 
reproducible data processing strategies in metabolomics studies. This chapter 
details the data processing workflow employed in the following chapters of this 
thesis that discuss metabolomics data (i.e. Chapters 4 and 5). The workflow 
incorporates data quality assurance (QA), downstream data processing, QC and 
subsequent multivariate statistical analyses. The workflow primarily employs 
vendor software made available through a collaboration with Agilent 
Technologies (Cheadle, UK), as these computational tools were considered the 
most compatible with the raw data files generated by an Agilent LC-QTOF-MS. 
The design of the workflow was guided by the proposed minimum reporting 
standards for data analysis in metabolomics (106). Note that the data presented 
in this chapter are for illustrative purposes only. These data were acquired as part 
of a wider, at present unpublished, LC-QTOF-MS profiling experiment of mouse 
urine. Also, this chapter concerns only the review of metabolomics data post-
acquisition. The methods for design of sample analyses (i.e. the analytical 
sequence) are outlined in Chapter 4 (section 4.2.4), the first results chapter of 
metabolomics analysis. 
3.2 Data Quality Assurance (QA) 
The initial step in this workflow is to perform several QA checks on the raw LC-
MS data. QA was performed in MassHunter Qualitative Analysis (Agilent, build 
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07.00) before any subsequent feature extraction on the data. The purpose of this 
step is to ascertain that the raw data are of sufficient quality to enable valid 
conclusions following downstream data processing and statistical analyses. The 
following sections consider two attributes that are fundamental to data integrity in 
LC-MS and downstream feature extraction and alignment; chromatographic 
reproducibility and mass accuracy. 
3.2.1 Chromatographic reproducibility 
The first QA step was to show that the LC conditions remained consistent 
throughout the analytical run. In LC, the RT of a given compound is determined 
by pressure, flow rate, column stationary phase composition (material and particle 
size), mobile phase solvent composition, pH and column temperature. Modern 
HPLC systems are designed to strictly control these parameters in order to make 
the analytical conditions consistent for each sample. However, longer analytical 
runs, such as those spanning across several days, are particularly susceptible to 
loss of chromatographic reproducibility. This variation could be systematic, for 
example relating to gradual shifts in chromatographic conditions over time. 
Variation might also be due to a specific event, for example a sudden increase in 
pressure resulting from blockage of the analytical column, or changes in pressure 
due to a leak within the LC system. 
An important indicator of chromatographic reproducibility is the binary pump 
pressure curves. The Agilent 1290 Infinity II system employed in all subsequent 
metabolomics analyses described has two identical pumps for high-pressure 
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solvent mixing to create binary chromatographic gradients. The binary pump 
contains a system pressure sensor so that pump pressure can be measured 
during the analysis. Figure 3.01A shows the individual LC binary pump pressure 
curves for each sample overlaid across an analytical sequence comprising 104 
injections. This figure shows the characteristic changes in pressure across each 
sample acquisition as a result of changes in mobile phase composition during the 
elution gradient (see mobile phase composition and elution gradient details for 
Method 2, as described in Chapter 2, section 2.2.2). The overlaid pressure curves 
show the high reproducibility of the chromatographic conditions across the entire 
analytical sequence, which lasted approximately 33 h in total.  
In addition to the reproducibility of binary pump pressure curves, another QA 
procedure employed was to check the reproducibility of the total ion 
chromatograms (TICs). This was done for the replicate injections of pooled 
samples, which were interspersed throughout the analytical sequence for QC 
purposes, as described in Chapter 4 (section 4.2.4). Figure 3.01B shows a 
representative example of overlaid TICs for replicate injections of each pooled 
group sample, which are represented by different colours. The traces for each 
replicate overlay tightly for each pooled group, further evidencing the 





Figure 3.01. Example of chromatographic reproducibility QA procedures 
performed on data from LC-QTOF-MS analysis of mouse urine. These data 
were acquired using the chromatographic method (Method 2) described in 
Chapter 2 (section 2.2.2); a reversed-phase method with an elution gradient of 1-
12 minutes. A: overlaid binary pump pressure curves of 104 consecutive 
injections of mouse urine. Note that pressure curves overlay tightly. B: overlaid 
total ion chromatograms (TICs) from replicate injections of three different pooled 
urine quality control (QC) samples interspersed throughout the analytical run: 
pooled QC samples for sample groups 1 and 2, and an overall pool comprising 
all urine samples from the profiling experiment. Note the reproducibility of 
replicate injections across the analytical run for each of the three QC samples, 
and also gross differences evident between the pooled samples, for example the 
peak at 3.5 minutes, which is markedly increased in pooled group 2 and the 
overall pooled QC. Urine samples were diluted 1:10 urine:water and analysed 




A final check of chromatographic reproducibility was to monitor RT across the run 
for a signal from a specific compound. Figure 3.02 shows a representative 
example of this step based on extracting the signal for creatinine (a compound 
present in urine) from the first and last replicate injections of the overall pooled 
mouse urine sample from this dataset. Here, extracted ion chromatograms (EICs) 
were obtained for creatinine using the find by formula option in Masshunter 
Qualitative Analysis (build 07.00). Figure 3.02A shows the EICs overlaid with the 
TICs from which they were extracted, and 3.02B (inset) shows just the EICs of 
the first and last replicate injections overlaid. The EICs show no evidence of an 
RT shift for this chromatographic peak across the 33-h analysis period. A 
metabolite standard in blank solvent matrix was also injected as a ‘check-out’ 
sample at the start and end of each run (tyrosine and HGA in positive and 
negative polarity respectively). This enabled an additional assessment of mass 
accuracy and chromatographic resolution; the latter can be compromised as a 
result of column stationary phase ageing, typically resulting in broader 
chromatographic peak shapes. 
During this step, TICs from all of the individual samples in an experiment were 
also overlaid onto one chromatogram. This procedure was used to identify any 
clear outlier samples based on their TIC. This helped to identify, for example, low 
abundance TIC profiles due to potential sample preparation errors or issues with 




Figure 3.02. Representative data showing retention time (RT) reproducibility 
between the first and last replicate injections across the run.  A: overlaid total 
ion chromatograms (TICs) from the first (black) and last (red) injections of the 
same overall pooled urine quality control (QC) sample over an analytical run 
comprising 104 injections. B: overlaid extracted ion chromatograms (EICs) for 
creatinine for the first (black) and last (red) overall pooled QC injections as above. 
EICs show minimal RT shift across the run, indicating no need for RT shift 
corrective measures. 
 
3.2.2 Mass accuracy 
In high-resolution mass spectrometric techniques such as QTOF-MS, mass 
accuracy is typically maintained by calibrating mass values to those obtained from 
the analysis of various known ions. In this workflow, AM on the 6550 QTOF-MS 
(Agilent) is maintained by continually infusing a solution of known ‘reference’ ions 
via a separate isocratic pump, as described in Chapter 2 (section 2.2.2) and 
according to manufacturer guidelines. Two reference ions are monitored in 
positive polarity, and 3 in negative polarity; these are designed to cover a broad 
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range in mass. The auto-calibration algorithm in the MassHunter Acquisition 
software (Agilent) automatically calibrates all ion masses to the reference ion 
signals, provided that the reference ion signals remain within a specified mass 
window and above a specified abundance threshold. The auto-calibration 
parameters employed in all LC-QTOF-MS analyses in this thesis were as follows: 
mass window of 100 ppm and raw abundance threshold of 500 counts. These 
values were designed for analysis of complex matrices such as urine, in order to 
ensure that AM auto-calibration was maintained even in the event of reference 
ion signal drop-out due to ion suppression or at times when there may be 
momentary increased deviation between the measured and theoretical mass of 
reference ions. 
Reference ion abundance and mass accuracy across the analytical sequence 
was ascertained by performing EICs of reference masses for all injections within 
a specified mass window. As shown in Figure 3.03A, all of the reference ions for 
a given polarity should remain observable within the specified EIC mass window 
across the entire analytical sequence; the mass window employed here was 
theoretical AM ±5 ppm. There is some evidence of reference ion dropout at 
certain points during the elution gradient, particularly in the initial column void (at 
approx. 1 min). The attenuation of reference ion signal at this point is likely due 
to ion suppression attributable to the co-elution of many non-retained ion species 
at this RT. As shown in Figure 3.03B, the reduced reference signal EIC intensity 
at 1-1.5 min coincides with a sharp increase in the overlaid TIC signal.  As the 
example shown is a reversed-phase method, highly-polar species such as salts 
104 
 
present in urine are likely to elute in the initial void and thus suppress the 
ionisation of reference ions. However, the momentary drop-out observed is 
considered acceptable given the complex matrix; it is short-lived and none of the 





Figure 3.03. Example of mass accuracy quality assurance (QA) based on 
monitoring the signal for reference ions. A: overlaid extracted ion 
chromatograms (EICs) for reference ions in negative polarity for the sample 
injections described in Figure 3.01. Reference ion EICs are represented by blue 
traces - trifluoroacetic acid ammonium salt (TFA; m/z 112.985587); red traces - 
hexakis(1H, 1H, 3H-tetrafluoropropoxy)phosphazine (HP-0921; m/z 
966.000725); and pink traces - HP-0921 TFA adduct (m/z 1033.988109). Data 
show that accurate mass calibration based on reference ions was maintained 
throughout the entire analytical sequence (EICs were obtained with a window of 
<5 ppm of theoretical reference ion accurate mass). B: individual mouse urine 
total ion chromatogram (TIC; black trace) overlaid with EICs for the reference ions 
as above. Traces show some limited attenuation of reference ion signal, 





3.3 Data pre-processing 
Data pre-processing is a critical step in the LC-MS metabolomics data analysis 
pipeline. In this step, the most important, biologically meaningful features are 
extracted from the raw data for downstream statistical analyses. A typical pre-
processing workflow of an LC-MS metabolic profiling experiment comprises the 
following stages: noise filtering, peak detection, deisotoping, feature alignment 
and feature identification (210).  
In this workflow, the above actions are performed within the MassHunter Profinder 
software package (Agilent, build 08.00). In Profinder, these functions are 
incorporated into the various batch feature extraction workflow algorithms 
available, which are described in the following section. The exact Profinder 
feature extraction parameters employed in profiling studies included this thesis 
are detailed in the respective results chapters. 
Raw LC-MS data files contain a list of unique signals, or m/z and RT pairings, 
rather than distinct chemical entities or metabolites. In the raw data, metabolites 
are represented as a union of chemical signals that should be grouped together 
during feature extraction (208). A general overview of feature extraction in 
Profinder is illustrated in Figure 3.04. There are different feature extraction 
algorithm workflows available in the Profinder software, as discussed below. The 
general principle behind these approaches is, however, the same; i.e. to extract 
metabolite signals from the raw, unprocessed data and to output this information 




Figure 3.04. Overview of the feature extraction process in pre-processing of 
untargeted LC-QTOF-MS data. A: two-dimensional m/z – RT (retention time) 
scatter plot of signals in unprocessed raw data. The raw data file contains the 
total number of signals detected by the spectrometer, which includes signals 
arising from electronic background noise and ion signals from contaminants within 
the samples, reagents and laboratory environment, in addition to the signals of 
interest representing metabolites within the biological sample. B: m/z – RT scatter 
plot for the same data file following pre-processing and feature finding to retain 
the signals representing ‘true’ chemical signals within the data, which includes 
metabolites. C: overlaid extracted ion chromatograms plotting RT and signal 
intensity for the chemical entities extracted from the dataset. D: exported data 
matrix comprising abundance values for each extracted chemical entity across all 
samples in the experiment.  
 
3.3.1 Two complementary feature extraction approaches 
A unique characteristic of metabolomics in comparison to other ‘omics 
approaches, such as genomics, transcriptomics and proteomics, is the large 
number of unidentified chemical structures detected (207). This reflects both the 
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scope of sensitive, high-resolution profiling technologies such as LC-QTOF-MS 
and the scale of the metabolome; to date there has been no accepted exhaustive 
characterisation of the metabolome for any organism (74). 
For increased coverage of the metabolome and to ensure that maximal biological 
information was extracted from the data, two complementary feature extraction 
algorithms were employed. These extraction workflows are available in Profinder; 
referred to as ‘batch targeted feature extraction’ and ‘batch recursive feature 
extraction for small molecules / peptides’. The former algorithm was used to mine 
datasets against the AMRT databases described in Chapter 2. The advantage of 
this approach is that the extracted entities are putatively identified by two 
orthogonal chemical properties, AM and RT. Using this targeted approach, it is 
manageable to manually review the (typically) resulting several-hundred 
extracted entities in Profinder, enabling generation of a cleaned and well-curated 
dataset. As this targeted approach is limited to the IROA MSMLS compounds 
(Sigma Aldrich, UK), the second feature extraction algorithm stated above was 
employed to mine the data in using a complementary non-targeted approach. The 
non-targeted ‘recursive’ approach typically results in considerably more extracted 
chemical entities (usually 1000+ entities from urine) compared to AMRT-based 
targeted feature extraction. The algorithm workflow steps for batch targeted 
feature extraction and non-targeted batch recursive feature extraction are 
summarised in Figures 3.05 and 3.06, respectively, and described in more detail 
below. A more exhaustive explanation of the technical details in each step is 
beyond the scope of this thesis but available in the Profinder 8 software quick 
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start guide accessible via 
https://www.agilent.com/cs/library/usermanuals/public/G3835-
90027_Profinder_QuickStart.pdf (211) and in the Profinder help manual 
accessible through the Profinder (build 08.00) software. 
Batch targeted feature extraction employs an algorithm referred to by the vendor 
as find by formula. The find by formula algorithm uses the molecular formula 
information contained within a compound database (e.g. an AMRT database 
created using Agilent PCDL Manager; see Chapter 2, section 2.2.5) to calculate 
the expected ion masses and isotope distributions and then use these as the 
means of extracting features from the data. The targeted feature extraction 
workflow comprises 5 steps. In the first step, an input chemical formula source is 
specified; i.e. the relevant AMRT database in this work, with the ‘mass and RT 
matches only’ option specified. Also specified in this step are the ion species to 
consider, for example multimers (monomers to trimers) and expected adducts 
based on mobile phase modifiers (e.g. NH4+ and COOH-) and ions present in the 
sample matrix (e.g. Na+ ions in urine), in addition to charge state range. This step 
therefore ensures that multiple ion species associated with the same metabolite 
are grouped together in the data extraction. In the second step, matching 
tolerances and scoring thresholds are specified. These include the size of the 
windows for AM and RT matching against the database and several composite 
scores employed in the software relating to mass, RT and isotope distribution. In 
step 3 the preferred integration algorithm is specified, which refers to the method 
for integrating data points across a chromatographic peak; ‘agile 2’ is the 
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integration algorithm currently recommended by Agilent and is the default method 
in Profinder build 08.00. There is an option to smooth EICs during this step, for 
example using a Gaussian function. Peak abundance thresholds to be applied 
during integration are also specified during step 3, as is the chromatogram data 
format (i.e. profile or centroid). In step 4, several parameters are specified as to 
how the spectra are extracted within a chromatographic peak. For example, one 
single spectrum can be extracted from the apex of the peak only, or alternatively 
an average of all spectra can be extracted where the corresponding point on the 
chromatogram is above a specified percentage peak height threshold. In the 5th 
and final step of the targeted extraction workflow, several filter thresholds can be 
applied to determine whether a compound should be considered ‘found’ or 
otherwise discarded. These filters can be based on absolute or relative height, or 
a composite score based on the match score against the target chemical formula. 
Additionally, it is possible to specify that the aforementioned filters are met for a 
certain number or percentage of samples in the dataset; this can refer to all 






Figure 3.05. Overview of the batch targeted feature extraction algorithm 
workflow performed in MassHunter Profinder. In the metabolomics studies 
described in this thesis, batch targeted feature extraction was employed to extract 
signals from the data that matched the AMRT compound databases that were 
generated as described in Chapter 2. Figure adapted from (211). 
 
The batch recursive feature extraction workflow for small molecules / peptides 
includes 8 distinct steps comprising two separate algorithms; molecular feature 
extraction and find by ion extraction (Figure 3.06). The molecular feature 
extraction component is similar to the above workflow described for targeted 
feature extraction, but with the exception that extraction here is not based on 
specified chemical formula targets. Instead of matching against AMRT targets, 
the data is binned according to AM and RT in a non-targeted fashion and the 
extracted entities are aligned across samples according to specified tolerances 
(see step 3, ‘compound binning & alignment’ in Figure 3.06). The tolerances for 
AM are in mDa or ppm, and for RT in minutes or percentage of the expected RT. 
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The find by ion extraction component of the non-targeted recursive workflow is 
almost identical to the find by formula algorithm employed in batch targeted 
feature extraction, as described above, except that the formula sources here are 
not from a database but the results from the molecular feature extraction. The 
proposed advantage of this two-component recursive workflow is that in the 
second stage, the generated features are found in the sample data files in a 
targeted fashion with greater accuracy. The same post-processing filter options 




Figure 3.06. Overview of the batch recursive feature extraction for small 
molecules / peptides algorithm workflow performed in MassHunter 
Profinder. This algorithm workflow was employed for non-targeted feature 
extraction. The purpose of this was to extract signals that were not limited to 
compounds in the AMRT databases described in Chapter 2. The recursive 
extraction workflow comprises 8 steps. The first 4 steps are part of the untargeted 
mining for chemical entities, molecular feature extraction, and the following 4 
steps are part of the find by ion extraction which performs targeted re-mining of 
the data to validate the entities generated from molecular feature extraction. 
Figure adapted from (211). 
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3.3.2 Manual curation of extracted data 
The automated algorithm workflows described above make it possible to perform 
extraction on large metabolomics datasets. However, it is important to manually 
review the quality of the results from the extraction, and to correct any errors of 
integration accordingly. This form of manual curation was performed for the 
datasets generated from targeted AMRT-based extraction, as these datasets 
were prioritised, and the relatively fewer extracted chemical entities (typically 300-
500), compared with non-targeted extraction (typically >1000) made this task 
more manageable. 
Manual curation was performed in Profinder (build 08.00) by reviewing each found 
compound individually. As shown in Figure 3.07, for each compound a 
chromatogram and mass spectrum is displayed in Profinder. It is possible to 
manually integrate chromatographic peaks for individual samples, groups of 
samples specified in the experiment or all samples within a dataset by overlaying 
the extracted chromatograms. In this way, the extracted data were manually 
curated to correct or optimise the alignment across the samples. It is important to 
note that this was only performed when considered necessary so as not to 
inadvertently introduce bias to the data. Figure 3.07A shows a clear example in 
which manual re-integration was necessary for one sample. For the sample 
shown in the bottom row, it was evident that chromatographic peak was present 
that matched the RT in other samples, but that the algorithm had not correctly 
integrated the peak. Figure 3.07B shows the manually re-integrated data, in which 




Figure 3.07. Example of manual curation of extracted data. Figure shows the 
results of AMRT-based feature extraction for xanthine, obtained from human urine 
in positive polarity. A: extracted data before manual curation. It can be seen from 
the chromatogram results (left panel) for the sample shown in the bottom row that 
there was a peak present that aligned with the other samples, but this had not 
been correctly integrated by the algorithm. B: results following manual re-
integration, showing correct extraction of the aligned chromatographic peak (left 
panel) with extracted mass spectrum (right panel) for the sample shown in the 
bottom row.  
 
3.3.3 Export of extracted data  
The above data extraction approaches (section 3.1.1) were applied to each 
experiment dataset in separate Profinder experiments and also separately for 
positive and negative polarity. This resulted in 4 separate Profinder projects for 
each dataset comprising targeted and non-targeted extracted data for positive 
and negative polarity. Each Profinder project was exported as one ‘compound 
exchange format’ (CEF) file per sample, which is Agilent’s data format for 
115 
 
interchanging between different programs within the MassHunter software suite. 
This file format encodes a standard metabolomics data matrix, in which each 
column represents an individual sample, each row a different entity, and 
abundance values (peak area was employed in the subsequent results chapters) 
for each entity to populate the matrix (Figure 3.03D). The sample CEF files from 
each Profinder project were then imported into Mass Profiler Professional (MPP; 
build 14.5, Agilent), in which the workflow actions in the following sections were 
performed.  
3.4 Data pre-treatment 
Data pre-treatment is the process of transforming the extracted, cleaned data to 
prepare them for statistical analyses. The following workflow actions in this 
section were performed in MPP (build 14.5) as part of the data import wizard. 
3.4.1 Normalisation of urine data based on creatinine  
As Chapters 4 and 5 report metabolomic analyses of urine, it is important to 
consider the need to account for inter-sample differences in urine concentration. 
Urine is unlike biofluids such as plasma in which solute concentrations are tightly 
controlled in order to maintain internal homeostasis. Urine volume is greatly 
influenced by water consumption and other physiological factors, which in turn 
affects its constituent solute concentrations (212). A routine procedure in urine 
analyses is therefore to normalise the observed signals for each sample to 
creatinine concentration; creatinine is a natural waste product of creatine 
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phosphate in muscle, and is often used for normalisation because it is excreted 
in urine at a constant, steady rate.  
For the patient urine samples studied in this thesis, 24-h creatinine output values 
were available from the Jaffe creatinine assay on a Cobas 6000 Analyzer (Roche, 
UK). These raw values were simply entered for each sample data file imported 
into MPP as an external scalar at the data import stage.  
Mouse urine samples were taken on a single-collection basis, therefore it was not 
possible to obtain 24-h urinary creatinine output for mice. It was also not possible 
to sub-aliquot part of the mouse samples for Jaffe creatinine analysis due to 
sample volume constraints. Creatinine was therefore measured for each sample 
using the internal signal that matched with creatinine by AMRT from the 
metabolomics data (Figures 3.08A & 3.08B). As creatinine is one of the most 
abundant compounds in urine (213), it was not surprising to find that the signal 
from the 12C+H positive polarity ion was saturated, as indicated by an asterisk in 
Figure 3.08B. However, it can also be seen in Figure 3.08B that the 13C+H ion 
was not saturated, and this therefore represented a better candidate ion from 
which to measure the creatinine signal for mice.  
Measurement of creatinine by the 13C+H ion signal for mouse urine samples was 
performed in MassHunter Quantitative Analysis (build 06.00). The raw peak area 
values from this analysis were used as an external scalar for each sample in the 





Figure 3.08. Extracted ion chromatogram (A) and mass spectra (B) for 
creatinine, which was used as an internal scalar for mouse urine data to 
correct for urine dilution effects. The total peak area representing the 13C +H 
ion of creatinine (highlighted in blue) in positive polarity was used as an internal 
scalar for mouse urine as 24-h creatinine values were unavailable. The 12C ion 




Currently there is no consensus on the most suitable normalisation strategy for 
urine metabolomics data. In the method described here, creatinine abundance is 
used as a proxy for urine concentration, and all observed metabolite abundances 
are corrected against this. Other normalisation approaches to correct for variation 
in urine concentration in metabolomics data include those based on urine volume, 
osmolality and use of data from multiple metabolites or single metabolites other 
than creatinine (212). It is important to note that urinary creatinine excretion 
varies, and it is influenced by external stressors such as renal impairment (214). 
Normalisation based on creatinine was considered appropriate in the 
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metabolomics studies detailed in subsequent chapters as there is no evidence 
that urinary creatinine is altered in AKU, neither untreated nor as a consequence 
of nitisinone therapy. Furthermore, systematic differences in creatinine between 
the major patient and mouse experimental groups in each dataset (i.e. AKU 
versus non-AKU or baseline versus nitisinone time points) were checked prior to 
further metabolomic statistical analyses; all comparisons showed non-significant 
differences in 24-h creatinine output (patients) or the measured internal creatinine 
abundance (mice) at the level of p <0.05. This increased confidence that the data 
were not confounded by creatinine and that the normalisation strategy applied 
was appropriate. 
3.4.2 Data scaling and transformation  
Additional procedures performed on the data in this workflow were scaling and 
transformation. Scaling was performed by ‘baselining’ each metabolite to its 
median values across all samples in the experiment. This is referred to as level 
scaling, which changes the raw abundance values for each metabolite into 
percentages compared to the median value. The median value was chosen for 
this scaling as it is considered a more robust alternative to using the mean and 
focusing on relative response in this way has been previously recommended for 
identification of biomarkers in metabolomics data (215).  
In MPP, imported data are automatically log transformed. Log transformation is a 
non-linear conversion of data designed to deal with ‘skewness’ or 
heteroscedascicity that is typical in bioanalytical data such as measured 
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metabolomes. These terms refer to the property of metabolomics datasets that 
the degree of data variation between samples can vastly differ between different 
metabolites. This unequal variation can be both biological and technical. An 
example of this phenomenon is the well-documented observation that analytical 
profiles often show increased variation with increased metabolite intensity, which 
can lead to a bias towards discovery of statistically significant changes for these 
more-abundant entities (215,216). The log transformation employed in this 
workflow is therefore a strategy to reduce the bias towards significant differences 
for certain chemical entities by means of normalising their variability. 
Another possible data processing procedure in LC-MS metabolomics data is RT 
shift correction. This is designed to account for systematic variations in RT that 
can sometimes occur across the analytical sequence, for example a gradual drift 
in RTs over time. It was determined that RT correction was not necessary in this 
workflow. Figures 3.01 and 3.02 provide representative examples of the high 
chromatographic reproducibility obtained in the following studies even when 
sample analysis spanned several days. Furthermore, as shown in Chapter 2 
(section 2.3.4), the RT shift of metabolites identified in urine by AMRT by the 
methods employed in this workflow were minimal; no compound was filtered out 
due to RT CV <25% across an analytical sequence spanning >48 h. RT correction 
is perhaps more necessary when analyses using the same method are performed 
over several batches within the same experiment, but this was not the case for 
the metabolomics studies described in subsequent chapters. 
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3.5 Data QC filtering 
Data QC filtering was performed using two approaches, first on a per-sample 
basis and second on a per-entity basis. Here ‘entity’ refers to a distinct compound 
signal represented by a group of chemical features (e.g. an [M+H]+ or [M-H]- ion 
and its associated isotopes and adducts). Entities could be referred to as 
metabolites, but the term is used cautiously here as non-targeted data extraction 
could potentially detect low molecular-weight chemical species that do not 
originate from biological samples but which are introduced artificially during the 
sample preparation and analysis (i.e. chemical contaminants can ‘masquerade’ 
as metabolites). Data QC was performed in MPP (build 14.5). 
3.5.1 QC on a ‘per sample’ basis 
The primary aim of QC on a per sample basis was to identify clear outlier samples. 
Samples may become outliers for various biological or technical reasons. These 
could relate to the subject’s metabolism, drug or environmental exposure, or 
issues with the instrumentation (see identification of outlier samples by TIC; 
section 3.2.1). The data from such outliers were removed so as not to bias 
statistical analyses. 
PCA was used to identify sample outliers. PCA is a data reduction technique used 
to characterise the structure of complex, multivariate datasets. Clear sample 
outliers should be observable in a PCA plot, as these samples would be expected 
to make a major contribution to the total variance in the dataset, and therefore be 
separated from the other samples in one of the first principal components. Figure 
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3.09 shows an example of identifying an outlier sample by PCA. The outlier 
sample, indicated by an arrow in Figure 3.09A, is separated from the other sample 
group clusters in principal component 1. The sample also falls outside of the grey 
ellipse, which represents the Hotteling’s T2 95% confidence interval; Hotteling’s 
T2 is a measure of the variation within the PCA model. Figure 3.09B shows the 
same PCA repeated with the outlier sample removed; here all samples now fall 





Figure 3.09. Example of principal components analysis (PCA) on LC-QTOF-
MS profiling data for quality control (QC) purposes. A: PCA plot of negative 
polarity urine profiling data from AKU mice. These mice comprised two different 
background strains; BALB/c and C57BL/6J. The mice were bred from the same 
laboratory stocks, but 12/18 of the BALB/c mice were housed at Liverpool John 
Moores University (LJMU); the other mice were housed at the University of 
Liverpool (UoL). PCA showed clear separation both between BALB/c and 
C57BL/6J strains, and also between the BALB/c mice housed at UoL compared 
with LJMU. Note the tight clustering of replicate injections of pooled samples from 
BALB/c and C57BL/6J strains, which were interspersed throughout the run, 
showing reproducibility of the analysis. The pooled samples also cluster with the 
individual samples from the appropriate group, with overall pooled samples 
clustering between the groups. PCA identified one anomalous sample (indicated 
by black arrow).  B: a repeated PCA plot of the above data but with the anomalous 
sample removed.   
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3.4.2. QC on a ‘per-entity’ basis 
Pooled QC samples were created for each metabolomics experiment by 
combining equal aliquots of undiluted individual samples. This gave an overall 
pooled sample, which contained equal aliquots of all samples included in the 
experiment, and separate pooled group samples, which contained equal aliquots 
of samples within a given experiment group. Chapter 4, section 4.2.4 describes 
how QC samples were incorporated into the design of the analytical sequence. 
Per-entity QC was performed in order to filter out non-reproducible entities, which 
can also introduce bias to downstream statistical analyses. This filtering was 
based on the data from the replicate injections of pooled QC samples which were 
interspersed throughout each analytical sequence: i.e. the pooled samples for 
each experiment group, and the overall pooled sample. This was based on the 
assumption that the pooled samples were representative of each entire 
experiment dataset, containing all compounds present across the respective 
sample set. The signals for each entity detected should therefore, in principal, 
remain consistent across the replicate injections of these pooled QC samples 
throughout the analytical sequence.  
First, entities were filtered based on frequency in pooled QC samples. Entities 
were retained if they were observed in 100% of replicates from at least one pooled 
QC sample. This threshold enabled entities that might only have been observed 
in one pooled QC sample to remain, but only if they were observed consistently 
across the replicate injections of this sample. 
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Filtering was then performed based on signal variability across the pooled QC 
replicates. Entities were retained if their peak area CV was <25% across all 
replicate injections within each pooled QC sample. Figure 3.10 illustrates a 
representative example of how this QC step filtered for entities with reproducible 
profiles across replicate injections of pooled QC samples. As shown in the Figure 
3.10A, profiles of a number of chemical entities (represented by individual lines in 
the profile plot) showed fluctuations in abundance across the replicate injections 
of each pooled QC. Fluctuations in these entities could be attributable to technical 
variation potentially introduced at various stages throughout the data acquisition 
and processing workflow described above but could also relate to the chemical 
instability or degradation of these compounds over the analytical period. Figure 
3.10B shows the same profile plot after application of the aforementioned 
variability filter; here it is clear that non-reproducible entities across the replicates 






Figure 3.10. The effect of quality control (QC) on profile plots of chemical 
entities across pooled QC samples. A: profile plot for negative polarity entities 
from replicate injections of pooled urine samples from BALB/c and C57BL/6J AKU 
mice interspersed throughout the analytical run pre- data QC. B: profile plot for 
the same data as in (A) following entity QC filtering based on (i) entities detected 
in 100% of replicate injections for at least one pooled sample group and (ii) entities 
with CV <25% across all replicate injections of each pooled sample. The profiles 
in (B) indicate removal of (189/365) less-reproducible entities across replicate 
injections. 
 
3.6 Statistical analyses: identification of differentially abundant entities 
As discussed in Chapter 1, multivariate statistical analyses are required to 
interpret the complex datasets such as those obtained from metabolomics 
experiments. This section describes the multivariate statistical techniques 
employed to investigate potential differences between sample groups in the 




3.6.1. Principal component analysis (PCA) 
PCA was employed to review the overall structure of each dataset and to identify 
any potential separation between different sample groups based on the first 
principal components, using 4-component models. This approach effectively 
reduced the data in each experiment to 4 orthogonal components (i.e. each 
sample was plotted in 4-dimensional space corresponding to these 4 principal 
components) that explained the most variation in the dataset. Figure 3.11A shows 
an example of how plotting each sample according to its position/value in the first 
2 principal components can identify clear differences between the overall 
metabolome profiles between different sample groups. In this example, BALB/c 
mice bred from the same laboratory stocks were separated in principal 
components 1 and 2 according to whether they were housed at the University of 
Liverpool (UoL) or Liverpool John Moores (LJMU) laboratories. This difference 
was attributed to slightly differences in diet and/or water supplied by the two 
laboratories. 
Review of the corresponding PCA loadings plot was performed in order to identify 
the entities that were contributing most to any separation observed between 
sample groups. Figure 3.11B shows an example of identifying important entities 
that contributed to PCA sample separation observed in Figure 3.11A. In Figure 
3.11B, these are the labelled entities that have the most extreme loading scores 




Figure 3.11. Example principal components analysis (PCA) as an approach 
to identify differentially abundant chemical entities. A: PCA plot showing 
separation between the urine metabolomes of BALB/c AKU mice housed at the 
University of Liverpool (UoL) and Liverpool John Moores University (LJMU) (in 
principal components 1 and 2, represented by x and y axes respectively). B: 
loadings plot showing the contribution of chemical entities to variation in PCs 1 
(x-axis) and 2 (y-axis). The labelled entities had the greatest loadings on PC 1 
and 2, indicating that these made the greatest contribution to the overall 
difference between mice from the two sites. 
3.6.2 Statistical significance analysis 
PCA was used as an approach to visualise and explore potential clear separation 
between the overall metabolome profiles of different sample groups. Statistical 
significance testing was performed in order to more extensively investigate 
potential group differences. The specific tests employed for each comparison are 
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described in the subsequent results chapters (Chapters 4 and 5). In order to 
mitigate the risk of false-positive results associated with multiple testing, 
Benjamini-Hochberg false-discovery rate (FDR) p-value adjustment was 
employed in all significance tests.  
Fold change (FC) was also calculated as an additional way to assess the 
magnitude of change for a given entity between groups. Figure 3.12 shows an 
example of how volcano plots were employed as a way of incorporating the p-
value and FC to visualise the differentially abundant entities between groups. This 
example also shows how entities that do not necessarily contribute towards clear 
separation between the sample groups in PCA (Figure 3.11) can be identified as 
differentially abundant by p-value and FC (i.e. α-ketoglutarate, 3-hyroxybenzoate 






Figure 3.12. Example volcano plot as an approach to identify differentially 
abundant chemical entities. Entities with p <0.05 (y-axis) and fold change >5 
(x-axis) in peak area between urine from BALB/c AKU mice housed at the 
University of Liverpool (UoL) compared with Liverpool John Moores University 




3.6.3 Data validation 
As previously noted (section 3.1), there is an inherent risk for ‘type 1’ false-
positive statistical errors in complex datasets such as those acquired in 
metabolomics. While the data processing workflow described this far was 
designed to minimise the FDR, the data from entities identified as important from 
statistical testing were subjected to further validation to rule out artefacts. 
For targeted AMRT-extracted datasets, the profiles across sample groups were 
assessed visually in MPP by box plots (as shown in Figure 3.12) to confirm the 
group difference. For these entities, the extracted, untreated profiles were also 
checked visually in Profinder across the sample groups as additional validation. 
For datasets from non-targeted feature extraction, an additional orthogonal data 
extraction approach was employed by using MassHunter Quantitative analysis 
(Agilent, build 06.00). This additional validation was performed because these 
datasets were not manually curated in Profinder, unlike the datasets from targeted 
AMRT feature extraction. A list of the differentially abundant entities was exported 
from MPP using the export for recursion option; this exported the measured AM 
and RT of the entity as a CEF file. The CEF file generated was then imported as 
a quantitative method in the Quantitative analysis software and used to re-mine 
the raw, unprocessed data files for these signals. The raw peak areas extracted 
using this method were then imported to GraphPad Prism (version 6.01; Graphad 
Software Inc., USA), where the data distribution between the sample groups were 
reviewed visually by dot plots. Only entities that still showed clear visual trends 
131 
 
(i.e. peak area difference) between the groups using this method were considered 
as validated. 
3.7 Chemical structure identification of entities from non-targeted 
feature extraction 
Putative chemical structure identifications were sought for validated differentially 
abundant entities from non-targeted feature extraction. This was performed using 
MassHunter ID Browser (Agilent, build 07.00), using the chemical formula 
sources from the MassHunter METLIN metabolites PCD/PCDL accurate mass 
database (Agilent, build 07.00). This version of the METLIN library contains 
formula and AM entries for >32,000 metabolites. The list of differential entities 
created in MPP was exported directly into ID Browser. The AM matching 
parameters employed in each experiment are described in subsequent chapters. 
The output of this procedure contains each exported entity, with potential METLIN 
metabolite matches based on the parameters and tolerances specified. The 
matches are ranked by a composite score, based on the degree of closeness 
between the expected versus observed mass and isotope distribution from the 
database formula.  
The METLIN database employed comprises a broad range of metabolites of both 
endogenous and exogenous origin. As the identification method described was 
based on formula-matching alone, it is necessary to review the matches. It is often 
challenging to assign a single chemical structure to a given entity using this 
approach due to the high number of isomers in comprehensive metabolite 
databases (compounds with the same chemical formula) and isobaric species 
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that have a different chemical formula but the same AM. Here, it was considered 
pragmatic to putatively assign the most likely candidate based on an informed 
judgement of AKU metabolism and the compounds that were likely to be observed 
or altered in this context of urine profiling. For example, the matches obtained for 
exogenous metabolites of a specific drug or environmental exposure that was 
either not possible for the laboratory mice, or highly unlikely for the patients, were 
rejected. For other matches however, it was often more difficult to distinguish 
between multiple hits with similar match scores. While this approach of matching 
based on formula alone is informative, it is acknowledged that the compound 
identifications from non-targeted data extraction are putative and require further 
validation, ideally by MS/MS data and/or analysis of chemical standards (if 
available). The number of alternative compound matches for putatively identified 
entities from non-targeted feature extraction are also specified in subsequent 
chapters. 
3.8 Workflow summary and conclusions 
The chemometric workflow described provides a method to extract biologically 
meaningful information from the large, complex datasets generated in LC-QTOF-
MS metabolomic analyses. Figure 3.13 provides a schematic overview of the 
workflow. The workflow is designed to identify differentially abundant chemical 
entities, or biomarkers in the following metabolomic analyses in AKU. Emphasis 
was placed on a) maximisation of the information extracted from the raw data, 
and b) limiting false discovery.  
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Feature extraction is primarily performed using the AMRT-based strategy 
described in Chapter 2, but with complementary non-targeted extraction 
performed in parallel to broaden the extraction beyond the compounds in the 
AMRT databases generated. The workflow incorporates a series of QA and QC 
measures to limit the FDR, which involve identification of outlier samples and 
filtering for reproducible entities based on pooled QC samples. The post-statistical 
validation of differentially abundant metabolites was performed by review of both 
the processed and unprocessed extracted data. For data from non-targeted 
extraction, additional confirmation was performed by re-mining the raw data using 
orthogonal data extraction (note additional flow arrow back to the raw data in 
Figure 3.13). These confirmatory procedures limit the potential for false discovery 





Figure 3.13. Overview of the LC-QTOF-MS chemometric workflow 
developed. The figure summarises the computational steps taken, starting from 
raw, unprocessed data and ending with the extrapolation of biologically-relevant 
information from the data based on the identification of differentially abundant 
entities/metabolites. The workflow comprises parallel targeted (AMRT-based) 
and non-targeted feature extraction on each dataset in order to extract maximal 
information from the dataset. The software programs used in each stage are listed 
on the left-hand side of the figure. 
 
Metabolomics is a burgeoning field, which is reflected by the ever-increasing 
development of new computational tools for data analysis. The need for 
harmonisation in computational approaches employed across the discipline has 
been highlighted in an international survey of the metabolomics community in 
2017 (100). A related but equally important consideration is the most suitable type 
of QC sample to use in metabolomics experiments. The present workflow uses 
pooled QC samples, which play a major part of the QA and QC filtering 
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procedures described here. QC filtering of entities based on pooled samples is 
particularly important in the data from non-targeted feature extraction here, as this 
type of processing typically resulted in several thousand extracted entities that 
were therefore beyond the scope of cleaning or curating manually. According to 
a 2017 survey of the metabolomics community conducted by the Metabolomics 
Society Data Quality Task Group (102), the majority of researchers in this area 
employ pooled project material for QC; 83% of the respondents. This approach 
was more popular than standard reference materials for QC, which were applied 
by 48% of respondents. There was variation between researchers in the way that 
pooled samples were used for QC however; 76% of respondents used QC 
samples for assessing chromatography column integrity, 69% applied replicate 
injections of QC samples and 15% analysed a single pooled sample. Importantly, 
the survey highlighted that 70% of respondents did not have access to a protocol 
for review of metabolomics data quality. This statistic underlines the importance 
of detailing clear QA and QC procedures to be employed in data processing, as 
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Published work resulting from content included in this chapter (see Supporting 
Material): 
 
Norman BP, Davison AS, Ross GA, Milan AM, Hughes AT, Sutherland H, Jarvis 
JC, Roberts NB, Gallagher JA, Ranganath LR. A comprehensive LC-QTOF-MS 
metabolic phenotyping strategy: Application to alkaptonuria. Clin Chem. 
2019;65(4):530–9. 
 
The above works report the data from metabolic profiling of urine from patients 
and mice before and after nitisinone treatment by employment of the analytical 
strategy reported in Chapter 2. BPN contributed to the laboratory analyses 
performed for sample analysis and was the main contributor to the writing of the 





Nitisinone is not currently licensed for AKU but has been used to treat patients 
attending the NAC in Liverpool, since 2012. Nitisinone works by inhibiting the 
activity of the enzyme HPPD (E.C. 1.13.11.27) responsible for the formation of 
HGA. It has been shown to reduce circulating and urinary HGA concentrations 
(11,12,14,18,217) and to completely arrest ochronosis in an HGD -/- murine model 
of AKU (50,69) and more recently in AKU patients (140). 
In HT-1, in which nitisinone is a licensed treatment, and AKU, one of the major 
upstream metabolic consequences of nitisinone is that the concentration of 
circulating tyrosine increases significantly  (11,12,14,46,217–220). The fate of the 
increased tyrosine is unknown. Tyrosine is the precursor for catecholamines, 
thyroid hormones and melanin, suggesting that increased tyrosine substrate, as 
in tyrosinaemia, could lead to dysregulation of these pathways. Concerns exist 
because in HT-1 it is believed that hyper-tyrosinaemia may contribute to 
neurodevelopmental delay (46,221–224); it is estimated that up to 35% of children 
treated with nitisinone have learning disabilities (46). Other undesirable side 
effects of nitisinone which metabolic phenotyping has potential to shed let on are 
ocular keratopathy and skin rash. These have been reported in a small minority 
of individual cases in the AKU literature (144), though such patients were not 
involved in this study as nitisinone treatment is withdrawn in these patients. 
Nevertheless it would be of clinical benefit to establish predictive markers to 
identify patients with susceptibility to these symptoms, whose treatment regimen 
is likely to require adjustment accordingly. 
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This chapter explores the impact of nitisinone on the urine metabolomes of mice 
and patients with AKU. Human AKU urine was from patients attending the NAC 
taken at baseline (when patients had not been administered nitisinone before) 
then after 3, 12 and 24 months on nitisinone. Mouse urine was from HGD-/- 
BALB/c mice taken at baseline then at 1 week on nitisinone (Figure 4.01). These 
treatment durations therefore represent an acute and chronic exposure to 
nitisinone in mice and humans, respectively. 
 
 
Figure 4.01. Summary of the overall study design comprising patients and 
mice with AKU. Urine was taken before and after commencement of nitisinone 
therapy to evaluate the consequences on the metabolome by LC-QTOF-MS 





All chemicals were as described for LC-QTOF-MS analysis in Chapter 2 (section 
2.2.2). 
4.2.2.  Urine collection  
24-h urine was obtained from 25 AKU patients attending the NAC (12 male, 13 
female; mean age ±SD 51 ±15 years). Samples were collected before nitisinone, 
then at 3 (2mg every other day), 12 and 24 (2mg daily) months on nitisinone and 
stored at -80°C until analysis. Samples were diluted 1:3 urine:deionised water 
and stored at -80°C as three separate aliquots for analysis by methods 1-3 (see 
Chapter 2, section 2.2.2). Metabolomics analysis was part of the diagnostic 
service to NAC patients with approval from the Royal Liverpool and Broadgreen 
University Hospitals Trust Audit Committee (audit no. ACO3836).  
Mouse urine was collected from 18 (9 male, 9 female; mean age ±SD 27 ±12 
weeks) HGD-/- BALB/c mice (50), bred from laboratory stocks at the University of 
Liverpool. Samples were obtained on a single-collection basis before treatment 
then after 1 week on nitisinone, administered in all drinking water (4 mg/L), 
supplied ad libitum. Mouse urine was collected onto cling film, pipetted into 
sample tubes and stored at -80°C. Analysis was performed on thawed samples, 
following dilution of 1:9 urine:deionised water (greater dilution than patient urine 
due to sample volume constraints). Mouse breeding and dosing was authorised 
under the Animals (Scientific Procedures) Act, UK. 
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Human and mouse urine samples were pooled separately for QA purposes. For 
each sampling time point, a representative sample was created by pooling 20 µL 
of each individual urine sample. An additional overall pool was created separately 
for human and mouse urine experiments by pooling equal proportions of the 
pooled urine groups detailed above. Pooled human and mouse samples were 
stored and treated as above prior to analysis. 
4.2.3.  LC-QTOF-MS analytical conditions 
Non-targeted LC-QTOF-MS analysis was performed on human and mouse urine 
samples separately using the strategy detailed in Chapter 2. Human urine was 
analysed by LC methods 1-3. Mouse urine was analysed by LC method 2 only 
due to limited sample volumes. The mass spectrometer was operated in non-
targeted MS mode (m/z range 50-1700; see Chapter 2 for detailed parameters).  
4.2.4. Design of metabolic profiling experiments 
Human and mouse urine were analysed separately. Human samples were 
analysed in three separate batches for methods 1-3. Mouse samples were 
analysed in one batch. Each batch comprised analysis in negative polarity 
followed by positive polarity. 
The analytical sequence of each profiling batch was designed according to 
published guidance (225). Each run commenced with 20 replicate injections of 
the overall pooled sample to condition the system. The order of individual samples 
was randomised computationally. Pooled samples were interspersed throughout 
the analytical sequence; every 10th injection. Injections of each sample group 
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pool and the overall pooled sample were also placed at the start (post-
conditioning) and end of each analytical sequence to assess reproducibility of the 
analysis for data QA (Figure 4.02). 
 
Figure 4.02. Illustration depicting the analytical sequence design for each 
LC-QTOF-MS profiling batch. The first 20 injections were of the overall pooled 
sample for system equilibration. Post-equilibration, each run commenced and 
ended with pooled samples from each sampling time point. Pooled samples were 
randomly interspersed throughout the sequence at regular intervals for QC 
purposes. The sequence of individual patient samples from each time point was 
randomised computationally across each analytical batch.  
 
4.2.5.  LC-QTOF-MS data processing 
Raw data were mined using two parallel strategies as outlined in Chapter 3 
(Figure 3.14).  Targeted feature extraction was employed to search for 
compounds from the AMRT databases generated from the IROA MS metabolite 
library of standards, as outlined in Chapter 2. Non-targeted feature extraction was 
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employed to search for compounds not included in the AMRT databases or of 
known association to nitisinone/AKU metabolism. 
4.2.5.1 Targeted data mining based on AMRT databases 
Data were mined for AMRT database compounds using targeted feature 
extraction in Profinder (build 08.00). Feature extraction parameters were the 
same as described for urine in Chapter 2 (section 2.2.3.) AM (±10 ppm) and 
database RT (±0.3 min) matches were required.  
Data were also mined by targeted feature extraction for the following compounds 
that were not from the IROA metabolite library AMRT databases, but of particular 
interest for their predicted role in AKU/nitisinone metabolism. These compounds 
were associated with a) increased tyrosine: 3-(4-hydroxyphenyl)pyruvic acid, 
acetyl-L-tyrosine, γ-glutamyl-L-tyrosine (226) and tyramine-sulfate; b) ochronotic 
pigment: dihydroxybenzaldehyde (see Chapter 6, section 6.3.2), hipposudoric 
acid and norhipposudoric acid (42); or c) nitisinone metabolism: hydroxy-
nitisinone, nitisinone and 2-nitro-4-trifluoromethylbenzoic acid (NTFA) (226). For 
non-AMRT compounds, the same RT (RT range <0.3 min) was required across 
samples. These compounds were identified based on theoretical AM ±10 ppm 
only, except for 3-(4-hydroxyphenyl)pyruvic acid and acetyl-L-tyrosine, which 
were analysed as standards and appended to the AMRT database for AMRT-
based feature extraction as described above.  
Allowed ion species for positive ionisation mode were: H+ and Na+, with the 
addition of NH4+ for methods 1 and 2 (mobile phases contained ammonium 
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formate); and for negative ionisation mode H- with the addition of CHO2- for 
methods 1 and 2. Monomers and dimers were allowed for both ionisation 
polarities. Charge state range was 1-2. 
4.2.5.2. Non-targeted data mining 
Non-targeted data mining was performed using recursive feature extraction in 
Profinder (build 08.00). Chemical entities were aligned across samples with mass 
and RT windows of 50 ppm and 0.3 min respectively (see Supporting Materials, 
Appendix 2 for details). Allowed ion species were as above. Entities were retained 
if observed in at least 2 samples per group (i.e. sampling time point) for human 
urine, or at least 50% of samples per group for mouse urine (n.b. stricter 
parameters for mice as diet and environment were controlled). 
4.2.6. NAC patient demographics and clinical data 
Data were collected from the patients involved in this study on a number of 
demographic and clinical parameters, which included gender, age, PET imaging 
data, HGD gene mutation data and scores from self-reported back pain and 
Beck’s Depression Inventory II (BDI-II). 
18F-NaF PET scanning was performed to assess spinal degenerative changes 
associated with ochronosis (data previously reported by Taylor (227)). With this 
technique, the injected 18F-NaF tracer is taken up into hydroxyapatite crystal, 
enabling quantification and assessment of the spatial distribution of calcified 
tissue in the spine, including the vertebrae and fibrocartilaginous intervertebral 
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disks. 18F-NaF uptake is greater in newly formed bone and therefore reflects the 
amount of actively mineralising bone, or the rate of bone metabolism more 
generally or blood supply. Increased uptake to bone has been observed in early 
stage OA, in which it is attributed to the accelerated bone remodeling associated 
with OA pathophysiology (228). Although 18F-NaF PET is typically used for 
studying bone as opposed to soft cartilaginous tissue, a previous study of this 
patient cohort found that 18F-NaF uptake to the lumbar and thoracic intervertebral 
disks was markedly increased in patients with AKU compared with controls. 
Increased 18F-NaF uptake in AKU was thought to reflect mineralisation, 
deposition of calcium hydroxyapatite or calcium pyrophosphate, of intervertebral 
disks as a consequence of cartilage degeneration associated with ochronosis. In 
contrast, 18F-NaF uptake to the bony vertebrae, a measure of bone turnover, was 
comparable between patients with AKU and controls, showing a generalised 
decline with age in both groups (227). Here, the imaging data studied were mean 
18F-NaF uptake values across the intervertebral disks and vertebrae of the lumbar 
and thoracic spine, as assigned to these patients by Taylor (227). 18F-NaF PET 
data were available for a sub-set of patients from the following visits to the NAC: 
baseline (n=15), 12 months on nitisinone (n=14) and 24 months on nitisinone 
(n=17).  
Data on back pain were available for a subset of 16 patients at baseline only; data 
previously described by Taylor (227). Back pain was self-reported across lumbar 
and thoracic regions separately, on a scale ranging from 0 (no pain) to 10 (severe 
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pain). The mean scores across lumbar and thoracic regions for each patient were 
used for the purpose of the present analyses. 
The BDI-II (229,230) is a 21-item, self-completed questionnaire designed to 
assess depression. Each item has four statements ranked in order of severity of 
depression (0-3). The questionnaire evaluates a range of moods and emotions 
linked with depression, including: pessimism, sense of failure, self-dissatisfaction, 
guilt, punishment, self-dislike, self-accusation, suicidal ideas, crying, irritability, 
social withdrawal, insomnia and loss of appetite. Total scores are divided into the 
following cut-offs to provide an overall measure of depression: 0-13 for minimal 
depression, 14-19 for mild depression, 20-28 for moderate depression and 29-63 
for severe depression. 
Data on HGD mutations were from sequencing of the HGD gene (231). 
Sequencing data were available for all patients included in this metabolomic 
analysis (n=25).  
4.2.7.  Data QC, statistical analyses and association with patient demographics 
and clinical data 
Additional QC filters were applied to the data, as detailed in Chapter 3 (section 
3.4). QC and statistical analysis were performed in MPP (build 14.5). First, urine 
creatinine values were used to scale metabolite abundances for each sample in 
order to account for urine dilution effects. 24-h creatinine excretions were used 
as an external scalar for human urine (average values across each sampling time 
point used for pooled samples). For mouse urine, the LC-QTOF-MS signal 
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identified as creatinine by matched AMRT was used as an internal scalar for each 
sample using the peak area of the 13C [M+H]+ ion (see Chapter 3, section 3.4.1). 
In short, QC was performed on a per-sample and per-entity basis. Per-sample 
QC identified anomalous samples using PCA. Per-entity QC was based on the 
data from pooled samples. Non-reproducible entities across replicate injections 
of the same pooled sample across each analytical run were removed from the 
data.  
Imputation was not used, as datasets from targeted extraction were carefully 
curated prior to statistical analyses in order to avoid missing data which could 
result from analytical or data processing errors, such as incorrect feature 
alignment across samples. Furthermore, filtering of entities in all data was 
performed based on QC samples (targeted and non-targeted feature extraction 
datasets), and additional post-validation of statistically significant entities 
(Chapter 3, section 3.6.3) helped to minimise the potential for spurious findings 
attributable to missing data. 
Statistical analyses were performed in MPP based on peak area. Human urine 
profiles were compared at 3, 12 and 24 months on nitisinone with baseline by 
one-way repeated-measures ANOVA. Mouse urine profiles were compared at 
baseline vs 1 week on nitisinone by paired t-test. Benjamini-Hochberg FDR 
adjustment was used in all statistical significance testing. FCs were calculated 
based on raw peak area. PCAs employing four-component models were also 
performed on each filtered dataset.  
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For statistically significant entities for each comparison in the data from non-
targeted feature extraction, additional confirmatory quality checks were 
performed in MassHunter Quantitative Analysis (Agilent, build 09.00), as 
described in Chapter 3 (section 3.6.3). The results from this additional data 
extraction were assessed visually by dot plots in order to compare the distribution 
of peak areas across individual samples in order to validate or reject the results 
from statistical analyses performed in MPP. This procedure was performed for 
the data from non-targeted extraction due to the increased number of entities 
post-QC and therefore the increased risk of false-positives. 
4.3 Results 
Data in the following sections are divided into those from targeted and non-
targeted feature extraction. In assessing the effect of nitisinone treatment on the 
urine metabolome, for targeted feature extraction data from the three 
complementary LC techniques were considered, as this was the primary focus of 
the study. For non-targeted extraction, data from LC method 2 (see Chapter 2, 
section 2.2.2) were considered only, as this method provided the greatest overall 
coverage of the metabolome, as shown in Chapter 2. 
For studying associations with patient demographics and clinical data, the 
metabolomic data were from LC method 2 only. This was considered the most 
pragmatic approach, as it was previously shown that method 2 provided the 
greatest overall coverage of the metabolome (see Chapter 2, section 2.3.4), and 
data were acquired from both human and mouse samples using this method. 
148 
 
The total number of compound identifications (from targeted feature extraction) 
and unidentified chemical entities (from non-targeted feature extraction) obtained 
across each dataset are summarised in Table 4.01 for human data and Table 
4.02 for mouse data. Data from one patient were excluded from each of the 
datasets from methods 1 and 2 in positive polarity following the identification of at 





Table 4.01. Summary of the number of chemical entities obtained and retained across human urine datasets and 
at each subsequent step of quality control (QC) filtering across human urine datasets. 
* Note: CV <25% filter was applied across all replicate injections in 4/5 pooled QC sample groups only (all entities removed with the 
filter applied to 5/5 QC sample groups as used for the other datasets) 
  
Targeted feature extraction 
 
Non-targeted extraction 
  Method 1  Method 3  Method 2 
Filtering step  (+) (-)  (+) (-)  (+) (-)  (+) (-) 










Present in 100% of replicate 
injections of at least one 









CV <25% across all replicate 
injections of each pooled 









P <0.05 (FDR-adjusted) and 
FC >2: baseline vs 3, 12 or 24 
months on nitisinone 
(targeted), or baseline vs all 












Table 4.02. Number of entities obtained and retained before and after each 
subsequent step of quality control (QC) filtering across mouse urine 
datasets.  
 
4.3.1. Effect of nitisinone treatment 
4.3.1.1. Targeted feature extraction  
PCA on the human data from targeted feature extraction showed clear separation 
between the samples taken at baseline compared with the time points on 
nitisinone Figure 4.03). This separation was in PCA component 2 (y-axis), which 
explained 12.14% and 14.68% of the total variation in the dataset in negative and 
positive polarity respectively. The PCA loadings plots in Figure 4.03 (lower 
section) show that a clear group of metabolites contribute to this separation, as 
they have the most extreme loadings on component 2 (comprising positive and 
  Mouse: baseline vs 1 week on nitisinone 
 
Targeted Non-targeted 
Filtering step (+) (-) (+) (-) 
Manual curation of entities only 399 374 2040 2671 
Present in 100% of replicate 
injections of at least one pooled 
group sample 
363 364 1278 2326 
CV <25% across all replicate 
injections of each pooled group 
sample  
192 185 208 341 
P <0.05 (FDR-adjusted) and FC 
>1.5: baseline vs 1 week on 
nitisinone 
27 21 26 49 
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negative values) and therefore change with nitisinone treatment. The metabolites 
with the greatest loadings on component 2 in negative polarity (left plot) were 
homovanillic acid (HVA), D-(+)-galactosamine, 4-coumarate, phenylacetic acid, 
3-(4-hydroxyphenyl)lactic acid (HPLA) and 4-hydroxybenzaldehyde.  In positive 
polarity (right plot), HGA, xanthosine, 3,5-cyclic AMP, L-kynurenine, L-tryptophan, 
4-hydroxyphenylacetic acid, tyramine, HPLA and 4-hydroxybenzaldehyde had 
the greatest loadings on component 2.  
PCA on the mouse data also showed clear separation of samples taken before 
and after nitisinone in component 2 (Figure 4.04). Loadings plots (lower) show 
that the metabolites with the greatest loadings on component 2 were HPLA and 
phenylacetic acid in negative polarity (left plot), as for the human data. In positive 
polarity, HPLA and 4-hydroxyphenylacetic acid were among the group of 
metabolites with the greatest loading on component 2, as for the human data. 
However, the positive polarity mouse data (right plot) showed the addition of 
metabolites identified as 2-hydroxy-4-(methylthiobutyric acid), N-acetyl-L-






Figure 4.03. PCA to assess the effect of nitisinone treatment on profiles 
from AKU human urine (targeted feature extraction). PCA plots (upper) in 
negative (left) and positive polarity (right) both showing clear separation in 
component 2 between profiles from urine samples taken at baseline compared to 
those taken at 3, 12 and 24 months on nitisinone. Loadings plots (lower) show 







Figure 4.04. PCA to assess the effect of nitisinone treatment in profiling data 
from AKU mouse urine (targeted feature extraction). PCA plots (upper) in 
negative (left) and positive polarity (right), both showing clear separation in 
component 2 between profiles from urine samples taken at baseline compared to 
those taken at 1 week on nitisinone. Loadings plots (lower) show the respective 
contributions of individual metabolites to components 1 and 2.  
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Paired one-way repeated measures ANOVA was performed on each dataset to 
investigate differentially abundant entities between baseline and the time points 
on nitisinone. An FC >2 was chosen in order to limit false-discovery and to focus 
on clear changes. The metabolites that showed statistically significant changes 
(p <0.05, FC >2) in abundance after 3, 12 or 24 months on nitisinone in humans 
or 1 week on nitisinone in mice are summarised in Figures 4.05 and 4.06 for 
AMRT-based feature extraction (n=36) and AM-only feature extraction (n=3), 
respectively. In patients with AKU, 16 metabolites increased and 15 decreased. 
In HGD-/- mice, 15 metabolites increased and 7 decreased. Fourteen metabolites 
changed in the same direction in humans and mice. Importantly, the well-
documented changes to urinary HGA, HPLA (both decreased) and tyrosine 
(increased) on nitisinone treatment were observed, which adds validity to the 
analytical technique and the data processing workflow. Data from targeted feature 
extraction also showed alteration (p <0.05, FC >2) to metabolites with a predicted 
association to AKU/nitisinone metabolism that were not from AMRT databases 
(Figure 4.06). 2,5-dihydroxybenzaldehyde, probably associated with ochronotic 
pigment, was decreased on nitisinone. The tyrosine metabolite γ-glutamyl-L-
tyrosine and the nitisinone metabolite hydroxy-nitisinone were increased. These 
changes were observed in human and mouse urine. Interestingly, D-(+)-
galactosamine was one of the major contributors to the separation observed in 
PCA, but it did not show statistical significance and visual inspection of its profile 
across the samples (in MPP) did not show consistent differences between 
baseline and on-nitisinone time points. 
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Together, the majority of metabolite changes observed could be categorised into 
three main metabolic pathways: those of tyrosine, tryptophan and purine. 
Increases and decreases are observed on nitisinone in metabolites from each of 
these pathways, but with notable trends of a greater number of increases in 





Figure 4.05. Summary of urinary metabolite changes in patients and/or mice with AKU following treatment with 
nitisinone, identified by AMRT-based targeted feature extraction. Red and blue indicate increases and decreases 
respectively. Fold changes (FCs) are indicated in brackets and were calculated from raw peak area. These compounds are 
from the Sigma IROA mass spectrometry metabolite library of standards, except 3-(4-hydroxyphenyl)pyruvic acid and 






Figure 4.06. Summary of urinary metabolite changes in patients and mice 
with AKU following treatment with nitisinone, identified by targeted feature 
extraction (accurate mass only). Red and blue indicate increases and 
decreases respectively. Fold changes (FCs) are indicated in brackets and were 
calculated from raw peak area. 
 
4.3.1.2. Non-targeted feature extraction 
Non-targeted feature extraction was performed in parallel to targeted feature 
extraction, only in the raw data acquired using LC method 2. The aim of this 
approach was to investigate the potential for metabolites/entities to be altered that 
were not included in the AMRT databases generated, or not previously predicted 
to have an association with the changes to tyrosine metabolism as a 
consequence of nitisinone.  
For the human data, in total 122 and 1594 entities were retained post-QC from 
non-targeted feature extraction in negative and positive polarity respectively. The 
decision was taken to relax the entity filtering parameters for method 2 in negative 
polarity for non-targeted feature extraction (see Table 4.01). This was because 
160 
 
no entities remained after filtering based on CV <25% across all replicate 
injections in each (5/5) pooled group QC sample. One-hundred and twenty-two 
entities remained in the negative polarity dataset after relaxing this filter to CV 
<25% in 4/5 of the pooled group samples; these entities were retained for 
subsequent statistical analyses. Figure 4.07 displays the profiles of the remaining 
entities in the negative polarity non-targeted feature extraction dataset across the 
pooled sample injection replicates following this relaxation of the CV-based 
filtering parameter. The 6th (of 7) replicate injection of the pooled baseline sample 
appears to be the single outlier, showing altered profiles for a subset of 
metabolites compared with the other replicates. This finding therefore provided 
confidence that the loss of technical reproducibility was limited to this individual 
injection in the analytical sequence run, as the same PCA-based sample outlier 






Figure 4.07. Profile plot of remaining chemical entities from non-targeted 
feature extraction on negative polarity human urine data following 
relaxation of filtering based on CV across replicate injections of pooled 
group samples. Filtering was relaxed to retain entities with CV <25% across all 
replicate injections in 4/5 pooled group QC samples (as no entities remained with 
a threshold of 5/5 as applied to other datasets). The 6th replicate injection of the 
baseline pooled sample (highlighted in pink) appears to be discrepant from the 
other replicates in this group. The clear reproducibility in profiles across the other 
replicates for each group shows that the compromised technical variation is 




Figure 4.08 shows the results from PCA on the human data from non-targeted 
feature extraction. In negative polarity, clear separation was observed between 
the baseline samples and those from the on-nitisinone time points in principal 
component 2, as with the targeted feature extraction data. Interestingly, a major 
separation of samples into two distinct groups is also evident in principal 
component 1. This separation was observed across all sampling time points and 
is discussed further in section 4.3.2.3. The corresponding loadings plot (Figure 
4.08, lower section) shows the unidentified chemical entities contributing to the 
separation of samples into baseline vs on-nitisinone time points; those with 
extreme loadings on principal component 2. In contrast, PCA on the data from 
positive polarity did not show clear separation in principal components 1-4 
between samples taken at baseline and on nitisinone. 
PCA on the non-targeted mouse data showed clear separation between samples 
at baseline and those after 1 week on nitisinone in positive and negative polarity. 






Figure 4.08. PCA to assess the effect of nitisinone treatment in profiling data 
from AKU human urine (non-targeted feature extraction). PCA plots (upper) 
in negative (left) and positive polarity (right). In negative polarity, clear separation 
was observed between profiles from urine samples taken at baseline compared 
to those taken at 3, 12 and 24 months on nitisinone, as with targeted feature 
extraction. In positive polarity, separation in components 1 and 2 between 
samples at baseline and the on-nitisinone time points was less clear. Loadings 
plots (lower) show the respective contributions of individual unidentified 






Figure 4.09. PCA to assess the effect of nitisinone treatment in profiling data 
from AKU mouse urine (non-targeted feature extraction). PCA plots (upper) 
in negative (left) and positive polarity (right), both showing clear separation 
between profiles from urine samples taken at baseline compared to those taken 
at 1 week on nitisinone. Separation was in component 1 and 2 for positive and 
negative polarities respectively. Loadings plots (lower) show the respective 
contributions of individual unidentified metabolites to components 1 and 2.
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Statistical significance testing was performed on data from non-targeted feature 
extraction as described above for targeted extraction. In the human data, attention 
was focused on metabolites that showed altered abundance at all three time 
points on nitisinone compared with baseline (p <0.05, FC >2). On nitisinone, 42 
entities showed altered abundance (29 increased, 13 decreased) in patients, and 
65 entities (48 increased, 17 decreased) in mice, both including positive and 
negative polarity. The altered entities spanned a relatively broad range in RT and 
were biased towards the lower mass range (upper limit of acquisition m/z range 
was 1700): in the patient data mass range was 115-433 Da, RT range was 1.7-
7.1 min; in the mouse data mass range was 56-514 Da, RT range was 1.4-10.4 
min.  
MassHunter ID Browser (Agilent, build 07.00) was employed for compound 
identification of these unknown entities of interest. The lists of entities were 
exported from MPP and into ID Browser. First, unknown entities that matched the 
AMRT databases generated in-house were identified (AM ±10 ppm, RT ±0.3 min), 
as these changes had already been noted previously (section 4.3.1.1.). 
Metabolites identified by this approach and therefore not of further interest given 
the aims of this complementary non-targeted analysis were: 4-
hydroxybenzaldehye, HGA, a known MS/MS fragment of HGA (same RT as HGA, 
mass = 138.0325, putative formula C7H6O3; see Chapter 6, section 6.3.2) and 
HPLA for patients, and phenylacetic acid for mice. Changes in these AMRT-
matched entities on nitisinone were in the same direction as noted above. 
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For the remaining unknown entities that did not match metabolites in the AMRT 
databases generated in-house, candidate compound identifications were 
generated by AM match (±5 ppm) against the MassHunter METLIN metabolites 
PCD/PCDL accurate mass database (Agilent, build 07.00) and also using ID 
Browser (Agilent, build 07.00). Tables 4.03 and 4.04 summarise the altered 
chemical entities from non-targeted extraction that yielded putative compound 
identifications in human and mouse data respectively. These putative 
identifications (putative as by AM only (107)) were either the only compound 
match obtained or were considered the most likely of a list of potential candidates 
based on predicted association with the metabolite changes observed from 
targeted feature extraction. The number of other candidate mass matches 
obtained for these entities is indicated in Tables 4.03 and 4.04. The most notable 
changes for these putatively identified metabolites were on nitisinone increases 
in phenylpyruvic acid, dihydroxyphenylpyruvic acid, salicylic acid β-D-glucoside 
(all FC >100), 3-hydroxymandelic acid (or 3,4-dihydroxymandelaldehyde 
[DHMA]; both catecholamine metabolites, FC = 16) for patients, and also elevated 
4-hydroy-L-glutamic acid (FC = 16) and decreased kynuramine (FC = 6.2) for 
mice. 
Tables S4.01 and S4.02 (Supporting materials, Appendix 3) summarise the 
altered chemical entities on nitisinone, listed by observed mass and RT, for which 





Table 4.03. Summary of putatively identified chemical entities with differential abundance in urine taken from 
patients with AKU at baseline vs on-nitisinone, from non-targeted feature extraction. Peak areas for these entities 
showed statistically significant differences (Benjamini-Hochberg false-discovery rate p <0.05, fold change >2) between 
baseline and each sampling time point (3, 12 and 24 months) on nitisinone. Putative compound identifications were assigned 
by reference to the MassHunter METLIN metabolites PCD/PCDL accurate mass database (build 07.00, Agilent), with a 
match criteria of accurate mass (±5 ppm, unless indicated otherwise by asterisks) only. Where multiple matches were 
obtained for the same entity, the compound ID shown here was considered the most likely based on a) filtering for 
endogenous metabolites and b) compounds more likely to be associated with wider tyrosine metabolism or with the 
metabolites shown to be altered from targeted AMRT-based feature extraction. Fold changes are for baseline vs 24 months 
on nitisinone time points. 
* compound putatively identified by accurate mass match ± 10 ppm (and ‘number of compound matches’ also with a mass window of 
±10 ppm) 
















Dihydroxyphenylpyruvic acid C9H8O5 196.038 1.7 2 (-) ↑ 100+ <0.0001 
Salicylic acid β-D-glucoside* C13H16O8 346.091 3.9 4 (-) ↑ 100+ <0.001 
Phenylpyruvic acid C9H8O3 164.047 4.7 10 (-) ↑ 100+ <0.0001 
3-Hydroxymandelic acid /  
3,4-Dihydroxymandelaldehyde 
C8H8O4 168.042 2.5 19 (-) ↑ 16 <0.0001 
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Homoveratric acid C10H12O4 196.074 6.1 20 (+) ↑ 6.9 <0.0001 
Hydroxydopamine* C8H11NO3 169.075 5.3 5 (+) ↑ 6.8 <0.0001 
N-Acetylvanilalanine C12H15NO5 253.096 5.3 2 (+) ↑ 6.1 <0.0001 
- C10H9NO3 191.058 4.88 4 (+) ↑ 5.5 <0.0001 
3-Methyleneoxindole C9H7NO 145.053 7 7 (+) ↑ 5.1 <0.0001 
Aspartyl-phenylalanine C13H16N2O5 280.107 3.9 4 (+) ↑ 5.1 <0.0001 
- C10H18N2O5 246.123 4.18 10 (+) ↑ 3.4 <0.001 
Vanillactic acid* C10H12O5 212.07 5.2 7 (+) ↑ 3.2 <0.001 
- C11H8O3 188.047 6.6 6 (+) ↑ 2.7 <0.001 
- C10H9NO3 191.059 3.4 4 (+) ↓ 5.2 <0.0001 
L-Cis-
cyclo(aspartylphenylalanyl) 
C13H14N2O4 262.095 6 1 (+) ↓ 5 <0.01 
4-Hydroxyindole* C8H7NO 133.053 4.1 6 (+) ↓ 3.1 <0.001 







Table 4.04. Summary of putatively identified chemical entities with differential abundance in urine taken from AKU 
mice at baseline vs 1 week on nitisinone, from non-targeted feature extraction. Putative compound identifications 
were assigned with reference to the MassHunter METLIN metabolites PCD/PCDL accurate mass database (build 07.00, 
Agilent), with a match criteria of accurate mass (±5 ppm, unless indicated otherwise by asterisks) only. Where multiple 
matches were obtained for the same entity, the compound ID shown here was considered the most likely based on a) 
filtering for endogenous metabolites and b) compounds more likely to be associated with wider tyrosine metabolism or with 
the metabolites shown to be altered from targeted AMRT-based feature extraction. P-values are adjusted by Benjamini-
Hochberg false-discovery rate. 
* compound putatively identified by accurate mass match ±10 ppm (and ‘number of compound matches’ also with a mass window of 
±10 ppm) 
















4-Hydroxy-L-glutamic acid C5H9NO5 163.0476 3.5 6 (-) ↑ 16 <0.0001 
5-Methoxyindoleacetate* C11H11NO3 205.0748 6.6 5 (+) ↑ 7.9 <0.0001 
5-Methoxytryptophol C11H13NO2 237.1096 7.2 4 (-) ↑ 2.7 <0.0001 
2-Hydroxyphenylacetic acid O-b-D-
glucoside 
C14H18O8 157.0535 4 6 (-) ↑ 2.5 <0.0001 





C7H12N2O4 188.081 2 2 (+) ↑ 2.4 <0.001 
Valyl-hydroxyproline /  
Hydroxyprolyl-valine 
C10H18N2O4 230.1279 4.6 2 (+) ↑ 2.4 <0.01 
γ-glutamyl-γ-aminobutyraldehyde / 
prolyl-threonine* 
C9H16N2O4 216.1119 3.6 4 (+) ↑ 2.2 <0.001 
Vanilloglycine C10H11NO5 225.0887 4.7 3 (-) ↑ 2.1 <0.001 
Kynuramine C9H12N2O 210.0999 3.4 5 (-) ↓ 6.2 <0.0001 
N-gamma-acetyldiaminobutyrate C6H12N2O3 160.0841 3.2 6 (-) ↓ 4 <0.0001 
Isovalerylglutamic acid C10H17NO5 231.111 3.1 5 (-) ↓ 3 <0.001 
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4.3.2. Associations with clinical data and patient demographics 
The clinical and patient demographic data parameters available were: gender, 
age, 18F-NaF PET imaging, back pain, BDI-II score and HGD gene sequencing. 
These parameters were investigated in the metabolic profiling data acquired using 
method 2 only. Data from these parameters were imported into each 
metabolomics dataset in MPP (build 14.5); separate projects for targeted and 
non-targeted feature extraction and for positive and negative polarity. Separate 
‘interpretations’, or grouping of sample data files, were created in MPP for each 
individual parameter to assess its relationship with the metabolomic data in each 
MPP project. As with studying the effect of nitisinone treatment, potential 
associations between metabolic profiles and clinical data / patient demographics 
were also studied in the data from non-targeted feature extraction in order to 
widen the scope of the analyses to compounds that were not included in the 
AMRT databases that had been generated (see Chapter 2). First, each 
clinical/demographic parameter was investigated at baseline only, by PCA, in 
order to investigate its effect in untreated AKU. For each parameter, if PCA 
revealed separation of metabolome profiles at baseline, the same parameter was 
additionally investigated in the data from the final 24 months on nitisinone time 
point in order to check whether the same separation remained after therapy for 





Data from patients with AKU were from 12 males and 13 females, and the 
mouse data were from 9 males and 9 females.  
 
Targeted feature extraction 
 
PCA on the data from targeted feature extraction showed no clear separation 
between male and female patients with AKU (Figure 4.10). Unpaired t-tests 
identified no entities with differentially abundant profiles between male and female 
patients at baseline (at the level of p <0.05) in positive or negative polarity.  
 
 
Figure 4.10. PCA to assess the effect of gender in profiling data from AKU 
human urine taken at baseline (targeted feature extraction). PCA plots in 
negative (left) and positive polarity (right) show limited separation of profiles by 





The apparent lack of a significant effect of gender in the human data contrasted 
with the mouse data. In the mouse data, striking separation was observed 
between males and females both at baseline and after 1 week on nitisinone; 
separation in principal component 1 in positive and negative polarity (Figure 4.11). 
The separation of mouse profiles into baseline versus on-nitisinone time points 
(in principal component 2; as described in section 4.3.1.) was secondary to the 
separation observed by gender. In positive polarity, histamine was the primary 
driver of this separation, with the greatest loading on principal component 1 
(0.42). Urinary histamine was markedly elevated in female mice (p <0.0001, 
FC=16). In the negative polarity data, the PCA separation by gender was driven 
by a larger group of compounds: 4-quinolinecarboxylic acid (p <0.0001, FC=3.15), 
4-hydroxyphenylacetate (p <0.0001, FC=4.27), riboflavin (p<0.0001, FC=18.49), 
5-valerolactone (p <0.0001, FC=16), erythritol (p <0.0001, FC=8.78), anthranilate 
(p <0.0001, FC=9.33) (all elevated in females), benzaldehyde (p <0.0001, 
FC=22.89), and thymine (p <0.001, FC=2.35) (both elevated in males) had the 
greatest loadings on principal component 1 and showed the most clear 
differences between male & female mice. The p-values and FCs indicated above 
are for male vs female mice at baseline. None of these metabolite changes were 






Figure 4.11. PCA to assess the effect of gender in profiling data from AKU 
mouse urine, taken at baseline then after 1 week on nitisinone (targeted 
feature extraction). Unlike the human data, PCA plots from mouse data show 
clear separation between male and female mice in negative (left plot) and positive 
(right plot) polarity. Gender appears to contribute to the greatest overall difference 
in the dataset, with separation between males and females in component 1. 
Separation by samples taken at baseline vs on nitisinone was in component 2 
and therefore secondary to the primary effect of gender.  
 
Non-targeted feature extraction 
Non-targeted feature extraction on the data from patients also showed no clear 
separation between males and females at baseline in principal components 1-4 






Figure 4.12. PCA to assess the effect of gender in profiling data from AKU 
human urine taken at baseline (non-targeted feature extraction). PCA plots 
in negative (left) and positive polarity (right) show limited separation of profiles by 
gender in components 1 and 2, as with the data from targeted feature extraction. 
 
4.3.2.2. Age 
To study the effect of age on metabolic profiles, patients were separated into the 
following age groups (age in years): 11-20 (n=2), 21-30 (n=5), 31-40 (n=4), 41-
50 (n=6), 51-60 (n=8), 61-70 (n=7), 71-80 (n=1). The effect of age was not 
investigated in the mouse data; mice of the same approximate age were chosen 
specifically as part of a tightly controlled experiment with the primary aim to 




Targeted feature extraction 
PCA on the data from targeted feature extraction showed limited separation 
between the different age groups at baseline (Figure 4.13). The data from 
negative polarity (left plot, Figure 4.13) showed some evidence of separation by 
age in component 1, with a tentative trend for positive scores for the profiles of 
younger patients on the x-axis (representing principal component 1). To identify 
potential differentially abundant metabolites between younger and older patients, 
the baseline time point data were separated into two larger age groups; <30 and 
>40 years. Unpaired t-tests were performed to compare the profiles between 
these groups but revealed no statistically significant (p <0.05) entities based on 




Figure 4.13. PCA to assess the effect of age in profiling data from AKU 
human urine taken at baseline (targeted feature extraction). PCA plots in 
negative (left) and positive polarity (right) showing limited separation of profiles 
by age in components 1 and 2. 
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Non-targeted feature extraction 
PCA on the data from non-targeted feature extraction also did not reveal clear 
separation at baseline between the profiles of patients from the different age 
groups (Figure 4.14). Similarly, unpaired t-tests revealed no statistically 





Figure 4.14. PCA to assess the effect of age in profiling data from AKU 
human urine taken at baseline (non-targeted feature extraction). PCA plots 
in negative (left) and positive polarity (right) show no clear separation of profiles 
by age in components 1 or 2, as with the data from targeted feature extraction. 
 
4.3.2.3. 18F-NaF PET imaging data 
The data from 18F-NaF PET imaging comprised two measures; 18F-NaF uptake 
to lumbar/thoracic intervertebral disks and 18F-NaF uptake to lumbar/thoracic 
vertebrae. For each of these measures, patients were divided into those with 
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‘high’ (values >10) versus ‘low’ (values <10) uptake. Increased 18F-NaF uptake to 
the vertebrae and intervertebral disks is associated with OA pathology, 
representing accelerated bone turnover and cartilage degeneration (i.e. soft 
tissue mineralisation), respectively (see section 4.2.6). For cartilaginous tissue, 
although there is no agreed exact 18F-NaF uptake threshold that defines benign 
or malignant lesions (227,232), one study established that values of 6.4 and 
above predicted hip OA incidence and progression (228). The cutoff applied here 
was increased to uptake value of 10 as this threshold explained the clear 
separation that was observed between patients in PCA (Figures 4.15 and 4.16).  
The patients in this cohort assigned to the ‘>10’ group for 18F-NaF uptake to 
intervertebral disks were therefore considered likely to show the most severe 
spinal OA. 
For patients for whom PET data were available, at baseline 6/15 and 4/15 were 
in the high uptake group for intervertebral disks and vertebrae respectively. At 24 
months on nitisinone, 9/17 and 4/17 patients were in the high uptake group for 
intervertebral disks and vertebrae respectively. Unpaired t-tests were performed 
to compare the abundance of entities from high versus low uptake patients for 
both measures at baseline and at 24 months on nitisinone. 
 
Targeted feature extraction 
 
PCA on data from targeted feature extraction showed evidence of separation 
between the metabolomic profiles of patients with high versus low 18F-NaF uptake 
to intervertebral disks. PCA separation between these patients was clearer in 
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negative polarity; partial separation observed in principal component 1 (Figure 
4.15). In positive polarity, separation was observed between these groups of 
patients in principal component 2, although limited. Across the targeted feature 
extraction data, 2-deoxyguanosine / adenosine (entity matched both compounds 
due to identical mass and RT in the AMRT database generated) was the only 
compound that showed a statistically significant difference in abundance 
(p=0.013, FC=3.5) between patients with high versus low intervertebral disk 18F-





Figure 4.15. PCA to assess the effect of 18F-NaF uptake scores to 
intervertebral disks in profiling data from AKU human urine taken at 
baseline (targeted feature extraction). PCA plots in negative (left) and positive 
polarity (right) show limited separation of profiles from patients with high (score 





A degree of PCA separation was also observed between the profiles of patients 
with high versus low 18F-NaF uptake to the vertebrae (Figure 4.16). As with the 
grouping by uptake to intervertebral disks, separation between the vertebral 18F-
NaF uptake groups was clearer in negative polarity (separation in principal 
component 1). Compounds with differential abundance between patients with 
high versus low vertebral 18F-NaF uptake were L-proline, malonate and mono-
methyl glutarate (both decreased in the high uptake group; p <0.0001, FC=16) 
from targeted feature extraction (Table 4.06). Interestingly, the decrease in L-
proline was observed both at baseline and 24 months on nitisinone. The 
decreases in malonate and mono-methyl glutarate were observed only at 






Figure 4.16. PCA to assess the effect of 18F-NaF uptake scores to 
lumbar/thoracic vertebrae in profiling data from AKU human urine taken at 
baseline (targeted feature extraction). PCA plots show some separation 
between profiles from patients with high (score >10) vs low (score <10) 18F-NaF 
uptake scores in negative polarity, but less clear separation between profiles in 
positive polarity.   
 
Non-targeted feature extraction 
PCA on data from non-targeted feature extraction showed clearer separation 
between the metabolomic profiles of patients with high versus low 18F-NaF uptake 
to the intervertebral disks in positive and negative polarity (Figure 4.17). In these 
data, 18F-NaF uptake appears to be the primary driver of the total variation 
observed in the dataset; separation in principal component 1. Given this degree 
of separation in the baseline data, the effect of 18F-NaF uptake was additionally 
visualised in the PCA on data from all time points. As shown in Figure 4.18, 
addition of all time points further reveals the marked separation of the profiles 
from patients with high versus low 18F-NaF uptake to the intervertebral disks. 
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Intervertebral 18F-NaF uptake appears to explain the bimodal distribution of 
profiles across all time points, which is orthogonal to the separation observed 
between baseline and nitisinone time points. Fourteen entities from non-targeted 
feature extraction showed statistically significant abundance differences (p <0.05, 
FC >2) between intervertebral 18F-NaF uptake groups at baseline and/or 24 
months on nitisinone (in high uptake group: 8 increased, 6 decreased). Putative 
AM identifications were obtained for 4/14 of these entities (Table 4.05). The 
remaining 10 differential entities are reported as unknowns in Table S4.03 
(Supporting Materials, Appendix 4). Of the putatively identified entities, the most 
notable was a metabolite of the painkiller drug acetaminophen (paracetamol), 
which was increased in the high 18F-NaF uptake group both at baseline and 24 
months on nitisinone in positive and negative polarity (p <0.0001, FC=40). Other 
metabolites showing marked differences were cyclodopa glucoside (increased in 
the high uptake group at baseline; p <0.0001, FC >100), and caffeic acid (3- or 4) 




Figure 4.17. PCA to assess the effect of 18F-NaF uptake scores to 
intervertebral disks in profiling data from AKU human urine taken at 
baseline (non-targeted feature extraction). PCA plots (upper) in negative (left) 
and positive polarity (right) show separation in component 1 between the urine 
profiles of patients with high (score >10) vs low (score <10) 18F-NaF uptake 
scores. Loadings plots (lower) show that a cluster of unidentified entities are 
contributing to this separation in component 1 in both polarities (extreme negative 







Figure 4.18. PCA to assess the effect of 18F-NaF uptake scores to 
intervertebral disks in profiling data from AKU human urine (non-targeted 
feature extraction), with all time points on nitisinone added. Plots show the 
same separation between the urine profiles of patients with high (score >10) vs 
low (score <10) 18F-NaF uptake scores both at baseline and on nitisinone 
treatment. In negative polarity, 18F-NaF uptake appears to account for the major 
bimodal distribution in the dataset, captured by principal component 1. In the non-
targeted data in positive polarity, although no clear separation was observed 
between profiles at baseline and on nitisinone, profiles are clearly separated into 
high and low 18F-NaF uptake groups in component 2. 
 
 
PCA on non-targeted data showed some evidence of separation between 
patients with high versus low 18F-NaF uptake to the vertebrae in positive polarity 
(partial separation in principal component 1; Figure 4.19). Across positive and 
negative polarity, 9 entities from non-targeted feature extraction showed 
statistically significant differences in abundance (p <0.05, FC >2) between 
patients with high versus low 18F-NaF uptake at baseline and/or 24 months on 
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nitisinone (in high uptake group: 3 entities increased, 6 entities decreased). 
Putative AM-based compound identifications were obtained for 7 of these entities 
(see Table 4.06); the other 2 entities are reported as unknowns (see Table S4.04, 
Appendix 4). The most notable of these putatively identified compounds were 
iduronic acid (increased in high uptake group), adrenochrome, L-tyrosine methyl 
ester 4-sulfate, diferulic acid, buchananine and clitidine (decreased in high uptake 




Figure 4.19. PCA to assess the effect of 18F-NaF uptake scores to 
lumbar/thoracic vertebrae in profiling data from AKU human urine taken at 
baseline (non-targeted feature extraction). PCA plots indicate separation 
between profiles from patients with high (score >10) vs low (score <10) 18F-NaF 




Table 4.05. Summary of putatively identified urinary chemical entities with differential abundance between patients 
with high (score >10) vs low (score <10) 18F-NaF uptake to intervertebral disks. Compound matches were by AMRT 
against the metabolite database generated in-house, unless indicated otherwise. Putative compound identifications for 
entities from non-targeted feature extraction were assigned by reference to the MassHunter METLIN metabolites 
PCD/PCDL accurate mass database (build 07.00, Agilent), with a match criteria of accurate mass (±5 ppm) only. In the data 
from non-targeted feature extraction, where multiple matches were obtained for the same entity the compound ID shown 
here was considered the most likely based on filtering for endogenous metabolites and known medications taken by patients 
attending the UK National Alkaptonuria Centre. P-values are adjusted by Benjamini-Hochberg false-discovery rate. 
* Entity putatively identified by accurate mass only (±5 ppm) 
† Entity with statistically significant difference between patients with high vs low uptake score at baseline 
‡ Entity with statistically significant difference between patients with high vs low uptake score at 24 months on nitisinone 
 












Cyclodopa glucoside *† C15H19NO9 618.1348 4.2 7 (-) ↑ >100 0.026 
Acetaminophen *†‡ C8H9NO2 151.0633 3.6 10 (+/-) ↑ 40.1 <0.0001 
Caffeic acid 3-sulfate /  
Caffeic acid 4-sulfate *† 
C9H8O7 259.9984 5.2 1 (-) ↓ 16 <0.0001 
2-Deoxyguanosine / 
Adenosine ‡ 
C5H9NO3S 163.0311 3.4 2 (+) ↓ 3.5 0.013 
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Table 4.06. Summary of putatively identified urinary chemical entities with differential abundance between patients 
with high (score >10) vs low (score <10) 18F-NaF uptake to lumbar/thoracic vertebrae. Compound matches were by 
AMRT against the metabolite database generated in-house, unless indicated otherwise. Putative compound identifications 
for entities from non-targeted feature extraction were assigned by reference to the MassHunter METLIN metabolites 
PCD/PCDL accurate mass database (build 07.00, Agilent), with a match criteria of accurate mass (±5 ppm) only. In the data 
from non-targeted feature extraction, where multiple matches were obtained for the same entity the compound ID shown 
here was considered the most likely based on filtering for endogenous metabolites and known medications taken by patients 
attending the UK National Alkaptonuria Centre. P-values are adjusted by Benjamini-Hochberg false-discovery rate. 
* Entity putatively identified by accurate mass only (±5 ppm) 
† Entity with statistically significant difference between patients with high vs low uptake score at baseline 




















Iduronic acid *‡ C6H10O7 194.0419 1.3 20 (-) ↑ 16 <0.0001 
Octanoic acid *‡ C14H24O8 320.1463 9.3 12 (-) ↑ 2.3 <0.0001 
L-proline †‡ C5H9NO2 115.0632 1.4 1 (-) ↓ 16 <0.0001 
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Malonate † C3H4O4 104.0109 1.6 1 (-) ↓ 16 <0.0001 
Mono-methyl 
glutarate ‡ 
C9H8O7 146.0575 5.3 1 (-) ↓ 16 <0.0001 
Adrenochrome *‡ C9H9NO3 225.0624 4.8 10 (-) ↓ 16 <0.0001 
L-tyrosine methyl 
ester 4-sulfate *‡ 
C10H13NO6S 275.0461 4.5 1 (-) ↓ 16 <0.0001 
Diferulic acid *† C20H18O8 386.0987 4.6 8 (+) ↓ 16 <0.0001 
Buchananine *‡ C12H15NO7 285.0846 1.3 1 (+) ↓ 16 <0.0001 
Clitidine *† C11H14N2O6 270.0828 3.7 1 (+) ↓ 3.8 <0.0001 
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4.3.2.4. Back pain 
Back pain data were mean values for pain across lumbar and thoracic spinal 
regions, self-reported on a scale from 0 (no pain) to 10 (severe pain). Back pain 
data were only available at baseline. For the purposes of the following statistical 
analyses, patients were divided into two groups for ‘high’ (score >5; n=6) and ‘low’ 
(score <5; n=10) pain. 
 
Targeted feature extraction 
PCA on data from targeted feature extraction showed no clear separation 
between patients with high versus low back pain (Figure 4.20). Unpaired t-test did 
not find any entities from targeted AMRT-based extraction with differential 






Figure 4.20. PCA to assess the effect of self-reported back pain scores in 
profiling data from AKU human urine taken at baseline (targeted feature 
extraction). PCA plots show no clear separation in components 1 and 2 between 
the profiles of patients with high (score >5) vs low (score <5) pain scores.  
 
 
Non-targeted feature extraction 
PCA on data from non-targeted feature extraction showed clearer separation of 
patients into high and low back pain groups in negative polarity (separation in 
principal component 2; Figure 4.21). Unpaired t-test revealed two entities with 
differential abundance between high and low pain groups; caffeic acid (3- or 4-)-
sulfate and an entity putatively identified as a dipeptide (prolyl-threonine or 
threonyl-proline). These entities were both increased in the high pain group, with 





Figure 4.21. PCA to assess the effect of self-reported back pain scores in 
profiling data from AKU human urine taken at baseline (non-targeted feature 
extraction). There is some evidence of separation between the profiles of 
patients with high (score >5) vs low (score <5) pain scores in negative polarity 
(left plot), but no clear separation in positive polarity. 
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Table 4.07. Summary of unidentified urinary chemical entities with differential abundance between patients with 
high (>5/10) vs low (<5/10) self-reported lumbar/thoracic pain scores at baseline. Putative compound identifications 
were obtained for these compounds using the MassHunter METLIN metabolites PCD/PCDL accurate mass database (build 
07.00, Agilent), with match criterion of accurate mass ±5 ppm. P-values are adjusted by Benjamini-Hochberg false-discovery 
rate.  
 













Caffeic acid 3-sulfate / 




259.9984 5.2 2 (-) ↑ 2.2 <0.0001 
Prolyl-threonine /  
Threonyl-proline  
C9H16N2O4 216.1109 3.1 8 (-) ↑ 2.2 <0.0001 
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4.3.2.5. BDI-II score 
Patients were divided into the following categories based on level of depression 
indicated by BDI-II score: minimal (n=19), mild (n=1), moderate (n=3) and severe 
(n=2). 
PCA on data from targeted (Figure 4.22) and non-targeted (Figure 4.23) feature 
extraction showed no clear separation between patient profiles by BDI-II score. 
Statistical analyses were not performed on the data from these groups due to the 





Figure 4.22. PCA to assess the effect of depression (Beck’s Depression 
Inventory II scores) in profiling data from AKU human urine taken at 
baseline (targeted feature extraction). PCA plots show no clear separation in 









Figure 4.23. PCA plots visualising the effect of depression (Beck’s 
Depression Inventory II scores) in profiling data from AKU human urine 
taken at baseline (non-targeted feature extraction). PCA plots show no clear 
separation in components 1 and 2 between the profiles of patients from the 
different depression score categories, as with targeted feature extraction. 
 
 
4.3.2.6. HGD gene sequencing data 
Based on the data from sequencing of the HGD gene, patients were divided into 
the following categories of mutation: substitution (n=19), nonsense (n=1), indel 
(n=2), substitution with - aberrant splicing / exon skipping / frameshift mutation 
(n=2), and substitution with indel and frameshift mutation (n=1) (231). Patients 
from ‘substitution’, ‘nonsense’ and ‘indel’ mutation categories were all bi-allelic for 
the same category of mutation but these categories also included patients with 




Data from targeted (Figure 4.24) and non-targeted (Figure 4.25) feature extraction 
at the baseline time point showed no clear separation between the profiles of 
patients from the different HGD mutation categories. As with the BDI-II score 
categories, statistical analyses were not performed to compare profiles between 
different mutation groups, due to the low number of patients with mutations other 




Figure 4.24. PCA to assess the effect of HGD mutation type in profiling data 
from AKU human urine taken at baseline (targeted feature extraction). PCA 
plots show no clear separation in components 1 and 2 between the profiles of 









Figure 4.25. PCA to assess the effect of HGD mutation type in profiling data 
from AKU human urine taken at baseline (non-targeted feature extraction). 
PCA plots show no clear separation in components 1 and 2 between the profiles 




4.4.1. Effect of nitisinone treatment 
The data described in this chapter show the power of the metabolomics approach 
developed for studying AKU. The findings extend what is currently known about 
nitisinone-induced hyper-tyrosinaemia by identifying for the first time the wider 
metabolic consequences of nitisinone treatment in AKU. In addition to confirming 
well-documented changes to the metabolites tyrosine, HPPA (both increased) 
and HGA (decreased) following nitisinone treatment (11,12,220), the data 
indicate alterations to three main metabolic pathways: tyrosine/dopamine 
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(Figures 4.26 and 4.27), tryptophan (Figure 4.28) and purine (Figure 4.29) 
pathways. These alterations are illustrated in the context of metabolic pathways 
in the aforementioned figures. The identification of the above well-known 
metabolite changes following nitisinone and the concordance between human 
and mouse data supports the validity of the data, as the HGD-/- mouse model 
studied here is shown to accurately recapitulate the early stages of the human 
AKU phenotype (50,68). Fourteen metabolites showed the same direction of 
alteration in both AKU human and mouse urine: 4-hydroxyphenylacetic acid, γ-
glutamyl-L-tyrosine, acetyl-L-tyrosine, HPLA, HPPA, hydroxy-nitisinone, L-
tyrosine, phenylacetic acid and tyramine increased on nitisinone; 2,5-
dihydroxybenzaldehye, 2-hydroxy-4-(methylthio)butyric acid, 3,5-cyclic-AMP, 
HGA and xanthosine decreased on nitisinone. 
4.4.1.1. Hyper-tyrosinaemia and alternative routes of tyrosine clearance 
Increases in the tyrosine derivatives acetyl-L-tyrosine, tyramine and 4-coumarate 
found here in urine could represent important clearance routes separate from the 
conventional tyrosine transamination pathway. These routes appear to be 
activated by the superphysiological tyrosine concentrations observed on 
nitisinone. In humans, tyrosine can be converted to tyramine from decarboxylation 
by aromatic-L-amino-acid decarboxylase (233); normally a minor metabolic route 
under physiological conditions. Increased plasma acetyl-L-tyrosine and γ-
glutamyl-L-tyrosine have been shown previously with increasing doses of 
nitisinone in AKU (226,234). Increased tyrosine following nitisinone has been 
attributed to adverse events such as dermal toxicity and corneal keratopathy 
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caused by high tyrosine concentrations in the aqueous humour of the eye 
(14,142–144). Incidence of tyrosine keratopathy in AKU is estimated at 5% on a 
daily dose of 2mg nitisinone (14). Conversion of tyrosine to the more soluble 
acetyl-L-tyrosine could help to prevent tyrosine crystallisation in the eye 
underlying corneal lesions observed in some patients. On-nitisinone increases in 
the tyrosine metabolites HPPA, HPLA and 4-hydroxyphenylacetic acid are likely 
to be direct consequences of nitisinone’s inhibition of HPPD activity (see Figure 
4.26). The changes to HPLA and 4-hydroxyphenylacetic acid have not been 





Figure 4.26. Non-conventional routes of tyrosine metabolism are activated 
as a consequence of nitisinone-induced hyper-tyrosinaemia. Red and blue 
indicate increased and decreased urinary abundance on nitisinone, respectively. 
Compounds in bold were altered in patients and mice with AKU. Nitisinone is used 
in AKU for reduction of HGA by its inhibition of HPPD. Consequently, the 
metabolites directly upstream of HGA accumulate; 3-(4-hydroxyphenyl)pyruvate 
3-(4-hydroxyphenyl)lactate and tyrosine. The present data show that alternative 
mechanisms are recruited for metabolism of the increased tyrosine apart from the 
conventional tyrosine trans-aminase pathway. These include its conversion to 
acetyl-L-tyrosine, γ-glutamyl-L-tyrosine, tyramine and 4-coumarate.  
AADC – aromatic amino acid decarboxylase, ALDH – alcohol dehydrogenase, C3H – p-
coumarate-3-hydroxylase, GGT – gamma-glutamyl transferase, HGD – homogentisate 1,2-
dioxygenase, HPPD – hydroxyphenylpyruvic acid dioxygenase, MAO – monoamine oxygenase, 
NAT –N-acetyl-transferase, PAH – phenylalanine hydroxylase, TAL – tyrosine ammonia-lyase, 
TAT – tyrosine aminotransferase (*enzyme not expressed in human or mouse).  
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4.4.1.2. Altered dopamine and tryptophan-serotonin metabolism 
Tyrosine is the precursor for catecholamines, thyroid hormones and melanin, 
suggesting that increased tyrosine substrate, as in tyrosinaemia, could lead to 
dysregulation of these pathways. Here, urinary profiles generally indicated 
increased levels of tyrosine-derived catecholamine metabolites and decreased 
levels of tryptophan-serotonin neurotransmitter metabolites on nitisinone therapy. 
Changes to catecholamine metabolites were increased 3-MT, a previously 
reported finding (235), and mandelic acid, and decreased HVA. These 
metabolites are derived from tyrosine via L-DOPA and dopamine. 3-MT is also 
derived directly from dopamine and is then converted to HVA. An increase in 
urinary 3-MT with decreased HVA therefore could suggest increased activity in 
the pathway dopamine catabolism from 3-MT, as opposed to alternative routes 
via noradrenaline and DOPAL. Alternatively, increased 3-MT could be a renal 
effect, reflecting decarboxylation of excess tyrosine delivered to the kidney to L-
DOPA (the tyrosine pathway in full is only present in liver and kidney). Changes 
to metabolites of tryptophan-serotonin metabolism on nitisinone were decreased 
L-tryptophan, L-kynurenine and indoxyl sulfate and increased xanthurenic acid, 
with the addition of increased 4-quinolinecarboxylic acid in mice. 
  
The data reported here corroborate but also add detail to previous reports of 
altered catecholamine and tryptophan-serotonin metabolism following nitisinone 
therapy. A previous report of increased urinary levels of the catecholamine 
metabolite 3-MT in nitisinone-treated AKU was replicated (235). It was also shown 
here for the first time that L-tryptophan is decreased in urine on nitisinone. 
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Decreased concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid 
(5-HIAA) have been reported in HT-1 CSF (236) and in AKU urine (235) following 
nitisinone treatment, although this was not found here. Also for the first time, it 
was shown that decreased tryptophan metabolism following nitisinone is 
associated with alterations to the downstream kynurenine metabolic pathway; 
decreased kynurenine and increased xanthurenic acid. Additionally, the finding of 
decreased indoxyl sulfate implicates the indole pathway derived directly from 
tryptophan. Alterations to indolepyruvate pathway metabolites indole-
carboxaldehyde, indole-lactate and indole-pyruvate were reported previously in 
AKU plasma following nitisinone, although these were increases (237). 
The biological significance of the alterations on nitisinone to catecholamine and 
serotonin metabolism reported here are not fully understood. Much of the 
literature on nitisinone-induced hyper-tyrosinaemia comes from HT-1, where 
there are concerns that increased tyrosine may contribute to neurodevelopmental 
delay (46,221–224). It is estimated that up to 35% of juvenile HT-1 patients 
treated with nitisinone have intellectual disabilities (46), but it is unknown whether 
this is attributable to tyrosinaemia, low phenylalanine concentrations, acute liver 
disease (which children with HT-1 usually present with) or an intrinsic effect of 
HT-1. Several biochemical mechanisms have been proposed for 
neurodevelopmental delay associated with tyrosinaemia in HT-1 (236,238–240). 
Those which directly relate to catecholamine and tryptophan metabolism include 
increased CNS dopamine, the precursor for catecholamines, or decreased 




Figure 4.27. Alterations observed to dopamine metabolism as a 
consequence of nitisinone-induced tyrosinaemia. Red and blue indicate 
increased and decreased urinary abundance on nitisinone, respectively. 
Compounds in bold were altered in patients and mice with AKU. Compounds in 
italics were altered in mice only. Increases were observed on nitisinone to 
compounds derived directly from L-DOPA (dihydroxyphenylpyruvic acid), 
dopamine (3-methoxytyramine and 6-hydroxydopamine) and noradrenaline (3,4-
dihydroxymandelaldehyde). Increased 3-hydroxymandelic acid was derived from 
increased tyamine via octopamine. Decreases were observed in homovanillic 
acid and 3,4-dihydroxyphenyl glycol, metabolites that are downstream of 
catecholamines and metadrenalines. 
AADC – aromatic L-amino acid decarboxylase, ALDH – aldehyde dehydrogenase, COMT – 
catechol-O-methyltransferase, DβT – dopamine β-hydroxylase, MAO – monoamine oxidase, 
PNMT - TβH – tyramine β-hydroxylase, TRANS – transferase, TyH – tyrosine hydroxylase, TYR 
– tyrosinase,  EC 2.6.1.49 – dihydroxyphenylalanine transaminase, EC 1.1.1.237 – 
hydroxypehnylpyruvate reductase, EC 2.3.1.140 – rosmarinate synthase (*enzyme not expressed 





Figure 4.28. Alterations to tryptophan-serotonin metabolism and 
tryptophan-derived kynurenine and indole pyruvate pathways observed 
following nitisinone. Red and blue indicate increased and decreased urinary 
abundance on nitisinone, respectively. Compounds in bold were altered in 
patients and mice with AKU. Compounds in italics were altered in mice only. 
Increases were observed in metabolites downstream of serotonin via 5-
hydroxyindole acetaldehyde; 5-methoxytryptophol and 5-methoxyindoleacetic 
acid. Conversely, decreased accumulation was observed in metabolites of the 
kynurenine and indole pyruvate pathways, which originate from tryptophan, were 
also observed. Metabolites in these pathways were decreased, with the exception 
of xanthurenic acid, a metabolite of kynurenine, which was increased. 
Kynuramine, derived from serotonin, was also decreased. It is previously 
suggested that metabolic alteration to tryptophan metabolism following nitisinone 
treatment is attributable to tyrosine’s inhibition of tryptophan hydroxylase.  
AADC – aromatic L-amino acid decarboxylase, ABDH – abhydrolase, ALDH – aldehyde 
dehydrogenase, AR – aldehyde reductase, HIOMT – hydroxyindole-O-methyltransferase, KAT – 
kynurenine aminotransferase, KMO – kynurenine monoxygenase, MAO – monoamine oxidase, 





4.4.1.3. Novel association between hyper-tyrosinaemia and alteration to 
the tryptophan-derived kynurenine pathway 
Decreased kynurenine following nitisinone is an interesting and potentially 
significant finding (Figure 4.28). The kynurenine pathway of tryptophan 
metabolism has received considerable interest for its involvement in a range of 
CNS pathologies including depression (241,242), pain, particularly pain 
associated with migraine (243,244), and neurodegenerative diseases such as 
Alzheimer’s, Parkinson’s and Huntington’s diseases and Multiple Sclerosis 
(241,242). Most metabolites of the kynurenine pathway possess neuroactive 
properties by their ability to act on N-methyl-D-aspartate (NMDA) and 
metabotropic glutamate receptors in the CNS, thereby modulating glutamate 
release and neuronal transmission (245,246). The kynurenine metabolite 
quinolinic acid is an NMDA receptor agonist and is thought to be an important 
contributor to neuronal excitotoxicity underlying neurodegeneration (247,248). 
The kynurenine metabolites 3-hydroxykynurenine and 3-hydroxyanthranilic acid 
can induce neuroinflammation by direct generation of free radical species even 
under physiological conditions (249). In contrast, kynurenic acid is considered to 
be neuroprotective by its antagonistic action on glutamate receptors (247).  
Of particular relevance to AKU, NMDA glutamate receptors also have important 
roles in peripheral tissue; they are present in osteoblast and osteoclast cells and 
are thought to regulate bone formation (250–252). Kynurenine metabolism is also 
linked with musculoskeletal diseases such as rheumatoid arthritis (RA) and 
osteoporosis. Decreased plasma tryptophan and 3-hydroxyanthranilic acid were 
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reported in osteoporosis and RA compared to healthy controls, with increased 
kynurenine and xanthurenic acid in RA only (253). Anthranilic acid, a direct 
metabolite of kynurenine was also increased in osteoporosis at baseline 
compared to healthy controls, and its decrease to control levels after two years of 
treatment was associated with clinical improvement indicated by bone 
densitometry (254). Tryptophan, kynurenine and anthranilic acid were increased 
in synovial fluid in RA compared with OA, suggesting that tryptophan-kynurenine 
metabolism is associated with the increased inflammatory or autoimmune 
pathophysiological component of RA (255). Given the association of kynurenine 
metabolism with a range of pathophysiological processes both in the CNS and 
periphery, the overall de-activation of this pathway following nitisinone in AKU, as 
indicated by urinary metabolite profiles, is potentially beneficial. Decreased 
bioavailability of kynurenine on nitisinone could reduce the levels of its derivative 
toxic metabolites 3-hydroxykynurenine, anthranilic acid, and 3-hydroxyanthranilic 
acid which are shown to induce oxidative stress. However, the protective effects 
of some kynurenine pathway metabolites, in addition to the diversity and 
complexity of their regulatory effects on glutamatergic signalling in the CNS and 
periphery should also be considered. However it is important to consider whether 
kynurenine pathway alteration is a compensatory effect to mitigate neuronal 
damage, a direct off-target effect of nitisinone or a consequence of nitisinone 




4.4.1.4. Altered purine metabolism 
The finding of altered purine metabolism following nitisinone is also novel. Most 
of the changes in this pathway were decreased metabolite levels (xanthosine, 
adenine, 3-ureidopropionate and allantoin), except for caffeic acid which was 
increased. The purine pathway is the metabolic route through which purines are 
broken down into uric acid. Levels of metabolites in this pathway are affected by 
endogenous purine production and exogenous purine pools (256).  Increased 
serum uric acid is implicated in a range of diseases including gouty arthritis (gout), 
type 2 diabetes and cardiovascular and neurological disease (257,258). 
Inflammation is one of the major pathogenic mechanisms by which uric acid 
causes disease in these conditions. This is perhaps most recognised in gout, 
where high uric acid leads to crystal deposition in joints, tendons and tissues, 
resulting in inflammation, swelling and pain in joints (258,259). Xanthosine and 
allantoin are also metabolites derived from xanthine that are known to accumulate 
in oxidative conditions associated with chronic inflammation (260–263). Allantoin 
is not usually observed in human urine although it can be formed from uric acid 
non-enzymatically under high levels of reactive oxygen species. It is therefore 
conceivable that reduced levels of uric acid precursors (such as the purine 
nucleobase adenine) which are strongly linked with inflammation, could have 
additional benefit in AKU arthritis. Caffeic acid has been grouped into the xanthine 
pathway as it, in addition to its oxidation product, is shown to inhibit activity of 
xanthine oxidase (EC 1.17.3.2) (264,265); the enzyme that converts 
hypoxanthine to xanthine and then to uric acid by oxidation. Increased caffeic acid 
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could also be an additional beneficial effect of nitisinone; caffeic acid is known to 
have a range anti-inflammatory, antioxidant, immunomodulatory and 
neuroprotective properties (266–269). As summarised in Figure 4.29, the 
alterations to metabolites of the purine pathway, particularly decreases in 
xanthine-derived compounds, following nitisinone treatment are possibly a 
reflection of reduced oxidative stress due to HGA reduction. Oxidative stress is 
thought to be an important pathological feature of AKU that is a direct 






Figure 4.29. Alterations to purine metabolism observed following nitisinone 
treatment. Red and blue indicate increased and decreased urinary abundance 
on nitisinone, respectively. Compounds in bold were altered in patients and mice 
with AKU. Altered compounds not in bold were observed in patients only. The 
purine pathway metabolites altered were decreased following nitisinone, except 
for caffeate which increased. Decreases in xanthosine and allantoin, metabolites 
derived from xanthine, are particularly noteworthy, as increases in these 
compounds have been linked previously with oxidative stress and inflammation. 
It is proposed that the decreases in xanthine metabolites are attributable to the 
inhibition of caffeate on xanthine oxidase activity. 
5Nc – 5’-nucleotidase, ADA – adenosine deaminase, ADK – adenosine kinase, AMPD – 
adenosine monophosphate deaminase, HPRT – hypoxanthine phosphoribosyltransferase, PDE 




4.4.1.5. Relationship between tyrosine, tryptophan and purine metabolism 
Interestingly, other metabolic profiling studies have also found a link between 
the three altered pathways here of tyrosine, tryptophan and purine metabolism. 
Analysis of CSF from subjects with mild cognitive impairment or Alzheimer’s 
disease found that these conditions were associated with an overlapping network 
of metabolic changes within tyrosine, tryptophan and purine pathways (270,271). 
The ratio of kynurenine : tryptophan was also increased in Alzheimer’s disease 
(270). The relationship between alterations to tyrosine, tryptophan and purine 
metabolic pathways is not well recognised nor understood, but the concurrent 
association with Alzheimer’s disease and nitisinone-treated AKU has important 
implications for cognitive function following nitisinone-induced tyrosinaemia which 
warrants further study. 
  
4.4.1.6. Miscellaneous metabolite alteration 
Changes were also observed for other metabolites on nitisinone that are not 
easily grouped into common metabolic pathways, therefore making interpretation 
challenging. 2-Hydroxybutyric acid, methyl vanillate, 3,5-cyclic AMP, 2-hydroxy-
4-(methylthio)butyric acid and L-threonine were decreased, and ethylmalonic acid 
was increased on nitisinone. These findings implicate a diverse range of 
metabolic alterations as a consequence of nitisinone therapy. Ethylmalonic acid 
and 2-hydroxy-4-(methylthio)butyric acid are short-chain organic acids. 
Decreased methyl vanillate could be a dietary change as it is derived from 
vanillate, a flavouring agent frequently used in foods. L-threonine is an essential 
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amino acid, which has been previously monitored in AKU serum by our group 
following nitisinone as part of a wider amino acid profiling study (220). This 
previous study found a trend of decreased serum threonine after 36 months on 
nitisinone, but this did not reach statistical significance. 2-Hydroxybutyric acid is 
produced in the conversion of cystathionine to cysteine in the methionine-
glutathione synthesis pathway (272). One could argue that decreased 2-
Hydroxybutarate on nitisinone is a marker of decreased oxidative stress; at times 
of increased oxidative stress more homocysteine is converted to cystathione to 
increase the production of glutathione via cysteine as a redox homeostasis 
mechanism (273). Regarding the on-nitisinone decrease in cAMP, the role of 
cAMP is well-recognised in the musculoskeletal system and in endocrinology 
more generally. cAMP is a key signal transduction secondary messenger in a 
range of physiological processes. The role of cAMP has been extensively studied 
in the cAMP – protein kinase A signalling pathway, which is highly linked to 
osteogenesis (274). cAMP is also thought to be involved in stimulation of native 
growth factors which has attracted interest in it as a therapeutic target in the fields 
of musculoskeletal engineering and regeneration (275). Given the diverse roles 
of cAMP in signalling cascades in various tissues, the exact significance of the 
urinary decrease in cAMP observed here on nitisinone is uncertain and requires 
further investigation. 
4.4.1.7. Consideration of potentially confounding factors 
The potential effect of diet on some of the metabolic changes observed on 
nitisinone should also be considered. Dietary proteins contribute significantly to 
213 
 
exogenous purines and tryptophan (256,276,277), so it is possible that general 
de-activation of these metabolic pathways could relate to diet. However, patients 
attending the NAC are not specifically advised to restrict their protein intake upon 
commencement of nitisinone therapy. The within-subjects study design (i.e. 
paired data) should also improve control over inter-individual differences in 
demographic or lifestyle factors such as diet. In the mouse study it was possible 
to strictly control potentially confounding factors that could affect metabolism, 
such as diet and genetic diversity. This increases the likelihood that the observed 
metabolite changes are attributable to nitisinone therapy.  
4.4.1.8. Contribution of complementary non-targeted data extraction 
It is worth noting the contribution of the complementary non-targeted feature 
extraction approach conducted in parallel to AMRT-based extraction. Although 
the considerable number of chemical entities from non-targeted feature extraction 
that remained unidentified (by AM match <10 ppm; see Tables S4.01 and S4.02 
in Supporting materials, Appendix 3) demonstrates the challenging nature of this 
approach, its employment helped to elucidate further individual metabolite 
changes within the pathway-level alterations discussed above. These included 
further increases in metabolites of the wider tyrosine pathway; 
dihydroxyphenylpyruvic acid, phenylpyruvic acid, 3-hydroxymandelic acid 
(DHMA), hydroxydopamine, N-acetylvanilalanine, vanillactic acid and vanillin 4-
sulfate. Hydroxydopamine and vanillactic acid are catecholamine metabolites 
deriving from tyrosine via L-DOPA (Figure 4.27). Concentrations of 5- and 6- 
hydroxydopamine were previously found to be increased in urine from patients 
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with Parkinson’s treated with L-DOPA, and 6-hydroxydopamine is thought to be 
derived from dopamine by the action of tyrosinase (278). Vanillactic acid is 
derived from L-DOPA via 3-O-methyldopa (279). 3-Hydroxymandelic acid could 
be associated with the increased tyramine on nitisinone, as it is a product of 
dopamine and octopamine; octopamine is derived from tyrosine via tyramine.  
Interestingly, non-targeted extraction on the mouse data also revealed further 
changes to metabolites associated with tryptophan-serotonin metabolism; 5-
methoxyindoleacetate and 5-methoxytryptophol increased and kynuramine 
decreased on nitisinone. Kynuramine is an endogenously-occurring di-amine 
metabolite, and its decrease on nitisinone appears to be in accordance with that 
also observed for L-kynurenine. Whereas L-kynurenine is derived from 
tryptophan, via formyl-kynurenine, kynuramine is thought to be formed via 
serotonin via formyl-kynuramine (280). 5-Methoxyindoleacetate and 5-
methoxytryptophol are metabolites of serotonin, formed via 5-hydroxyindole 
acetaldehyde. Increases in these metabolites therefore appear to be related, but 
are perhaps unexpected given previous reports of decreased urinary 5-HIAA in 
AKU patients on nitisinone (235). Together with the data discussed above, these 
additional findings could be taken to suggest the following urinary pathway 
alterations on nitisinone a) accumulation of downstream products of serotonin 
following its conversion to 5-hydroxyindole acetaldehyde via monoamine oxidase, 
b) decreases in metabolites of the tryptophan-derived kynurenine pathway, and 
c) decreases in metabolites of the tryptophan-derived indolepyruvate pathway. 
These observations are incorporated into the tryptophan-serotonin pathway 
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summary in Figure 4.28. Further analysis should aim to confirm the compound 
assignments of entities obtained from non-targeted feature extraction by 
obtaining chemical standards, where possible, and analysing them under the 
same conditions to match RT and also generate MS/MS spectra for confirmatory 
matching of fragmentation spectra. 
  
4.4.2. Associations between the metabolome and demographic or clinical data 
4.4.2.1. Associations with 18F-NaF PET imaging data 
 
In these studies, also investigated for the first time in AKU were potential 
associations between metabolome-wide profiles and clinical/demographic data. 
These associations were of interest aside from the effect of nitisinone and were 
therefore primarily studied in the data at the baseline time point (or additionally at 
24 months on nitisinone if an effect was observed at baseline). The clinical 
variables with the clearest observable impact on the metabolomes of these 
patients were those related to monitoring the progression of osteoarthropathy; 
18F-NaF PET imaging data and self-reported lumbar/thoracic back pain. These 
clinical data from the NAC patient cohort are described extensively by Taylor 
(2018). In this form of PET imaging, the injected 18F-NaF tracer binds to tissue 
actively undergoing mineralisation and is therefore designed to measure the rate 
of bone remodelling or metabolism (281). Employment of this form of PET 
imaging has identified early pathological changes in OA before the emergence of 
clear radiographic evidence of cartilage degeneration. For example, in patients 
216 
 
with early-stage OA it was shown that increased bone remodelling in the hip, as 
measured by 18F-NaF, correlated with radiographic stage of OA and severity of 
hip pain (282). 18F-NaF uptake to the spinal musculoskeletal system shows a 
unique distribution in AKU, with increased uptake to intervertebral disks compared 
with the bony vertebrae. The inverse of this pattern is usually observed for healthy 
subjects. Increased 18F-NaF uptake to the intervertebral disks in AKU is thought 
to reflect calcification of the cartilaginous intervertebral disks associated with 
ochronotic osteoarthropathy. In this patient cohort it was previously shown that 
18F-NaF uptake to intervertebral disks increases with age, reaching maximum 
values at around 60 years. Mean 18F-NaF uptake to the vertebrae or intervertebral 
disks did not change significantly across visits over this period for patients 
attending the NAC. Combined lumbar/thoracic pain scores were previously 
shown to be positively correlated with age and 18F-NaF uptake to the 
intervertebral disks, consistent with this form of uptake as a marker of OA 
progression. Interestingly, 18F-NaF uptake to the vertebrae was found to be 
negatively correlated with pain and showed a general decline with age in these 
patients; the opposite pattern to that observed for 18F-NaF uptake to the 
intervertebral disks.  
From the imaging data, 18F-NaF uptake to the intervertebral disks appeared to 
have the greatest influence on the metabolomic data. This was particularly true in 
the data from non-targeted feature extraction, in which the major bimodal 
distribution of the data across all time points observed from PCA corresponded 
to the grouping of patients by high (value >10) versus low (value <10) uptake to 
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the intervertebral disks (Figure 4.18). Clearer PCA separation was observed in 
the data from non-targeted feature extraction for ‘high’ versus ‘low’ groups for 
both intervertebral disk 18F-NaF uptake and back pain, which supports the parallel 
approach of mining the data for chemical entities/compounds that were not 
contained in the AMRT databases generated. The identification of one chemical 
entity, AM-matched with caffeic acid sulfate, that increased in patients with high 
intervertebral disk 18F-NaF uptake and back pain was particularly interesting. The 
biological interpretation of this finding is not clear and warrants further attention. 
Caffeic acid sulfate is presumably a metabolic product of caffeic acid (caffeate), 
an antioxidant which was also shown to be increased in these patients while on 
nitisinone (section 4.3.1.1.).  
Decreased urinary adenosine/2-deoxyguanosine was also observed for patients 
with high 18F-NaF uptake to intervertebral disks. The method employed cannot 
distinguish between these two possible compound identifications, as both have 
identical AM and RT using the chromatographic technique employed here 
(Method 2; Chapter 2, section 2.2.2.). Adenosine is associated with oxidative 
stress observed in chronic inflammatory conditions such as arthritis (283). 
Furthermore, methotrexate, an approved therapy for RA, is proposed to act by 
inhibiting adenosine-mediated inflammation (284). In RA, methotrexate results in 
an increase in extracellular adenosine, which binds to cell surface adenosine 
receptors. As a consequence of this binding, lymphocyte proliferation is inhibited, 
decreasing the levels of inflammatory cytokines and promoting an anti-
inflammatory environment (285). There is also evidence that increased adenosine 
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production induces chondrocyte apoptosis. Adenosine in the presence of 
adenosine deaminase or adenosine kinase inhibitors induced cell death in a 
murine chondrocyte cell line, and activity of 5’-nucleotidase, the enzyme that 
produces adenosine, increased with development of OA in the STR/ort mouse 
model of spontaneous OA and was particularly elevated close to the sites of OA 
lesions (286). In addition, concentrations of 5’-nucleotidase have been found to 
be markedly elevated in synovial fluid from patients with RA, and slightly elevated 
in OA (287). However, the association between local increases in adenosine in 
tissues affected by OA and urinary excretion of adenosine is unclear. For 
example, relatively increased concentrations of urinary 5-aminoimidazole-4-
carboxamine, an analogue of adenosine monophosphate, but not adenosine was 
associated with reduced disease severity in patients with RA treated with 
methotrexate (285). Nevertheless, the implied association in the present data 
between decreased urinary adenosine and increased OA and inflammation in 
AKU, as indicated by intervertebral 18F-NaF uptake, is worthy of further study. 
The observation of entities with differential abundance between patients with high 
versus low 18F-NaF uptake to the vertebrae was also of interest. Previous studies 
have found bone 18F-NaF uptake to increase in OA and in bone tissues subject 
to greater mechanical stress, such as loading (227,282,288), which are both 
known to stimulate bone turnover or remodelling. However, it is unclear whether 
the increased 18F-NaF to the vertebrae in the present AKU cohort is a true 
reflection of the aberrant bone remodelling observed as a consequence OA. 
Uptake of 18F-NaF to the vertebrae generally decreased with age in this cohort, 
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the opposite of the trend for intervertebral disks, possibly reflecting the well-
recognised decrease in bone density in older populations. These entities should 
therefore be considered potential markers of bone remodelling or turnover more 
generally, but not necessarily as a specific consequence of osteoarthropathy.  
The entity identified as iduronic acid, increased in the ‘high’ vertebral 18F-NaF 
uptake group, is a particularly interesting potential marker of bone tissue 
degradation. Iduronic acid is the major uronic acid component of the GAGs 
dermatan sulfate and heparin (289). GAGs are polysaccharides made from 
disaccharide repeating units comprising an amino sugar and an uronic sugar or 
galactose. GAGs are an important component of the extracellular matrix; their 
high polarity enables them to bind and organise water molecules, which supports 
the lubricating or shock-absorbing properties that GAGs lend to tissues such as 
bone and cartilage (290). The increased urinary iduronic acid in these patients 
could therefore reflect the breakdown of the aforementioned GAGs as part of the 
process of tissue remodelling. Proline was another entity associated with 
vertebral 18F-NaF uptake in this study. Urinary proline is a potential marker of 
bone turnover, as it contributes 12% of the total protein content of type I bone 
collagen (291). Increased urinary proline would support this interpretation, but in 
contrast proline was decreased in patients with high vertebral 18F-NaF uptake. 
Malonic acid was also decreased in patients with high vertebral 18F-NaF uptake. 
In vitro, malonic acid supplementation is shown to select for bone marrow stromal 
cells that subsequently undergo mineralisation to become osteoprogenitor cells, 
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which are the precursors for specialised bone cells (292). However, the role of 
malonic acid in bone metabolism more generally is not clear.  
One entity that was increased in patients with high 18F-NaF uptake to 
intervertebral disks is particularly noteworthy. This entity was initially of high 
interest as a potential endogenous marker of osteoarthropathy, but was 
subsequently identified as paracetamol (acetamainophen). This finding therefore 
highlights the importance of also considering exogenous drug metabolites when 
attempting to chemically identify unknown potential biomarkers. This finding is not 
surprising, but can be considered to validate the approach employed to search 
for novel markers associated with osteoarthropathy and/or pain. 
It is also important to note absence of an association between entities attributable 
to ochronotic pigment itself and the PET imaging and pain data. As ochronosis is 
central to the osteoarthropathy and joint destruction observed in AKU (16), one 
might expect the concentrations of compounds attributable to ochronotic pigment 
to be highly associated with these clinical data. It is therefore somewhat surprising 
that HGA was not found to correlate with 18F-NaF uptake to the intervertebral 
disks or vertebrae. In support of this finding, previous studies of a separate cohort 
of non-treated AKU patients showed no statistically significant correlation 
between urinary or serum HGA and these 18F-NaF-PET imaging measures in the 
lumbar and thoracic spine (227). These data therefore suggest that there is not a 
simple linear relationship between concentrations of HGA in the circulation or 
urine and the degree of spinal osteoarthropathy as indicated by 18F-NaF-PET. A 
potential explanation is that compounds related to ochronotic pigment have a 
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closer relationship with osteoarthropathy than HGA, but that these were not 
detected here. As discussed in Chapter 7, chemical analysis of ochronotic 
pigment poses a serious challenge for various reasons, some of which specifically 
relate to the ESI MS technique employed here. Furthermore, neither the chemical 
structure nor the formation mechanism of ochronotic pigment are known, 
therefore mining the data for specific associated chemical entities is challenging. 
It is possible that some of the chemical entities of interest that remained unknown 
are derived from aggregation of HGA or ochronotic pigment. However, none of 
these unidentified entities matched the mass of entities observed in the mass 
spectra of HGA or BQA standard, or pigment derived from synthetic HGA (see 
Chapter 7). Further biochemical analyses in larger patient cohorts, such as the 
recently completed SONIA (Suitability of Nitisinone in Alkatonuria) II clinical trial 
(139), are encouraged in order to capture the complex pathophysiological factors 
that mediate progression of ochronotic osteoarthropathy in AKU. Additionally, it 
is worth pointing out that serum and urinary HGA (and flux down the tyrosine 
pathway more generally) represent snapshots in time. Lifetime exposure to HGA 
is probably more relevant and could explain the lack of correlation observed 
between HGA and osteoarthropathy measured by18F-NaF-PET. 
4.4.2.2. Associations with gender 
There was a marked effect of gender in the metabolomic data (from targeted 
AMRT-based feature extraction) for mice, but not patients. This prominent gender 
difference was perhaps only observed for mice due to the strict control over 
environmental factors with potential to have major influences on the metabolome, 
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including age, diet and genetic diversity. The most notable gender difference was 
in a group of metabolites that were clearly elevated in urine from female mice: 4-
hydroxyphenylacetate, 4-quinolinecarboxylic acid, 5-valerolactone, anthranilate, 
erythritol, histamine and riboflavin. Of these metabolites, the greatest increases 
were for histamine (FC = 16), riboflavin (FC = 18) and 5-valerolactone (16). These 
findings are potentially relevant to the observation that disease is more severe in 
males with AKU; symptoms in females tend to lag behind those in males by 
approximately 10 years (18). 
Previous research has shown increased urinary histamine excretion in the rat 
(293,294), but not the mouse to my knowledge. It is hypothesised that in the rat, 
the reason for this observation is that males, but not females, possess an 
additional minor histamine-metabolising pathway (294). Riboflavin (also known 
as vitamin B2) is a vitamin of dietary origin. Riboflavin is an essential component 
of flavin mononucleotide and flavin adenine dinucleotide; coenzymes that play 
major roles in energy production and other diverse functions such as cellular 
function, growth and development and metabolism of fats, drugs and steroids 
(295). Excess riboflavin is excreted in the urine in free form. In humans, urinary 
riboflavin (µg/g creatinine) was previously shown to be slightly increased for 
females compared with males in a cohort of 412 adults in South Korea (296), 
although this could reflect the increased ratio of dietary riboflavin intake to energy 
intake for females in this study. Anthranilate (anthranilic acid) is an aromatic acid 
of the tryptophan biosynthesis pathway. Increased urinary anthranilic acid was 
previously observed in female mice, compared with males, injected with the food 
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flavouring and fragrance agent cinnamyl anthranilate (297). Increased excretion 
of anthranilic acid in female mice was proposed to reflect the increased capacity 
of female mice to metabolise cinnamyl anthranilate, by cytochrome P450-
mediated hydrolysis, resulting in formation of anthranilic acid which was excreted 
in urine. Increased 4-hydroxyphenylacetate in urine of female mice is an 
interesting finding, as this metabolite was elevated in patients and mice on 
nitisinone (see section 4.3.1.1) and thought to be associated with tyrosine 
accumulation. However, the reason for its increase in female mice is unclear; it is 
unlikely to be associated with gender-related differences in response to nitisinone, 
as 4-hydroxyphenylacetate was increased in females at baseline, and gender 
differences were not observed for tyrosine or HGA on nitisinone. 
Prominent gender differences were also observed in the metabolites 
benzaldehyde and thymine; these were increased in urine from male mice. The 
reason for the marked increase in benzaldehyde (FC = 23) is unclear. 
Benzaldehyde is a volatile compound used in some cosmetics and flavouring 
agents and it is perhaps surprising that this compound is found in mouse urine. 
Thymine is a pyrimidine nucleobase, and increases in urinary thymine is a 
diagnostic indicator of dihydropyrimidine dehydrogenase deficiency (OMIM 
222748), a rare inherited disease caused by a disruption in pyrimidine catabolism. 
In accordance with the present data, a previous study of 276 Japanese adults 
found that urinary thymine (and dihydrothymine) was significantly increased in 
males compared with females, and markedly increased beyond normal reference 
ranges in patients with dihydropyrimidine dehydrogenase deficiency (298). 
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4.4.2.3. Lack of clear associations with age, BDI-II score and HGD gene 
sequencing data 
Stratification of patients according to age, BDI-II score and HGD mutation type at 
baseline did not show any clear effect of these variables on metabolome profiles. 
These factors were investigated at baseline in order to assess potential sub-
groups of patients based on disease aside from the effect of nitisinone. These 
analyses were somewhat limited by the low numbers of patients in some 
categories, specifically the oldest and youngest age categories, BDI-II score 
categories other than ‘minimal’ and HGD mutations other than bi-allelic 
substitutions.  
4.4.3. Inferring alterations to metabolism from urine 
The metabolite changes reported here are urinary, so it is important to consider 
whether they relate to changes in the circulation and CNS. CNS concentrations 
are particularly important for the altered tryptophan metabolites given their 
neuroactive properties.  
Urine metabolomics is recognised as a powerful technique for studying novel 
metabolic markers and biochemical pathways of disease (299). Urine is readily 
available, easily obtained, and often simpler to analyse than other bodily fluids, 
such as blood, which typically requires deproteinisation in metabolomics 
applications. Urine concentrations of metabolites are determined by renal 
clearance of waste products which serves to achieve homeostasis. The 
comparison of metabolite concentrations in different bodily fluids is highly 
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complex as there are numerous sites of synthesis for many metabolites. The 
catecholamines, for example, as altered here, have a complex pattern of 
synthesis involving sympathetic neurons of the CNS, the adrenal medulla, the 
gastrointestinal and mesenteric systems and the liver (300). In addition, some 
catecholamine metabolites, such as MHPG (3-methoxy-4-hydroxyphenylglycol; 
derived from VMA) are observed primarily in their conjugated forms in urine; only 
3% of MHPG in urine is in its free non-conjugated form, the remainder is present 
as glucuronide or sulfate conjugates (301). 
The source of a given metabolite observed in urine, and therefore its role in a 
given state or disease, can sometimes be unclear. Nevertheless, some of the 
urine metabolite alterations reported here agree with changes previously 
observed in plasma/serum on nitisinone; these include HGA (decreased), 
tyrosine, N-acetyltyrosine and HPPA (all increased). This supports that urinary 
concentrations of metabolites can be indicative of their concentrations in the 
circulation or CNS, although further research is required to confirm the indication. 
  
4.5 Chapter 4 conclusion 
In conclusion, employment of the developed metabolic profiling strategy, as 
described in Chapter 2, helped to identify previously unreported urinary 
metabolite changes following treatment with the HGA-reducing agent nitisinone. 
In these data, novel associations were identified between nitisinone treatment 
and alterations to the tryptophan-kynurenine and purine metabolic pathways. 
Together the findings suggest that nitisinone-induced tyrosinaemia induces a 
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pattern of altered metabolism to three main metabolic pathways which previously 
were generally considered to operate independently; namely the pathways of 
tyrosine, tryptophan and purine metabolism. Use of the profiling strategy 
developed has therefore significantly advanced our knowledge of metabolism in 
AKU, and supports its application to other key questions relating to the 
pathogenesis and treatment of AKU.  
Also considered here, for the first time in AKU, were potential associations 
between metabolomic profiles and patient demographics and clinical data. The 
parameters that showed the greatest impact on urinary metabolomes were 
gender (in mice only) and clinical data relating to musculoskeletal disease; 18F-
NaF PET imaging and pain. The metabolites/entities with profiles that correlated 
with these clinical parameters are potential markers of ochronotic 
osteoarthropathy, the central pathological feature of AKU that is responsible for 
tissue and joint destruction.  
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5.0  METABOLOMIC CHARACTERISATION OF A NEW TARGETED HGD-/- 





Metabolic profiling has clear potential in AKU as both a phenotyping and 
biomarker discovery tool. However, untreated AKU has not been compared with 
non-AKU at the metabolome level before. Here the aforementioned LC-QTOF-
MS profiling strategy was employed to characterise the metabolome of a mouse 
model of AKU by targeted homozygous knockout of the HGD gene (HGD-/-; see 
Chapter 1, section 1.1.8), with non-AKU heterozygous knockout (HGD+/-) mice as 
controls (Experiment 1; Figure 5.01). The HGD-/- mouse accurately recapitulates 
the human AKU disease phenotype and closely matches that of a previously 
reported AKU mouse with HGD knockout by ENU mutagenesis (50,69), with the 
hallmark features of elevated plasma and urine HGA, development of ochronosis 
and its inhibition by nitisinone (302). Validation of metabolite alterations observed 
was performed by assessing whether the direction of alteration was reversed 
following nitisinone treatment in HGD-/- mice or patients with AKU (Experiment 2, 
Figure 5.02). Additional validation of the entities that were increased in HGD-/- 
mice was sought by performing a metabolic flux experiment in which mice were 
injected with stable isotopically-labelled HGA (Experiment 3, Figure 5.01). This 
HGA flux experiment aimed to establish whether the increased metabolites were 
directly derived from HGA.  
The overall aim of these experiments was to investigate metabolic markers of 
disease in AKU. Identification of novel metabolite alterations has potential to 
elucidate novel disease mechanisms and to improve current strategies for 
monitoring the AKU disease process and its response to treatment. The reason 
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for studying the HGD-/- mouse was that in these mice HGD disruption is performed 
in a targeted and controlled way, and that potentially confounding genetic and 
environmental influences on the metabolome could be carefully controlled; the 
mice were bred from the same colonies, fed the same diet and housed in identical 
conditions. In this way, studying homozygous versus heterozygous HGD 
knockout mice is considered to offer the most relevant comparison of the AKU 





Figure 5.01. Schematic overview of the overall study design, incorporating 
Experiments 1-3. In Experiment 1, urine was collected from HGD-/- and HGD+/- 
mice and profiled by LC-QTOF-MS. Targeted and non-targeted feature extraction 
was performed on the data in parallel and subsequent unpaired t-tests were 
employed to identify differentially abundant chemical entities between HGD-/- and 
HGD+/-. These entities were then further investigated in LC-QTOF-MS data from 
two additional datasets; a previously published study examining the effect of 
nitisinone on the urine metabolome of HGD-/- BALB/c mice and patients with AKU 
(Experiment 2, see Chapter 4 (303)) and a plasma flux analysis using a 13C6 
labelled HGA tracer (Experiment 3). These further studies were designed to add 
validation to the differentially abundant entities between HGD-/- and HGD+/- mice 
by reversal of their direction of alteration following nitisinone (Experiment 2), or 
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for entities that were increased in HGD-/- mice in Experiment 1, observation in the 
tracer study (Experiment 3) that they are directly derived from the injected labelled 
HGA. 
5.2  Methods  
5.2.1 Chemicals 
All chemicals were as described for LC-QTOF-MS analysis in Chapter 2 (section 
2.2.2). 
5.2.2 Urine collection (Experiment 1) 
For metabolomic analysis of the targeted HGD knockout phenotype (302), urine 
was collected from 15 HGD-/- (mean age ±SD 12.8 ±0.1 weeks) and 14 HGD+/- 
(mean age 11.6 ±0.3 weeks) male C57BL/6 mice. The ages of HGD-/- and HGD+/- 
mice at the time of sampling were purposely designed to be as equivalent as was 
pragmatically possible, however the age difference of approximately 1 week 
between these mice was statistically significant (unpaired t-test, p <0.0001). 
Despite this difference in age, the measured weight of mice at the time of urine 
collection did not differ significantly between HGD-/- (mean weight 28.5 ±1.8 g) 
and HGD+/- (mean weight 28.1 ±0.8 g) groups (unpaired t-test, p = 0.39), indicating 
that both groups of mice had reached equivalent skeletal maturity. 
Mouse urine was collected and samples were stored as described in Chapter 4 
(section 4.2.2). Samples and group pools for QC were also prepared as described 




5.2.3 Investigating the effect of nitisinone on metabolites showing alteration in 
HGD-/- mice (Experiment 2) 
The effect of nitisinone treatment on the abundance of the urinary metabolites 
shown to be altered in HGD-/- mice (Figure 5.01, Experiment 1) was studied in the 
raw profiling data from Chapter 4. These data were acquired under identical 
analytical conditions to those employed here. The data were from urine collected 
from HGD-/- mice at baseline then after 1 week on nitisinone (in drinking water at 
4 mg/L) and from patients with AKU at baseline then after 24 months on nitisinone 
(2 mg daily). For these mice, HGD disruption was by ENU mutagenesis; the 
disease phenotypes of HGD-/- mice from targeted knockout and ENU 
mutagenesis models are identical (302). 
5.2.4 Design of in vivo metabolic flux experiment and sample collection 
(Experiment 3) 
Metabolic flux analysis was performed by injecting mice with a stable 13C6-labelled 
HGA tracer and taking blood samples at various intervals over the course of 60 
min. Eight C57BL/6 mice were used in this experiment; 4 HGD-/- (3 male, 1 female, 
mean age ±SD 56 ±2.3 weeks) and 4 HGD+/- (4 female, mean age ±SD 58 ±0 
weeks). 
A 1.96 mg/mL 13C6 HGA tracer solution was prepared in sterile saline. Mice were 
kept anaesthetised throughout the experiment with isoflurane. 13C6 HGA tracer 
solution was then injected into the tail vein of each mouse. Injection volume was 
adjusted for each mouse in order to achieve an approximate 1 mmol/L final blood 
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concentration of the tracer. This calculation was based on the estimated total 
blood volume of each mouse from its weight, based on the assumption of a total 
blood volume of 75 mL/Kg for a C57BL/6 mouse (304). Venous tail bleed samples 
were taken at intervals of 2, 5, 10, 20, 40 and 60 min (or as many of these time 
points as possible, according to LASA guidelines (304). Blood was collected into 
Microvette 300 µL lithium heparin capillary tubes (Sarstedt, Germany) and 
centrifuged at 1500 g for 10 min. 25 µL of plasma supernatant was removed and 
stored at -80 °C prior to analysis. Individual plasma samples were analysed 
following dilution by 1:9 plasma:deionised water. Protein precipitation was not 
performed due to sample volume constraints associated with taking consecutive 
samples from the same mice. In addition, plasma samples were analysed by 
method 2 only, in which the LC column used is less susceptible to blockage by 
proteins, due to the larger particle size (3 µm), compared with the columns used 
in methods 1 (1.8 µm) and 3 (1.7 µm). 
5.2.5 LC-QTOF-MS analysis 
All samples were analysed as described in Chapter 4 (section 4.2.3) using LC 
method 2 (Chapter 2, section 2.2.2) The analytical sequence was designed as 
described in Chapter 4 (section 2.4.4). 
5.2.6  LC-QTOF-MS data processing and statistical analyses 
Experiment 1: parallel targeted and non-targeted data mining 
Parallel targeted and non-targeted feature extraction was performed on the data, 
according to the strategy outlined in Chapter 3.  
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Targeted feature extraction was used to extract signals matching the 466-
compound AMRT database generated using parameters detailed in Chapter 2 
(section 2.2.3.); AM (±10 ppm) and database RT (±0.3 min) matches were 
required. Eighty-five additional metabolites (Table S5.01, Supporting Material, 
Appendix 5) were appended to the database for targeted extraction as they were 
of potential interest in AKU or from wider tyrosine metabolism. Forty-three were 
from the following pathway databases available from Pathways to PCDL (build 
07.00, Agilent, UK): ‘citrate degradation’, ‘noradrenaline and adrenaline 
degradation’ and ‘superpathway of phenylalanine, tyrosine and tryptophan 
biosynthesis’. Six metabolites were added as they were predicted to show 
potential alteration in HGD-/- due to association with tyrosine conjugation (acetyl-
L-tyrosine, and γ-glutamyl-tyrosine) based on the data presented in Chapter 4 
(303) or predicted association with ochronotic pigment derived from HGA (2,5-
dihydroxybenzaldehyde, di-dehydro-homogentisic acid, hipposudoric acid and 
norhipposudoric acid). Thirty-six metabolites were from a list of potential 
biotransformation products directly derived from HGA and compiled using the 
Biotransformation Mass Defects application (Agilent; see Supplementary Table 
S5.01, Appendix 5). This tool provides a list of potential metabolic 
biotransformation products covering both phase I (n=19) and II (n=17) metabolism 
for a given compound based on its empirical formula (Figure 5.02). The data were 




Non-targeted feature extraction was performed on the data using the parameters 
described in Chapter 4 (section 4.2.5.2) for mouse urine. 
 
Figure 5.02. Screenshot depicting application of the Biotransformation 
Mass Defects (Agilent) tool for the generation of accurate mass targets for 
theoretical biotransformation products derived from HGA. For a given 
compound empirical formula, the tool can be used to generate predicted products 
from phase I and II metabolism. For HGA, the example shown here (compound 
formula; C8H8O4), 92 theoretically possible biotransformations were generated, 
36 of which had predicted formulae and accurate mass targets; these 36 




Experiment 1: data processing, QC and statistical analyses 
Creatinine normalisation and QC, using data from pooled samples, was 
performed as described in Chapter 4 (section 4.2.7). Statistically significant 
entities were then identified in each dataset by unpaired t-test, comparing HGD-/- 
vs HGD+/- mice with multiple testing correction performed using Benjamini-
Hochberg FDR adjustment. FCs were calculated for differentially abundant 
entities, also after normalisation and QC; these were log2-transformed and based 
on peak area. FC cut-off was not applied for entities with FDR-adjusted p <0.05 
however, in order to retain entities that showed consistent although relatively low 
magnitude abundance differences between comparison groups. PCA was 
performed on each filtered dataset using four-component models. 
Experiment 2: data processing and statistical analyses 
Entities with FDR-adjusted p<0.05 in Experiment 1 (HGD-/- vs HGD+/-) were mined 
in data from Experiment 2 (HGD-/- mice at baseline then after 1 week on 
nitisinone). This was performed by creating a custom AMRT database containing 
only these compound targets, using PCDL Manager (build 08.00, Agilent). The 
dataset was mined for these compounds using targeted feature extraction, also 
in Profinder (build 08.00, Agilent) using the same parameters as for Experiment 
1. The profiles of the extracted entities were compared between baseline and 1 
week on nitisinone samples with paired t-tests (FDR adjusted) and log2-




Experiment 3: data processing and statistical analyses 
Data from plasma samples obtained from Experiment 3 were mined using the 
batch isotopologue extraction function in Profinder (build 08.00). This algorithm 
uses an AMRT target database to extract features and their AM isotopologues to 
perform flux analysis. Here, extraction was performed using the same AMRT 
database employed in Experiment 2 comprising the differentially abundant 
metabolites between HGD-/- vs HGD+/- mice. Database hits were investigated for 
potential association with the 13C6 HGA tracer by examining the relative 
abundances of the M+0 to M+6 isotopologues. Extraction was performed with AM 
and RT match windows of ±5 ppm and ±0.3 min respectively. 
The results from isotopologue extraction on plasma 13C6 HGA metabolic flux data 
were reviewed visually in Profinder for clear evidence of an isotope label likely to 
be derived from HGA. This data review was performed for compound matches 
individually, taking into account the predicted number of 13C atoms derived from 
the HGA tracer based on the compound’s chemical structure. 
5.3 Results 
5.3.1 Identification of differentially abundant urinary metabolites between  
HGD-/- vs HGD+/- mice (Experiment 1) 
PCA showed clear differences between the urine profiles of HGD-/- and HGD+/- 
mice with targeted (Figure 5.03A & B) and non-targeted feature extraction, with 
separation in principal component 1. Data from targeted and non-targeted 
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extraction are presented separately in the following sections. Table 5.01 details 
the number of entities extracted from each method and the number retained 
following QC. 
 
Table 5.01. Number of entities retained before and after quality control (QC). 
QC filtering using pooled group sample data was performed in Mass Profiler 
Professional. ‘Targeted’ and ‘non-targeted’ refer to feature extraction 
approaches. Entities from targeted feature extraction are AMRT-matched against 
a database generated from IROA Technology MS metabolite library of standards 
(466 compounds) or AM-matched against an appended list of compounds from 
wider tyrosine metabolism (85 metabolites). Entities from non-targeted feature 
extraction are unidentified. 
 
  HGD-/- vs HGD+/-  
 
Targeted Non-targeted 
QC filtering step (+) (-) (+) (-) 
Manual curation of entities only 323 324 662 552 
Present in 100% of replicate 
injections of at least one pooled 
group sample 
323 324 569 525 
CV <25% across replicate 
injections of each pooled group 
sample  





Targeted feature extraction 
Targeted feature extraction was performed to search for metabolites based on 
AMRT (AM ±10 ppm, RT ±0.3 min) or AM (±5 ppm) alone. 27/250 and 15/243 
metabolites showed abundance differences (FDR-adjusted p <0.05) between 
HGD-/- and HGD+/- in negative and positive polarity respectively. Table 5.02 shows 
the altered metabolites ranked in order of FC. PCA loadings plots (Figure 5.03C 
& D) and volcano plots (Figure 5.03E & F) show that the greatest differences 
between HGD-/- and HGD+/- urine were in metabolites associated with HGA in 
negative and positive polarity. HGA and 8 predicted HGA biotransformation 
products were markedly elevated in HGD-/-. Interestingly, HGA-sulfate (FC=9.3, p 
<0.0001) showed a greater FC increase than HGA (FC=7.9, p <0.0001). Six other 
HGA products were increased with FC >1.5 and p <0.0001: HGA-glucuronide, 
HGA-hydroxyl-sulfate, HGA-N-acetylcysteine, HGA-hydrate, HGA-(de-alkene)-
epoxide and HGA-(de-ethyl)-carboxylate. Acetyl-HGA was elevated in HGD-/- 
(FC=2.3, p <0.0001) but did not pass QC filtering by CV <25% across replicate 
injections of pooled QC samples; a decrease in signal across the run indicated a 
sample stability issue (despite the autosampler being maintained at 4°C). 
Twenty-six significantly altered entities, excluding the aforementioned HGA, were 
AMRT-matched with compounds from the 466-compound library developed in-
house. The most significantly altered (p <0.05 and FC >1.5) of these were:  
thymidine-5’-diphospho-α-D-glucose, DL-3,4-dihydroxymandelic acid, 2-
aminophenol, p-hydroxyphenylacetic acid (all increased in HGD-/-), malic acid, 







Figure 5.03. Clear differences between the urine metabolomes of HGD-/- and 
HGD+/- mice. A-D: principal components analysis (PCA) on data from targeted 
feature extraction, with PCA plots showing separation between HGD-/- and HGD+/- 
mice by component 1 in A, negative, and B, positive ionisation polarities. Lower 
plots show the corresponding PCA loadings of metabolites on components 1 and 
2 in C, negative, and D, positive polarity. E-F: volcano plots illustrating selection 
of statistically significant urinary chemical entities between HGD-/- and HGD+/- 
mice based on p-value and fold change (FC). E, negative polarity; F, positive 
polarity. Entities with p <0.05 (Benjamini-Hochberg FDR adjusted) and FC >1.5 
are labelled, with red and blue indicating increased and decreased abundance, 
respectively, in HGD-/-. Turquoise indicates adjusted p <0.05 but FC <1.5. 
Bold text indicates that the increase observed in HGD-/- was confirmed in mouse plasma 
following injection with 13C6 HGA tracer. 






Table 5.02. Summary of identified metabolites or chemical entities showing altered abundance in HGD-/- mice. 
Direction of alteration and fold change is indicated in HGD-/- (relative to HGD+/-) and following nitisinone treatment in HGD-/- 
(paired data; on nitisinone relative to baseline). P-values are false discovery rate adjusted. Where entities were significantly 
different in positive and negative polarity, the result with the lowest fold change is provided.  
* Compound identification by matched accurate mass (±10 ppm) and RT (±0.3 min) (otherwise, identification by accurate mass ±5 
ppm only). 
† Entity obtained from non-targeted data mining with putative identification by accurate mass (±10 ppm) only 
‡ Note acetyl-HGA failed quality control filtering (CV >25% across replicate injections of QC pooled samples; due to suspected 
compound stability issue over analysis period). 
Compound Neutral mass RT (min) 
Direction of 
alteration in  
HGD-/- 
Fold change p-value 
HGA-sulfate 247.9996 2.6 ↑ 9.3 <0.0001 
HGA* 168.0434 3.4 ↑ 7.9 <0.0001 
HGA-glucuronide 344.075 2.4 ↑ 5 <0.0001 
HGA-hydroxyl-sulfate 263.9931 2.8 ↑ 4.2 <0.0001 
HGA-N-acetylcysteine 329.057 4.5 ↑ 4 <0.0001 
Thymidine-5’-diphospho-alpha-D-
glucose* 
564.0758 2.4 ↑ 3.3 <0.0001 
Unknown 268.9662 2.6 ↑ 2.8 <0.0001 
Unknown 367.0289 3.4 ↑ 2.6 <0.0001 
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DL-3,4-Dihydroxymandelic acid* 184.037 1.9 ↑ 2.5 <0.0001 
HGA-hydrate 186.053 3.4 ↑ 2.4 <0.0001 
Unknown 507.141 3.4 ↑ 2.4 <0.0001 
Acetyl-HGA‡ 210.053 6.2 ↑ 2.3 <0.0001 
Unknown 287.9939 6.0 ↑ 2.3 0.025 
HGA-(de-alkene)-epoxide 184.0369 1.8 ↑ 2.2 <0.0001 
2-Amino-6-(benzylthio)purine† 257.0758 3.5 ↑ 2.2 <0.0001 
Unknown 257.0391 3.4 ↑ 2.0 <0.0001 
HGA-(de-ethyl)-carboxylate 184.0017 3.4 ↑ 1.8 <0.0001 
2-Aminophenol* 109.0534 1.9 ↑ 1.7 0.035 
Unknown 294.0949 3.6 ↑ 1.7 <0.001 
p-Hydroxyphenylacetic acid* 152.0478 5.5 ↑ 1.6 <0.0001 
Unknown 361.0827 1.7 ↑ 1.5 <0.001 
3-Dehydroshikimic acid* 172.0373 1.8 ↑ 1.2 <0.01 
Hydroxymethyl-HGA 198.0526 4.8 ↑ 1.1 <0.0001 
Aceturic acid* 117.0426 1.7 ↑ 0.94 <0.01 
Nicotinic acid* 123.032 1.8 ↑ 0.8 0.015 
4-Hydroxybenzaldehyde* 122.0368 5.6 ↑ 0.8 0.014 
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Vanillylmandelic acid* 198.0528 3.3 ↑ 0.75 <0.01 
N-Acetyl-DL-serine* 147.0532 1.6 ↑ 0.66 <0.01 
N-Acetylaspartate* 175.0481 1.8 ↑ 0.64 0.018 
Xanthosine* 284.0762 3.4 ↑ 0.53 0.028 
N-Alpha-acetyl-l-asparagine* 174.0641 1.6 ↑ 0.52 <0.01 
N-Acetyl-L-phenylalanine* 207.0895 6.8 ↑ 0.52 0.049 
3,5-Cyclic-AMP* 329.0525 3.4 ↑ 0.44 0.012 
Malic acid* 134.0211 1.5 ↓ 2.6 <0.001 
Isocitrate* 192.0278 1.7 ↓ 2.1 <0.001 
Vanilyl pyruvic acid† 256.0582 5.0 ↓ 2.1 <0.001 
Inosine 5’-monophosphate* 348.05 1.8 ↓ 2 <0.001 
Unknown 242.0427 4.0 ↓ 1.7 <0.0001 
Unknown 362.086 9.6 ↓ 1.6 <0.01 
Glucuronolactone* 176.0321 1.6 ↓ 1.4 <0.01 
Methylmalonic acid* 118.0266 2.0 ↓ 1.1 <0.0001 
Monomethyl-glutaric acid* 146.0579 5.1 ↓ 0.82 0.029 
N-Acetyl-L-glutamic acid* 189.0637 2.1 ↓ 0.76 <0.01 
Citramalic acid* 148.039 2.6 ↓ 0.7 <0.0001 
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L-anserine* 240.1222 1.3 ↓ 0.59 <0.01 
2,3-Cyclic AMP* 329.0525 2.7 ↓ 0.58 <0.01 
O-Succinyl-L-homoserine* 219.0743 2.0 ↓ 0.35 0.019 
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Non-targeted feature extraction 
Non-targeted feature extraction was performed using recursive feature extraction, 
resulting in 359 and 213 chemical entities post-QC in negative and positive 
polarity respectively; mass range = 54-3108 Da and RT range = 1.1-11.5 min. 
Comparison of HGD-/- and HGD+/- revealed entities with clear abundance 
differences (p <0.05, FC >1.5); 9 entities in negative polarity (6 increased in   
HGA-/-, 3 decreased in HGD-/-) and 2 entities in positive polarity (both increased 
in HGD-/-). The mass range of these entities was 242-507 Da, and RT range was 
1.7-9.6 min (Table 5.02). The chemical identities of these entities are unknown, 
but potential candidates were obtained for two entities based on AM match (<10 
ppm) with the Masshunter METLIN metabolites PCD/PCDL accurate mass 
database (build 07.00); 2-amino-6-(benzylthio)purine (increased in HGD-/-) and 
vanilyl pyruvic acid (decreased in HGD-/-). The METLIN database used contains 
30,232 compound entries and was accessed through PCDL Manager (build 
08.00, Agilent, UK). 
5.3.2 The effect of nitisinone treatment on chemical entities altered in HGD-/-
 
mice 
To investigate the effect of nitisinone treatment on the chemical entities shown to 
be altered here in HGD-/-, they were searched in the data from previous mouse 
and human urine profiling experiments (Figure 5.01, Experiment 2). These data 
were acquired from HGD-/- mice at baseline then after 1 week on nitisinone, and 
from patients with AKU at baseline then after 24 months on nitisinone. Entities 
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were extracted by targeted molecular feature extraction, with AM (±10 ppm) and 
RT (±0.3 min) matches required. Targeted data extraction and subsequent QC 
parameters were as described above. 
Eight entities from targeted feature extraction that were altered in HGD-/- vs HGD+/- 
mice were significantly altered in the opposite direction in urine from both HGD-/- 
mice and patients with AKU following nitisinone (based on peak area; baseline vs 
on nitisinone, Benjamini-Hochberg FDR-adjusted p <0.05; Table 5.03); 7 
decreased, and 1 increased. The 7 decreased metabolites were HGA, the HGA 
biotransformation products HGA-sulfate, HGA-glucuronide, HGA-hydrate and 
hydroxymethyl-HGA, and also xanthosine and 3,5-cyclic-AMP. The increased 
metabolite was monomethyl-glutaric acid. Interestingly, p-hydroxyphenylacetic 
acid and 4-hydroxybenzaldehyde were increased both in HGD-/- vs HGD+/- and 
also following nitisinone in HGD-/- mice and patients with AKU. 
In addition, 19 entities that were altered in HGD-/- vs HGD+/- mice were significantly 
altered in the opposite direction following nitisinone in urine from either HGD-/- 
mice (n=14; 9 decreased, 5 increased on nitisinone) or patients (n=5; 4 
decreased, 1 increased on nitisinone) with AKU only (Table 5.03). These 
compounds comprised the remaining HGA biotransformation products, with the 
exception of HGA-(de-ethyl)-carboxylate, which were all decreased following 
nitisinone. Following nitisinone, acetyl-HGA was decreased in human urine only, 
and HGA-hydroxyl-sulfate, HGA-N-acetylcysteine and HGA-(de-alkene)-epoxide 
were decreased in mouse urine only. 
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Table 5.03. The effect of nitisinone treatment in HGD-/- mice and patients with AKU on the abundance of urinary 
chemical entities altered in HGD-/- vs HGD+/- mice. The entities that showed differences between HGD-/- vs HGD+/- mice 
(Table 5.02) were examined in two additional datasets. Paired t-tests were employed to compare the abundances at 
baseline versus 1 week on nitisinone (4 mg/L, in drinking water) for HGD-/- mice and 24 months on 2mg daily nitisinone for 
patients with AKU. Only entities with false discovery rate adjusted p<0.05 baseline vs on nitisinone in mouse or human are 
displayed. Direction of alteration and fold change are indicated. Where entities were significantly different in positive and 
negative polarity, the result with the lowest fold change is provided. Note: no fold change indicated for hydroxymethyl-HGA 
in humans, as this compound was not detected for any patient on nitisinone. 
* Compound identification by matched accurate mass (±10ppm) and RT (±0.3min) (otherwise, identification by accurate mass ±5ppm 
only). 
† Entity obtained from non-targeted data mining with putative identification by accurate mass (±10ppm) only 
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HGA-glucuronide 344.075 2.4 ↓ 2.4 <0.0001  ↓ 2.4 <0.0001 
HGA-(de-alkene)-epoxide 184.0369 1.8 ↓ 2.3 <0.0001  -   
HGA-hydroxyl-sulfate 263.9931 2.8 ↓ 2.3 <0.0001  ND   
2-Aminophenol* 109.0534 1.9 ↓ 2.2 <0.001  -   
HGA-sulfate  247.9996 2.6 ↓ 2.2 <0.0001  ↓ 3.5 <0.0001 
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Unknown 268.9662 2.6 ↓ 2.0 <0.0001  ND   
DL-3,4-Dihydroxymandelic 
acid* 
184.037 1.9 ↓ 1.6 <0.0001  -   
HGA* 168.0434 3.4 ↓ 1.6 <0.0001  ↓ 3.4 <0.0001 
Hydroxymethyl-HGA  198.0526 4.8 ↓ 1.1 <0.001  ↓ - <0.0001 
Aceturic acid* 117.0426 1.7 ↓ 1.1 <0.0001  -   
Xanthosine* 284.0762 3.4 ↓ 1 <0.0001  ↓ 2.2 <0.0001 
HGA-hydrate 186.053 3.4 ↓ 0.8 <0.0001  ↓ 3.8 <0.0001 
HGA-N-acetylcysteine  329.057 4.5 ↓ 0.7 <0.001  -   
N-Acetyl-DL-serine* 147.0532 1.6 ↓ 0.5 0.031  -   
Nicotinic acid* 123.032 1.8 ↓ 0.4 0.014  -   
3,5-Cyclic-AMP* 329.0525 3.4 ↓ 0.3 0.041  ↓ 2 <0.0001 
Acetyl-HGA 210.053 6.2 -    ↓ 2.7 <0.0001 
Vanillylmandelic acid* 198.0528 3.3 -    ↓ 1 <0.01 
2-Amino-6-
(benzylthio)purine† 
257.0758 3.5 -   
 
↓ 0.9 0.035 
N-Alpha-acetyl-l-asparagine* 174.0641 1.6 -    ↓ 0.4 <0.01 
Malic acid* 134.0211 1.5 ND    ↑ 0.8 0.028 
p-Hydroxyphenylacetic acid* 152.0478 5.5 ↑ 3.3 <0.0001  ↑ 3 <0.0001 
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4-Hydroxybenzaldehyde* 122.0368 5.6 ↑ 2.32 <0.0001  ↑ 6.6 <0.0001 
N-Acetyl-L-phenylalanine* 207.0895 6.8 ↑ 1.8 <0.0001  -   
Unknown 294.0949 3.6 ↑ 1.8 <0.0001  ↓ 0.6 <0.001 
Unknown 362.086 9.6 ↑ 1.4 <0.0001  ND   
Isocitrate* 192.0278 1.7 ↑ 1.2 <0.01  -   
N-Acetylaspartate* 175.0481 1.8 ↑ 0.9 0.023  -   
Citramalic acid* 148.039 2.6 ↑ 0.8 0.023  -   
N-Acetyl-L-glutamic acid* 189.064 2.1 ↑ 0.8 <0.0001  -   





5.3.3. Confirmation of HGA biotransformation products by 13C6 HGA metabolic 
flux analysis (Experiment 3) 
Data from isotopologue extraction were compared between plasma collected 
from the same mice across the time intervals available (2-60 min). The M+6 
isotopologue was of particular interest as mice were injected with 13C6-labelled 
HGA (although M+ 0-5 isotopologues were also considered for compounds where 
the labelled 13C carbons of the benzene ring could potentially be removed through 
metabolism of HGA). 
The M+6 peak was clearly observable for HGA over the sampling time course in 
HGD-/- and HGD+/- mice, although the signal decreased considerably from 10-20 
min post-injection (Figure 5.04). As indicated in Figure 5.03 (compounds in bold 
text), 2 HGA biotransformation products that were increased in HGD-/- urine were 
observed with clear M+6 peaks in plasma over the time course; HGA-glucuronide 
and HGA-sulfate. These data confirm that the compounds are derived from HGA. 
HGA-sulfate showed a similar time course profile to HGA. For this compound the 
native M+0 isotopologues were also absent from HGD+/- plasma at all time points, 
in contrast to the M+6 isotopologue whose profile appeared to closely follow that 
of the HGA M+6 peak over the time course in both HGD-/- and HGD+/-. For HGA-
glucuronide, the native M+0 isotopologue was also absent from HGD+/- plasma, 
but the M+6 isotopologue was only observed in HGD-/-, indicating that 






Figure 5.04. Isotopologue extraction results on plasma from the in vivo metabolic flux experiment using injected 
13C6-labelled homogentisic acid (HGA). Data shown are from HGD-/- and HGD+/- samples taken at intervals of 2, 5, 10, 
20, 40 and 60 min (when possible) after injection. Extracted ion chromatograms (EICs) represent the M+0 (native 
compound) and M+6 (13C6-labelled form) isotopologue signals for homogentisic acid (HGA), HGA-sulfate and HGA-
glucuronide. EICs show clear M+6 peaks for these compounds following injection (but only from HGD-/- mice for HGA-




AKU holds a unique place in history as the first disease shown to follow Mendelian 
inheritance (305). The genetic cause of AKU has therefore long been understood. 
Mutations in a single gene, HGD, have the clear biochemical consequence of 
elevated HGA which is deposited in tissues and forms ochronotic pigment; the 
central pathophysiological event that causes the morbidity observed in AKU (16). 
Despite this archetypal genotype-phenotype relationship, the data reported here 
from the first metabolome-wide comparison of non-treated AKU vs non-AKU 
(HGD-/- vs HGD+/- mice; Experiment 1) reveal that the biochemical consequences 
of HGD-deficiency are wider-reaching than previously recognised and extend 
beyond tyrosine metabolism. The data also reveal that previously 
uncharacterised phase I and II metabolic processes are recruited as detoxification 
mechanisms in AKU for clearance of the markedly increased HGA. The 
observation of a reversed direction of alteration for a number of these urinary 
metabolites following nitisinone treatment in mice and patients with AKU 
(Experiment 2) indicates that these changes observed in the mouse model of AKU 
also apply to the human form of the disease. 
5.4.1 Phase I and II metabolic biotransformation processes are recruited for 
clearance of HGA in AKU 
The clearest differences between the urine metabolomes of HGD-/- versus HGD+/- 
mice were associated with increased HGA; HGA and 8 previously unreported 
HGA-derived biotransformation products were increased in HGD-/- (FDR-adjusted 
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p<0.0001). The HGA-derived products result from a range of phase I and II 
metabolic processes and represent alternative metabolic routes that appear to be 
activated at the supraphysiological circulating concentrations of HGA observed in 
AKU. Figure 5.05 shows the predicted structures for 7 of these novel compounds 
and the enzyme families responsible for their production. The observation of 
reversed alteration (decreases) in HGA-sulfate, HGA-glucuronide, HGA-hydrate, 
acetyl-HGA and hydroxymethyl-HGA following nitisinone treatment in urine from 
patients with AKU (Experiment 2) adds validation and indicates that these newly-
identified HGA biotransformation processes are also recruited in human AKU. 
Observation of 13C6-labelled forms of HGA-glucuronide and HGA-sulfate in 
plasma following intravenous injection of 13C6-HGA in mice (Experiment 3), giving 
final blood concentrations up to 1 mmol/L, confirmed that these products are 
directly derived from HGA. 13C6-HGA-sulfate was observed for HGD-/- and HGD+/- 
mice and followed the profile of the 13C6-HGA across the sampling time course. 
Interestingly, 13C6-HGA-glucuronide was only observed in HGD-/-, suggesting that 
glucuronidation is an additional reaction recruited only in HGD deficiency and 
perhaps reflective of prior upregulation of glucuronyltransferase activity for HGA 
clearance as part of the pre-existing AKU phenotype. HGA-glucuronide (FC=5) 
and HGA-sulfate (FC=9.3), together with HGA (FC=7.9), showed the greatest 
overall increases in HGD-/- versus HGD+/-. The magnitude of these alterations are 
of potential high clinical importance in AKU both in monitoring the disease and in 
the development of rational disease management strategies in AKU, as they 
reveal for the first time the specific metabolic processes that are major 
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mechanisms for clearance and excretion of the elevated HGA in HGD-/- mice and 
patients with AKU. HGA is the culprit molecule in AKU which causes the 
pathological manifestations of the disease. HGA forms ochronotic pigment, 
purportedly through its reactive oxidation products, which binds to collagenous 
tissues and modifies the extracellular matrix (15). Ochronosis of articular cartilage 
causes it to become stiff and brittle, leading to the mechanical failure that 
underlies the inevitable and severe osteoarthropathy observed in AKU (306). 
Oxidative stress is also considered a major consequence of ochronosis. The 
benzoquinone compounds that are intermediates in ochronotic pigment formation 
are thought to be highly reactive species capable of inducing oxidative changes 
to proteins and lipids (41,307). These oxidative alterations are likely to perpetuate 
the chronic inflammation present in AKU as a result of ochronotic 
osteoarthropathy and could account for cases of acute fatal metabolic 
consequences reported in the literature (21). I propose that the phase I and II 
biotransformations identified are detoxification mechanisms to render HGA 
chemically inert in order to prevent its participation in these pathological 
processes. 
The HGA biotransformation data further current knowledge of metabolism in AKU 
considerably, as very little exists in the literature about HGA clearance beside its 
conversion to maleylacetoacetic acid by the HGD enzyme in the traditional 
tyrosine degradation pathway. Phase I and II pathways are traditionally 
considered as routes for drug metabolism with their enzymes primarily located in 
the liver; and within close proximity to enzymes of the major tyrosine pathway 
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(174). Phase I metabolism comprises reactions to introduce reactive or polar 
groups to substrates and includes hydroxylation, oxidation, reduction and 
hydrolysis. Phase II metabolism involves conjugation reactions to form 
glucuronide, glutathione, mercapturic acid, amino acid, methyl and acetyl 
conjugates (308,309). There is heterogeneity in the reactions required for 
metabolism of different drugs/compounds; phase I and II reactions may occur 
sequentially, or some compounds may only undergo phase I or II metabolism 
(310,311). Clearance of HGA in AKU by alternative phase I and II metabolic 
reactions has been predicted previously by reference to acetylsalicylic acid 
(aspirin), a structurally analogous weak organic acid whose metabolism is well-
characterised (174). The present data confirm these predictions for the first time 
by revealing that in HGD-/- mice a range of phase I and II mechanisms, alone and 
in combination, are recruited for HGA clearance. The phase I metabolites 
observed were formed via hydration (HGA-hydrate), alkene epoxidation (HGA-
(de-alkene)-epoxide) and ethyl to carboxylate (HGA-(de-ethyl)-carboxylate) 
transformations. Phase II metabolite products were formed via conjugation with 
glucuronic acid (HGA-glucuronide), N-acetylcysteine (HGA-N-acetylcysteine 
desaturate) and sulfate (HGA-sulfate) and acetyl (acetyl-HGA) groups. 
Sequential phase I and II reactions were hydroxylation with subsequent 




Figure 5.05. Predicted structures of newly-identified homogentisic acid 
(HGA) clearance products resulting from phase I and II metabolism. The 
proposed sites for metabolism/conjugation were those with the greatest 
probability from in silico prediction tools Stardrop (Optibrium, UK) and Reacting 
Atom (Way2Drug, Russia), for phase I and II biotransformations respectively. 
Note: HGA positions labelled 7 and 11 have equal probability for sulfation (deltaP 
= 0.8). 
 
The phase I and II processes identified are catalysed by enzymes belonging to 
supergene families that can act on a broad range of substrates. For example, 
glucuronidation is quantitatively one of the most important phase II 
biotransformation reactions and is known to be carried out by 15 UPD-
glucuronosyltransferase enzymes in humans (312,313). Identification of the 
specific enzymes within these families that catalyse these HGA 
biotransformations could inform future therapeutic interventions aimed at 
enhancing their activity in AKU. However, potential off-target effects of such 
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approaches should be considered given the range of substrates that enzymes of 
phase I and II metabolism can act upon. It is also worth highlighting that not all 
products of phase I and II metabolism reflect adaptive clearance mechanisms, as 
some biotransformation reactions produce reactive metabolites. Such 
‘bioactivation’ reactions increase the risk of adverse effects and are therefore a 
major concern in drug design (314,315). In relation to the present data, HGA-(de-
alkene)-epoxide is likely a product of HGA bioactivation, as epoxide metabolites 
are generally reactive, electrophilic compounds that require further enzymatically-
mediated detoxification (316,317). 
5.4.2 Associated alteration to tyrosine, purine and TCA cycle metabolism in 
AKU 
Previous metabolomic studies in AKU have focused solely on the impact of 
nitisinone on the metabolome (220,234,235,303,318) (52), which was also the 
main focus of Chapter 4. Nitisinone reversibly inhibits HPPD, the enzyme 
responsible for production of HGA, and it has emerged as a promising therapeutic 
agent in AKU. Nitisinone reduces plasma and urine HGA concentrations 
(11,12,14,18,219), completely arrests ochronosis in AKU mice (50,69) and more 
recently was shown to slow progression of morbidity in AKU patients with access 
to nitisinone (2mg daily dose) through the NAC in the UK (140). LC-QTOF-MS 
metabolomics employing the AMRT identification strategy also used here showed 
for the first time that nitisinone treatment resulted in a host of previously 
undescribed changes in urine (303) and serum (234) metabolites beyond the 
tyrosine pathway in patients and mice with AKU. On nitisinone, a complex pattern 
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of alteration was observed in metabolites of tyrosine, tryptophan, purine and TCA 
cycle pathways. These findings are of clinical importance in AKU and also HT-1, 
in which nitisinone is licensed, as there are concerns surrounding the wider 
metabolic fate of the markedly increased tyrosine levels observed in patients on 
nitisinone (46). 
This study explored the metabolome-wide consequences of HGD deficiency for 
the first time, revealing that in untreated HGD-/- vs HGD+/- mice there is alteration 
to tyrosine, purine and TCA cycle urinary metabolites (Figure 5.06). These data 
add to a growing body of evidence from metabolomic studies that perturbations 
in tyrosine, purine and energy metabolism are linked in numerous disease states. 
Two CSF metabolic profiling studies in Alzheimer’s disease report an overlapping 
network of perturbations in tyrosine, tryptophan, purine and tocopherol pathways 
(270,271). LC-MS metabolomics also revealed altered phenylalanine, tyrosine, 
purine, TCA cycle, energy and lipid metabolism in serotonin-deficient (tryptophan 
hydroxylase knockout) mice (319): serotonin deficiency is associated with 
numerous neuropathologies including Alzheimer’s and Parkinson’s diseases, 
schizophrenia and depression. Associated network-level alteration to tyrosine, 
phenylalanine, purine, pyrimidine and energy metabolism was also reported more 




Figure 5.06. Summary of metabolites altered in HGD-/- mouse urine grouped 
by their associated pathways. Left: the tyrosine degradation pathway showing 
lack of the enzyme HGD in AKU and the consequential increase in homogentisic 
acid (HGA). Right (boxes): observed metabolite alterations grouped by pathway; 
red and blue indicate increased and decreased abundance respectively. Tyrosine 
metabolites including HGA, and HGA clearance products from phase I and II 
metabolism were elevated. Metabolites associated with the TCA cycle were 
decreased. A combination of increased and decreased abundance was observed 
for purine pathway metabolites. 
  
Alteration to tyrosine metabolism 
The observed increases in tyrosine metabolites (excluding HGA-associated 
clearance products) were not expected in untreated AKU. Increases in tyrosine 
metabolites previously observed in nitisinone-treated AKU were thought to be a 
direct consequence of the markedly elevated tyrosine induced by inhibition of 
HPPD (234,303). Increased p-hydroxyphenylacetic acid and 4-
hydroxybenzaldehyde were observed previously in serum (234) and urine (303). 
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The biological significance of these changes is unknown. p-Hydroxyphenylacetic 
acid is generated from gut microbiota and its increase following nitisinone was 
proposed to reflect enhanced microbial metabolism due to reduced oxidative 
stress upon commencement of treatment (234). 4-Hydroxybenzaldehyde is a 
naturally occurring metabolite thought to have various therapeutic benefits in 
numerous diseases (320). Benzaldehydes may also relate to the proposed 
benzoquinone intermediates involved in the formation of ochronotic pigment from 
HGA, but the reason for the further increase in 4-hydroxybenzaldehyde following 
nitisinone is inconsistent with this and requires explanation. 
DL-3,4-Dihydroxymandelic acid and vanillylmandelic acid (VMA) were also 
increased in HGD-/- mice; these are catecholamine metabolites derived from 
noradrenaline. Noradrenaline is derived from tyrosine via L-DOPA and dopamine, 
and it can be metabolised to DL-3,4-dihydroxymandelic acid (via DHMA) then to 
VMA or alternatively to adrenaline or NMA. Increased DL-3,4-dihydroxymandelic 
acid and VMA indicate increased metabolism of noradrenaline via DHMA as 
opposed to adrenaline or NMA in untreated AKU, which is also supported by a 
previous observation of  decreased urinary NMA in patients with AKU following 
nitisinone (235). Neuroblastomas secrete catecholamine and MA metabolites, 
and the elevation of these compounds in urine forms part of the primary diagnostic 
criteria (321,322). Increased urinary output of DHMA and VMA is well-recognised 
in neuroblastoma, although the main markers of interest are usually increased 
urinary 3-MT, dopamine and HVA. 
 Together, it is not clear how these unexpected changes to tyrosine and peripheral 
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neurotransmitter metabolism are related to the increased HGA observed in 
untreated AKU. Previous metabolomics studies, including the data reported in 
Chapter 4, found similar alteration to peripheral neurotransmitter metabolism in 
patients with AKU on nitisinone treatment (234,235,303), and this was thought to 
result from the well described hyper-tyrosinaemia observed following nitisinone 
therapy through its action on the HPPD enzyme. However, these studies did not 
include a non-AKU control group, preventing comparison of the untreated AKU 
metabolome with that of healthy individuals. The data reported here reveal that 
even in untreated AKU, HGD deficiency leads to accumulation of tyrosine 
pathway metabolites upstream of HGA. The mechanism for altered peripheral 
neurotransmitter metabolism in untreated AKU is unknown. One could speculate 
that the alteration relates to the increased HGA or an unknown feature of the 
disease. For example, it is conceivable that HGA could act on other enzymes of 
neurotransmitter metabolites and therefore alter their activity. Further research is 
required to explore this potential mechanism.  It is also important to determine 
whether the changes observed in peripheral neurotransmitter metabolism are a 
true reflection of altered CNS homeostasis. Recent mass spectrometric mouse 
brain imaging analyses support that in nitisinone-treated AKU, CNS metabolic 
alteration is limited to tyrosine and tyramine (52). Further analyses of CNS tissues 
and biofluids (CSF) are required to provide a clearer picture of neurotransmitter 





Alteration to purine metabolism 
In nitisinone-treated AKU the previously reported purine metabolite changes were 
generally decreased concentrations. Following nitisinone, 3-ureidoproprionate, 
adenine and allantoin were decreased in human urine, and 3,5-cyclic AMP and 
xanthosine were decreased in human and mouse urine (303). The present data 
indicate a more complex pattern of alteration to purine metabolism in non-treated 
AKU, with increased 3,5-cyclic AMP and xanthosine, and decreased 2,3-cyclic 
AMP and inosine 5’-monophosphate. 
The link between altered tyrosine metabolism, as observed in nitisinone-treated 
and untreated AKU, and purine metabolism is unclear. The alteration in purine 
metabolism perhaps most associated with pathology is elevated uric acid, the 
classic example being gout, in which elevated blood uric acid leads to formation 
of crystals in and around joints, causing painful arthritis. Increased urinary uric 
acid is also a well-known risk factor for renal dysfunction, hypertension, 
hyperlipidemia, diabetes and obesity (323). Purine catabolism is very important 
in the homeostatic response to various states of mitochondrial oxidative stress, 
with shifts occurring to favour breakdown to xanthine and uric acid (324,325). The 
increased xanthosine and decreased 2,3-cyclic AMP and inosine 5’-
monophosphate reported here for HGD-/- mice is consistent with a shift in purine 
catabolism in response to oxidative conditions, as xanthosine is a direct precursor 
for xanthine and uric acid. In support of this interpretation, xanthosine is reportedly 
increased in urine from rats with the inflammatory conditions chronic kidney 
disease (260) and diabetes nephropathy, and decreased markedly following 
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administration of nephroprotective therapy (261). It is however, unclear why 
concomitant increases were not observed for xanthine and uric acid in this study. 
There is equilibrium between xanthosine and xanthine, but the explanation of an 
apparent equilibrium shift in favour of xanthosine specifically remains unknown. 
It is also unclear why accumulation of xanthosine but not allantoin was observed 
in HGD-/-, as allantoin is also derived from xanthine, and formed spontaneously 
from uric acid under conditions of oxidative stress (see Chapter 4, Figure 4.29).  
As discussed in Chapter 4, nitisinone treatment led to decreases in urinary 
concentrations of the purine metabolites 3,5-cyclic AMP, 3-ureidopropionate, 
adenine, allantoin and xanthosine. The increased xanthosine in untreated HGD-/- 
here supports the interpretation that nitisinone alleviates the shift in purine 
metabolism towards xanthine that is a consequence of the oxidative conditions 
associated with AKU pathology. Oxidative stress is considered a major 
pathological feature of AKU that is a consequence of elevated HGA and 
ochronotic osteoarthropathy (16,41). Significant oxidative modification has been 
observed in AKU for a range of serum and chondrocyte proteins in addition to 
lipid peroxidation and depletion of endogenous anti-oxidants (41). These 
oxidative conditions are thought to induce further inflammation and to initiate a 
vicious circle of disease in AKU, in which oxidative stress leads to further 
ochronosis and tissue destruction, which in turn stimulates further inflammation 
and oxidation. 




Alteration to TCA cycle metabolism 
Decreases in TCA-related metabolites in HGD-/- mice is the first indication of 
perturbed energy metabolism in untreated AKU. Citramalic acid, isocitrate and N-
acetyl-L-glutamic acid were also increased following nitisinone in HGD-/-, 
suggesting for the first time that nitisinone is at least partially restorative. Malic 
acid and isocitrate are major intermediates of the TCA cycle; the primary energy-
producing pathway of the cell. Citramalic acid and N-acetyl-L-glutamic acid are 
more peripheral to the TCA cycle but have been included here as they are derived 
from succinic acid and glutamine respectively. Blood and urine levels of TCA 
metabolites are generally considered to directly reflect overall TCA cycle activity 
(326). Inhibited TCA cycle activity could be due to overall mitochondrial 
biogenesis, decreased expression of genes encoding TCA cycle enzymes or 
reduced substrate availability. The latter explanation seems the most likely in 
AKU, in which HGD deficiency prevents further metabolism of HGA to fumaric 
acid, an intermediate of the TCA cycle. Decreased bioavailability of fumaric acid 
may then explain the decreases observed for other TCA cycle metabolites. 
Previous analyses have investigated the serum levels of TCA cycle metabolites 
in AKU, but these were limited to studying the effect of nitisinone. In contrast to 
the present urinary data, the TCA metabolites succinic acid and α-ketoglutaric 
acid were decreased in serum from patients with AKU following nitisinone (234). 
The significance of these decreases is not known, and further studies should 
investigate whether the alteration to urinary TCA cycle metabolites reported here 
also applies to serum in untreated AKU. 
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Decreased urinary citrate (precursor for and structural isomer of isocitrate) is a 
well-known risk factor for kidney stone formation. It is possible that the decreased 
isocitrate reported here for HGD-/- mice is associated with the increased risk of 
kidney stones in AKU (327). In this analysis isocitrate was the closest match 
obtained for this particular entity (RT = 1.7 min) based on its AMRT in our 
database generated from standards (RT = 1.6 min), but citric acid is also a 
potential match, with the same AM but slightly different database RT (1.9 min). It 
is important to note that the database RTs were obtained from standards 
analysed in blank matrix, therefore a degree of RT shift can be expected in urine 
matrix due to effects such as pH. Hypocitratururia is generally defined as citric 
acid excretion <320 mg (1.67 mmol) per day in adults (328). The present profiling 
data are semi-quantitative, therefore targeted quantitative assays are required to 
determine exact urinary citric acid concentrations in AKU patients and the 
additional therapeutic value of nitisinone in this regard. 
5.4.3  Study strengths and limitations 
 A major challenge in studies aiming to characterise the metabolome-wide profile 
of a human disease is the selection of a suitable control group. The metabolome 
is extremely sensitive to genetic and environmental influences (93) which can bias 
the interpretation of classic ‘case versus control’ comparisons unless careful 
measures are taken to control them. Studying gender and age-matched 
genetically related mice housed in identical living conditions and with targeted 
disruption to the HGD gene (homozygous versus heterozygous knockout) limited 
potentially confounding genetic and environmental variation and increased 
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confidence that the metabolite alterations observed are associated with the AKU 
phenotype. 
A limitation of urine metabolomics studies in mice is the increased difficulty of 24-
h urine collection compared with human subjects, meaning that metabolite 
abundances obtained here could not be normalised to total creatinine output over 
this period to account for urine dilution. Attempts were made to overcome this by 
normalising metabolite signals to that obtained for creatinine in this analysis by 
matched AMRT against a standard, as described in Chapter 3 (section 3.4.1)  
(303). A second limitation in Experiment 3 was that the final predicted blood 
concentration of the injected 13C6 HGA (1mmol/L) was in excess of HGA 
concentrations observed in AKU; 30 ±12.9 µmol/L in untreated AKU patients (12). 
This concentration was designed to overcome potential issues of analytical 
sensitivity associated with rapid metabolism of the tracer to downstream products. 
Further studies employing quantitative assays for the HGA clearance metabolites 
identified could more accurately assess the contribution of each of the phase I 
and II metabolic processes at HGA concentrations observed in AKU. 
5.5 Chapter 5 conclusion 
The metabolome-wide profiles of untreated AKU (HGD-/- mice) versus non-AKU 
(HGD+/- mice) were compared for the first time. The data indicate that targeted 
homozygous disruption to the HGD gene in mice, which causes a clear AKU 
phenotype, is associated with a host of previously unknown metabolite changes 
in a complex network of pathways associated with altered tyrosine metabolism. 
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Using biotransformation prediction tools it was also revealed for the first time that 
a range of phase I and II metabolic processes are important for clearance of the 
elevated HGA that is central to the pathological manifestation of AKU. Decreases 
in 5/8 HGA biotransformation products were also observed in urine from patients 
with AKU following nitisinone therapy for HGA reduction, indicating that these 
HGA clearance mechanisms are also recruited in the human disease. These data 
also have wider, clinically-significant implications beyond AKU by showing that 
phase I and II metabolic processes are recruited for detoxification of endogenous 
metabolites that can accumulate as a consequence of inherited metabolic 
disease. The findings in this chapter therefore highlight that it is a fundamental 
misconception to view these ancient, evolved processes solely as mechanisms 
for drug clearance. 
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Ochronotic pigment is derived from HGA and central to disease pathology in AKU. 
Elucidation of the chemical structure of ochronotic pigment and the mechanism 
by which it interacts with the cartilage matrix is fundamental to understanding the 
destructive process of ochronosis (329).  
One of the simplest approaches to studying ochronotic pigment formation is from 
pure solutions of HGA in vitro in the absence of the complex macromolecular 
collagen matrix. It is well-known that pigment can be formed non-enzymatically 
via spontaneous autoxidation of HGA (150). As discussed in Chapter 1 (section 
1.3), it has long been generally assumed in the literature that ochronotic pigment 
formation adheres to the classic scheme, whereby HGA is oxidised to the 
intermediary BQA, which then undergoes subsequent self-polymerisation to 
produce ochronotic pigment (Figure 1.01B). However, there is a lack evidence 
that ochronotic pigment is polymeric in proportion, and even less evidence that 
ochronotic pigment meets the classic definition of a polymer in that it comprises 
regularly repeating chemical subunits that are covalently bound. 
In the following series of experiments, a range of NMR- and MS-based analytical 
techniques were employed to study pigment formed in the laboratory under 




6.2.1 Solutions of HGA, BQA and HGA-derived pigment 
The following solutions were prepared from synthetic HGA (≥98% purity; Sigma-
Aldrich, UK). All solutions were prepared using deionised water (purified in-house 
via DIRECT-Q 3UV Millipore water purification system) and in glass. A 
photograph of solutions 1-5 is shown in Figure 6.01. 
1. HGA (no alkalinisation) 
2. BQA (by nitrous acid method) 
3. HGA – to BQA (by autoxidation): pH 9.5 
4. HGA – to BQA (by autoxidation): pH 11  
5. Pigment from HGA aged for 4 months at 37°C (referred to as ‘HGA-
derived pigment’ from here onwards) 
First, 10 mL of a 100 mmol/L stock solution of HGA was prepared from HGA 
powder. Solution 1 was prepared by 1:49 dilution of the HGA stock in water, 
resulting in a 2 mmol/L solution of HGA.  
Solution 2 was prepared following the nitrous acid method described by Consden 
et al. (152). First, 0.1 mL of a 0.15 mol/L sodium nitrite (Sigma-Aldrich, UK) 
solution was added to 0.1 mL of the 100 mmol/L HGA stock solution. 2 mL of a 
0.01 mmol/L phosphate buffered saline (PBS) solution (pH 6.8) was then added, 
followed by 0.5 mL of 0.1 mmol/L HCl. The solution was left to stand for 5 min, 
then 2.3 mL PBS (as above) was added, giving a final BQA concentration of 2 
mmol/L. The pH was adjusted to 6.7 using 5 mmol/L NaOH.  
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Solutions 3 and 4 were prepared from dilution of the HGA stock in 0.01 PBS 
solution (as above) to give HGA solutions of 2 mmol/L. Autoxidation of HGA was 
initiated by adjusting the pH to 9.5 and 11, for solutions 3 and 4 respectively, using 
NaOH as above. These solutions are referred to as BQA formed via autoxidation. 
For formation of pigment from synthetic HGA (solution 5), the HGA stock solution 
was diluted 1:9 with water to give 10 mL of a 10 mmol/L aqueous solution of HGA. 
The solution was incubated in a glass vial at 37°C. A gradual darkening of the 
solution was observed across the total incubation period of approximately 4 
months. The solution was then diluted 1:4 in deionised water for concentration 
equivalence (2 mmol/L) with the other solutions.  
A solution of melanin was prepared for comparison. The melanin was formed 
synthetically by oxidation of tyrosine with hydrogen peroxide (Sigma-Aldrich, UK). 
Melanin powder was dissolved in 1 mL dimethyl sulfoxide to give a 10 mmol/L 
stock solution. The stock solution was diluted 1:4 in water, also for concentration 
equivalence. 
6.2.2 Incubation of HGA and BQA with amino acids 
A series of incubations were performed at 37°C between HGA/BQA and several 
amino acids to assess potential interactions. Incubations were between HGA and 
arginine, cysteine, glycine or hydroxylysine, and between BQA and glycine or 
cysteine. Incubations were performed in glass. 
HGA and BQA (nitrous acid method) were from the same stock solutions 
described above. All solutions were prepared at 37°C from 0.01 mmol/L PBS (pH 
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7.4) that had equilibrated to this temperature. Separate solutions were prepared 
for each amino acid (Sigma-Aldrich, UK). Two concentrations were prepared for 
each amino acid (1 and 0.1 mmol/L) while the concentration of HGA or BQA 
remained constant (33 µmol/L). Control solutions were the amino acid (1 mmol/L) 
without HGA/BQA, and HGA/BQA (33 µmol/L) without amino acid. All solutions 
were adjusted to pH 7.4 with NaOH or HCl.  
Samples were taken from each solution over the course of the incubation (0–48 
h) and stored immediately at -80°C prior to analysis. 
6.2.3 Ultrafiltration of HGA-derived pigment 
Ultrafiltration was performed on solutions of HGA-derived pigment and melanin. 
HGA-derived pigment (prepared from 10 mmol/L HGA) and melanin (10 mmol/L) 
solutions were prepared as described above (section 6.2.1). Ultrafiltration was 
performed on 4 mL of each solution using Amicon Ultra-4 centrifugal 10 KDa filter 
units (Merck-Millipore, Ireland); centrifugation at 2500x g for 10 min.  
6.2.4 Spectrophotometry 
Absorbance measurements were taken across the UV-visual range (200-1000 
nm) using a Spectrostar Nano absorbance reader (BMG Labtech, UK) and 
Microvette cuvettes (Sigma-Aldrich, UK).  
6.2.5 Mass spectrometry 
LC-QTOF-MS analysis of HGA-derived solutions 1-5 (analysed at 10 µmol/L 
concentrations, injection volume 5 µL) of and samples taken from the HGA/BQA 
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amino acid incubation experiments (analysed neat, injection volume 1 µL) was 
performed on an Agilent 6550 QTOF mass spectrometer. Analysis was by Method 
2 (reversed-phase LC), as described in Chapter 2 (section 2.2.2).  
Additional flow injection analysis (FIA; i.e. direct injection of sample into the mass 
spectrometer without chromatography) was performed for the following samples 
by QTOF-MS to rule out potential artefacts arising from interaction with the LC 
column. Sample injection was via a coupled Agilent 1290 Infinity II HPLC system 
with a zero dead volume connector in place of the LC column. Mobile phase 
delivery was isocratic (A, water and B, methanol at ratio of 1:1, both with 0.1% 
formic acid) at flow rate 0.4 mL/min. For HGA-derived pigment (solution 5), 
melanin and samples taken from the ultrafiltration experiment FIA was performed 
on an Agilent 6545 QTOF-MS (analysed at 20 µmol/L concentrations, injection 
volume 10 µL). For samples from the amino acid incubation experiment FIA was 
performed on an Agilent 6550 QTOF-MS (analysed neat, injection volume 1-2 
µL). MS acquisition parameters were identical to those described in section 2.2.2.  
In addition to the MS analyses described above which employed ESI (Agilent dual 
AJS ESI source), HGA-derived pigment was also analysed by QTOF using APCI. 
APCI analyses were performed on an Agilent 6546 QTOF-MS via FIA, with the 
dual AJS source replaced with an APCI source (Agilent) (concentration 100 
µmol/L, injection volume 1 µL). The MS acquisition parameters were unchanged 
(except acquisition rate 2 GHz). 
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Raw MS data files were reviewed in MassHunter Qualitative Analysis (Agilent; 
build 07.00). 
6.2.6 NMR spectroscopy 
NMR was performed on HGA-derived pigment and samples from the incubation 
of HGA with cysteine (48 h at 37°C). Samples were prepared to final 
concentration of 10% sample with 500 mmol/L phosphate (pH 7.4), and 10% 2H2O 
200 µL of each prepared sample was then transferred to a 3 mm outer diameter 
NMR tube (Bruker, UK). 
1D 1H NMR spectra were acquired at 700 MHz using a Bruker Avance III HD 700 
MHz NMR spectrometer fitted with a 5 mm triple resonance (TCI) cryoprobe at 
25°C. Spectra had spectral widths of 17.16 ppm, 4 s relaxation delay, 32 scans 
with 4 dummy scans collected into 73 k data points (3.067 s acquisition time). 
All spectra were zero filled to 128 k data points with exponential line broadening 
of 0.3 Hz applied before Fourier transformation, spectra were automatically 
phased, referenced and baseline corrected in Topspin using vendor supplied 
automated routines (version 3.5, Bruker, UK). 
2D NMR was performed on a 700 MHz spectrometer in two separate experiments 
known as 1H13C HSQC and 1H1H TOCSY. Single quantum coherence 
spectroscopy (HSQC) is a heteronuclear 2D NMR experiment that detects 
correlations between a carbon and its attached protons (one-bond correlation). 
The resulting spectrum is plotted with 1H chemical shift in one dimension and 
another heteronucleus (in this case 13C) on the other axis, as with the HETCOR 
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2D NMR spectra presented in Chapter 7 (also see Chapter 1, section 1.5.2). Total 
Correlation SpectroscopY (TOCSY) is a homonuclear 2D NMR experiment which 
detects correlations between all protons within a given spin system. All HSQC 
and TOCSY spectra were acquired at 25oC with 1s relaxation delay 1H spectral 
width of 12 ppm and 256 increments in the indirect dimension, additionally 
TOCSY was acquired with 4 scans and HSQC with 16 scans. The spins of these 
nuclei are interconnected by through-bond interactions, known as ‘spin-spin’ 
coupling. In the resulting 2D spectrum, two 1H chemical shift dimensions are 
plotted against each other and ‘cross peaks’ represent the correlated proton 
signals (typically hydrogens/protons between 3 and 6 bonds away from each 
other). 
All spectra were referenced in both 1H and 13C dimensions to selectively (d4) 
deuterated trimethylsilylpropanoic acid (Sigma, UK).  
6.3 Results 
6.3.1 Oxidation of HGA: clear change in colour and absorbance  
Formation of BQA and HGA-derived pigment (solutions 2-4) from colourless HGA 
solution was accompanied by clear change in colour (Figure 6.01). Various 
degrees of darkening were observed for solutions 2-4. The colour of the HGA-
derived pigment sample developed gradually over the 4-month incubation period, 
whereas immediate colour change was observed for the BQA samples formed by 
nitrous acid method or alkalinisation. Interestingly, the BQA sample formed by 




Figure 6.01. Solutions prepared from synthetic HGA for subsequent 
analysis. Conversion to of HGA (solution 1) to BQA (solution 2) was 
accompanied by a marked change in UV-visual absorbance (Figure 6.02A). There 
was a clear shift in the absorbance peak from 290 nm for HGA (hydroquinone) to 
250 (benzoquinone) for BQA as previously described (152,330). A series of 
absorbance measurements were taken at various time points from HGA 
incubated at 37°C over 48 h (the HGA control solution in the amino acid 
experiment), as shown in Figure 6.02B. The clear HGA solution at 0 h was visibly 
pigmented after 48 h (see inset photograph). The UV-visual absorbance traces 
showed a clear trend across the time series. First, there was a shift in the 290 nm 
hydroquinone peak to the 250 nm benzoquinone peak (maximum value at 12 h), 
indicating oxidation of HGA. At 24-28 h there was a decrease in the 250 nm 
benzoquinone peak accompanied by a more general increase in absorbance 
across the UV-visual range (200-650 nm), indicating further conformational 





Figure 6.02. Clear change in UV-visual absorbance upon autoxidation of 
HGA. A: conversion of HGA to BQA by nitrous acid method was accompanied by 
a shift in the peak at 290 nm (hydroquinone; HQ) to 250 nm (benzoquinone, BQ), 
as previously described (152). Inset figure adapted from (330). B: incubation of 
HGA over 48 h at 37°C showed gradual development of the 250 peak at 1.5-12 
h, indicating oxidation to benzoquinone, followed by a broader increase in 
absorbance across the UV-visual range at 24-48 h. Inset photograph shows the 
visibly darkened end product of the HGA incubation at 48 h. 
279 
 
6.3.2 HGA-derived pigment is fundamentally different to synthetic melanin  
The LC-QTOF-MS FIA spectra obtained from HGA-derived pigment were first 
compared with freshly prepared HGA and melanin (Figure 6.03). Melanin was 
analysed as a reference biological pigment. The data presented are from negative 
polarity for HGA and HGA-derived pigment and positive polarity for melanin, as 
these showed the greatest signal.  
There was remarkable similarity between the spectra from HGA-derived pigment 
and HGA. Both spectra were dominated by low molecular weight ions in the m/z 
range 100-400 with no discernible peaks >500 m/z. Signal corresponding to HGA 
(m/z 167.035) was also prominent in the pigment spectrum; this was particularly 
surprising given the long incubation period at 37°C and the disappearance of the 
sharp 290 nm hydroquinone absorbance peak for HGA within 24 h, as discussed 
above (Figure 6.02). 
The most prominent peaks in the HGA-derived pigment spectrum were ≤167 m/z, 
indicated by arrows in Figure 6.03. These peaks remained after subtracting the 
background spectra (removing reference ion signals and background noise). The 
peaks were also present in the spectrum from HGA, except the 137.0245 ion 
which appeared to be unique to HGA-derived pigment in FIA. This ion was 
therefore initially of interest, but it was also observed for fresh HGA in subsequent 




Figure 6.03. Flow injection analysis (FIA) mass spectra from analysis of 
HGA-derived pigment, HGA and melanin. The spectra for HGA and HGA-
derived pigment are remarkably similar and both dominated by low molecular 
weight ions. Red arrows indicate fragment ions in the pigment that are known to 
be derived from HGA. In contrast, the spectrum for melanin shows regularly 
repeating units (in the m/z range 270-400) typical of a polymer. Spectra were 
acquired by FIA with electrospray ionisation. 
 
Targeted MS/MS fragmentation analysis was performed (also by FIA) to identify 
the chemical structures of the most prominent peaks detected from HGA-derived 
pigment. Candidate compound/formula matches with the observed fragmentation 
spectra were obtained using the MassHunter METLIN metabolites PCD/PCDL 
accurate mass database (Agilent, build 07.00) and Molecular Structure Correlator 
(Agilent, build 07.00). These tools were used for comparing acquired targeted 
MS/MS spectra against published MSMS spectra (METLIN) for candidate 
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compounds and correlating acquired fragmentation patterns against 
fragmentations predicted in silico (Molecular Structure Correlator). Candidate 
compounds and structures were generated for each entity, except for the 
141.0168 m/z ion which did not yield any formula hits by either approach (Table 
6.01). The ions with m/z 167, 123 and 108 were confirmed to be associated with 
HGA based on the structures identified using this approach. The 167 ion is the 
monoisotopic [M-H]- ion for HGA, and 123 and 108 are known fragments of HGA 
(fragmentation spectra from the METLIN library noted above). The 137 m/z ion is 
not a known fragment of HGA from METLIN but does appear to be associated 
with HGA. Interestingly, the compound match for this ion was 2,5- or 3,4- 
dihydroxybenzaldehyde; how this structure relates to HGA and/or pigment 
formation is, however, unclear. The 141 m/z ion is also not a known fragment of 
HGA but was observed in the spectra of HGA and HGA-derived pigment; no 
formula matches were obtained for this entity. The presence of these ions in the 
spectra from MS analysis without application of collision energy (i.e. not MS/MS), 
as shown in Figure 6.03, suggest that they are fragments of HGA formed in the 
ionisation source; a well-known phenomenon in LC-MS analyses by ESI (331). 
However, the ions remained after reducing the source fragmentor voltage from 





Table 6.01. Compound structure identifications for ions observed from 
HGA-derived pigment. Structures were identified in negative polarity by 
matched MS/MS fragmentation spectra using the MassHunter METLIN 
metabolites PCD/PCDL accurate mass database (Agilent, build 07.00) or 








167.0349 C8H8O4 HGA 
 



















The spectrum obtained from melanin was strikingly different to HGA and HGA-
derived pigment. Melanin showed a spectral pattern comprising ions spaced at 
regular mass intervals in the m/z range 270-400. This pattern suggests a classic 
polymeric structure composed of regularly repeating units. Molecular feature 
extraction was performed on ions in the m/z range 270-400 and candidate 
molecular formulae generated (Table 6.02). The formulae show that the mass 
intervals observed, 14 and 16 m/z units, are due to successive incorporation of 




Table 6.02. Positive polarity ion species and formula matches for the 
regularly repeating mass units obtained from melanin. Formulae shown were 
the top matches generated following molecular feature extraction in MassHunter 
Qualitative Analysis (Agilent; build 07.00).  
m/z Formula match 
273.1673 C10 H20 N6 O3 
275.1463 C9 H18 N6 O4 
289.1622 C10 H20 N6 O4 
303.1776 C11 H22 N6 O4 
317.1937 C12 H24 N6 O4 
331.173 C12 H22 N6 O5 
331.2093 C13 H26 N6 O4 
333.1884 C12 H24 N6 O5 
345.1884 C13 H24 N6 O5 
345.2244 C14 H28 N6 O4 
347.2044 C13 H26 N6 O5 
361.2199 C14 H28 N6 O5 
375.2353 C15 H30 N6 O5 
389.2508 C16 H32 N6 O5 
 
Ultrafiltration was performed on HGA-derived pigment and melanin solutions 
using a 10 KDa filter as an additional simple assessment of molecular weight. 
First, both solutions were centrifuged prior to filtration. As seen in Figure 6.04A, 
a small pellet was formed in in the HGA-derived pigment sample by undissolved 
pigment particulates. However, the supernatant remained heavily pigmented 
(Figure 6.04B, solution 2). In contrast to melanin, which remained black (Figure 
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6.04B solutions 5-8), HGA-derived pigment solution became noticeably lighter in 
colour post-filtration (Figure 6.04B, solution 4). The portion of the solution that 
had not passed the filter after 10 min of centrifugation appeared slightly darker, 
indicating retention of pigment by the filter. Together, these findings suggest that 
HGA-derived pigment, but not melanin, contains a portion of compounds with 
molecular weight >10 kDa. 
 
 
Figure 6.04. Ultrafiltration of HGA-derived pigment and melanin solutions.  
A: HGA-derived pigment (left) and melanin (right) solutions post-centrifugation. 
Blue arrow indicates pellet formed by undissolved particulates of HGA-derived 
pigment. B: samples from HGA-derived pigment (top photograph) and melanin 
(bottom photograph) taken pre- (samples 1 & 5) and post-centrifugation (samples 
2 & 6). Samples 3 and 7 are the portions that had not passed the 10 kDa filter 
after 10 min at 2500x g. Samples 4 and 8 are samples of the filtrate from both 
solutions. The filtrate was visibly lighter for HGA, indicating some retention of 
pigment species by the filter.  
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6.3.3 HGA-derived pigment does not behave as a polymer in mass 
spectrometry 
Given the indication of high molecular weight (>10 kDa) species in HGA-derived 
pigment from ultrafiltration, it was surprising that the mass spectrum of HGA-
derived pigment was dominated by low molecular weight ions (100-300 m/z). LC-
QTOF-MS analysis was performed to further compare HGA-derived pigment with 
HGA and BQA intermediates (solutions 1-5, section 6.2.1). TICs showed no clear 
differences between the solutions. Consistent with the data shown in Figure 6.03, 
a clear HGA signal (HGA [M-1H]- and [2M-H]- ions) was observed for HGA, BQA 
and HGA-derived pigment, with RT matching that of HGA from the AMRT 
database described in Chapter 2 (Figure 6.05, left panel). Interestingly, the HGA-
associated signal was removed for the HGA – BQA solution formed by raising the 
pH was to 11 (solution 4), but without clear formation of other ion products.  
The extracted mass spectra (Figure 6.05, right panel) were almost identical for 
solutions 1-3 and 5. The ions indicated by red arrows have been highlighted 
because here they were previously confirmed as compounds originating from 
HGA and not HGA-derived pigment (see Table 6.01). Further confirmation of this 





Figure 6.05. Mass spectra from LC-QTOF-MS analysis of HGA, BQA and HGA-derived pigment. Spectra show 
remarkable similarity, dominated by low molecular weight ions and ion signals known to be associated with HGA (indicated 
with arrows). No signal for BQA (expected m/z 165) was observed for any solution. Solutions analysed by reversed-phase 
LC method 2 (Chapter 2, section 2.2.2) in electrospray ionisation.
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Clear observation of HGA-associated ions was surprising for BQA (solution 2) 
given that the UV-visual absorbance spectrum confirmed conversion to the 
benzoquinone form (Figure 6.02). The m/z of the HGA ion observed was 167 but 
the expected m/z for BQA would be 165; i.e. loss of 2 hydrogens from HGA upon 
oxidation (Figure 6.06). One consideration was that potential redox artefacts were 
being introduced by the ESI technique. It has been shown previously that the 
electron-rich environment in the ESI source can result in reduction of a range of 
quinones (332). In the same way, benzoquinone species in BQA solutions or 
HGA-derived pigment could be reduced back to HGA during ESI due to gain of 









In order to rule out potential BQA/HGA-derived pigment reduction artefacts 
attributable to ESI, pigment was also analysed by an alternative ionisation 
technique; APCI (via FIA). Figure 6.07 shows the mass spectra obtained from 
HGA-derived pigment solutions 2-4 from the ultrafiltration experiment (Figure 
6.04) by APCI. As with ESI, the spectra from these solutions were dominated by 
the HGA [M-H]- signal (167 m/z), without evidence of a 165 m/z ion from BQA. 
This indicated predominance of the reduced hydroquinone species in the pigment 
(Figure 6.06). Extending the acquisition mass range to 3200 m/z (from 1700 m/z) 
did not reveal any discernible high molecular weight signals beyond those in the 
mass range shown in Figure 6.07. In summary, given the striking dark 
appearance of HGA-derived pigment solution, there is remarkably minimal 






Figure 6.07. HGA signal dominates the mass spectra of HGA-derived 
pigment in MS by ESI and APCI. The HGA ([M-H]- ion 167 m/z) signal is 
prominent in solutions of HGA-derived pigment before (darker in colour) and after 
(lighter in colour) ultrafiltration (see Figure 6.04). No discernible signal was 
observed corresponding to BQA (expected m/z 165) or for ions greater than the 
mass range shown. ESI revealed a series of ions from pigment samples (but not 
freshly prepared HGA) with m/z greater than that of the HGA [M-H]- ion, which 
could potentially represent aggregation products formed by HGA in the process 
pigment formation. The 375.0531 ion is highlighted (red box); targeted MS/MS 




6.3.4 First observation of an aggregate from HGA-derived pigment by mass 
spectrometry 
Closer inspection of the ESI spectra from FIA (shown in Figure 6.07) shows a 
collection of ions with m/z >167 (HGA [M-H]- signal), up to 400 m/z, that were 
observed from the pigment samples but not fresh HGA. These could therefore 
represent potential candidate aggregate structures resulting from HGA oxidation. 
Targeted MS/MS analysis was performed on these ions to investigate their 
structures. As shown in Figure 6.08, fragmentation of the 375 ion (blue diamond) 
generated a series of peaks, the most prominent being negatively charged ions 
with m/z 209.0259, 167.035 (HGA), 137.0252, 121.0295, 108.0217 (HGA 
fragments; see Table 6.01) and 165.0195. The 209 and 165 ions were particularly 
interesting as they are not known fragments of HGA. The 165 ion appears to 
represent BQA (AM match = 1.01 ppm). The only formula match generated for 
the 209 ion was C13H6O3, but no compound match (mass match <10 ppm) was 
obtained in the MassHunter METLIN metabolites PCD/PCDL database (Agilent, 
build 07.00). Together, these data reveal for the first time compound ions that are 
structural components of the oxidation/aggregation of HGA and BQA in formation 





Figure 6.08. Targeted MS/MS analysis identifies constituent fragments of 
potential HGA aggregation compound. Fragment ions generated from 
collision-induced dissociation (CID; at 0-40 V) of the 375 ion (present in HGA-
derived pigment but not HGA) revealed constituent ion fragments relating to HGA 
and known sub-structures of HGA (indicated by black arrows). Other generated 
fragments were an ion of greater mass than HGA (m/z 209.0259, formula match 
C13H6O3) and BQA (red arrow). The data suggests that these ions are involved in 
the oxidation and/or aggregation of HGA in forming pigment. 
 
6.3.5 Interaction between HGA or derived species with amino acids in solution 
HGA and BQA (by nitrous acid method) were incubated with various amino acids 
in solution in order to indicate potential interaction/binding sites in the cartilage 
matrix. The LC-QTOF-MS mass spectra obtained from these solutions after 48-h 




Figure 6.09. Evidence of interaction between HGA/BQA and amino acids.  
A-F: extracted ion chromatograms (EICs) for HGA ([M-H]- ion 167.035 m/z) 
obtained from solutions incubated for 48 h at 37°C (pH 7.4). EICs indicated 
interactions for HGA and BQA with glycine and hydroxyproline, and to a lesser 
extent HGA with cysteine (HGA signal attenuated by increased amino acid 
concentration). G: representative extracted mass spectrum for HGA (12C – 14C 
isotope distribution visible). Solutions analysed by reversed-phase LC method 2 




Interaction between HGA and glycine and hydroxylysine was indicated by 
attenuation of the HGA ([M-H]- ion 167.035 m/z]) signal at high (1 mmol/L) versus 
low (0.1 mmol/L) concentrations of these amino acids. For these solutions, HGA 
incubated with the low concentration of amino acid showed approximately 
equivalent HGA signal to that of the HGA control (HGA incubated alone over the 
same 48-h period). There was also evidence of a weaker interaction between 
HGA and cysteine, but no interaction between HGA and arginine. Interactions 
were also indicated between BQA and glycine and cysteine; HGA was no longer 
detectable at the high 1 mmol/L concentrations for these amino acids. 
Despite evidence of these interactions, newly formed products were not detected 
(i.e. amino acid + HGA/BQA expected adducts). Potential products were 
searched in the data based on the predicted amino acid + HGA/BQA adducts; AM 
calculated from the combination of their formulas (with loss of H2O). Additional 
analysis by FIA also did not show emergence of any new peaks indicating 
formation of new products. 
6.3.6 NMR spectroscopy confirms HGA conformational change  
Analyses were performed by NMR spectroscopy to confirm that HGA had 
undergone significant structural change in the formation of HGA-derived pigment. 
First, a series of 1D 1H experiments were performed on HGA (0.33 mmol/L) that 
had been incubated at 37°C for 48 h at pH 7.4 with and without 1 mmol/L cysteine 
(samples from the amino acid incubation experiment; section 6.2.2).  
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As shown in Figure 6.10, 3 distinct groups of signals (‘poses’ or ‘conformers’) 
were observed in the 1H aromatic region for both samples over the 14-day 
analysis period. The three poses refer to distinct pairs of 1H resonances which 
increased and decreased at the same rates. The poses had characteristic profiles 
over the time period. At the earliest time points, pose 1 (red shading) dominated 
the spectra for HGA with and without cysteine. For HGA without cysteine, pose 2 
(blue shading) dominated at days 2-5, then pose 3 (magenta shading) emerged 
from day 4 onwards. At day 14, each of these signals were undetectable / 
attenuated considerably. Interestingly, presence of cysteine appeared to stabilise 
the peaks observed at day 0 (pose 1). For HGA with cysteine, the 3 poses showed 
the same temporal profiles across the period but with decreased rate of 
progression, indicating slower conformational change; an effect presumably 
attributable to cysteine being a reducing agent and therefore attenuating the rate 
of oxidation. This interpretation was also supported by the colour of the solutions 
after the 48-h incubation; darkening was observed for HGA (see Figure 6.02B; 
inset photograph) and the colouration was visibly lighter, though still darkened, 







Figure 6.10. 1D 1H NMR spectra show signals associated with HGA turnover 
over 14 days. A time series of spectra (aromatic 1H range shown) were obtained 
from solutions of HGA and HGA + cysteine (1 mmol/L); both solutions had been 
pre-incubated for 48 h at 37°C, pH 7.4). At day 0, pose 1 (red shading) dominated, 
followed by increase in the peaks representing pose 2 (blue shading). Pose 3 
(magenta shading) was the last signal to emerge, remaining longer than poses 1 
and 2. Presence of cysteine appeared to stabilise this rate of conformational 
change, with pose 1 predominating the spectra for a longer period. 
Note: Over the 14-day analysis period temperature fluctuated between 25°C (in storage) 
and 4°C (during acquisition). Both samples experienced identical temperatures for 
equivalent time frames.   
 
 
2D NMR was performed to further investigate the 1D 1H NMR signals observed. 
The 1H 1H TOCSY 2D spectrum (Figure 6.11) confirmed the relationship between 
each of the 1H pairings within the poses observed in Figure 6.10. Each of the 
297 
 
cross peaks (peaks away from the diagonal) represent direct correlations 
between the three pairs of aromatic protons. 
 
Figure 6.11. 2D NMR confirms the three different temporal conformations of 
HGA (i). 1H1H 2D TOCSY (total correlation spectroscopy; signal shown in teal) 
confirms the three different conformations of the HGA aromatic resonance by 
presence of cross peaks demonstrating that peaks can be attributed to the three 
sets of resonances (three conformations/poses indicated by red, blue and 
magenta dashed lines). 1D spectra shown in red. 
 
 
Heteronuclear 2D NMR (1H13C HSQC) confirmed that the 1H signals observed 
from HGA/pigment in the 3 conformational pairings were from protons attached 
to an aromatic ring. As shown in Figure 6.12, the 1H signals were paired with 
aromatic carbons (aromatic 13C chemical shift range shown). Here the signals 
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were also more intense for 1H-13C pairings for pose 1 (highlighted by red shading) 
at 0 days (blue 2D spectrum) compared with 7 days (red 2D spectrum). 
 
Figure 6.12. 2D NMR confirms the three different temporal conformations of 
HGA (ii). 1H13C 2D HSQC for HGA without cysteine at time 0 (blue) and time 7 
days (red) overlaid. 2D spectra show 1H pairings with between aromatic carbons 
(aromatic 13C chemical shift range shown), confirming attachment of the protons 
to an aromatic ring. Equivalent 1D 1H spectra are overlaid. 
 
6.4 Discussion 
The data presented in this chapter are fundamental to understanding ochronosis, 
the primary cause of pathophysiological manifestations in AKU. Generation of 
pigment formed from HGA in vitro enabled the study of ochronosis in pure form 
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in the absence of complex biological matrix. The most striking results from these 
studies were from MS analyses: a) mass spectra obtained from HGA-derived 
pigment were dominated by low molecular weight ions in the m/z range 100-400 
including HGA and fragment ions derived directly from HGA; b) the first 
demonstration of an aggregate structure from HGA-derived pigment by MS.  
The spectra obtained from HGA-derived pigment showed marked contrast to that 
of synthetic melanin formed by oxidation of tyrosine by hydrogen peroxide. While 
HGA-derived pigment showed a general broadband increase in absorbance 
across the UV-visual range (Figure 6.02B) similar to that described previously for 
melanin (160), its mass spectra are not consistent with a polymeric structure. In 
contrast, melanin gave a mass spectrum comprising ions at regularly repeating 
mass intervals indicating a highly-organised, well-defined structure. 
The mass spectra of HGA-derived pigment were unexpected for a number of 
reasons. First, the marked colour change and change in UV-visual absorbance 
profiles upon alkalinisation or formation of BQA via nitrous acid method indicated 
oxidation to benzoquinone (MS signals indicated dominance of HGA, i.e. the 
reduced form). Second, ultrafiltration of HGA-derived pigment solution indicated 
partial presence of species >10 kDa. The final reason is the widespread 
assumption in the literature that ochronotic pigment is a polymer (see Chapter 1, 
section 1.3.1).  
Closer inspection of the spectra acquired by ESI MS (by FIA) revealed the first 
aggregate structure obtained from HGA-derived pigment by MS. Targeted 
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fragmentation of this ion (m/z 375.0529) revealed constituent fragments 
comprising a smaller aggregate (m/z 209.0259), HGA and BQA. The data 
therefore reveal that these fragment ions are part of the oxidation/aggregation 
process resulting in pigment. This also suggests that pigment is formed by a 
combination of HGA and BQA aggregation. 
In the literature there is scant evidence to support the widespread assumption 
that ochronotic pigment is a polymer. One piece of evidence comes from the 
fascinating case of an Egyptian mummy diagnosed with AKU following 
observation of ochronosis in hip cartilage and osteoarthropathy indicated by joint 
space narrowing and extensive intervertebral disk calcification (329). Presence of 
methylene groups and six-seven membered ring ketones was deduced from the 
absorbance spectra of ochronotic pigment extracted from cartilage. These data 
were interpreted as indication of an oxidised HGA polymer. However, these 
findings are confounded by the cartilage matrix from which the pigment was 
extracted; it is not certain whether the compound observed was from ochronotic 
pigment or the cartilage matrix. This underlies the value of comparatively simpler 
experiments on solutions of purified HGA and HGA-derived pigment formed under 
controlled conditions in the laboratory, as discussed here. 
It was interesting in the present analyses that the fragment ion identified as BQA 
was not readily detectable by MS analysis (even in solutions of BQA), but 
observed upon breaking the bonds of the observed aggregate structure by 
application of 20 V collision energy. One potential explanation is that MS 
ionisation via ESI and APCI caused reduction of benzoquinone species 
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(proposed intermediates in the classic HGA polymerisation scheme) back to HGA 
in the HGA-derived pigment samples. This phenomenon has been described 
previously in ESI MS for quinones including 1,4-benzoquinone, methyl-p-
benzoquinone, 1,4- and 1,2-naphthoquinone and 1,4-anthraquinone (333) and 
attributed to conditions that bring about severe corona discharge. Additional APCI 
MS analysis was performed in order to rule out this potential explanation, but the 
pigment spectra obtained were still dominated by the reduced form, HGA. It is 
worth noting that reduction may also have been induced in-source in APCI; in 
APCI, analytes are not subjected to the electron-rich environment as in ESI 
sources, but the ionisation is by corona discharge. Another potential explanation 
is that fragmentation of a high molecular-weight polymer was being induced in-
source. However, ESI and APCI are known as soft ionisation techniques, and 
decreasing the source fragmentor voltage (120 V to 80 V) had little to no 
observable effect on the spectra. Alternatively, a more general explanation is that 
HGA-derived pigment is an analytically challenging compound due to the inherent 
tendency of benzoquinone to undergo redox cycling (benzoquinone to 
hydroquinone) (174,334).   
The NMR studies confirmed that the formation of pigment from HGA is 
accompanied by significant structural conformation change. The three different 
conformations observed represented different proton environments associated 
with an aromatic ring structure. This conformational change related to the carbons 
on an aromatic ring structure, which is likely to reflect the oxidation/aggregation 
of HGA and BQA that was informed by the MS experiments. 
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The MS data also indicated interaction between HGA and the amino acids 
cysteine, glycine, and hydroxylysine, and also for BQA with glycine and cysteine. 
These findings are in line with previous work demonstrating that BQA binds to 
amino acids via free amino or thiol groups (177). A glycine-HGA adduct is also 
previously reported in AKU urine; this adduct was predicted to represent 25% of 
total urinary glycine in this patient (335). The interactions with glycine and 
hydroxyproline are particularly interesting, as these amino acids are major 
components of type-II cartilage collagen, as therefore could present potential 
binding sites for HGA-derived species in cartilage. Such binding sites could 
explain the high affinity that HGA or its derivatives have for cartilage; cartilage is 
the major accumulation site for ochronotic pigment. It is important to show that 
these interactions can occur in pure solutions in vitro, as identification of specific 
binding sites is complicated in vivo due to the complexity of the cartilage 
extracellular matrix. 
 
In summary, these data fundamentally challenge the widely-held idea that 
ochronotic pigment is a classic polymer comprising covalently-bound and 
regularly repeating sub-structures. The data confirm that HGA undergoes 
significant conformational change in forming pigment, but this change is more 
consistent with non-covalent aggregation of a number of species including HGA 
and BQA. These self-aggregation mechanisms appear to be more complex and 
less organised than those involved in the formation of melanin formed by 
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The exact mechanism by which ochronotic pigment interacts with collagen is not 
yet fully elucidated. The exposed collagen hypothesis of ochronosis predicts that 
natural, age-related alteration to cartilage type-II collagen renders it susceptible 
to binding by HGA and any derived products in AKU (9). In AKU, ochronotic 
cartilage shows different bulk mechanical properties compared to non-ochronotic 
cartilage (306), therefore it was predicted that there are structural changes at a 
molecular and even atomic lengthscale in the collagen proteins that underlie and 
predate the onset of arthritic symptoms. Despite the lifelong elevation in plasma 
HGA, ochronosis and joint degeneration is not evident until later life in AKU (18); 
therefore, the preceding changes to the cartilage matrix that facilitate binding of 
pigment are likely to be age-related and of broader interest in understanding other 
cartilage diseases. 
In the current model of pigmentation, HGA is first oxidised to BQA, then 
undergoes aggregation or polymerisation to yield a final pigment species that 
would include conjugated carbon-carbon double bonds containing benzoquinone 
moieties, giving rise to the dark colour (42). If the pigment becomes polymerised 
extensively and intertwined in the ECM, it would potentially provide a mechanism 
of the irreversibility of the pigmentation process, though low molecular-mass 
pigments are also known (42) and the presence of colouration is not concrete 
proof of a polymer species (16). As shown in Chapter 6, ochronotic pigment 
(HGA-derived pigment) can be generated in the laboratory, but it is unclear how 
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similar pigment derived from purified synthetic HGA is to pigment observed in 
tissue matrices in vivo.  
ssNMR provides a means to attempt structural characterisation of the pigmented 
tissue without extracting the pigment from its native environment. However, a 
previous ssNMR study on AKU cartilage tissue only revealed a global increase in 
disorder in pigmented cartilage compared to non-pigmented cartilage from the 
same patient (336). No distinct signal was identified as the HGA-derived pigment 
species specifically, possibly due to the low level of pigment species relative to 
the rest of the collagen matrix, thus preventing the observation of a pigment 
species due to low sensitivity. With the recent developments in DNP in MAS 
ssNMR (193), whereby the observed signal can be enhanced by factors of one to 
two orders of magnitude, it is attractive to revisit the ssNMR approach for studying 
intact AKU tissues.  
It can be challenging to obtain sufficient sensitivity on non-isotopically enriched 
organic and biological samples. However, DNP-enhanced ssNMR has been 
successfully applied to non-isotope enriched (unlabelled) organic materials 
(337,338) and crystalline biological materials (339,340) to yield well-resolved 2D 
spectra. In terms of application to heterogeneous biomaterials, DNP-enhanced 
ssNMR has enabled 1H-13C HETCOR experiments on bone (341). I therefore 
expected to obtain 2D spectra on natural abundance cartilage samples in the 
following studies, which could potentially resolve signals that are normally 
overlapping in 1D spectra.  
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The aim in the following studies was therefore to employ ssNMR in order to better 
understand ochronotic pigment as it occurs in vivo in cartilage tissues. The 
specific objectives were as follows: to investigate how HGA or the HGA-derived 
pigment binds into the collagen matrix, to determine the chemical identity of the 
pigment species, and to understand the effect of such binding on the collagen 
matrix at an atomic level. Identifying the lengthscale at which the HGA-derived 
pigment induces disruption of the collagen matrix, whether at the fibre, fibril or 
triple helical level, will be key to understanding the mechanism by which HGA 
binds to and reacts with tissue, and will improve our understanding of disease 
progression in AKU. Understanding the mechanism of binding may illuminate new 
treatment strategies, not only to prevent or arrest the ochronotic process, but also 
potentially to find alternative therapeutic approaches for patients already with 
long-term exposure to high levels of HGA and a high degree of cartilage 
ochronosis.  
Since the most debilitating symptom of AKU is a chronic and accelerated form of 
OA, potential structural changes to collagen within OA cartilage matrix were also 
investigated, in order to determine whether such disruptions occur in a similar 
manner. This comparison was designed to test the hypothesis that AKU is an 
extreme form of OA in which similar molecular changes occur. This insight is 
essential in supporting the study of AKU as a model for common idiopathic OA, 
potentially leading to the discovery of novel biomarkers of OA, for which there is 
a very pressing need, or suggesting methods to ameliorate and potentially 




7.2.1 Human cartilage tissue collection 
Human joint tissue was obtained at the time of surgery from the knee of a 55-
year-old male previously diagnosed with AKU, and the knee of a 71 year old 
female with OA. Both patients underwent a complete knee replacement due to 
osteoarthropathy. All cartilage tissue was obtained as surgical waste under ethical 
approval from the Liverpool Research Ethics Committee with informed consent 
from patients with diagnosis of AKU or OA undergoing joint replacement. For the 
AKU specimen, macroscopically pigmented and non-pigmented sections of 
articular cartilage were dissected from the same tissue sample. For the OA 
specimen, samples were taken from regions of articular cartilage that were 
visually worn, ‘damaged’ tissue, and also from regions of articular cartilage that 
were not visually damaged, referred to as ‘control’ tissue. Samples were 
dissected using a No. 10 disposable scalpel (Swann-Morton, UK) and washed 






Table 7.01. Details of human cartilage samples analysed by ssNMR. 
NMR 
sample 
Pigmentation Fixation Soaking 
after 
fixation 
Disease Gender Age 
(years) 
1 Pigmented Formalin No 
AKU Male 55 
2 Pigmented Formalin Yes 
3 Non-pigmented Formalin No 
4 Non-pigmented Formalin Yes 
5 Non-pigmented Formalin Yes OA  Female 71 
 
 
7.2.2 Mouse tissue collection 
The distal condyles of the femur, which are covered by cartilage, were taken from 
HGD-/- and wild type mice using a No. 10 disposable scalpel (Swann-Morton, UK). 
Due to the small size of the condyles, separation of cartilage from the underlying 
bone was not attempted. Cartilage of the HGD-/- mice is microscopically 
pigmented, while cartilage of wild type mice is not pigmented. Tissue from BALB/c 
and C57BL/6J mouse strains were combined in both of the above groups to give 
sufficient material for rotor packing. Samples were washed in sterile PBS and 
stored at -80°C unless intended for subsequent fixation. Further details are 




Table 7.02. Details of mouse tissue samples analysed by ssNMR. 
NMR 
sample 
Genotype Fixation Strain Sex Age 
(months) 
6 Wild type None 
BALB/c Female 7  
BALB/c Female 7  
7 Wild type Formalin 
C57BL/6J Female 15  
BALB/c Female 7  
8 HGD-/- None 
C57BL/6J Male 9  
C57BL/6J Male 9  
9 HGD-/- Formalin 
C57BL/6J Male 9  
BALB/c Male 16  
 
7.2.3 Tissue fixation 
Mouse tissues underwent fixation immediately following dissection. Human 
tissues were removed from -80°C storage and thawed prior to fixation. Tissues 
were soaked in twice the tissue volume of 10% formalin (pH 7.4) for 48 h with 
gentle agitation. The formalin was changed after 24 h. After 48 h, tissues were 
removed from the formalin and stored short-term at 4°C in tubes containing paper 




In order to remove the large NMR signal from the formalin fixative, some of the 
fixed cartilage was washed by rinsing in distilled water, then soaked in distilled 
water with one change of water for up to one week prior to the NMR experiments. 
7.2.4 Formation of pigment from synthetic HGA 
A solution of pigment (referred to as HGA-derived pigment) was formed from 
synthetic HGA as described in Chapter 6 (section 6.2.1). In this study, 30 μL 
NaOH (5 mol/L) was added to raise the pH, and an immediate darkening of the 
solution was observed which progressed over the total incubation period of 
approximately 4 months. A brittle brown solid was obtained following drying under 
a stream of dry nitrogen gas.  
7.2.5 Rotor packing  
No grinding or cryomilling procedures were used on the biological samples. The 
mouse condyles were used without further dissection, while the cartilage samples 
were cut into smaller pieces prior to rotor filling. The samples were gently dried 
by a combination of two techniques: brief blotting using a paper towel, or brief 
pressing between two layers of parafilm to expel water, which was then removed 
with a fine pipette. No freeze drying was used. For all NMR experiments, 3.2 mm 
outer diameter zirconia rotors with Vespel caps were used. The small pieces of 
human cartilage were placed directly into the rotor with slight compaction if 
necessary. For the mouse tissue, condyles from the different mice had to be 
pooled within each group to provide sufficient sample mass. 
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Due to the difficulty of transferring small amounts of the synthetic HGA-derived 
brown solid into the rotor, the solid was dissolved in a small amount of water. The 
brown solution was transferred to the rotor, then a stream of dry nitrogen gas was 
used to remove the water. For DNP experiments, AMUPol (342), bcTol (343), and 
bcTol-M (344) were prepared as solutions in D2O only, to a concentration of 20 
mmol/L for AMUPol and 40 mmol/L for bcTol and bcTol-M. A range of radicals 
was used due to development of new and improved radicals over the course of 
the project. Depending on the tissue mass, 5-7 μL of the radical solution was 
added to the filled rotor. No glycerol was used as it was previously shown to bind 
to native collagen and modify its stability (345). No H2O was added; as the 
samples were well-hydrated, a sufficient amount of H2O was expected to remain 
even after the gentle drying process. The procedure was based on the incipient 
wetness impregnation technique that is used widely in DNP NMR studies of 
various materials (346,347). 
After adding the radical solution, the packed rotors were centrifuged to distribute 
the radical solution throughout the sample, and then left to equilibrate overnight 
at 4°C before the start of DNP experiments. 
7.2.6 ssNMR spectroscopy experiments 
NMR experiments were performed on Bruker (Germany) Avance III wide-bore 
spectrometers operating at static magnetic fields of 9.4 T and 14 T, with 1H Larmor 
frequencies of 400 and 600 MHz respectively. The 600 MHz spectrometer was 
equipped with a 3.2 mm (1H-13C-15N) triple resonance probe, with the MAS rate 
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set to 13333 Hz, and the sample temperature set to 265 K (actual temperature 
found to be 285 K after calibration) using a Bruker cooling unit with a gas flow of 
1200 L per h. The 400 MHz spectrometer was equipped for DNP enhancement 
experiments, with a gyrotron operating at 9.7 T and a 3.2 mm (1H-13C-15N) triple 
resonance low temperature MAS (LTMAS) probe. The MAS rate was set to 8889 
Hz, and the sample temperature set to 100 K (actual temperature estimated to be 
110 K) using the LTMAS cooling cabinet with a variable temperature gas flow of 
2000 L per h.  
NMR parameters on the 400 MHz DNP spectrometer were: 1H 90° pulse length 
2.5 μs, 13C 90° pulse length 3.8 μs, 88 kHz 1H decoupling. DNP-enhanced 
experiments were carried out under 20-30 mA microwave irradiation. NMR 
parameters on the 600 MHz spectrometer were: 1H 90° pulse length 3.25 μs, 13C 
90º pulse length 5 μs, 73 kHz 1H decoupling.  
1H-13C CP experiments are widely used in ssNMR. This technique is based on 
dipolar coupling and therefore specifically detects immobile and solid species. 
600 μs 1H-13C CP contact time was used on the 400 MHz DNP spectrometer. 
1000 μs 1H-13C CP contact time was used on the 600 MHz spectrometer. A 
ramped shape was used on the carbon channel during the CP contact to broaden 
the matching condition (348). 
1H-13C refocused insensitive nuclei enhanced by polarisation transfer (INEPT) 
(349,350) experiments are a common technique for spectral editing in ssNMR, 
specifically for detecting mobile and soluble species (351) as the transfer is based 
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on J-coupling, which is not averaged to zero under MAS, and the relatively long 
delays lead to broadening of solid signals from T2 relaxation. This experiment was 
only carried out on the 600 MHz spectrometer at 285 K and not carried out at 
DNP conditions. The INEPT delay was 1.5 ms and the refocusing delay was 0.9 
ms. 
1H-13C 2D HETCOR spectra were carried out with an FSLG sequence during 1H 
evolution (352,353) to improve resolution, with a square shape applied on both 
1H and 13C during the CP contact step. On the 400 MHz spectrometer, under DNP 
conditions, CP contact times of 20–100 μs were recorded. For some samples 
additional contact times of 10 and 500 μs were also recorded (as detailed in the 
results section). Each HETCOR experiment was signal averaged for 5-10 h. On 
the 600 MHz spectrometer, for each human cartilage sample, two experiments 
with contact times of 500 μs and 1000 μs were recorded, with each experiment 
taking 27-47 h. 
7.2.7 NMR spectra processing 
For 1D 13C spectra, 1024 points of the experimental FID (12.5 ms) was zero filled 
to 8192 points. A Gaussian window function was applied, with 10 Hz line 
broadening and a Gaussian max position (GB in the Bruker Topspin program) of 
0.1, prior to Fourier transform. Baseline correction was applied to the whole 
spectral range of -100 to 300 ppm. 13C spectra were externally referenced to 
tetramethylsilane to enable comparison to the chemical literature of polyquinones. 
However, this referencing method leads to a small (2.7 ppm) discrepancy of the 
315 
 
chemical shift values of any protein signals from those found in the literature of 
other protein NMR studies, which are often referenced to 2,2-
dimethylsilapentane-5-sulfonic acid DSS. Previous collagen NMR chemical shifts 
were reported by referencing to TMS. 
For 2D 1H-13C spectra, 1024 points of the direct dimension (13C, 12.5 ms) was 
zero filled to 8192 points, and 96 points of the indirect dimension (1H, 5 ms) was 
zero filled to 512 points. As is common for FSLG experiments, the 1H dimension 
scaling factor was empirically determined. A Gaussian window function was 
applied to the direct dimension, with 30 kHz line broadening and a Gaussian max 
position (GB in Bruker Topspin) of 0.1. For the indirect dimension, two processing 
regimes were used: for plots of the carbon aromatic region, a Gaussian window 
function was applied with 20 Hz line broadening and a Gaussian max position of 
0.1; for plots of the glycine Cα region, a sine bell squared function was applied 
with a sine bell shift of 4. Baseline correction was applied to the full spectral range. 
7.3 Results 
7.3.1 Enhancement of ssNMR signals from cartilage samples by DNP 
Employment of DNP successfully achieved enhancement of the NMR signals 
obtained from both human and mouse cartilage. Enhancement was observed for 
both formalin-fixed and unfixed tissue. Under DNP, the 1D 13C CP ssNMR spectra 
of human cartilage sample showed enhancement (ε) values of 22.5 - 35.4, and 
mouse cartilage spectra showed ε values of 12.5 - 20.3 (Table 7.03).  
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Table 7.03. Samples investigated in this study by DNP-enhanced ssNMR, 
and enhancement values (microwave on/off intensity ratio) obtained from 
CP-MAS ssNMR 13C 1D spectra. 256 transients were acquired per 1D spectrum 
for human samples, while 3072 transients were acquired for mouse samples. The 
choice of radicals used, including AMUPol (342), bcTol (343) and bcTol-M (344) 
was based on improved radicals being available through the course of the study. 





















bcTol-M 25.5 ± 3.5 
Mouse WT 
(unpigmented) 
Femoral condyles No treatment bcTol 12.5 ± 5.2 
Mouse HGD-/- 
(pigmented) 






bcTol 20.3 ± 12.3 
Mouse HGD-/- 
(pigmented) 
Femoral condyles Formalin 
fixation 
AMUPol 16.1 ± 4.5 
HGA-derived 
pigment 
- Drying bcTol  0 
7.3.2 The effects of fixation on ssNMR spectra of cartilage tissues 
Analyses were performed on cartilage tissue from a patient with AKU and from 
another patient with idiopathic OA. The osteoarthritic cartilage served firstly as a 
non-pigmented control sample, and secondly enabled comparison to AKU 
pigmented cartilage at a molecular level. All human tissues were formalin-fixed to 
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reduce possible hazards of transmissible diseases. However, tissue fixation may 
introduce structural changes that could potentially confound any effects due to 
pigmentation, though previous reports suggest that protein secondary structure is 
not affected by formalin fixation (354). Therefore, a comparison of mouse tissue 
from wild type and HGD-/- mice (as a model for AKU) (50), with and without 
fixation, was first carried out. The aim of these experiments was to distinguish 
between the effects of fixation on NMR spectra and any effects of cartilage 
pigmentation.  
The main effect of fixation on 13C NMR spectra acquired under DNP conditions 
appears to be a large signal at 82.2 ppm, and a smaller signal at 84.5 ppm. These 
signals can be clearly observed in Figure 7.01A, which shows the comparison of 
fresh, unfixed mouse tissue with fixed mouse and human tissue. The occurrence 
of these signals in the 70-100 ppm region associated with hydroxylated carbons 
is due to the formation of methylene glycol and polyoxymethylene glycol from 
formaldehyde under aqueous conditions (355,356). As shown in Figure 7.01B, 
the signals from residual methylene glycol were eliminated following soaking of 






Figure 7.01. 13C 1D spectra of various samples analysed in the study, 
illustrating the effect of fixation. Signals arising from the fixative are highlighted 
by yellow boxes. A: DNP-enhanced CP-MAS ssNMR spectra of fresh/unfixed 
mouse tissue (top), fixed mouse tissue (middle) and fixed human tissue (bottom). 
Black spectra represent non-pigmented tissue, while red spectra represent tissue 
that was pigmented macroscopically (human tissue) or microscopically (mouse 
tissue). B: non-pigmented human cartilage NMR spectra at 285K (no DNP 
enhancement, 600 MHz spectrometer) and 110K (with DNP enhancement, 400 
MHz spectrometer). Of the six spectra, the top two were INEPT experiments, the 
bottom four were CP experiments. Cartilage samples that were not soaked (black 
traces) showed a signal arising from the fixative, which disappeared after soaking 
(green traces). C: spectrum from autoxidized synthetic HGA-derived pigment 
(right) with each signal assigned to a carbon on the HGA structure (left). D: 
reaction of formaldehyde with water to give methylene glycol and 
polyoxymethylene glycol. E: pigmented human cartilage NMR spectra at 285K 
(no DNP enhancement, 600 MHz spectrometer) and 110K (with DNP 




From the spectra shown in Figures 7.01B and 7.01E, it is evident that 
significant inhomogeneous line broadening occurred under DNP conditions, to 
the extent that there appears to be little to no difference between the NMR 
spectra of pigmented and non-pigmented cartilage. Comparing the CP spectra 
obtained at 285K (Figures 7.01B and 7.01E), the pigmented and non-
pigmented cartilage do show a difference in linewidth under conventional 
ssNMR conditions as previously demonstrated (336), and this difference was 
maintained after soaking both samples. This observation indicates a loss of 
motional averaging and dynamics of the cartilage tissue under DNP 
conditions.  
It was important to show next that methylene glycol signals generated by 
formaldehyde did not interfere with the potential observation of any signals 
representing HGA-derived pigment in human AKU cartilage. For this purpose, 
the ssNMR spectra of pigment formed from synthetic HGA was studied. As 
shown in Figure 7.01C, it is clear that the signals that arise from fixation are 
well clear of the 13C signals found in the pigment. Therefore, it was concluded 
that the presence of the methylene glycol signals would not hinder the potential 
observation of pigment signals in these analyses. 
7.3.3 SsNMR observation of HGA-derived pigment in cartilage 
Both the structure of HGA and the spectra of the synthetic HGA-derived 
pigment (Figure 7.01C) suggests that any pigment signals should be most 
intense in the aromatic region, from 100-150 ppm in the 13C NMR spectrum. 
As shown in Figure 7.02, this spectral region in the DNP-enhanced 1H -13C 
HETCOR 2D experiments was also the least crowded. In these spectra, the 
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signals represent 1H and 13C nuclei whose spins are associated; i.e. indicative 
of 1H and 13C nuclei that are directly or indirectly bound within a chemical 
structure. Consistent with the above predictions, clear differences were 
observed between the spectra of pigmented and non-pigmented human AKU 





Figure 7.02. 2D 1H-13C FSLG HETCOR DNP-enhanced ssNMR spectrum 
of pigmented (brown spectrum) and non-pigmented (green spectrum) 
human AKU cartilage. The 13C NMR range of 110-140 ppm is the region 
where pigment signals are expected (expanded in Figure 7.03). The glycine 
Cα 13C signal is centred at 42.5 ppm (expanded in Figure 7.04). Photographs 
of the respective cartilage samples from which these data were obtained are 
shown to the right of each spectrum; note the striking dark appearance of the 





For further analysis of HGA and its derivatives in the human AKU cartilage 
samples, a series of 1H-13C HETCOR experiments with different CP contact 
times was performed (Figures 7.03 - 7.05).  Increasing CP contact time led to 
an increase in the number of signals, with signals from more distal 1H and 13C 





Figure 7.03. Similarity between the 2D 1H-13C FSLG HETCOR ssNMR 
spectra obtained from synthetic HGA-derived pigment and pigmented 
AKU human cartilage. These spectra were obtained under DNP conditions 
at 20-100 μs contact times, and the 110-140 ppm region is shown. Grey 
shading highlights the aromatic 13C signals at 120 ppm, which were present in 
the spectra from synthetic HGA-derived pigment (brown, top row) and 
pigmented AKU human cartilage (red, second row) but not those from non-
pigmented AKU human cartilage (green, third row), and OA human cartilage 
(purple, bottom row). On the right, slices extracted from the 2D spectra 
highlight (grey) where the HGA-derived pigment and pigmented AKU cartilage 
show signals in the same 13C chemical shift range, which are weaker in non-
pigmented AKU cartilage and not observable above noise in OA cartilage. An 




Figure 7.04. 13C spectra extracted from the 2D ssNMR 1H-13C FSLG 
HETCOR DNP-enhanced ssNMR spectra. Spectra highlight the increased 
signal at 120 ppm that was attributable to ochronotic pigment in the pigmented 
AKU cartilage sample. The spectra shown were from pigmented AKU human 
cartilage (red), non-pigmented AKU human cartilage (green) and OA human 
cartilage (purple) at 50 μs contact times. To aid visual comparison, the top 
shows all three overlaid, the middle and bottom show just two out of the three 
same spectra overlaid. The vertical height of the largest signal in each 
spectrum were scaled to match each other. The AKU pigmented cartilage 
spectrum shows a broadening/smearing of signal intensity at 120 ppm that is 
clearly absent from the AKU non-pigmented cartilage, and is also weak or 
absent from the OA damaged cartilage though it is harder to gauge due to the 




In Figure 7.03 it is evident that the 20 μs contact time HETCOR spectra of all 
cartilage samples (furthest left column) have a broad 13C signal at 130 ppm 
that corresponds to aromatic residues such as tyrosine, phenylalanine and 
histidine. In pigmented cartilage (Figure 7.03, second row), there is an 
additional 13C signal at 120 ppm that is not present in the non-pigmented AKU 
cartilage nor the non-AKU OA cartilage. This 120-ppm pigmented cartilage 
signal corresponds to signal intensity that is also present in the spectrum of 
the synthetic HGA-derived pigment (Figure 7.03, top row), and this signal was 
therefore assigned to the aromatic carbons in the HGA-derived pigment. 
Despite the differences in this area of the spectra, overall, the spectra from 
cartilage are still dominated by collagen signals. 
In the HETCOR experimental series expanded in Figure 7.05, the contact time 
was increased incrementally from 50-500 μs. These experiments were 
designed to probe the different chemical structures represented by the signals, 
as their intensity over differing contact times reflects the distance between the 
1H and 13C pairings. As the contact time increased, more signals were 
observed in the spectra from synthetic HGA-derived pigment (dark brown). 
The signal at 13C 116.8 ppm correspond to carbons directly bonded to a proton 
in the aromatic ring and is present in all spectra. In the 100 and 500 μs contact 
time spectrum (Figure 7.05, 2 furthest-right rows), an additional signal 
emerges at 13C 148.5 ppm, corresponding to carbons that are directly bonded 
to a hydroxyl group (i.e. a phenyl carbon), where the rate of signal build-up is 
distinctly slower than the 116.8 ppm signal as the distance to the nearest 
proton is greater (Figure 7.05, lower portion). The signal at 148.5 ppm 
therefore indicates presence of a hydroquinone structure in the synthetic HGA-
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derived pigment as opposed to an oxidised quinone, for which the 1H and 13C 





Figure 7.05. 1H-13C FSLG HETCOR ssNMR spectra, showing emergence 
of an additional signal at 148.5 ppm for pigment derived from synthetic 
HGA. The spectra were obtained from unsoaked pigmented AKU human 
cartilage (top), non-pigmented AKU human cartilage (middle) and pigment 
derived from synthetic HGA (bottom) under DNP conditions at various contact 
times from 10 μs - 500 μs; the signal at 148.5 ppm emerges with increased 






7.3.4 Change in collagen structure of pigmented cartilage 
It is interesting to consider the effects of pigmentation on cartilage collagen 
structure. Even though pigment levels are low, there are profound material 
differences between non-pigmented and pigmented AKU cartilage. Apart from 
its dark colour, ochronotic cartilage is stiffer and resistant to enzymatic 
degradation (306), suggesting changes in collagen structure throughout the 
cartilage tissue. Particular attention was therefore paid to the glycine Cα NMR 
signals as a marker of collagen structural integrity more generally. These 
signals were combined into a single 13C peak at 42.7 ppm, well-separated from 
other Cα signals. In NMR spectra of tissues with a high proportion of collagen, 
such as cartilage, this signal is one of the most intense due to the fact that 
glycines occur every third residue along each collagen chain. In Figure 7.06A, 
this spectral region is expanded from the 1H-13C HETCOR spectra acquired at 








Figure 7.06. Spectra from human cartilage, indicating loss of collagen 
integrity in AKU pigmented cartilage by alteration to the type-II collagen 
glycine signal. A: 2D 1H-13C FSLG HETCOR obtained from pigmented AKU 
human cartilage (brown, left column), non-pigmented AKU human cartilage 
(green, middle column) and OA human cartilage (purple, right column) under 
DNP conditions at 20-100 μs contact times, showing only the 13C 30-55 ppm 
range. Alteration, or ‘smearing’ of the signals obtained at 42.7 ppm in the 13C 
dimension is evident for the AKU pigmented cartilage sample. The signal at 
42.7 ppm corresponds to the collagen glycine Cα. The signals at 3.3 ppm and 
9.6 ppm in the 1H dimension are correlated with the glycine Cα signal and 
correspond to directly bonded glycine Hα and the and the protons on the amide 
HN (‘Cα-HN’ signal), respectively. Alteration of these signals in the pigmented 
sample therefore reflects disruption to the inter-chain hydrogen bonds 
between glycine residues in the three chains of the type-II collagen triple helix 
(Figure 7.01D); these changes indicate loss of structural integrity of type-II 
collagen in ochronotic cartilage more generally.  This experiment was repeated 
on fixed and unsoaked AKU human cartilage samples with 10-100 μs contact 
times with similar results (Figure 7.07). B: overlay of extracted slices from the 
2D spectra in Figure 7.06A (from the 1H dimension obtained at 100 μs contact 
time), highlighting broadening/smearing of the signal at 6.7 ppm observed for 
the AKU pigmented cartilage sample only. C: chemical structure of glycine, 
highlighting the sites of hydrogens for which build-up of NMR signal was 
observed with increasing CP contact time (Cα-Hα and Cα-HN; see section Figure 
7.06A). D: graphical representation of the type-II collagen triple helix, 
highlighting the inter-chain hydrogen bonds (red dashed lines) between the 
amide (N) and Cα of neighbouring glycine residues. These bonds are critical 




In Figure 7.06A, for all cartilage spectra obtained at short contact times (top 
row), the glycine Cα signal at 42.7 ppm mainly correlates to a 1H signal 
centered at 3.3 ppm, which correspond to the directly bonded glycine Hα (1.1 
Å). As the contact time is increased to 50 μs and beyond, a second clear 
correlation emerges, centered at 9.6 ppm (1H) in the spectra of the non-
pigmented AKU cartilage (green, middle column) and the OA cartilage (purple, 
right column). This signal can be attributed to correlations between glycine Cα 
and the respective protons on the amide HN (2.1 Å); ‘Cα-HN’ signal. This proton 
occurs at a much higher chemical shift value of 9.6 ppm due to the interchain 
hydrogen bonding that is a defining feature of all collagen triple helices. 
Looking at the same signals in the pigmented cartilage spectra (Figure 7.06A, 
left column, middle and bottom rows), the glycine Cα-HN signal is not as well-
defined, and appears to be smeared towards lower 1H chemical shift (ppm) 
values, which can also be seen in the 1H spectra extracted at 13C 42.5 ppm 
(Figure 7.06B). This indicates that the hydrogen bonds that the glycine HN are 
participating in are disrupted, suggesting at least partial dissociation of the 
collagen triple helix in the pigmented AKU cartilage sample (Figure 7.06D). 
Finally, as the experiments acquired under DNP conditions exhibited 
inhomogeneous line broadening, it was thought that better spectral resolution 
in the glycine region might be obtained by conducting the 1H-13C HETCOR 
experiments at room temperature. For this, standard ssNMR was performed 
at 287 K on a 600 MHz spectrometer. The displayed spectra were acquired 
over a much longer experiment time (47-h instead of 10-h per experiment) but 
still showed reduced sensitivity without DNP-enhancement, therefore no clear 
improvement in spectral line width was achieved. However, in confirmation of 
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the results from DNP ssNMR, a glycine Cα-amide HN signal can be observed 
in non-pigmented cartilage, but is absent from pigmented cartilage (Figure 
7.07). 
 
Figure 7.07. 1H-13C FSLG HETCOR ssNMR spectra obtained on human 
cartilage without DNP-enhancement, corroborating the finding of 
disruption to the type-II collagen glycine signal. Standard ssNMR was 
performed at 285 K on a 600 MHz spectrometer in an attempt to improve 
spectral resolution. These samples were human AKU cartilage; pigmented 
(brown spectrum) and non-pigmented (green spectrum). The 13C ppm range 
shown is 30-55 ppm, as with Figure 7.06A. In agreement with the data shown 
in Figure 7.06A, alteration is observed to the glycine Cα-HN signal, at 42.7 ppm 
in the 13C dimension and 9.6 ppm in the 1H dimension; here there is complete 
absence of this signal from the pigmented sample. These data further support 
widespread disruption to the type-II collagen protein structure in ochronotic 




7.4.1 Potential of DNP-enhanced ssNMR for studying fixed tissue samples 
Using a variety of human and mouse tissue samples the data presented here 
show, to my knowledge, for the first time that 1D and 2D NMR spectra with 
DNP-enhancement values of 10-40 can be reliably obtained from formalin-
fixed tissue using a range of water-soluble biradicals. As chemical fixation is a 
ubiquitous technique for preserving tissue samples across biological 
disciplines, these studies highlight the further opportunities for NMR analyses 
of archival specimens. The structural capabilities of NMR would complement 
traditional histological approaches and other analytical techniques that have 
been described for studying fixed tissues, such as magnetic resonance 
imaging (357–359) and various types of MS (360–364). 
Importantly, these results show that fixation did not significantly alter the NMR 
signals from the protein component of the cartilage tissue, especially under 
the low temperature DNP enhancement conditions where there is significant 
inhomogeneous broadening. The main effect in the case of formalin fixation, 
where no attempt is made to remove the fixative, is the detection of a variable 
intensity 13C signal at 82.2 ppm due to frozen methylene glycol, and a 
generally weak signal at 84.5 ppm due to adsorbed methylene glycol. These 
signals can potentially interfere in the case where the aim is to observe GAG 
species in the sample, but present little interference for the HGA-derived 
pigment signals, which was the primary interest in this study. Moreover, it was 
shown that these methylene glycol 13C signals could be easily removed by 
rinsing and soaking in water (Figure 7.01B & E). 
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7.4.2 Similarities between the HGA-derived pigment and polyquinones 
One advantage of ssNMR is its ability to provide specific insight into the 
chemical composition of heterogeneous samples and polymers, such as the 
solid brown pigment derived from benchtop oxidation of synthetic HGA, and to 
also provide direct comparison to other known/related substances in the 
literature (Table 7.04). The synthetic HGA pigment sample had a relatively 
simple 13C NMR spectrum dominated by four signals (Figure. 7.01C), therefore 
it seems that the structure of the HGA-derived pigment is simpler than the L-
dopa-derived melanins. By comparing the NMR spectra in the current study 
with previous ssNMR analyses on melanin in fungal cell wall (365), hair 
samples (366), and squid ink (367), it is clear that the structure of HGA-derived 
pigment is different from L-dopa and derivatives (such as eumelanin and 
pheomelanin) but bears similarities to HGA. Since HGA is known to form 
pyomelanin, the present data are in agreement with prior work suggesting that 
the AKU pigment is pyomelanin (42). Pyomelanin is produced mainly from 
bacteria and has thus far, to my knowledge, not been subjected to NMR 
analysis. 
In order to gain insight into the chemical structure of the pigment, the NMR 
literature was surveyed for likely candidates that align with the observations 
reported here. Formation of lactone, which was previously reported as an HGA 
derivative in AKU urine (368), can be ruled out, as this would be expected to 
give a 13C chemical shift less than 178 ppm. The 181-ppm chemical shift 
observed here for the synthetic HGA-derived pigment is close to that observed 
in solution-state NMR at 183.4 ppm (Table 7.04) suggesting that the 
carboxylate functionality of HGA had not undergone significant change. 
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The broad signals centred at 116.8 ppm and 148.5 ppm in the 13C ssNMR 
spectrum of the brown pigment sample are characteristic of carbon atoms 
situated in phenol-like rings, in agreement with hydroquinone-like or HGA-like 
ring structures (369–371). If benzoquinone rings are present in the pigment, 
13C signals should be observed at 136 ppm and 181 ppm. The former signal 
was clearly not observed. While a signal at the latter position was observed, it 
is likely to correspond to the carboxylic acid functionality in HGA rather than 
the carbonyl of benzoquinone. It cannot be ruled out that benzoquinone-like 
structures were present within the substance at low quantities, as this sample 
failed to show any DNP signal enhancement, presence of a minority of 
benzoquinone-like rings can be expected from the colour of the sample alone. 
However, it is clear that hydroquinone rings were much more prevalent than 
benzoquinone rings in the HGA-derived pigment sample. Although it may 
seem like a conflict that the colour of the substance indicated presence of 
benzoquinone-like species and the NMR spectra indicated a dominance of 
hydroquinone-like species, this is in agreement with the common observation 





Table 7.04. 13C NMR chemical shifts of the structures relevant to 
ochronotic pigment, as obtained from literature. 
 
* Bruker-format data of HGA in aqueous solution was downloaded from the Madison 
Metabolomics Consortium Database (MMCD) and the referencing taken as is. Note 
that the chemical shift values reported on the HGA page of the MMCD 
(http://mmcd.nmrfam.wisc.edu/test/cqsearch.py?cqid=cq_00389) do not seem to 
match the values from the spectrum downloaded 
(http://mmcd.nmrfam.wisc.edu/rawnmr/expnmr_00219_3.tar), but the chemical shifts 
of the spectrum downloaded showed reasonable agreement with the solid-state 13C 
NMR spectrum of the HGA-derived pigment in this study. 
† Experimental values were not found for BQA, likely due to its instability. Expected 
chemical shift values were derived with reference to benzoquinone and HGA values 
in the literature. 
‡ In addition, similar values can be found in the following references: (370–372). 
  
Chemical entity Carbon (by 
position) 
Respective 13C 
chemical shift (ppm) 
Homogentisic acid  
(HGA)* 
1, 4  




150.4, 151.6  




Benzoquinone acetic acid 
(BQA)† 
1, 4 









Hydroquinone‡ 1,2 151.5, 118.5 
Benzoquinone‡ 1,2 187.0, 136.4 
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The following discussion therefore focuses on known benzoquinone- and 
hydroquinone-related multimeric structures and their properties. Oligomeric 
benzoquinones and hydroquinones (dimers and trimers) are unstable and 
frequently undergo further polymerization (372,373). Stable, well-defined 
dimers and trimers have only been synthesized with the protection of bulky     
t-butyl groups that prevent further polymerisation (372). By referring to 
previous solid-state 13C NMR study of benzoquinones and hydroquinones 
(371) and their well-characterized oligomers (372), the NMR chemical shifts 
obtained here from the pigment are in agreement with those obtained from 
hydroquinone rings in monomers and oligomers. From the literature cited here, 
it is expected that under the benchtop conditions in which the pigment sample 
was formed from HGA standard solution, the final product is unlikely to be 
strictly restricted to low molecular weight compounds such as dimers and 
trimers. 
Hydroquinone and benzoquinone are known for their redox properties (374); 
these chemicals and their polymeric forms have been used as inhibitors 
against radical polymerization, e.g. as antioxidants in rubber (375). 
Polyhydroquinone, polyquinone and polybenzoquinone are increasingly 
oxidised polymeric forms, with the intermediate polyquinone being a mix of 
hydroquinone and benzoquinone rings, and susceptible to both oxidation and 
reduction. While pure polyhydroquinone can be formed as a white solid by 
reduction of polyquinone, it is easily reoxidised on exposure to oxygen in air 
(376). The redox activity of polyquinone would trap and quench any added 
radical species, thus explaining the inability here to obtain any DNP 
enhancement on the synthetic HGA-derived pigment sample. The reducing 
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capability of HGA also explains the negative interference observed in samples 
with elevated HGA concentration on a range of routine clinical assays that are 
based on the production of hydrogen peroxide (377). In this respect, the 
pigment is also chemically similar to bacterial pyomelanin, which has been 
reported to scavenge free radicals (378). Based on the data discussed here, I 
propose that the HGA-derived pigment is polyquinone-like, substituted with 
alkyl carboxylic acids. 
7.4.3 Identification of an NMR signal representing HGA-derived pigment in 
human tissue samples 
A fundamental question in these studies was whether the NMR spectra of 
pigment derived from synthetic HGA bears any resemblance to that of the 
pigment species present in ochronotic AKU cartilage. Despite the black 
appearance and brittle texture of ochronotic cartilage (306), the 1D 13C NMR 
spectra obtained from pigmented and non-pigmented cartilage here and in 
previous studies (336) are very similar; all significant NMR signals can be 
attributed to collagen proteins. Clear differences only became apparent with 
the enhanced sensitivity enabled by DNP in this study, which made it possible 
to acquire a series of 2D 1H-13C correlation experiments on cartilage samples 
from patients. In the case of the fixed tissues, when searching for specific 
signals representing the pigment, it was important to consider potential 
spectral interference from either residual fixative or the cartilage tissue.  
Importantly, the formalin fixative could be eliminated as a source of 
interference, as it was shown that no fixative signals occurred in the aromatic 
region of interest at 110-160 ppm (Figure 7.01), where signals representing 
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HGA or its derivatives would be expected. Of the natural amino acids, 
phenylalanine and histidine side chain signals would be expected to to overlap 
with those arising from benzoquinone/BQA, while tyrosine side chain signals 
would be expected to overlap with hydroquinone/HGA. Fortunately, the type- 
II collagen of cartilage has a low proportion of aromatic residues: 
phenylalanine (1.4% of the triple helix), histidine (0.2%), and tyrosine (0.2%). 
These side chains in the aromatic region should therefore be minor signals in 
the spectra. Tryptophan is not part of the triple helix and is therefore excluded. 
Moreover, the non-pigmented AKU cartilage and OA cartilage samples were 
used as controls to establish the expected relative signal intensities arising 
from these minor aromatic side chains prior to extracting information specific 
to the pigment species. 
A 13C signal centered at 120 ppm was observed from both the synthetic HGA-
derived pigment and the pigmented AKU cartilage and therefore attributable 
to pigmentation. I acknowledge that in all cartilage samples, 13C signals were 
observed at 115 ppm; these are likely to be primarily attributable to tyrosine 
side chains from collagen and other ECM proteins. Since the hydroquinone 
functionality is similar in structure to the phenol ring in tyrosine, the HGA-
derived pigment also shows this signal. The fact that the pigment signal occurs 
centered at 120 ppm strongly supports the presence of hydroquinone 
functionality, but not the benzoquinone functionality. 
7.4.4 Investigating the sites of disruption in AKU cartilage 
Having established the chemical similarities of the synthetic HGA-derived 
pigment and the pigmented cartilage, I briefly consider the process by which 
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HGA and derived species can bind to collagen. One possible point in time is 
during secretion of collagen proteins from the cell. The cytoplasmic 
environment is reducing (379), while the extracellular space is oxidizing (380), 
which is likely to promote non-enzymatic oxidation of BQA and other 
polyquinone species. It is therefore possible that collagen triple helices are 
vulnerable to binding and disruption only when secreted into the extracellular 
space, prior to or during fibrillization. The local redox environment may explain 
observations that pigmentation is localized to individual chondrocytes and their 
pericellular matrices in the calcified zone of articular cartilage (50) and that 
early pigmentation follows the periodicity of collagen fibrils (381,382). That 
said, cartilage is a slow turnover tissue and the osteoarthropathy in AKU is not 
from birth but only after 30-40 years of life, so it seems unlikely for 
pigmentation during secretion to be the dominant mechanism in advanced 
ochronosis. 
There are similarities between ochronotic cartilage and the normal ageing of 
cartilage; in both processes, cartilage becomes stiffer and more resistant to 
enzymatic degradation. In the normal ageing process, these changes are 
associated with loss of proteoglycans, and increases in both enzymatic and 
non-enzymatic cross-linking of the collagen matrix (383–385). In OA, 
increased ECM stiffness is thought to be an early pathophysiologic event, 
rendering cartilage susceptible to further damage by loading (385,386). 
Presumably, the altered physico-mechanical properties of ochronotic cartilage 
exacerbate progression of osteoarthropathy in AKU, as the altered cartilage 
no longer supports normal loading due to aberrant transmission. The data 
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reported in this chapter pinpoint a mechanism of structural disruption that can 
lead to this type of material change. 
The 1H-13C HETCOR spectra showed remarkable changes in triple helix 
integrity between non-pigmented and pigmented AKU cartilage. The 
observation that the 1H chemical shift of the glycine amide moves to lower 
values is particularly interesting, indicating a lengthening and weakening of 
these hydrogen bonds (387,388). In collagen, where these interchain 
hydrogen bonds are pervasive, this level of molecular structure change is likely 
key to the mechanical and functional failures of pigmented cartilage. From the 
structure of the collagen triple helix, it is expected that glycine residues are 
buried in the centre of the collagen triple helix and naturally protected against 
disruptive bindings. I hypothesise that the binding of HGA and/or derived 
species occurs in regions where the triple helix is under strain. Such strain 
leads to partial uncoiling or unfolding of the triple helix, exposing the glycine 
amide site for binding. In the case of AKU, possibly due to the high binding 
affinity of benzoquinone rings, the usually temporary uncoiling or unfolding of 
the triple helix becomes exacerbated by the presence of ochronotic pigment 
and perhaps even leads to an “unzipping” of the triple helix. A similar process 
could also apply in general OA, where temporary strain or change to the triple 
helix becomes permanent damage. 
While the spectra obtained from OA cartilage was broadly similar to that from 
non-pigmented AKU cartilage, in the OA cartilage spectrum the most intense 
part of the glycine HN signal showed a drift to lower chemical shift (Figure 
7.06). A possible interpretation is that in OA cartilage, the collagen triple helix 
degradation is more than that in non-pigmented AKU cartilage, but less than 
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that in pigmented AKU cartilage. This supports the idea that common, age-
related cartilage degeneration not only precedes ochronosis in AKU but also 
acts as a pathophysiological event that renders cartilage susceptible to 
ochronosis at specific sites (9). However, without 13C enrichment, it is difficult 
to correlate pigment and collagen proteins signals to directly identify a potential 
specific binding site for AKU-derived species within the cartilage matrix. 
7.5 Chapter 7 conclusion 
The data presented in this chapter support that the process of ochronosis in 
AKU causes widespread molecular disorder to the cartilage collagen matrix. 
This fundamental alteration to the triple helical structure of collagen is likely to 
underlie its mechanical failings responsible for severe osteoarthropathy in 
AKU. Moreover, the comparison of AKU to OA cartilage shows that similar, but 
milder molecular alteration occurs in OA. This suggests that the onset of 
ochronosis in AKU, which is not usually observed until the third-fourth 
decades, is facilitated by common, age-related osteoarthritic degradation of 
cartilage. Currently, there is still no biomarker that accurately predicts the 
onset of OA. In AKU, development of osteoarthropathy is both predictable and 
inevitable, therefore providing a unique opportunity to model early-stage 
osteoarthritic changes to cartilage. Together, the data highlight that the study 
of a rare disease can provide valuable lessons about widespread, 
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8.0  OVERALL CONCLUSION 
The work presented in this thesis represents the most comprehensive 
biochemical investigation of AKU to date. Metabolomic analyses revealed for 
the first time the wider biochemical consequences of a) targeted HGD gene 
deletion in mice and b) nitisinone treatment beyond the tyrosine metabolic 
pathway. Studies on ochronotic pigment suggested for the first time a) a 
specific compound structure from ochronotic pigment formed by aggregation 
of HGA-related species and b) alteration to a specific site in the cartilage 
matrix, which is likely to explain susceptibility to ochronosis. 
The biochemical alterations observed in the metabolomics experiments reflect 
a complex, inter-connected network of metabolites across multiple metabolic 
pathways. Many of these changes were unexpected, both at the level of 
individual metabolites and the pathways involved. These data therefore offer 
an array of novel insights into AKU pathology, including potential biomarkers 
of OA progression. Mechanistic evaluation of the metabolite changes 
observed is beyond the scope of this thesis, but the wealth of novel insights 
that these experiments have provided will stimulate a plethora of further 
research projects in AKU. At the heart of these projects will be the clinical 
implications of the changes observed.  
The analytical data acquired from ochronotic pigment have significantly 
advanced our knowledge of its chemical properties. Ochronotic pigment 
represents the major knowledge gap in AKU at present. Ochronosis is central 
to the devastating consequences of the disease, yet its chemical structure and 
the mechanism through which it binds to cartilage is not known. The analyses 
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carried out on pigment produced from HGA in vitro fundamentally challenge 
the idea that ochronotic pigment is a polymer, and instead support the 
aggregation of a combination of HGA and BQA by weaker, non-covalent 
interactions. The data from in vivo studies indicate that ochronosis is 
accompanied by widespread alteration to the structure and organisation of the 
cartilage matrix. The observed alteration to the glycine signal in ochronotic 
cartilage, an abundant amino acid residue in type-II cartilage collagen, 
potentially pinpoints the specific structural alteration that enables pigment 
deposition.  
8.1 Next steps 
The metabolomic analysis workflow described here is a system for 
comprehensive metabolic phenotyping more generally. The strategy will be an 
invaluable tool to AKU researchers going forward and has great potential to 
be used in a clinical context more broadly. For AKU, the SONIA-II clinical trial 
(139), which finished recently, is a particularly exciting opportunity to further 
deploy this technique. SONIA II is an international, multicentre randomised 
control clinical trial including the largest AKU patient cohort studied to date. 
This cohort provides an opportunity to independently validate the metabolite 
changes observed here on nitisinone and the metabolite correlations with 
clinical parameters, for example measures of osteoarthropathy disease 
severity. Furthermore, the increased size of the SONIA II patient cohort 
compared with the NAC cohort studied here will enhance statistical power, 




Further work will also aim to gain mechanistic insights into the metabolomic 
alterations observed. There are a number of potential hypotheses that could 
explain the surprising widespread network of changes observed here as a 
consequence of both nitisinone treatment and targeted HGD disruption in 
untreated AKU. A series of further metabolic flux experiments have been 
planned in mice using stable isotopically labelled compounds (HGA and 
tyrosine), with the aim of identifying the whole range of metabolites that are 
increased due to being derived from the elevated tyrosine and HGA observed 
in treated and untreated AKU respectively.  
An alternative hypothesis is that some of the metabolite changes observed are 
due to the indirect effects of compounds that are markedly elevated in treated 
or untreated AKU. For example, it has been shown that the enzyme tryptophan 
transaminase, which converts tryptophan to indoxyl sulfate (decreased here in 
mice on nitisinone) via indolepyruvate, has increased affinity for tryptophan in 
the presents of keto acids such as HPLA which are markedly increased on 
nitisinone (389). In contrast, it has been suggested from HT-I that increased 
tyrosine, as a result of nitisinone therapy, inhibits the activity of tryptophan 
hydroxylase, resulting reduced conversion of tryptophan to serotonin (236). It 
is therefore conceivable that elevated HGA in untreated AKU, and elevated 
tyrosine and/or keto acids in nitisinone-treated AKU impact upon the activity 
of other enzymes in tyrosine and neighbouring metabolic pathways. The 
potential for these markedly elevated compounds to act upon specific 
enzymes within neighbouring metabolic pathways could explain the complex 
network of metabolite alteration beyond those increases that are likely to be 
derived directly from HGA or tyrosine.   
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Enzyme inhibition or enhancement attributable to increased concentrations of 
such metabolites could be studied in a series of in vitro experiments. These 
experiments could involve tissue homogenates, cell cultures or isolated 
enzymes in the presence of varying concentrations of the above metabolites, 
with enzyme activity indicated by the rates of metabolite substrate conversion 
and product formation. A ‘systems’ approach, whereby metabolomics data are 
combined with data from other ‘omics modalities such as transcriptomics and 
proteomics, could be particularly informative. Such an approach could 
investigate potential associations between metabolite levels and the 
expression of individual enzymes of tyrosine metabolism and neighbouring 
metabolic pathways.  
Nitisinone is a very promising treatment for AKU, but it is important to note that 
its mechanism of action is not ideal; its inhibition of HPPD essentially shifts the 
metabolic ‘block’ observed in the tyrosine pathway in AKU further upstream of 
HGA. The gold-standard therapy for AKU is restoration of HGD activity in the 
liver by enzyme replacement or gene therapy, for example; such approaches 
have shown promise in other inborn errors of metabolism, including 
monogenic disorders of the liver (390,391). It is most likely a question of ‘when’ 
and not ‘if’ these approaches are adopted as standard treatments in AKU, and 
the metabolomics strategy developed as part of this thesis could be invaluable 
in assessing the wider metabolic impact or off-target effects of future therapies 
compared with nitisinone. 
The studies reported here on ochronotic pigment and cartilage could be 
extended in a series of further NMR analyses using stable isotopically labelled 
HGA for enhancement of signals in the 13C dimension. These analyses would 
347 
 
be performed on pigment formed in vitro from 13C6 HGA and on cartilage tissue 
explants incubated with 13C6 HGA; non-ochronotic cartilage explants have 
been shown to develop ochronosis macroscopically in ex vivo cultures over a 
period of weeks-months (63). Enhancement of NMR 13C signals in these 
studies would improve signal-to-noise in 2D studies aimed at further probing 
the molecular conformation of ochronotic pigment and its association with the 
cartilage extracellular matrix. It would also be of interest to study the effect of 
specific sites of damage to the cartilage matrix, induced by natural ageing or 
under controlled conditions in the laboratory by chemical/mechanical means, 
on the interaction of HGA, pigment or associated species with cartilage. NMR 
analyses on samples from these studies could help to elucidate a specific 
binding site for HGA or pigment within the type-II collagen matrix. This 
information will be key to the development of future treatment strategies that 
directly target cartilage in AKU and potentially in other diseases of cartilage 
more generally; identification of an agent with a specific affinity for cartilage 
would also be of major interest in common OA. 
Other analytical techniques should be explored in order to solve the chemical 
structure of ochronotic pigment. Raman spectroscopy has emerged as a 
sensitive technique for detection of ochronosis ex vivo (183) and is therefore 
worth considering as a means of obtaining more detailed chemical information 
on the pigment itself. MALDI-MS could offer a more suitable mass 
spectrometric technique for testing the presence of polymer species in 
ochronotic pigment due to its ability to generate singly-charged polymer ion 
distributions with minimal fragmentation (392,393).  
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The indication of co-existing hydroquinone & quinone functionalities in the data 
acquired from ochronotic pigment is interesting and provides novel insights 
into its chemistry. These data are in line with the observation that pigment, an 
oxidised quinone product of HGA, is able to simultaneously act as a reducing 
agent, (e.g. it reduces of Schmorl’s stain to result in a blue colouration (62)), 
which indicates co-presence of reduced hydroquinone electron-donating 
groups. This is an important and previously under-recognised feature of 
ochronotic pigment. As discussed in Chapter 6, detection of oxidised quinone 
products of HGA poses a significant challenge in mass spectrometric analyses 
of ochronotic pigment. Electrochemical techniques could be particularly 
informative in understanding the oxidised quinone-like sub-component of 
ochronotic pigment, as oxidation of hydroquinone-containing species such as 
HGA produces free electrons. In summary, a range of further studies 
employing a range of analytical techniques will be required to probe the 
diverse chemical properties of ochronotic pigment in order to finally elucidate 
its complex chemical composition. 
8.2 Concluding remarks 
The data reported in this thesis, particularly from metabolomic analyses, 
highlight several important points beyond AKU. These findings demonstrate 
the power of metabolomic analyses combining high-sensitivity, high-resolution 
modern instruments such as LC-QTOF-MS with chemometric data analyses. 
Second is that targeted deletion of an enzyme can result in a complex pattern 
of metabolite alteration which extends to other unexpected pathways, 
including those that were previously thought to operate independently. Single-
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gene disorders of metabolism, such as AKU, therefore present unique 
windows into metabolism that can uncover associations between metabolite 
pathways in physiology more generally. In conclusion, this work therefore 
serves as a reminder of the value of studying rare diseases as gateways to 
understanding common conditions and human physiology (9). As stated 
elegantly by William Harvey: 
“Nature is nowhere accustomed more openly to display her secret mysteries 
than in cases where she shows tracings of her workings apart from the beaten 
paths; nor is there any better way to advance the proper practice of medicine 
than to give our minds to the discovery of the usual law of nature, by careful 
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10.0  SUPPORTING MATERIAL 
Appendix 1 
 







2,3-Dihydroxybenzoic acid C7 H6 O4 3.23 154.0266 
2-Hydroxyphenylacetic acid C8 H8 O3 4.258 152.0473 
2-METHYLMALEATE C5 H6 O4 1.168 130.0266 
3-hydroxy-3-methyl-Glutaric 
acid C6 H10 O5 1.218 162.0528 
4-acetamidobutanoate C6 H11 N O3 1.339 145.0739 
4-Hydroxybenzaldehyde C7 H6 O2 3.746 122.0368 
4-Hydroxyphenyllactic acid C9 H10 O4 2.928 182.0579 
4-Pyridoxic acid C8 H9 N O4 1.305 183.0532 
Acetoacetic acid C4 H6 O3 0.947 102.0317 
Caffeic Acid C9 H8 O4 3.836 180.0423 
Citramalic acid C5 H8 O5 1.052 148.0372 
Citric acid C6 H8 O7 0.8 192.027 
Ethylmalonic acid C5 H8 O4 1.946 132.0423 
Hippuric acid C9 H9 N O3 3.674 179.0582 
Homogentisic acid C8 H8 O4 1.619 168.0423 
Homovanillic acid C9 H10 O4 4.193 182.0579 
Hypoxanthine C5 H4 N4 O 0.847 136.0385 
L-Phenylalanine C9 H11 N O2 2.045 165.079 
L-Tryptophan C11 H12 N2 O2 2.82 204.0899 
L-Tyrosine C9 H11 N O3 0.917 181.0739 
Methyl N-(a-
methylbutyryl)glycine C9 H16 O4 6.455 188.1049 
m-Salicylic acid C7 H6 O3 3.749 138.0317 
N-Acetyl-L-phenylalanine C11 H13 N O3 5.14 207.0895 
N-Acetylserotonin C12 H14 N2 O2 3.639 218.1055 
Oxoadipic acid C6 H8 O5 0.863 160.0372 
Pantothenic Acid C9 H17 N O5 2.731 219.1107 
Phenylpyruvic acid C9 H8 O3 3.546 164.0473 
p-Hydroxyphenylacetic acid C8 H8 O3 3.585 152.0473 
Pimelic acid C7 H12 O4 4.179 160.0736 
p-Salicylic acid C7 H6 O3 3.116 138.0317 
Pyroglutamic acid C5 H7 N O3 0.897 129.0426 
Salicylic acid C7 H6 O3 4.994 138.0317 
Suberic acid C8 H14 O4 5.39 174.0892 
Theophylline C7 H8 N4 O2 3.366 180.0647 
trans-Aconitate C6 H6 O6 0.982 174.0164 
Uridine C9 H12 N2 O6 0.932 244.0695 
Vanillylmandelic acid C9 H10 O5 1.399 198.0528 
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(+)-α-Tocopherol C29 H50 O2 11.652 430.3811 
(±)-Mevalonolactone C6 H10 O3 1.472 130.063 
12-Hydroxydodecanoic acid C12 H24 O3 9.022 216.1725 
1-Methyladenosine C11 H15 N5 O4 2.719 281.1124 
2,3-Pyridinedicarboxylic acid C7 H5 N O4 0.825 167.0219 
2-Aminophenol C6 H7 N O 0.975 109.0528 
2-Hydroxyphenylacetic acid C8 H8 O3 4.258 152.0473 
3-(2-Hydroxyphenyl)propionic acid C9 H10 O3 5.322 166.063 
3,4-Dihydroxybenzoic acid C7 H6 O4 2.211 154.0266 
3-Amino-4-hydroxybenzoic acid C7 H7 N O3 0.975 153.0426 
3-hydroxy-3-methyl-Glutaric acid C6 H10 O5 1.218 162.0528 
3-Indoleacetic Acid C10 H9 N O2 5.531 175.0633 
3-Methoxytyramine C9 H13 N O2 1.549 167.0946 
3-O-Methyl-L-DOPA C10 H13 N O4 1.357 211.0845 
4-acetamidobutanoate C6 H11 N O3 1.339 145.0739 
4-Hydroxybenzaldehyde C7 H6 O2 3.746 122.0368 
4-Hydroxyphenyllactic acid C9 H10 O4 2.928 182.0579 
4-Pyridoxic acid C8 H9 N O4 1.305 183.0532 
4-Quinolinecarboxylic acid C10 H7 N O2 1.399 173.0477 
5′-Deoxy-5′-(methylthio)adenosine 
C11 H15 N5 O3 
S 3.674 297.0896 
Acetoin C4 H8 O2 9.57 88.0524 
Acetyl-L-Cysteine C5 H9 N O3 S 1.367 163.0303 
Acetyl-L-Leucine C8 H15 N O3 5.058 173.1052 
Caffeic Acid C9 H8 O4 3.836 180.0423 
Caffeine C8 H10 N4 O2 4.155 194.0804 
cAMP 
C10 H12 N5 O6 
P 1.318 329.0525 
Citramalic acid C5 H8 O5 1.052 148.0372 
Citric acid C6 H8 O7 0.8 192.027 
Cortisol C21 H30 O5 7.716 362.2093 
d-Dethiobiotin C10 H18 N2 O3 5.288 214.1317 
Deoxyadenosine C10 H13 N5 O3 1.489 251.1018 
Deoxyguanosine C10 H13 N5 O4 1.382 267.0968 
Desmosterol C27 H44 O 13.159 384.3392 
DL-3,4-Dihydroxymandelic acid C8 H8 O5 0.837 184.0372 
Dopamine C8 H11 N O2 0.804 153.079 
ferulic acid C10 H10 O4 5.153 194.0579 
Guanosine C10 H13 N5 O5 1.194 283.0917 
Hippuric acid C9 H9 N O3 3.674 179.0582 
Homogentisic acid C8 H8 O4 1.619 168.0423 
Hypoxanthine C5 H4 N4 O 0.847 136.0385 
Indoleacetaldehyde C10 H9 N O 2.43 159.0684 
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Kynurenine C10 H12 N2 O3 1.672 208.0848 
Linoleic acid C18 H32 O2 12.207 280.2402 
L-Nicotine C10 H14 N2 0.999 162.1157 
L-Phenylalanine C9 H11 N O2 2.045 165.079 
LTB4 C20 H32 O4 11.378 336.2301 
L-Tryptophan C11 H12 N2 O2 2.82 204.0899 
L-Tyrosine C9 H11 N O3 0.917 181.0739 
Lumazine C6 H4 N4 O2 1.141 164.0334 
Lumichrome C12 H10 N4 O2 6.514 242.0804 
Methyl jasmonate C13 H20 O3 8.787 224.1412 
Methyl N-(a-methylbutyryl)glycine C9 H16 O4 6.455 188.1049 
MG(18:1(9Z)/0:0/0:0)[rac] C21 H40 O4 12.212 356.2927 
mono-Ethyl malonate C5 H8 O4 2.854 132.0423 
Monomethyl glutaric acid C6 H10 O4 3.643 146.0579 
N,N-Dimethyl-1,4-phenylenediamine C8 H12 N2 1.038 136.1 
N6-(DELTA2-ISOPENTENYL)-
ADENINE C10 H13 N5 5.995 203.1171 
N-Acetyl-DL-methionine C7 H13 N O3 S 3.263 191.0616 
N-Acetyl-L-alanine C5 H9 N O3 1.134 131.0582 
N-Acetyl-L-phenylalanine C11 H13 N O3 5.14 207.0895 
Niacin (Nicotinic acid) C6 H5 N O2 0.894 123.032 
Niacinamide C6 H6 N2 O 1.003 122.048 
Nitrotyrosine C9 H10 N2 O5 2.225 226.059 
Palmitic acid C16 H32 O2 12.36 256.2402 
Pantothenic Acid C9 H17 N O5 2.731 219.1107 
Phenylethylamine C8 H11 N 2.617 121.0891 
p-Hydroxyphenylacetic acid C8 H8 O3 3.585 152.0473 
Pimelic acid C7 H12 O4 4.179 160.0736 
Quinaldic acid C10 H7 N O2 3.815 173.0477 
RAC-GLYCEROL 1-MYRISTATE C17 H34 O4 11.572 302.2457 
Resorcinol monoacetate C8 H8 O3 5.251 152.0473 
salsolinol C10 H13 N O2 0.931 179.0946 
Suberic acid C8 H14 O4 5.39 174.0892 
Theobromine C7 H8 N4 O2 2.75 180.0647 
trans-Aconitate C6 H6 O6 0.982 174.0164 
Tryptamine C10 H12 N2 3.197 160.1 
Tyramine C8 H11 N O 1.069 137.0841 
Uridine C9 H12 N2 O6 0.932 244.0695 
Xanthine C5 H4 N4 O2 0.903 152.0334 












2-METHYLMALEATE C5 H6 O4 2.836 130.0266 
4-Hydroxybenzaldehyde C7 H6 O2 5.843 122.0368 
4-Hydroxyphenyllactic acid C9 H10 O4 4.751 182.0579 
4-Pyridoxic acid C8 H9 N O4 3.219 183.0532 
Acetoacetic acid C4 H6 O3 2.19 102.0317 
Adipic acid C6 H10 O4 4.615 146.0579 
Citramalic acid C5 H8 O5 2.412 148.0372 
Citric acid C6 H8 O7 1.924 192.027 
Ethylmalonic acid C5 H8 O4 3.825 132.0423 
Galactaric acid C6 H10 O8 1.346 210.0376 
Gentisic acid C7 H6 O4 4.668 154.0266 
Gulonolactone C6 H10 O6 1.38 178.0477 
Hippuric acid C9 H9 N O3 5.476 179.0582 
Homogentisic acid C8 H8 O4 3.542 168.0423 
Hypoxanthine C5 H4 N4 O 2.065 136.0385 
Isocitrate C6 H8 O7 1.625 192.027 
Lithocholic acid C24 H40 O3 13.732 376.2977 
L-Tyrosine C9 H11 N O3 2.169 181.0739 
Maleic acid C4 H4 O4 2.007 116.011 
Malic acid C4 H6 O5 1.577 134.0215 
Malonic acid C3 H4 O4 1.706 104.011 
Methyl N-(a-
methylbutyryl)glycine C9 H16 O4 8.124 188.1049 
Methylglyoxal C3 H4 O2 2.195 72.0211 
m-Salicylic acid C7 H6 O3 5.702 138.0317 
N-Acetyl-DL-serine C5 H9 N O4 1.674 147.0532 
N-Acetyl-L-phenylalanine C11 H13 N O3 6.897 207.0895 
N-Acetylneuraminic Acid C11 H19 N O9 1.466 309.106 
N-Acetylserotonin C12 H14 N2 O2 5.38 218.1055 
N-ALPHA-ACETYL-L-
ASPARAGINE C6 H10 N2 O4 1.606 174.0641 
Oxoglutaric acid C5 H6 O5 1.671 146.0215 
Pantothenic Acid C9 H17 N O5 4.337 219.1107 
Phenyl acetate C8 H8 O2 4.751 136.0524 
p-Hydroxyphenylacetic acid C8 H8 O3 5.314 152.0473 
p-Salicylic acid C7 H6 O3 5.312 138.0317 
Pyroglutamic acid C5 H7 N O3 2.119 129.0426 
Quinic acid C7 H12 O6 1.469 192.0634 
Sarcosine C3 H7 N O2 1.304 89.0477 
Succinic acid C4 H6 O4 2.391 118.0266 
tartaric acid C4 H6 O6 1.461 150.0164 
Taurine C2 H7 N O3 S 1.267 125.0147 
Theophylline C7 H8 N4 O2 5.226 180.0647 
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Uric acid C5 H4 N4 O3 1.902 168.0283 












(±)-Mevalonolactone C6 H10 O3 3.125 130.063 
10-hydroxy capric acid C10 H20 O3 9.269 188.1412 
12-Hydroxydodecanoic acid C12 H24 O3 10.523 216.1725 
1-Methyladenosine C11 H15 N5 O4 4.389 281.1124 
2-Aminophenol C6 H7 N O 2.162 109.0528 
2-hydroxypyridine C5 H5 N O 3.114 95.0371 
3,4-Dihydroxybenzoic acid C7 H6 O4 4.312 154.0266 
3-Hydroxy-DL-kynurenine C10 H12 N2 O4 2.193 224.0797 
3-Methoxytyramine C9 H13 N O2 3.197 167.0946 
3-Methyladenine C6 H7 N5 1.703 149.0701 
3-O-Methyl-L-DOPA C10 H13 N O4 3.129 211.0845 
3-Ureidopropionic acid C4 H8 N2 O3 1.717 132.0535 
4-acetamidobutanoate C6 H11 N O3 3.142 145.0739 
4-Hydroxybenzaldehyde C7 H6 O2 5.843 122.0368 
4-Pyridoxic acid C8 H9 N O4 3.219 183.0532 
4-Quinolinecarboxylic acid C10 H7 N O2 3.229 173.0477 
5′-Deoxy-5′-
(methylthio)adenosine C11 H15 N5 O3 S 5.335 297.0896 
5-Hydroxytryptophan C11 H12 N2 O3 3.079 220.0848 
5-Methylcytosine C5 H7 N3 O 1.391 125.0589 
Acetoin C4 H8 O2 1.339 88.0524 
Acetyl-L-Cysteine C5 H9 N O3 S 3.112 163.0303 
Arachidic Acid C20 H40 O2 14.297 312.3028 
Benzaldehyde C7 H6 O 9.367 106.0419 
Butanal C4 H8 O 8.759 72.0575 
Caffeic Acid C9 H8 O4 6.168 180.0423 
Caffeine C8 H10 N4 O2 5.967 194.0804 
cAMP C10 H12 N5 O6 P 3.474 329.0525 
Carnitine C7 H15 N O3 1.228 161.1052 
Cortisol C21 H30 O5 9.27 362.2093 
Creatine C4 H9 N3 O2 1.321 131.0695 
Creatinine C4 H7 N3 O 1.211 113.0589 
Cytidine C9 H13 N3 O5 1.449 243.0855 
Cytosine C4 H5 N3 O 1.444 111.0433 
Dehydroascorbic acid C6 H6 O6 1.367 174.0164 
Deoxyadenosine C10 H13 N5 O3 3.404 251.1018 
Deoxycytidine C9 H13 N3 O4 1.583 227.0906 
D-Glucosamine 6-phosphate C6 H14 N O8 P 1.218 259.0457 
D-Glucuronic acid C6 H10 O7 1.328 194.0427 
Diacetyl C4 H6 O2 9.478 86.0368 
Dihydrouracil C4 H6 N2 O2 1.321 114.0429 
Dihydroxyphenylacetic acid C8 H8 O4 4.432 168.0423 
Dioctyl phthalate C24 H38 O4 13.507 390.277 
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Dopamine C8 H11 N O2 1.663 153.079 
D-Saccharic acid C6 H10 O8 1.423 210.0376 
Elaidic Acid C18 H34 O2 13.64 282.2559 
Gluconic acid C6 H12 O7 1.365 196.0583 
Glucosaminic acid C6 H13 N O6 1.251 195.0743 
Glutamine C5 H10 N2 O3 1.262 146.0691 
Glyceraldehyde C3 H6 O3 1.399 90.0317 
Glyceryl phosphate C3 H9 O6 P 1.426 172.0137 
Guanidineacetic acid C3 H7 N3 O2 1.388 117.0538 
Guanidinosuccinic Acid C5 H9 N3 O4 1.325 175.0593 
Guanine C5 H5 N5 O 1.724 151.0494 
Gulonolactone C6 H10 O6 1.38 178.0477 
Hippuric acid C9 H9 N O3 5.476 179.0582 
Homocysteine thiolactone C4 H7 N O S 1.339 117.0248 
Hypoxanthine C5 H4 N4 O 2.065 136.0385 
Inosine C10 H12 N4 O5 2.956 268.0808 
Isocitrate C6 H8 O7 1.625 192.027 
Itaconic acid C5 H6 O4 3.444 130.0266 
Kynurenic acid C10 H7 N O3 5.313 189.0426 
Kynurenine C10 H12 N2 O3 3.505 208.0848 
L-2-Aminoadipic acid C6 H11 N O4 1.375 161.0688 
L-Asparagine C4 H8 N2 O3 1.253 132.0535 
L-Aspartic Acid C4 H7 N O4 1.276 133.0375 
L-Cystine C6 H12 N2 O4 S2 1.234 240.0238 
L-Dopa C9 H11 N O4 1.768 197.0688 
lipoamide C8 H15 N O S2 8.158 205.0595 
L-Methionine C5 H11 N O2 S 1.852 149.051 
L-Phenylalanine C9 H11 N O2 3.881 165.079 
L-Serine C3 H7 N O3 1.246 105.0426 
L-Tryptophan C11 H12 N2 O2 4.603 204.0899 
L-Tyrosine C9 H11 N O3 2.169 181.0739 
Maleamic acid C4 H5 N O3 1.87 115.0269 
Maleimide C4 H3 N O2 1.873 97.0164 
Methyl jasmonate C13 H20 O3 10.209 224.1412 
Methyl N-(a-
methylbutyryl)glycine C9 H16 O4 8.124 188.1049 
N-acetylaspartate C6 H9 N O5 1.893 175.0481 
N-Acetyl-DL-serine C5 H9 N O4 1.674 147.0532 
N-Acetyl-L-glutamic acid C7 H11 N O5 2.262 189.0637 
N-Acetylneuraminic Acid C11 H19 N O9 1.466 309.106 
N-Acetylputrescine C6 H14 N2 O 1.374 130.1106 
N-ALPHA-ACETYL-L-
ASPARAGINE C6 H10 N2 O4 1.606 174.0641 
Niacinamide C6 H6 N2 O 2.39 122.048 
N-Methylhistamine C6 H11 N3 1.257 125.0953 
Norepinephrine 
(noradrenaline) C8 H11 N O3 1.23 169.0739 
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Normetanephrine C9 H13 N O3 1.606 183.0895 
Octopamine (p-
Hydroxyphenylethanolamine) C8 H11 N O2 1.387 153.079 
Oleic Acid C18 H34 O2 13.101 282.2559 
O-Phosphorylethanolamine C2 H8 N O4 P 1.25 141.0191 
Orotic acid C5 H4 N2 O4 1.76 156.0171 
O-Succinyl-L-homoserine C8 H13 N O6 1.763 219.0743 
p-Aminobenzoic acid C7 H7 N O2 4.405 137.0477 
Pantothenic Acid C9 H17 N O5 4.337 219.1107 
Phenylethylamine C8 H11 N 4.163 121.0891 
p-Hydroxyphenylacetic acid C8 H8 O3 5.314 152.0473 
Picolinic acid C6 H5 N O2 1.786 123.032 
Pimelic acid C7 H12 O4 5.903 160.0736 
Pterine C6 H5 N5 O 2.826 163.0494 
Purine C5 H4 N4 2.754 120.0436 
Pyridoxine (Vitamin B6) C8 H11 N O3 1.794 169.0739 
Pyrocatechol C6 H6 O2 4.698 110.0368 
Pyroglutamic acid C5 H7 N O3 2.119 129.0426 
Quinaldic acid C10 H7 N O2 5.751 173.0477 
Quinic acid C7 H12 O6 1.469 192.0634 
R-(-)-Mandelic acid C8 H8 O3 4.852 152.0473 
Riboflavin (Vitamin B2) C17 H20 N4 O6 6.495 376.1383 
salsolinol C10 H13 N O2 2.153 179.0946 
Suberic acid C8 H14 O4 7.096 174.0892 
Taurine C2 H7 N O3 S 1.267 125.0147 
Theobromine C7 H8 N4 O2 4.547 180.0647 
Thymine C5 H6 N2 O2 3.052 126.0429 
Thyrotropin releasing hormone C16 H22 N6 O4 2.121 362.1703 
Trigonelline C7 H7 N O2 1.397 137.0477 
Tyramine C8 H11 N O 2.291 137.0841 
Uracil C4 H4 N2 O2 1.811 112.0273 
Urocanic acid C6 H6 N2 O2 1.613 138.0429 
Valeric acid C5 H10 O2 9.487 102.0681 
Xanthine C5 H4 N4 O2 2.266 152.0334 
Xanthosine C10 H12 N4 O6 3.493 284.0757 












2-METHYLMALEATE C5 H6 O4 3.995 130.0266 
3-hydroxy-3-methyl-Glutaric acid C6 H10 O5 3.881 162.0528 
3-Hydroxybenzaldehyde C7 H6 O2 1.549 122.0368 
4-Methylcatechol C7 H8 O2 1.779 124.0524 
Allantoin C4 H6 N4 O3 5.489 158.044 
cAMP 
C10 H12 N5 O6 
P 7.801 329.0525 
Citramalic acid C5 H8 O5 4.344 148.0372 
Creatinine C4 H7 N3 O 4.994 113.0589 
D-(+)-GALACTURONIC ACID C6 H10 O7 7.122 194.0427 
D-Glucuronic acid C6 H10 O7 6.803 194.0427 
DL-3,4-Dihydroxymandelic acid C8 H8 O5 4.341 184.0372 
Gluconic acid C6 H12 O7 6.946 196.0583 
Glutamine C5 H10 N2 O3 7.307 146.0691 
Glyceric acid C3 H6 O4 4.309 106.0266 
Gulonolactone C6 H10 O6 4.77 178.0477 
Hypoxanthine C5 H4 N4 O 5.117 136.0385 
Indoxylsulfuric acid C8 H7 N O4 S 4.217 213.0096 
L-Phenylalanine C9 H11 N O2 5.681 165.079 
L-Tryptophan C11 H12 N2 O2 5.681 204.0899 
L-Tyrosine C9 H11 N O3 6.262 181.0739 
N-acetylaspartate C6 H9 N O5 4.539 175.0481 
N-Acetyl-DL-serine C5 H9 N O4 4.389 147.0532 
N-Acetyl-L-glutamic acid C7 H11 N O5 4.403 189.0637 
N-Acetylneuraminic Acid C11 H19 N O9 7.019 309.106 
N-ALPHA-ACETYL-L-
ASPARAGINE C6 H10 N2 O4 4.876 174.0641 
N-Formylmethionine C6 H11 N O3 S 3.439 177.046 
Pantothenic Acid C9 H17 N O5 3.983 219.1107 
p-Coumaric acid C9 H8 O3 1.723 164.0473 
Pyridoxal (Vitamin B6) C8 H9 N O3 4.317 167.0582 
Pyroglutamic acid C5 H7 N O3 4.136 129.0426 
Salicylic acid C7 H6 O3 1.7 138.0317 
Taurine C2 H7 N O3 S 6.791 125.0147 
trans-Aconitate C6 H6 O6 4.441 174.0164 
Uracil C4 H4 N2 O2 4.05 112.0273 
Uric acid C5 H4 N4 O3 6.615 168.0283 
Vanillylmandelic acid C9 H10 O5 3.535 198.0528 












1-Methyladenosine C11 H15 N5 O4 6.182 281.1124 
1-methylhistidine C7 H11 N3 O2 7.636 169.0851 
2-Aminophenol C6 H7 N O 1.744 109.0528 
3-O-Methyl-L-DOPA C10 H13 N O4 6.137 211.0845 
4-Guanidinobutanoate C5 H11 N3 O2 4.957 145.0851 
4-Hydroxy-L-proline C5 H9 N O3 6.981 131.0582 
5′-Deoxy-5′-
(methylthio)adenosine C11 H15 N5 O3 S 4.466 297.0896 
5-Hydroxytryptophan C11 H12 N2 O3 6.27 220.0848 
5-Methylcytosine C5 H7 N3 O 5.524 125.0589 
6-Deoxy-L-galactose C6 H12 O5 5.77 164.0685 
Acetyl-L-Leucine C8 H15 N O3 1.715 173.1052 
Acetyllysine C8 H16 N2 O3 6.06 188.1161 
Adenosine C10 H13 N5 O4 5.374 267.0968 
Caffeine C8 H10 N4 O2 1.659 194.0804 
cAMP C10 H12 N5 O6 P 7.801 329.0525 
Carnitine C7 H15 N O3 4.492 161.1052 
Citrulline C6 H13 N3 O3 7.46 175.0957 
Creatine C4 H9 N3 O2 5.838 131.0695 
Creatinine C4 H7 N3 O 4.994 113.0589 
Cytidine C9 H13 N3 O5 6.459 243.0855 
Cytosine C4 H5 N3 O 5.842 111.0433 
DL-pipecolic acid C6 H11 N O2 6.246 129.079 
D-MANNOSAMINE C6 H13 N O5 7.18 179.0794 
D-Tagatose C6 H12 O6 6.317 180.0634 
Glucosamine C6 H13 N O5 7.553 179.0794 
Glucosaminic acid C6 H13 N O6 8.308 195.0743 
Glutamine C5 H10 N2 O3 7.307 146.0691 
Guanidineacetic acid C3 H7 N3 O2 6.214 117.0538 
Guanidinosuccinic Acid C5 H9 N3 O4 6.401 175.0593 
Guanine C5 H5 N5 O 6.058 151.0494 
Guanosine C10 H13 N5 O5 6.394 283.0917 
Histamine C5 H9 N3 7.093 111.0796 
Hypoxanthine C5 H4 N4 O 5.117 136.0385 
Indole-3-methyl acetate C11 H11 N O2 1.706 189.079 
Inosine C10 H12 N4 O5 5.735 268.0808 
Kynurenic acid C10 H7 N O3 5.023 189.0426 
Kynurenine C10 H12 N2 O3 5.793 208.0848 
L-Arginine C6 H14 N4 O2 7.983 174.1117 
L-Asparagine C4 H8 N2 O3 7.501 132.0535 
L-Cystathionine C7 H14 N2 O4 S 8.802 222.0674 
L-Cystine C6 H12 N2 O4 S2 8.987 240.0238 
L-Histidine C6 H9 N3 O2 8.075 155.0695 
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L-Leucine C6 H13 N O2 5.417 131.0946 
L-Serine C3 H7 N O3 7.372 105.0426 
L-Tryptophan C11 H12 N2 O2 5.681 204.0899 
L-Tyrosine C9 H11 N O3 6.262 181.0739 
Melibiose C12 H22 O11 8.325 342.1162 
N-Acetylneuraminic Acid C11 H19 N O9 7.019 309.106 
N-Acetylputrescine C6 H14 N2 O 5.281 130.1106 
Niacinamide C6 H6 N2 O 3.514 122.048 
N-Methylhistamine C6 H11 N3 6.779 125.0953 
Nε,Nε,Nε-Trimethyllysine C9 H20 N2 O2 7.377 188.1525 
Pantothenic Acid C9 H17 N O5 3.983 219.1107 
Paraxanthine C7 H8 N4 O2 3.528 180.0647 
Pyroglutamic acid C5 H7 N O3 4.138 129.0426 
Raffinose C18 H32 O16 8.653 504.169 
Retinoic acid C20 H28 O2 1.499 300.2089 
Riboflavin (Vitamin B2) C17 H20 N4 O6 5.598 376.1383 
S-(Carboxymethyl)-L-
cysteine C5 H9 N O4 S 6.989 179.0252 
S-Adenosylhomocysteine C14 H20 N6 O5 S 7.664 384.1216 
salsolinol C10 H13 N O2 4.423 179.0946 
Serotonin C10 H12 N2 O 4.512 176.095 
Stachyose C24 H42 O21 9.382 666.2219 
Taurine C2 H7 N O3 S 6.791 125.0147 
Tryptamine C10 H12 N2 1.736 160.1 
Tyramine C8 H11 N O 3.417 137.0841 
Uric acid C5 H4 N4 O3 6.615 168.0283 
Xanthine C5 H4 N4 O2 5.448 152.0334 
Xanthosine C10 H12 N4 O6 5.958 284.0757 








Non-targeted feature extraction parameters (LC-QTOF-MS data) 
Molecular feature extraction (MFE) parameters for ‘recursive non-targeted 
feature extraction’ were as follows: peak height >5000 counts, charge state 
range 1-2, minimum ion count = 1, binning and alignment tolerances - RT 
window = 0.3 min and mass window = 50 ppm, MFE score >70 in 60% of 
samples in at least one sample group. ‘Find by ion’ parameters (as part of the 
recursive feature extraction workflow) were as follows: mass score = 100, 
isotope abundance score = 60, isotope spacing score = 50, RT score = 100, 
expected data variation = 50ppm (15%) and RT 0.3 min, integration - ‘Agile 2’ 
algorithm, EIC smoothed before integration, smoothing function - Gaussian, 
peaks filtered by height (absolute height >1000 counts), spectra to include - 
average scans >40% of peak height, exclude if >20% of saturation, centroiding 
- maximum spike width = 2, required valley = 0.7, ‘find by ion’ filters - score 
>60 in at least one sample group. Allowed ion species and sample groupings 






Table S4.01. Summary of unidentified chemical entities with differential 
abundance in urine taken from patients with AKU baseline vs on 
nitisinone treatment, from non-targeted feature extraction. Peak areas for 
these entities showed statistically significant differences (Benjamini-Hochberg 
false-discovery rate p <0.05, fold change >2) between baseline and each 
sampling time point (3, 12 and 24 months) on nitisinone. Putative compound 
identifications were not obtained for these compounds using the MassHunter 
METLIN metabolite PCD/PCDL accurate mass database (build 07.00, 
Agilent), with a match criteria of accurate mass ±5 ppm. Fold changes are for 
baseline vs 24 months on nitisinone time points. 







264.085 3.2 (-) ↑ >100 <0.0001 
407.12 4.7 (-) ↑ >100 <0.0001 
326.088 5.1 (-) ↑ >100 0.025 
378.116 4.8 (-) ↑ >100 <0.0001 
386.099 4.6 (+) ↑ 29.6 <0.0001 
343.2 4.4 (+) ↑ 21.2 <0.0001 
204.055 3.9 (+) ↑ 20.8 <0.0001 
326.115 5 (+) ↑ 9.6 <0.0001 
120.058 2.3 (+) ↑ 9.5 <0.0001 
293.102 3.4 (+) ↑ 6.7 <0.0001 
115.1 2.3 (+) ↑ 5.7 <0.0001 
295.143 4.3 (+) ↑ 5.6 <0.0001 
433.135 4.8 (+) ↑ 3.7 <0.0001 
260.091 2.6 (+) ↑ 2.6 <0.0001 
312.134 2.1 (+) ↑ 2.6 <0.01 
189.055 3.4 (+) ↓ 24.6 <0.0001 
185.068 3.4 (+) ↓ 16.6 <0.0001 
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150.032 3.4 (+) ↓ 7.9 <0.0001 
208.091 3.5 (+) ↓ 6.9 <0.0001 
205.999 3.4 (+) ↓ 5.1 <0.01 
303.122 5.7 (+) ↓ 3.9 <0.0001 
212.081 7.1 (+) ↓ 2.9 <0.001 
144.043 4.6 (+) ↓ 2.7 <0.0001 





Table S4.02. Summary of unidentified urinary chemical entities with 
differential abundance in urine taken from AKU mice at baseline vs 1 
week on nitisinone, from non-targeted feature extraction. Putative 
compound identifications were not obtained for these compounds using the 
MassHunter METLIN metabolite PCD/PCDL accurate mass database (build 
07.00, Agilent), with match criterion of accurate mass ±5 ppm. P-values are 












232.005 4.1 (-) ↑ 76.7 <0.0001 
182.058 4.7 (-) ↑ 53.7 <0.0001 
261.067 4.7 (-) ↑ 31.5 <0.0001 
508.141 3.9 (-) ↑ 17.6 <0.0001 
514.125 4.8 (-) ↑ 16 <0.0001 
174.029 5.3 (-) ↑ 13.7 <0.0001 
367.001 4.7 (-) ↑ 11.3 <0.0001 
235.979 2.5 (-) ↑ 10.1 <0.0001 
417.049 4.7 (-) ↑ 10 <0.01 
127.051 1.6 (+) ↑ 7.8 0.036 
461.133 5.6 (-) ↑ 5.4 <0.01 
472.009 4.2 (-) ↑ 5 <0.0001 
242.983 3.8 (-) ↑ 4.6 <0.0001 
444.165 5.6 (-) ↑ 4.1 <0.0001 
508.18 6.6 (-) ↑ 3.7 <0.001 
253.956 4.3 (-) ↑ 3.6 0.035 
229.071 6.9 (+) ↑ 3.1 <0.0001 
274.116 3.6 (-) ↑ 3 <0.01 
140.001 4.6 (+) ↑ 2.9 <0.001 
298.11 4 (-) ↑ 2.8 <0.0001 
240.009 5.3 (-) ↑ 2.7 <0.0001 
225.073 4.7 (+) ↑ 2.7 <0.0001 
155.014 1.4 (+) ↑ 2.6 <0.0001 
170.092 1.6 (+) ↑ 2.5 <0.0001 
199.122 8.9 (+) ↑ 2.3 <0.001 
229.168 10.4 (-) ↑ 2.2 <0.0001 
386.194 6.9 (+) ↑ 2.2 0.036 
300.06 9.7 (-) ↑ 2.1 <0.0001 
191.092 4.8 (+) ↑ 2.1 <0.01 
246.138 7.5 (+) ↑ 2.1 <0.01 
191.098 4.8 (+) ↑ 2.1 <0.01 
199.125 8.5 (-) ↑ 2 <0.0001 
389 
 
184.146 7.6 (-) ↑ 2 0.021 
56.0624 4.7 (-) ↑ 2 <0.001 
195.071 4.1 (+) ↑ 2 <0.001 
243.037 2.5 (-) ↓ 16 <0.0001 
509.209 4.2 (-) ↓ 16 <0.0001 
182.005 4.9 (-) ↓ 14.5 <0.01 
403.158 3.7 (-) ↓ 11.1 <0.0001 
432.221 3.6 (+) ↓ 3.9 <0.0001 
110.003 6 (-) ↓ 3.1 <0.01 
96.0213 2.3 (-) ↓ 2.8 <0.0001 
309.081 4.7 (+) ↓ 2.4 <0.0001 
287.993 4.6 (-) ↓ 2.2 <0.0001 
324.084 3.4 (+) ↓ 2.2 <0.01 
324.093 3.4 (+) ↓ 2.2 <0.01 
397.998 5.7 (-) ↓ 2.1 <0.01 
217.005 4.4 (-) ↓ 2.1 <0.001 







Table S4.03. Summary of unidentified urinary chemical entities with 
differential abundance between patients with high (score >10) vs low 
(score <10) 18F-NaF uptake to intervertebral disks. Putative compound 
identifications were not obtained for these compounds using the MassHunter 
METLIN metabolite PCD/PCDL accurate mass database (build 07.00, 
Agilent), with match criterion of accurate mass ±5 ppm. P-values are adjusted 
by Benjamini-Hochberg false-discovery rate.  
† Entity with statistically significant difference between patients with high vs low uptake 
score at baseline 
‡ Entity with statistically significant difference between patients with high vs low uptake 













618.1348 † 4.1 (-) ↑ >100 0.026 
370.0571 † 4.8 (-) ↑ >100 <0.0001 
277.0071 ‡ 5.0 (-) ↑ >100 0.013 
151.0877 †‡ 4.2 (+) ↑ 54.4 0.039 
231.0212 ‡ 3.6 (+) ↑ 29.3 0.012 
231.0212 † 3.6 (+) ↑ 18.7 0.026 
351.0947 † 6.0 (-) ↓ 16.0 <0.0001 
145.0753 † 2.2 (+) ↓ 16.0 <0.0001 
289.0952 † 8.8 (+) ↓ 3.2 <0.0001 
174.0897 † 3.5 (+) ↓ 2.5 <0.0001 





Table S4.04. Summary of unidentified urinary chemical entities with 
differential abundance between patients with high (score >10) vs low 
(score <10) 18F-NaF uptake to lumbar/thoracic vertebrae. Putative 
compound identifications were not obtained for these compounds using the 
MassHunter METLIN metabolite PCD/PCDL accurate mass database (build 
07.00, Agilent), with match criterion of accurate mass ±5 ppm. P-values are 
adjusted by Benjamini-Hochberg false-discovery rate.  
† Entity with statistically significant difference between patients with high vs low uptake 
score at baseline 
‡ Entity with statistically significant difference between patients with high vs low uptake 






Direction of alteration 





188.0151 ‡ 5.9 (-) ↓ 41.1 <0.0001 







Table S5.01. Compounds appended to databases for targeted feature extraction (Chapter 5). Includes compounds of 
potential interest in AKU and potential biotransformation products of HGA. 
 
Name Formula Mass CAS METLIN KEGG HMP  
1-(2-Carboxyphenylamino)-1'-deoxy-D-
ribulose 5'-phosphate C12H16NO9P 349.056268 5962-18-5 3492 C01302   
2,5-Dihydroxybenzaldehyde C7H6O3 138.031694 1194-98-5 44699 C05585   
2-aminomuconic acid semialdehyde C6H7NO3 141.042593  45872 C03824 HMDB01280  
2-Dehydro-3-deoxy-D-arabino-
heptonate 7-phosphate (DAHP) C7H13O10P 288.024633 2627-73-8 3414 C04691   
3,4-Dihydroxymandelaldehyde C8H8O4 168.042259 13023-73-9 58374 C05577 HMDB06242  
3-Dehydroquinic acid C7H10O6 190.047738 10534-44-8 3327 C00944 HMDB12710  
3-Hydroxytyrosol C8H10O3 154.06299      
3-Hydroxytyrosol sulfate C8H10O6S 234.01981      
3-Methoxy-4-hydroxymandelate C9H9O5 197.0449984   C05584   
3-Methoxy-4-
hydroxyphenylglycolaldehyde C9H10O4 182.057909 17592-23-3 58200 C05583 HMDB04061  
4-Hydroxyphenylacetaldehyde C8H8O2 136.052429 7339-87-9 63506 C03765   
4-Hydroxyphenylpyruvic acid C9H8O4 180.042259 156-39-8 3315 C01179   
5-O-(1-Carboxyvinyl)-3-
phosphoshikimate C10H13O10P 324.024633 74708-67-1 3454 C01269   
5-phosphoribosyl-1-diphosphate C5H13O14P3 389.951815 7540-64-9 158 C00119 HMDB00280  
Acetic acid C2H4O2 60.021129 64-19-7 3206 C00033 HMDB00042  
Acetyl-CoA C23H38N7O17P3S 809.125773   C00024 HMDB01206  
Acetyl-L-tyrosine C11H13NO4 223.084458 537-55-3 5827  HMDB00866  
Adenosine triphosphate (ATP) C10H16N5O13P3 506.995745 987-65-5 95 C00002 HMDB00538  
Aminomuconic acid C6H7NO4 157.037508  6440 C02220   
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Chorismic acid C10H10O6 226.047738 617-12-9 368 C00251 HMDB12199  
Coenzyme A (CoA) C21H36N7O16P3S 767.115208 85-61-0 242 C00010 HMDB01423  
Dehydro-HGA C8H6O4 166.02661      
D-Erythrose 4-phosphate C4H9O7P 200.008589 585-18-2 355 C00279 HMDB01321  
D-Glyceraldehyde 3-phosphate C3H7O6P 169.998024 591-57-1 3294 C00118   
D-Pantetheine 4'-phosphate C11H23N2O7PS 358.096358 2226-71-3 398 C01134 HMDB01416  
Glutamyl-Tyrosine C14H18N2O6 310.116486  85745  HMDB28831  
Hipposudoric acid C16H8O8 328.02192      
Indole C8H7N 117.057849 120-72-9 286 C00463 HMDB00738  
Indoleglycerol phosphate C11H14NO6P 287.055874 4220-97-7 3412 C03506   
Metanephrine C10H15NO3 197.105193 5001-33-2 65 C05588 HMDB04063  
N-(5-Phospho-D-ribosyl)anthranilate C12H16NO9P 349.056268 27695-85-8 3493 C04302   
NADH C21H29N7O14P2 665.1247717   C00004 HMDB01487  
NADPH C21H30N7O17P3 745.091102 2646-71-1 3691 C00005   
N-Methyltyramine C9H13NO 151.099714 370-98-9 58167 C02442 HMDB03633  
Norhipposudoric acid C15H8O6 284.03209      
Oxaloacetate C4H4O5 132.005873 328-42-7 123 C00036 HMDB00223  
Phenylpyruvic acid C9H8O3 164.047344 156-06-9 328 C00166 HMDB31629  
Phloretic acid C9H10O3 166.062994 501-97-3 4148 C01744 HMDB02199  
Prephenic acid C10H10O6 226.047738 126-49-8 369 C00254 HMDB12283  
Pyrophosphate H4O7P2 177.943225 03/09/2466 3306 C00013 HMDB00250  
Pyruvate C3H4O3 88.016044 127-17-3 117 C00022 HMDB00243  
S-Acetylphosphopantetheine C13H25N2O8PS 400.106923  66032 C03725   
S-Adenosylmethionine C15H23N6O5S 399.145064 29908-03-0 3289 C00019   
Salicyluric acid C9H9NO4 195.05316      
Shikimate-3-phosphate C7H11O8P 254.019154 63959-45-5 3384 C03175   
Tyramine glucuronide C14H19NO7 313.116152 27972-85-6 61650 C03033 HMDB10328  
Tyramine-O-sulfate C8H11NO4S 217.040879 30223-92-8 58408  HMDB06409  
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Tyrosol C8H10O2 138.06808      
Tyrosol 4-sulfate C8H10O5S 218.024894  96137  HMDB41785  
       Phase 
HGA_Hydroxylation + Glucuronide C14H16O11 360.06926     II 
HGA_Acetylation C10H10O5 210.05282     II 
HGA_Alkenes to Dihydrodiol C8H10O6 202.04774     I 
HGA_Demethylation and Methylene to 
Ketone C7H4O5 168.00587     I 
HGA_Demethylation C7H6O4 154.02661     I 
HGA_1,4-Dihydropyridines to 
Pyridines C8H6O4 166.02661     I 
HGA_Ethyl Ether to Acid C6H2O5 153.99022     I 
HGA_Hydroxylation and Methylation C9H10O5 198.05282     II 
HGA_Glycine Conjugation C10H11NO5 225.06372     II 
HGA_Cysteine Conjugation C11H15NO6S 289.06201     II 
HGA_Cysteine Glycine Conjugation C13H18N2O7S 346.08347     II 
HGA_(O, N, S) Methylation C9H10O4 182.05791     II 
HGA_N-Acetylcysteine Conjugation 
and Desaturation C13H15NO7S 329.05692     II 
HGA_Alcohols Dehydration C8H6O3 150.03169     I 
HGA_Glutamine Conjugation C13H16NO6 282.09776     II 
HGA_Demethylation and 
Hydroxylation C7H6O5 170.02152     I 
HGA_Demethylation and two 
Hydroxylations C7H6O6 186.01644     I 
HGA_Ethyl to Carboxylic Acid C7H4O6 184.00079     I 
HGA_Hydration, Hydrolysis (Internal) C8H10O5 186.05282     I 
HGA_Hydroxylation and Desaturation C8H6O5 182.02152     I 
HGA_Hydroxymethylene Loss C7H6O3 138.03169     I 
HGA_Decarboxylation C7H8O2 124.05243     I 
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HGA_Cysteine Conjugation and 
Desaturation C11H13NO6S 287.04636     II 
HGA_Ketone to Alcohol C8H10O4 170.05791     I 
HGA_Taurine Conjugation C10H13NO6S 275.04636     II 
HGA_Hydroxylation and Sulfation C8H8O8S 263.99399     II 
HGA_Sulfate Conjugation C8H8O7S 247.99907     II 
HGA_2x Sulfate Conjugation C8H8O10S2 327.95589     II 
HGA_Glucuronide Conjugation C14H16O10 344.07435     II 
HGA_Sulfate Conjugation C8H8O7S 247.99907     II 
HGA_N-Acetylcysteine Conjugation C13H17NO7S 331.07257     II 
HGA_Deethylation C6H4O4 140.01096     I 
HGA_Alkene to Epoxide C8H8O5 184.03717     I 
HGA_Tert-Butyl to Acid C5O6 155.96949     I 
HGA_1,4-Dihydropyridines to 
Pyridines C8H6O4 166.02661     I 
HGA_Isopropyl to Acid C6H2O6 169.98514     I 
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Ochronosis is the process in Alkaptonuria (AKU) that causes all the debilitating 
morbidity. The process involves selective deposition of homogentisic acid-derived 
pigment in tissues altering the properties of these tissues, leading to their failure. Some 
tissues like cartilage are more easily affected by ochronosis while others such as the 
liver and brain are unaffected for reasons that are still not understood. In vitro and 
mouse models of ochronosis have confirmed the dose relationships between 
homogentisic acid and ochronosis and also their modulation by HPPD inhibition. 
Ochronosis cannot be fully reversed and is a key factor in influencing treatment 
decisions. Earlier detection of ochronosis preferably by non-invasive means is 
desirable. A cause-effect relationship between HGA and ochronosis is discussed. The 
similarity in AKU and familial hypercholesterolaemia is explored, and lessons learnt. 





Introduction: Archibald Garrod is the father of inborn errors of metabolism and 
studied four disorders, namely alkaptonuria, pentosuria, cystinuria and albinism. 
Pentosuria (OMIM#260800) is a defect in l-xylulose reductase, necessary for xylitol 
metabolism, leading to overproduction of pentose sugars and pentosuria, but is 
otherwise harmless as it does not accumulate in the body or produce a disease 
process of its own (Knox 1958). This is unlike alkaptonuria (AKU) (Figure 1) 
(OMIM#203500) where ochronosis is the key pathophysiological event (Garrod 1902; 
Galdston et al. 1952; O’Brien et al. 1963). Ochronosis-like processes have also been 
described in non-AKU states and termed pseudo-ochronosis or exogenous ochronosis 
(as opposed to endogenous ochronosis in AKU). Exogenous ochronosis has been the 
subject of previous reviews and will not be discussed further here (Levin and Maibach 
2001; Bhattar et al. 2015).   
 
Ochronosis is the term used to describe a process by which a yellowish (ochre) 
discoloration develops (Figure 2A), due to the deposition of pigment. First described 
by Rudolf Virchow in 1866, ochronosis was observed in miscroscopic examination of 
connective tissues (Virchow 1866).  The tissues affected by ochronosis 
macroscopically, however, appear to be blue grey or black when large amounts of 
pigment are present. Virchow noticed that the pigment also specially accumulated in 
damaged or inflamed sites, such as irritated joint synovia and arteriosclerotic plaques. 
He hypothesised that non-crystalline colouring matter, whose nature was then 
unknown, slowly saturates the cartilage, a special target in AKU. 
  
It is now known that AKU is a condition characterised by the absence of homogentisate 
dioxygenase enzyme (HGD) (EC:1.13.11.5) (Figure 1) leading to an inability to 
metabolise homogentisic acid (HGA) (La Du et al. 1958). HGA, an intermediary in the 
phenylalanine/tyrosine pathway, is normally completely and rapidly metabolised to 
yield fumarate and acetoacetate (Phornphutkul et al. 2002). The degradation of 
phenylalanine (an essential amino acid) and tyrosine (a non-essential amino acid) 
proceeds to fumarate and acetoacetate through homogentisic acid so rapidly that in 
normal subjects there is no increase in circulating HGA and very little in urine (Davison 
et al. 2015). The HGD deficiency in AKU causes excessive HGA production, causing 
homogentisicaciduria, while also increasing HGA concentrations within body tissues. 
Alkaptonuria is an autosomal recessive disorder with a delayed slowly-progressive 
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multisystemic damage for which there is still no approved disease modifying therapy, 
even though a drug called nitisinone decreases HGA (Introne et al. 2011). Although 
HGA by itself causes morbidity such as renal, prostate, gall bladder and salivary 
stones, the main disease process leading to tissue destruction and debilitating clinical 
sequelae is ochronosis, the focus of this review. 
Formation of ochronotic pigment (OP): Overproduction of HGA: With an inability to 
metabolise HGA, there is an increase in whole body HGA despite massively increased 
renal excretion of HGA (Figure 1). The most important pathophysiological 
consequence in tyrosine pathway in AKU is conversion of accumulating HGA to OP. 
HGA is a reducing agent and especially under alkaline conditions it is itself rapidly 
oxidised via benzoquinone acetic acid turning solutions and tissues black (Zannoni et 
al. 1969). Slow spontaneous blackening of urine is usual in AKU, but adding alkali 
instantly turns urine black; acidifying the black urine does not return the black colour 
to normal, suggesting a potential irreversible change.  
Apparently slow formation of pigment: Despite the metabolic defect existing from birth, 
pigmentation of eyes and ears is slow to develop externally, taking up to two or three 
decades to appear, presumably a reflection of the gradual accretion of the pigment. 
Similarly, back and knee pain, due to development of critical ochronosis in these sites, 
are also apparent in the second and third decades (Cox and Ranganath 2011). 
Formation of OP is markedly increased in renal failure, consistent with increased 
retention of HGA, and accelerates severe morbidity and debility (Introne et al. 2002).  
Factors supporting molecular interaction of HGA with cartilage matrix (Figure 2B, C): 
The molecular mechanism through which HGA interacts with collagen matrix is 
unknown. Ultrastructural examination of pigmented cartilage showed that initial 
pigmentation is closely associated with the periodicity of collagen fibres. A periodic 
banding pattern of OP was observed on individual collagen fibres, with very early 
pigmentation appearing as small granules on the surface of fibres (Taylor et al. 2010b). 
These findings suggest that a nucleation-like event underlies ochronosis, where initial 
granular deposits on individual collagen fibres is followed by further rapid pigment 
deposition (Gallagher et al. 2016). The data also suggest that collagen fibrils provide 
specific binding sites for pigment.  
Close observation of tissues obtained from AKU patients (Taylor et al. 2011b, 2012) 
and mice (Taylor et al. 2012; Preston et al. 2014) and in vitro (Tinti et al. 2011b) models 
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of AKU show that cartilage is initially resistant to pigmentation. It is proposed that 
biomechanical and biochemical changes, such as those that occur in cartilage as part 
of the natural ageing process, render tissues susceptible to ochronosis. The ‘exposed 
collagen hypothesis’ theorises that binding sites become available for HGA following 
the loss of protective molecules such as proteoglycans and glycosaminoglycans 
(Figure 2C) (GAGs) (Gallagher et al. 2016). In support of this hypothesis, AKU 
cartilage is shown to have lower levels of extractable GAGs and oligomeric matrix 
protein than osteoarthritic and non-osteoarthritic cartilage (Taylor et al. 2017). There 
is also evidence that the structure and maturity of the collagen matrix can influence 
pigment deposition. Newly-synthesised aberrant matrix proteins in scar tissue also 
appear to pigment rapidly, as reported in the case of a mediastinal mass from an AKU 
patient (Taylor et al. 2011a). Solid-state NMR analysis of AKU articular joint cartilage 
also observed spectra indicative of marked collagen disorder at the atomic level (Chow 
et al. 2011), further supporting the idea that disruption to the collagen matrix supports 
OP deposition. 
Further work is required to elucidate a specific binding site for OP within the collagen 
matrix. It is also not known whether the initial binding occurs as HGA, the oxidised 
intermediate benzoquinoneacetic acid (BQA) or OP. 
Reversibility of pigment: It is currently believed that the OP process is not fully 
reversible, although there are indications of some reversal of pigment; the mechanism 
of such reversal is currently unknown (Ranganath et al. 2018). It is not known if OP 
process is dynamic i.e. formation and removal co-existing, although macrophages with 
pigment has been described in case reports (Gaines et al. 1987; Fisher and Davis 
2004; Damian et al. 2013).  
Diet and OP: Tyrosine and phenylalanine are not limiting amino acids in the diet and 
are consumed in vast excess of requirement. The attempts to retard progression of 
AKU by reducing the amounts phenylalanine and tyrosine flux is in keeping with the 
belief that amounts of protein intake could influence AKU morbidity. 
Generation of OP in vitro and ex vivo (Figure 2D): Model systems have been 
developed for investigating various effects of HGA exposure under controlled 
conditions in vitro and ex vivo. In vitro models include human serum (Braconi et al. 
2010a, 2011) and osteoblastic (cell line) and chondrocytic (cell line and isolated from 
human cartilage) cell cultures (Braconi et al. 2010b; Tinti et al. 2010, 2011b; Braconi 
401 
 
et al. 2012; Millucci et al. 2012; Spreafico et al. 2013; Millucci et al. 2015b; Mistry et 
al. 2016). Incubation of cell cultures with HGA leads to OP formation by four weeks. 
The amount of OP formed is proportionate to the concentrations of HGA in the medium 
(Tinti et al. 2011b). Ex vivo ‘organotypic’ approaches have modelled AKU by studying 
the effect of HGA on human cartilage explants (Tinti et al. 2011a; Millucci et al. 2012; 
Bernardini et al. 2019). In these studies, pericellular pigmentation of cartilage explants 
is visible after two months of incubation with HGA (Tinti et al. 2011a).  
Development of these model systems has not only been useful in studying the 
development of OP under controlled conditions, but also a number of other 
pathophysiological events closely associated with ochronosis including secondary 
amyloidosis (Millucci et al. 2012; Spreafico et al. 2013; Millucci et al. 2015b), perturbed 
redox homeostasis (Braconi et al. 2010a, b, 2011, 2012, 2015; Tinti et al. 2010; 
Spreafico et al. 2013) and disorder of the cartilage extracellular matrix, including 
proteoglycan loss and collagen fibril re-arrangement (Tinti et al. 2010; Millucci et al. 
2015b; Bernardini et al. 2019). Oxidative stress is a frequent and major consequence 
of HGA exposure in these studies, as indicated by direct oxidative modification to 
proteins and depletion of endogenous antioxidants such as glutathione (Braconi et al. 
2010a, b, 2011, 2012, 2015; Spreafico et al. 2013). In vitro studies have also been 
important in firmly establishing the pro-oxidant role of ascorbic acid in the presence of 
HGA. These studies indicate that ascorbic acid is not efficacious as a mediator of 
HGA-induced oxidative stress and secondary amyloidosis, unless combined with other 
reducing agents (Tinti et al. 2010).  
Animal model of OP formation: In addition, mouse models of AKU, previously only 
considered to be models of AKU biochemistry, have been shown to develop OP 
(Taylor et al. 2012; Preston et al. 2014). Despite a marked elevation in plasma and 
urinary HGA, these mice do not develop the striking macroscopic ochronosis observed 
in adult humans, except in the kidneys after 13 months (Taylor et al. 2012). Several 
potential explanations for the lack of widespread macroscopic pigmentation in AKU 
mice have been postulated. We suggest that the most likely explanations are a) 
reduced joint-loading of quadrupedal mice, b) faster cellular turnover for removal of 
pigment and c) that the shorter lifespan of mice compared with humans might be 
insufficient for gross pigment deposition (Preston et al. 2014). However, pigmentation 
is observed in AKU mice microscopically; chondrocytes within the articular cartilage 
begin to show pigmentation at 15 weeks (Preston et al. 2014). This pigmentation 
402 
 
progressively increases over the lifespan of the AKU mouse. Pigmentation of 
individual chondrocytes in AKU mice mirrors the focal initiation of ochronosis observed 
in human AKU, in which pigment deposition begins within single chondrocytes of the 
calcified cartilage and eventually results in widespread extracellular pigmentation 
(Taylor et al. 2011b). An exact serum HGA concentration threshold at which OP 
develops is not known, but a threshold range of 40-60 µM/L has been reported in mice 
(Lewis 2018).   
In AKU mice administration of p-hydroxyphenylpyruvate dioxygenase (EC:1.13.11.27) 
(HPPD) inhibitors, such as nitisinone, soon after birth resulted in failure to pigment, 
while a similar administration of HPPD inhibitors during the middle of the life span of 
the mouse, when pigmentation has already developed, prevented progression, but not 
reversal, of pigmentation (Keenan et al. 2015). This suggests that HPPD inhibitors, by 
decreasing HGA, can modify the OP process in AKU mice. 
Structure of OP: The classic view of OP formation: A fundamental question in 
understanding the process of ochronosis and the development of therapeutic 
interventions aimed at its prevention or potential reversal concerns the structure of OP 
itself. The prevailing view on the mechanism by which HGA produces OP in AKU 
largely comes from work carried out by Zannoni and colleagues in the 1960’s. These 
authors stated that guinea pig cartilage and skin contain enzymes, namely HGA 
polyphenol oxidases, which were shown to catalyse the in vitro oxidation of HGA into 
a dark, ochronotic-like pigment (Zannoni et al. 1969). BQA was demonstrated as an 
intermediate in the in vitro enzymatic oxidation of HGA, and it was proposed that BQA 
may polymerize to form OP in AKU (Zannoni et al. 1962, 1969). However, it is 
important to note the lack of evidence that polyphenol oxidase enzymes are expressed 
in human or other mammals (Taylor et al. 2016). Enzymes that can oxidise HGA, 
‘HGA-oxidases’, are observed in various species of bacteria known to produce 
‘pyomelanin’ pigment derived from HGA (Hunter and Newman 2010; Roberts et al. 
2015). In these species, HGA-derived pyomelanin is thought to serve various adaptive 
functions including resistance to environmental stress such as UV light and oxidising 
agents. Subsequent research showed that HGA oxidation can occur non-
enzymatically between pH 6.8 and 9.5 in the presence of oxygen (Martin and Batkoff 
1987); it is still widely-stated in the literature that oxidation of HGA to benzoquinone 




An alternative view of OP chemical structure: Given the general assumption that OP 
is a product of HGA oxidative polymerisation, it is important to define the term 
‘polymer’. The accepted definition of a polymer is a large molecule, or 
‘macromolecule’, composed of multiple repeating subunits of a relatively lower 
molecular weight monomer (McNaught and Wilkinson 2014). The classic concept of a 
polymer is that the monomer subunits are covalently bound (Allcock et al. 2003). 
Roberts et al. (2015) question the widely-held assumption that OP is polymeric. These 
authors cite the lack of conclusive evidence for this in the literature, and make the 
point that a polymeric structure is not necessarily required to produce the visual 
properties of a dark pigment; there are numerous examples of low molecular weight 
biological pigments. More recent analysis of synthetically-derived OP solutions using 
size exclusion chromatography suggest that OP has greater molecular weight than 
HGA, as indicated by a peak at shorter retention time. However, visually pigmented 
solutions could be formed from HGA (over a shorter period of time; 10 days as 
opposed to 2 years) without evidence of the peak corresponding to OP and no 
observed decrease in the HGA peak (Taylor and Vercruysse 2017). This suggests that 
the visual darkening of the solution due to increased pH can be due to presence of the 
low molecular weight oxidised form of HGA over a relatively shorter period. 
OP has been referred to as ‘melanin-like’ in the literature (Roberts et al. 2015); largely 
because melanin is another dark biological pigment derived from tyrosine and 
classically considered to be formed by polymerisation. However there is a growing 
body of evidence that melanin and OP are not covalently bound structures, and that 
their macromolecules do not comprise regularly repeating monomers. A recent study 
reports data from physicochemical analyses on the ‘pyomelanin’ pigment produced in 
the bacteria rubrivivax benzoatilyticus (strain JA2) (Mekala et al. 2019). This bacteria 
mirrors the conditions of OP pigment production in AKU; absence of the HGD gene 
causes accumulation of HGA, resulting in a brown pigment under aerobic conditions 
and in the presence of phenylalanine (Mekala et al. 2018). Fourier-transform infrared 
spectroscopy (FTIR) showed a range of band stretching vibrations indicating various 
chemical groups (aromatic and aliphatic C-H stretches, phenolic C-O stretches, 
aromatic ring C=C bonds, and C=O stretches due to –COOH groups) characteristic of 
a pigment structure derived from HGA. X-ray diffraction spectra of the pigment showed 
similar characteristics to that of melanin, with broad diffraction indicating an 
‘amorphous’ compound structure. The absorbance spectra showed a broad band at 
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wavelengths 280-350 nm, with increased general absorbance across the UV-visual 
range without distinct peaks. Similar absorbance properties have been reported 
previously for OP (Roberts et al. 2015; Taylor and Vercruysse 2017) and also melanin 
(eumelanin derived from 5,6,-dihydroxyindole-2-carboxylic acid; Tran et al. 2006), and 
are thought to reflect a chemically heterogeneous structure of oligomers formed by a 
range of different bonding mechanisms, also referred to as ‘chemical disorder’ (Riesz 
2007). These absorbance properties might also account for the physical appearance 
of some pigmented substances, which in the case of melanin is thought to provide its 
physiologically important optical characteristics, i.e. its ability to absorb UV light (Chen 
et al. 2014; Roberts et al. 2015). In contrast, specific, well-defined chemical signatures 
have been obtained for BQA, the proposed low molecular weight oxidation product of 
HGA. Specific visual-range absorbance peaks corresponding to BQA have been 
reported in a series of publications by Tokuhara and colleagues. These peaks were 
observed at 406 and 430 nm from analysis of solutions of HGA or AKU urine following 
alkalinisation (Tokuhara et al. 2014, 2018) although other authors have been unable 
to replicate these findings (Roberts et al. 2015). Specific BQA signals were also 
recently reported by Tokuhara et al. (2018) from LC-QTOF-MS and NMR analyses. 
Computational analyses of eumelanin support a structure formed by stacked 
eumelanin protomolecules with random-like arrangement; in other words loosely-
bound aggregates as opposed to a covalent polymer (Chen et al. 2014). This 
aggregate structure of melanin is further supported by mass spectrometric and 
spectrophotometric analyses indicating a possible formation mechanism by self-
aggregation of L-dopa by a combination of non-covalent mechanisms including 
hydrogen bonds, π- π stacking and ionic bonds (Li et al. 2015). The same aggregation 
was observed for other structurally similar catecholamines which, like HGA, are 
derived from tyrosine. In support of this data, a recent ultrafiltration study on solutions 
of pigment derived from synthetic HGA in our laboratory (Norman [unpublished data]) 
using a 10,000 Da molecular-weight filter suggested a heterogeneous mixture of 
compounds of varying molecular weight. The filtered solution was still pigmented, 
although visually lighter in appearance, suggesting presence of some OP molecules 
>10,000 Da (Figure 5E). Together, these more recent data are inconsistent with the 
idea that OP or melanin are polymers comprised of regularly repeating units with 
distinct chemical signatures. The term ‘polymer’ therefore does not appear to 
accurately describe the chemical nature of OP or melanin, as currently understood.  
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Chemical characterisation of OP in human AKU tissue: Another approach employed 
to study the chemical structure of OP is chemical analysis of heavily pigmented AKU 
cartilage samples. Solid-state NMR analyses revealed remarkably similar spectra 
between deeply pigmented and non-pigmented cartilage from AKU patients (Chow et 
al. 2011; Norman et al. 2018). The spectra were dominated by clear amino acid signals 
attributable to collagen protein. The absence of a specific NMR signal attributable to 
OP or related structures could be due to the reduced sensitivity of NMR compared 
with other analytical platforms such as mass spectrometry. However, with NMR signal 
enhancement achieved by recent developments using dynamic nuclear polarisation, 
Norman et al. (2018) observed the first NMR signal attributable to OP in cartilage. A 
signal at 116.8 ppm in the 13C spectrum (1H-13C FSLG HETCOR 2D NMR experiment) 
was observed from analysis of pure, dried OP derived from synthetic HGA (3-month 
incubation at 37°C, as above) and heavily pigmented AKU cartilage. The same signal 
was observed in non-ochronotic AKU cartilage but much weaker, and even weaker in 
non-AKU osteoarthritic cartilage. The 2D NMR spectra were more indicative of a poly-
hydroquinone versus poly-benzoquinone structure, suggesting that the final structure 
of OP may not be formed simply by polymerisation of the BQA intermediate. 
Raman spectroscopy has recently been identified as a promising analytical technique 
for studying the nature of OP. Studies of cartilage samples from AKU patients revealed 
distinct spectra for ochronotic versus non-ochronotic cartilage. Ochronotic samples 
were highly fluorescent and, unlike non-ochronotic samples, provided limited to no 
discernible Raman spectral peaks. A novel peak was obtained from the ochronotic 
sample that was also observed in the spectra from pigment derived from synthetic 
HGA (Taylor et al. 2019). The ability of Raman spectroscopy to clearly distinguish 
between ochronotic and non-ochronotic tissue warrants further study, as the technique 
appears to have potential to provide fundamental information on the chemical nature 
of OP. Furthermore, there is potential for the technique to be employed as an in vivo 
tool for measuring and monitoring ochronosis progression in a clinical setting (Taylor 
et al. 2019). 
Distribution of ochronosis is not uniform (Table 1; Figures 3, 4): At post-mortem, 
pigment is patchy and present in areas of stress/damage in non-cartilaginous tissues, 
suggesting that ‘damaged’ tissue undergoes pigmentation whereas ‘undamaged’ 
tissue is resistant to pigmentation; all cartilage is more consistently and highly 
pigmented, but also unevenly (Helliwell et al. 2008). Possible factors involved in 
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‘damaging’ tissues and producing pigment are shown in Table 1. It is not known if the 
OP structure is similar in nature in these diverse areas. Despite the constant exposure 
of all body tissues to HGA in AKU, most tissues are resistant to pigmentation.  
Cartilages are especially affected, and these include highly loaded tissues such as 
articular cartilage, fibrocartilage (intervertebral discs, pubic symphysis), 
costochondral, as well as less stressed cartilage in the pinna and nose, and the 
trachea-bronchial system (Helliwell et al. 2008). Highly stressed tissues such as joints, 
spine, tendons and ligament are pigmented. OP has been noticed in the skin, 
especially at the interface of the palmar and dorsal skin of the hands, possibly sites of 
greater stress (Vijaikumar et al. 2000). Pigmentation of the nails of the hands and feet 
has been described. Secretory glands in the axilla, groin and eyelids pigment (Srsen 
et al. 1982). Ocular tissues, the conjunctivum, cornea and sclera, pigment in the 
second and third decade. Ochronosis has been observed in the tympanic membrane 
and ear wax. Cardiac valves are affected by OP more in left side of heart, and aortic 
more than mitral valve (Helliwell et al. 2008); the pulmonary vascular system and the 
right side of the heart is much less pigmented. Pigmentation can be observed in the 
arterial system, mostly around branch points and tributaries, areas of greater stress 
(Helliwell et al. 2008). There is currently no information on pigmentation in the venous 
system. Renal parenchyma, especially the medulla and pyramidal tissues, show OP. 
The periosteum has been shown to pigment but not the bone itself, raising the 
possibility of bone mineral binding to collagen preventing HGA-derived molecules from 
binding. Teeth enamel have been said to pigment, but needs more evidence given 
that bone does not pigment (Siekert and Gibilisco 1970). It is generally held that 
muscle, liver, lung (excluding the bronchial system) and brain are not affected by OP. 
There is no convincing description of gastrointestinal and genital pigmentation. There 
is no description of pigment in pancreas, an organ where alkaline secretions are 
produced unlike the salivary gland. It is not known if there is biliary excretion of HGA, 
even though pigmented gall stones make this likely. Paucicellular tissues such as 
cartilage, tendon and ligament appear to pigment easily compared to highly cellular 
tissues such as liver. 
It is likely that HGA is increased in the CSF, tears and saliva although direct evidence 
is lacking. Circulating HGA is well characterised but tissue HGA, i.e. intracellular HGA, 
has not been directly assessed. It is likely HGA (and other metabolite acids) is protein-
bound but requires characterisation.  
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Detection of ochronosis: Gross ochronosis is easily visible as blue-black pigment in 
tissues such as the cartilage of the ears and sclera of the eyes. Photographs of the 
eyes and ears have been used to follow the OP process, both in terms of 
understanding the natural history as well as to study the effect of reducing HGA 
concentrations on OP using HPPD inhibitors, and may be the most efficacious way to 
follow pigment change (Ranganath et al. 2018). 
However, to detect small amounts of pigment, more sensitive techniques are required. 
Such techniques can employ the property of HGA as a reducing agent and can be 
used in tissues in vitro and ex vivo to more easily detect the OP; one such approach 
employs Schmorl’s stain, a ferricyanide reduction method (Figure 5B) for tissue 
reducing substances, to detect microscopic OP (Tinti et al. 2011b); this supports the 
idea that OP originated from HGA. Biopsy of tissues such as ear cartilage reveals OP 
even when it is not visible externally visually through the intact skin (Vijaikumar et al. 
2000). 
Investigations such as arthroscopy and bronchoscopy can reveal OP and suggest 
diagnosis of AKU for the first time. Diagnosis due to black aorta at open heart surgery 
for aortic valve replacement has been made (Karavaggelis et al. 2017). Direct 
detection of OP in vivo by Raman spectroscopy is possible. Such a technique has 
been validated in ex vivo tissue (Cox et al. [in press]) and is being adapted as an in 
vivo technique using ear cartilage and Achilles tendon, both tissues with little 
subcutaneous tissue (Taylor et al. 2019).  
Ochronosis can be seen in ex vivo samples especially from joints and these can vary 
in extent and degree of pigment. The earliest pigment is articular cartilage is seen in 
calcified cartilage cells at the junction between the calcified cartilage and subchondral 
bone (Taylor et al. 2010c). Similarly, OP is found in intervertebral discs and adjacent 
articular cartilage (Helliwell et al. 2008). Investigations such as arthroscopy and 
bronchoscopy can reveal OP and suggest diagnosis of AKU for the first time. 
Diagnosis due to black aorta at open heart surgery for aortic valve replacement has 
been made (Cox et al. [in press]).  
It would be an advantage to quantify the pigmentation in vivo but such a technique is 
not available at present. Availability of techniques to monitor changes in whole body 
pigment, increase or decrease or no change over time, would be highly informative.  
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Magnitude of flux in OP: It can be difficult to know how much metabolite flux is taking 
place in the phenylalanine/tyrosine pathway as these amino acids are normally fully 
degraded and utilised. Justus Von Liebig’s theory of the minimum applied to dietary 
amino acid consumption suggests that amino acids lysine, threonine, methionine, and 
tryptophan are limiting in diet (Liebig 1831). Tyrosine and phenylalanine are not 
limiting and are therefore consumed to excess. Since only 5% of consumed 
phenylalanine and tyrosine are needed to meet normal needs, these surplus aromatic 
amino acids require degradation via HGA. An attempt has been made to quantify the 
flux in the pigment pathway following HPPD inhibitor therapy (Milan et al. [under 
review]); data suggests a large flux in the ochronotic pathway.  
Effect of ochronosis (Table 2): The deposition of OP in tissue including cartilage 
alters its material properties leading to the tissue becoming hard and brittle. The 
Young’s modulus is altered depending upon the degree of pigmentation in AKU. Our 
group has proposed a model of joint failure based on initiation of ochronosis in calcified 
cartilage before progressing to involve the entire cartilage and spiralling into joint 
failure, requiring joint replacement (Taylor et al. 2011b).  
This process of ochronotic stiffening also compromises intervertebral discs and 
adjoining bone leading to severe spinal disease characterised by severe pain as well 
as kyphosis and scoliosis; spinal cord compression by involved discs can require 
decompressive spinal surgery. Spinal fusion can ensue in the latter stages resulting in 
loss of mobility and flexibility in all parts of the spine, but especially in the cervical and 
lumbar regions.  
Although all cardiac valves can show ochronosis, it is the aortic valve and the aortic 
root that are subject to more pigmentation resulting in severe aortic stenosis requiring 
valve replacement surgery. Valve replacement surgery is often hazardous due to the 
friable ochronotic aortic root and valve. 
Scleral ochronosis can distort the corneal curvature and result in astigmatism 
(Ranganath [unpublished observations]; Lindner and Bertelmann 2014). Ochronotic 
ear cartilage may be associated with pain in pinna of the ear (Ranganath 
[unpublished observations]). Hearing loss especially to high frequency is a feature of 
AKU (Pau 1984; Steven et al. 2015). Rigid articular cartilage can lead to subchondral 
osteopenia. Generalised osteoporosis is also noted in AKU and associated with 
increased fracture (Cox and Ranganath 2011). The failure of ochronotic connective 
tissue results in tendon ruptures, especially of the Achilles tendon, but other tendon 
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ruptures have also been observed such as flexor and extensor foot, patellar, bicipital 
and gluteal regions (Manoj Kumar and Rajasekaran 2003; Ranganath and Cox 
2011). Similarly ruptures of ochronotic ligaments have been described. Muscle 
rupture has also been reported more frequently in AKU. Stone formation featuring 
OP has been found in kidney, prostate, gall bladder and salivary gland, resulting in 
symptomatic obstruction of these organs (Taylor et al. 2010a). Renal failure can 
ensue both due to obstruction and renal parenchymal ochronosis, sometimes leading 
to fatal intractable haemolytic anaemia (Mullan et al. 2015; Davison et al. 2016).  
Interestingly, the frequency of atheromatous vascular disease is not increased, 
despite pigmentation of atherosclerosis plaques. Neo-angiogenesis has been 
reported in the synovia of AKU patients (Millucci et al. 2016). Millucci and colleagues 
propose that in AKU angiogenesis and inflammation are inter-related pathological 
manifestations. These authors postulate that newly-formed blood vessels provide 
inflammatory cells with oxygen and nutrients, resulting in the release of pro-
inflammatory cytokines which support angiogenesis. In this way angiogenesis may 
contribute to the progression from acute to chronic inflammation in AKU, as is the 
case in the chronic rheumatic disease synovitis (Millucci et al. 2016). In AKU, the 
exact association between angiogenesis and OP specifically is not fully understood. 
However, it is plausible that neo-vascularisation increases access of circulating HGA 
to the synovium, thereby further propagating ochronosis and associated 
inflammation.   
Despite a sedentary lifestyle imposed by the morbidity of AKU, overweight and 
obesity is not more common in AKU, and also consequently, there is no increased 
prevalence of diabetes. It is debatable whether this relates to loss of nutrient, i.e. 
HGA, in the urine from birth, comparable to the use of inhibitors of renal glucose 
transport, to induce nutrient loss, in diabetes management.  
 
Mechanism of ochronotic joint and spine disease (Figure 5C): Ageing causes 
changes in the composition and organization of the extracellular matrix. These 
include loss of proteoglycans and disruption of collagen fibrils. Trauma can 
exacerbate these changes. Reactive molecules attack collagen fibres lacking 
protective proteoglycans. In AKU, homogentisic acid is the culprit leading to 
ochronosis (Taylor et al. 2010b). HGA-pigment modified collagen fibres become 
stiffened and less resistant to mechanical loading, leading to a downward spiral of 
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structural damage. In AKU this cascade is initiated in calcified cartilage and spreads 
throughout the hyaline cartilage to the articular surface. Ochronosis initiates in 
calcified articular cartilage, beginning with the deposition of pigment in individual 
chondrocytes and their territorial matrix in calcified cartilage, spreading to other 
chondrons in the calcified matrix, then proliferating throughout the hyaline cartilage. 
Ochronotic cartilage shields the underlying bone from normal mechanical loading, 
leading to aggressive resorption of the subchondral plate, including calcified cartilage 
and bone, leading to catastrophic failure of the cartilage and joint itself, with 
fragments of cartilage escaping into the synovial space as well as impacting into 
underlying trabecular bone and bone marrow (Taylor et al. 2011b).  
It is postulated that a similar sequence of events may also take place in the spine 
with OP build up in the intervertebral disc and adjacent articular cartilage, leading to 
increased stress in the vertebral bodies and bone loss. Direct experimental evidence 
for this is at present lacking. 
OP and amyloid: Amyloidosis involves the accumulation of normally soluble proteins 
into insoluble fibrillar aggregate structures. A growing literature suggests that it is a 
secondary effect of ochronosis in vitro (Millucci et al. 2012; Spreafico et al. 2013; 
Braconi et al. 2017) and in vivo (Millucci et al. 2012, 2014, 2016, 2017). A number of 
observations report presence of amyloid A protein aggregates and fibrils in AKU serum 
and ochronotic tissue from a number of locations including cartilage, synovia, heart, 
periumbrical abdominal, articular fat and labial salivary gland. Amyloidosis is well-
recognised in the chronic inflammatory condition rheumatoid arthritis (Obici et al. 
2009), and in AKU it is also proposed to result from oxidative protein modification due 
to presence of reactive oxygen species (Millucci et al. 2015a). The co-localisation of 
amyloid with shards of OP suggests a close association with ochronosis (Millucci et 
al. 2015a), although the clinical significance of amyloidosis in AKU remains unknown. 
In addition, the observation that OP can reverse (Ranganath et al. 2018) is difficult to 
explain on the basis of amyloid being the major component of pigment. 
Linking HGA, ochronosis and damage: The genetic defect and the disease 
manifestations can be linked as follows. The genetic defect in AKU leads to an 
increase in HGA. Ochronosis is the result of increased HGA. Ochronotic tissue breaks 
down causing the multisystem damage in AKU. Conversely, lowering HGA should 
decrease ochronosis, in turn reducing damage and tissue breakdown. 
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Incubating osteoblastic (Figure 2D) and chrondrocytic cell lines with HGA leads to 
development of OP within 3 weeks (Tinti et al. 2011b). OP is seen both within and 
outside cells. The amount of OP formed is directly proportional to the concentration of 
HGA in the medium. In the AKU mouse model, OP develops by around 15 weeks 
increasing progressively in articular joints around the body of the mouse (Taylor et al. 
2012; Preston et al. 2014). Decreasing HGA in mice by employing HPPD inhibitors 
prevents ochronosis when started soon after birth and arrests ochronosis when started 
later (Taylor et al. 2012; Preston et al. 2014). In humans, the OP process is 
accelerated when renal failure supervenes and this also leads to more rapid clinical 
deterioration (Introne et al. 2002). 
HGA and causation of Alkaptonuria: Despite the fact that HGA is normal in those 
without AKU, regulators still consider HGA a biomarker of disease rather than a cause 
of AKU in their decisions regarding approval of drugs. Debates about causative agents 
in disease have raged for a long time. In the nineteenth century bacteria were blamed 
for causing all sorts of diseases, including alkaptonuria. A bacterium in the intestine 
was blamed as the culprit of the black urine of affected patients that was said to convert 
tyrosine to homogentisic acid. In the midst of this chaos, Robert Koch established 
objective rules through which a causative role could be attributed to an 
organism/agent/factor (Koch 1876; Brown and Goldstein 1992). We have applied 
Koch’s postulates to AKU as seen in Table 3.  
Koch's postulates and AKU (Table 3): Over time it came to be recognized that 
Koch’s postulates did not comply with all situations to establish a causal relationship 
and other criteria have been proposed such as the Bradford-Hill criteria or Hill’s criteria 
for causation (Hill 1965). We have applied Hill’s criteria for HGA in AKU also as shown 
in Table 3. It is clear that HGA conforms to the requirements for a causative molecule. 
Lessons for AKU from the cholesterol and atherosclerosis and cardiovascular 
disease (Table 4): What can AKU learn from other disorders? There are strong 
similarities between familial hypercholesterolaemia (FH) and AKU; both are inherited 
diseases that form a template for the more common conditions cardiovascular disease 
(CVD) and osteoarthritis, respectively. AKU and FH are present from birth but the 
effects are delayed. HGA is the culprit molecule in AKU, while cholesterol is the 
molecule in CVD. Ochronosis is the process by which HGA causes the morbidity, while 
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the comparable process in CVD is atherosclerosis. HPPD inhibitors decrease HGA 
production, while HMG-CoA reductase inhibitors (statins) decrease cholesterol 
production. Recent data suggests partial reversibility of external ochronosis by HPPD 
inhibition, while data from imaging studies have shown a similar partial reversal of 
atherosclerosis by reducing cholesterol (Nissen et al. 1991). A study has been 
reported showing a slower progression of AKU using HPPD inhibition, similar to statin 
trials on CVD progression (Ranganath et al. 2018). However it is worth noting 
differences in the inheritance of AKU and FH; AKU is autosomal recessive with 
prevalence of 1:250,000 worldwide, whereas FH is autosomal dominant 
(Nordestgaard et al. 2013) and relatively more common with estimated worldwide 
prevalence of 1:200-300 (Vallejo-Vaz and Ray 2018). Table 4 shows the comparison 
between AKU and FH.  
It is worth emphasizing that modification of the disease process (atherosclerosis) by 
imaging has been used as outcomes in a number of studies in CVD. This is consistent 
with a proposal to similarly approve the use of modification of the OP process in AKU 
as acceptable outcomes in clinical interventional studies. Statins have revolutionised 
the management of cardiovascular disease, and in FH it has been shown that earlier 
use of statins at low dose is superior in prevention terms compared to use of high dose 
statins later on in the natural history (Nordestgaard et al. 2013). Mouse studies indicate 
that nitisinone treatment from soon after birth completely prevents ochronosis, the 
main pathophysiological process in AKU (Preston et al. 2014). 
Therapy and ochronosis:  
Antioxidant therapy by preventing oxidation of HGA to BQA, is expected to decrease 
ochronosis but for reasons which are unclear antioxidant ascorbic acid therapy has no 
clear benefit in AKU, a condition with a proposed oxidant-damage hypothesis in terms 
of ochronosis formation (Roberts et al. 2015); this is analogous to the lack of efficacy 
of antioxidant strategies in coronary artery disease studies despite the well-validated 
oxidised LDL theory of atherogenesis (Ranganath et al. 2013). 
Lower protein intakes should also in theory be associated with less ochronosis and 
less morbidity in AKU. However, except occasional case reports in childhood, there is 
no evidence that restricting dietary protein decreases ochronosis. Anecdotally 
vegetarians and vegans are noted to have less ochronosis and lower morbidity but no 
systematic evidence exists to support low protein diet in AKU (Ranganath 
[unpublished observations]). All other approved therapies used in clinical practice are 
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supportive and palliative and do not address the HGA and its effects (Ranganath et 
al. 2013). 
The use of HPPD inhibition employing nitisinone to decrease flux in the tyrosine 
pathway has revolutionised the treatment of hereditary tyrosinaemia (Lindstedt et al. 
1992; McKiernan 2013). Nitisinone was first suggested as a treatment for HGA in AKU 
in 1998 (Anikster et al. 1998), and is now shown to be highly effective in reducing HGA 
despite not being approved in AKU (Ranganath et al. 2018). Nitisinone not only 
decreases HGA but also arrests ochronosis in mice (Preston et al. 2014). A recent 
publication shows photographic evidence of partial reversal of ochronosis in sclera 
and ear cartilage in AKU patients (Ranganath et al. 2018). 
The NIH carried out a nitisinone interventional study in AKU between 2005 and 2009 
and showed a sustained and marked decrease in urine HGA over the 3-year duration 
of the study (Davison et al. 2015). However, their agreement with the regulatory 
agency, the FDA, to approve nitisinone for AKU, required them to show a difference 
in range of motion at the hip between the nitisinone-treated and untreated groups; 
statistical significance was not found for the range of motion comparison and the study 
reported inconclusive. 
The dose of nitisinone used in the NIH study was 2 mg daily. This same dose is being 
used in the NAC, as mentioned in a recent publication (Ranganath et al. 2018). Further 
the NAC data in the publication confirmed the biochemical efficacy of nitisinone in AKU 
in terms of urinary HGA, but also showed slower progression of morbidity. Finally, the 
NAC data showed overt partial reversal of ochronosis, the primary pathogenetic event 
in AKU. 
It is important to note that nitisinone, while shown to be a highly effective therapy for 
preventing ochronosis, is not a perfect therapy in AKU. It is well recognised that 
nitisinone treatment results in siginificant hyper-tyrosinaemia in AKU (Phornphutkul et 
al. 2002) and hereditary tyrosinaemia type-I (HT-I) (Lindstedt et al. 1992; McKiernan 
2013). The consequences of hyper-tyrosinaemia are not fully understood in AKU, but 
concerns have been raised that it may contribute to the neurodevelopmental delay 
observed in infants with HT-I on nitisinone therapy (McKiernan 2013). Recent analyses 
did not find changes to monoamine neurotransmitters in brain tissue from nitisinone-
treated mice (Davison et al. 2019), although more data are required to fully ascertain 
the impact of hyper-tyrosinaemia on central nervous system homoeostasis. Other 
potential future therapies for AKU may employ approaches to directly restore HGD 
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activity for example by enzyme replacement therapy and gene therapy. However 
research into these approaches is still in very early stages, and they are also not 
without their own concerns and challenges, for example potential off-target effects.  
We believe that it is time that the scientific community recognised the fundamental role 
played by pigmentation due to ochronosis in AKU and to take this into consideration 
when assessing the disease as well as effectiveness of treatments for the disease. 
The accumulation of HGA in AKU is comparable to the increase in xylulose in 
pentosuria, but unlike pentosuria where there is no syndrome associated with pentose 
sugar accumulation, the situation is different in AKU, a condition dominated by 
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Table 1. Factors influencing tissue ochronotic pigmentation 
Tissue Damaging factor 
Spine intervertebral discs Weight bearing stress 
Joints Weight bearing stress, movement 
damage 
Tendons Tensile stresses 
Ligaments Tensile stresses 
Aortic valve Systemic blood pressure, expansile 
stress 
Aortic root Systemic blood pressure, expansile 
stress 
Arterial tree branch points Shear stress, Bernoulli effect 
Airways cartilage Expansion, lengthening and contracting 
Ear cartilage Pressure on ears during sleep 
Sclera and conjunctiva UV light damage, stress arising from 




Table 2. The effect of ochronosis on tissues 
Tissue with ochronosis Effect 
Articular cartilage Resorption of calcified articular cartilage 
and subchondral bone and joint failure 
Articular cartilage Osteopenia due to resorption activated 
by stiff pigment 
Intervertebral discs Spondylosis, fracture, osteopenia, 
scoliosis, kyphosis, cord compression, 
radiculopathy 
Ligament Rupture 
Aortic valve and root Aortic stenosis and Aortic rigidity 
Tendons (e.g.Achilles, foot flexor and 
extensor, patellar, gluteal, biceps) 
Rupture 
Sclera Distortion in corneal curvature; 
astigmatism, glaucoma 
Ear cartilage Possible pain in ear  
Middle/inner ear Hearing loss, ear ossicles disorder 
leading to conductive deafness and high 





Table 3. Koch’s postulates and its application to Alkaptonuria 
Koch’s postulates rules Relevance to AKU  
The agent must be found in abundance 
in all organisms suffering from the 
disease, but should not be found in 
healthy organisms 
HGA found in abundance in AKU but 
not in non-AKU 
The microorganism must be isolated 
from a diseased organism and grown in 
pure culture. 
HGA can be isolated from AKU patients 
by preparative HPLC techniques to yield 
pure HGA. 
The cultured microorganism should 
cause disease when introduced into a 
healthy organism. 
HGA can be incubated with cell cultures 
and shown to produce the features of 
AKU namely pigment. 
The microorganism must be re-isolated 
from the inoculated, diseased 
experimental host and identified as 
being identical to the original specific 
causative agent. 
Producing a mutation of the HGD gene 
in a normal mouse can produce an AKU 
mouse showing high HGA. 
 
Hill’s Criteria and HGA and cause in AKU 
Bradford-Hill criteria for causation How does AKU fit in 
Strength: A small association does not 
mean that there is not a causal effect, 
though the larger the association, the 
more likely that it is causal 




Consistency: Consistent findings 
observed by different persons in 
different places with different samples 
strengthens the likelihood of an effect. 
Link between HGA in AKU and disease 
by various dispersed researchers. 
Specificity: Causation is likely if there 
is a very specific population at a specific 
site and disease with no other likely 
explanation. The more specific an 
association between a factor and an 
effect is, the bigger the probability of a 
causal relationship 
Only HGA causes the disease process 
characteristic of AKU 
Temporality: The effect has to occur 
after the cause (and if there is an 
expected delay between the cause and 
expected effect, then the effect must 
occur after that delay) 
In mouse models where the mutation of 
HGD has been produced, HGA levels 
increase after the mutation. The disease 
process however develops after slight 
delay both in mouse and humans. 
Biological Gradient: Greater exposure 
should generally lead to greater 
incidence of the effect. However, in 
some cases, the mere presence of the 
factor can trigger the effect. In other 
cases, an inverse proportion is 
observed: greater exposure leads to 
lower incidence 
Places with high frequency of HGD 




Plausibility: A plausible mechanism 
between cause and effect is helpful (but 
Hill noted that knowledge of the 
mechanism is limited by current 
knowledge) 
HGA can reproduce the disease 
process ochronosis in vivo and is 
therefore plausible. 
Coherence: Coherence between 
epidemiological and laboratory findings 
increases the likelihood of an effect. 
The relationship between mutations of 
the HGD gene, high HGA, increasing 
ochronosis over time and increasing 
morbidity is coherent. 
Experiment: Occasionally it is possible 
to appeal to experimental evidence 
Tissues exposed to HGA produce a 
similar disease process to naturally 
occurring condition AKU 
Analogy: The effect of similar factors 
may be considered 
HGA in AKU is similar to cholesterol in 









Frequency Heterozygote 1 in 500  
Homozygote 1 in 1,000,000 
Heterozygote 1 in 500 
Homozygote 1 in 
1,000,000 




Genetic defect  LDL receptor, Apo-B 
defects, PCSK9 mutations  
HGD mutations 
Disease process Atherosclerosis Ochronosis 
Main consequence Atherosclerosis Ochronosis 
Main disease Myocardial infarction  Spondyloarthropathy 
Childhood Minimal disease Minimal disease 
Latent period 40 -50 years in 
heterozygous 
20 years in homozygous 
20-30y  
Prevention Yes, lifestyle and statins Nitisinone 
Lifestyle factors Yes, hypertension, physical 
activity, Smoking, diabetes, 
others 
Diet, activity, occupation 
Disease modifying 
therapy 














Figure 1. Tyrosine metabolic pathway – highlighting (1) the metabolic fate of tyrosine 
in health, (2) site of the enzyme defect observed in Alkaptonuria, homogentisate 
dioxygenase (HGD EC 1.13.11.5) and Hereditary Tyrosinaemia type 1, 
maleylacetoacetate isomerase (MAI EC 5.2.1.2), and (3) the site where nitisinone 
inhibits 4-hydroxyphenylpyruvate dioxygenase (HPPD EC 1.13.11.27) activity 
Figure 2. Ochronotic pigmentation features (1). A. Ochre or yellowish discoloration 
due to ochronotic pigment in the unstained ear cartilage in two patients with 
alkaptonuria; less in left panel, more in right panel. B. TEM image of ochronotic 
ligamentous capsule. Collagen fibres in longitudinal section show a distinct electron-
dense pigment on their surface. Not all fibres present with pigment deposition. 
Numerous pigment shards can be seen on single fibres. Gradient of pigmentation 
can be seen running left (no pigment on fibres) to right (large electron-dense shards 
replacing fibres). Arrows indicate a distinct periodic binding pattern associated with 
pigment granules on a single fibre. C. Schematic representation of the development 
of ochronosis. Genetic lack of homogentisate 1,2-dioxygenase leads to an increase 
in concentration of homogentisic acid (HGA). HGA, its oxidation product, 
benzoquinone acetic acid or the final product ochronotic pigment binds to 
collagenous matrices. Initially, matrix is resistant to pigmentation, but following loss 
or breakdown of specific constituents, including proteoglycans (PG), HGA-
associated compounds access binding sites which are associated with the 
ultrastructural periodicity of the collagen fibrils. It is proposed that the initial binding 
event initiates ochronosis and that the process of widespread joint pigmentation 
occurs over time. Pigmentation increases the stiffness of the collagen fibres, which 
leads to further biomechanical and biochemical damage and a downward spiral of 
ochronosis and tissue destruction. D. Schmorl’s staining of HGA-derived pigment 
deposits in cultures of SaOS-2 cells. E. Samples obtained during ultrafiltration of 
solutions of ochronotic pigment formed via incubation of an aqueous solution of HGA 
(10 mmol/L) at 37 °C for 3 months. Solutions 1 and 2 are samples pre- and post-
centrifugation (10 min at 2500 x g) respectively. The pigment solution was filtered 
using an Amicon Ultracel 10 K filter (Merck Millipore) by centrifugation (10 min at 
2500 x g). Solution 3 is taken from the portion of the solution that had not passed the 
filter after 10 min centrifugation. Solution 4 is a sample of the filtrate and is visibly 
lighter in colour, indicating that the 10 K filter had retained some of the pigment. 
Figure 3. Ochronotic pigmentation features (2). A. Dark urine of AKU. B. External 
ear cartilage pigmentation. C. Dark pigmentation of temporal aspect of sclera in right 
eye with vessels coursing superficial to pigmentation. D. Unstained cut section of 
femur condyle showing little pigment on left side progressing to full thickness on the 
right side. E. Longitudinal cut section of abdominal aorta and common iliac 
bifurcation, showing more pigment at bifurcation and branch point orifices. F. 
Pigment at junction of palmer and dorsal skin of hands. 
Figure 4. Ochronotic pigmentation features (3). A. Markedly ochronotic bulging 
intervertebral discs and vertebral body seen from within abdominal cavity. B. Spine 
seen from posterior or dorsal aspect showing ochronotic pigment. C. Dark 
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pigmentation seen in arthroscopy of knee joint showing fibrillar blackened cartilage. 
D. Appearance of pigmented head of femur showing uniform pigmentation. E. Hip 
joint showing rim of cartilage and marked cartilage loss with exposure of underlying 
bone. F. Low pressure pulmonary trunk and valve showing little pigment. G. Aortic 
root and valve with marked pigmentation. 
Figure 5. Presence of ochronotic pigment in the knee joint and its progression in 
AKU. A. Ochronotic pigment in the joint capsule of the knee of a patient with AKU. 
Pigment deposits are seen as brown granules in the ECM and within fibroblasts. 
Section stained with nuclear fast red. B. Near serial section of the joint capsule with 
Schmorl’s stain. Ochronotic deposits are stained green. Bar: 50 μm. C. Schematic 
representation of the progression of ochronosis in articular cartilage from initiation in 
calcified cartilage to eventual destruction of the joint: a) ochronosis begins with the 
deposition of pigment in individual chondrocytes and their territorial matrix in calcified 
cartilage. Pigmentation leads to focal increases of stiffness altering the load 
distribution and inducing stress risers; b) ochronosis spreads to other chondrons in 
the calcified matrix, then c) proliferates throughout the hyaline cartilage; d) 
ochronotic cartilage shields the underlying bone from normal mechanical loading, 
leading to aggressive resorption of the subchondral plate, including calcified cartilage 
and bone; e) despite the increased stiffness, the pigmented shell of the remaining 
articular cartilage fails catastrophically. Pigmented cartilage becomes impacted on 










































Norman BP, Davison AS, Ross GA, Milan AM, Hughes AT, Sutherland H, Jarvis 
JC, Roberts NB, Gallagher JA, Ranganath LR. A comprehensive LC-QTOF-MS 
metabolic phenotyping strategy: Application to alkaptonuria. Clin Chem. 
2019;65(4):530–9.  
 
[Author accepted manuscript] 
 
Title: A comprehensive LC-QTOF-MS metabolic phenotyping strategy: application to 
alkaptonuria 
 
Running Head: Comprehensive metabolic phenotyping by LC-QTOF-MS 
 
Authors: Brendan P Norman1,†,*, Andrew S Davison1,2,†, Gordon A Ross3, Anna M 
Milan1,2, Andrew T Hughes1,2, Hazel Sutherland 1,4, Jonathan C Jarvis4, Norman B 
Roberts1, James A Gallagher1,‡, Lakshminarayan R Ranganath1,2,‡ 
 
1Musculoskeletal Biology I, Institute of Ageing & Chronic Disease, William Henry 
Duncan Building, University of Liverpool, Liverpool, UK; 2Department of Clinical 
Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Royal Liverpool 
University Hospitals Trust, Liverpool, UK; 3Agilent Technologies UK Ltd., Cheadle, UK; 
4School of Exercise Science, Liverpool John Moores University, Liverpool, UK 
 
*Corresponding Author: Brendan P Norman, Musculoskeletal Biology I, Institute of 
Ageing & Chronic Disease, William Duncan Building, University of Liverpool, Liverpool, 
UK, L7 8TX; Telephone: (0)151 794 9063; Email: bnorman@liverpool.ac.uk 
 
Key words: alkaptonuria, LC-QTOF-MS, metabolomics, metabolite identification, 
accurate mass, retention time   
 
Number of tables and figures: 5 figures (3 supplemental figures), 1 table 
 
Abbreviations: LC – liquid chromatography; QTOF-MS – quadrupole time-of-flight 
mass spectrometry; AMRT - accurate mass/retention time; MS – mass spectrometry; 
AKU – alkaptonuria; HGD – homogentisate 1,2-dioxygenase; HGA – homogentisic 
acid; NAC – National Alkaptonuria Centre; RT – retention time; QC - quality control; 
CV – coefficient of variation; FC – fold change; HT-1 - hereditary tyrosinaemia type-1 
List of human genes: HGD - homogentisate 1,2-dioxygenase 
 
† Joint first author 






Background: Identification of unknown chemical entities is a major challenge in 
metabolomics. To address this challenge, we developed a comprehensive targeted 
profiling strategy, combining three complementary liquid chromatography (LC) 
quadrupole time-of-flight mass spectrometry (QTOF-MS) techniques and in-house 
accurate mass retention time (AMRT) databases established from commercial 
standards. This strategy was used to evaluate the effect of nitisinone on the urinary 
metabolome of patients and mice with alkaptonuria (AKU). Because hypertyrosinemia 
is a known consequence of nitisinone therapy, we investigated the wider metabolic 
consequences beyond hypertyrosinemia. 
Methods: 619 standards (molecular weight 45-1354 Da) covering a range of primary 
metabolic pathways were analyzed using three LC methods, two reversed phase and 
one normal phase, coupled to QTOF-MS. Separate AMRT databases were generated 
for the three methods, comprising chemical name, formula, theoretical accurate mass 
and measured retention time. Databases were used to identify chemical entities 
acquired from non-targeted analysis of AKU urine; match window theoretical accurate 
mass ±10 ppm and retention time ±0.3 min.  
Results: Application of the AMRT databases to data acquired from analysis of urine 
from 25 patients with AKU (pre-treatment and after 3, 12 and 24 mo on nitisinone) and 
18 HGD-/- mice (pre-treatment and after one week on nitisinone) revealed 31 
previously unreported statistically significant changes in metabolite patterns and 
abundance, indicating alterations to tyrosine, tryptophan and purine metabolism post-
nitisinone. 
Conclusions: The comprehensive targeted profiling strategy described here has the 
potential of enabling discovery of novel pathways associated with pathogenesis and 




Metabolic profiling has potential to advance knowledge of disease beyond established 
biochemical pathways and will play a major role in precision medicine (1-5). However, 
metabolite identification is a major challenge in untargeted profiling studies using mass 
spectrometry (MS) (6,7) since they generate many chemical signals representing 
‘unknowns’. To address this challenge, we generated three accurate mass/retention 
time (AMRT) databases from 619 metabolite standards using liquid chromatography-
quadrupole time-of-flight-mass spectrometry (LC-QTOF-MS). We applied this strategy 
to the inborn error of metabolism alkaptonuria (AKU, OMIM 203500). In AKU, bi-allelic 
mutations in the homogentisate 1,2-dioxygenase (HGD) gene result in a lack of 
homogentisate 1,2-dioxygenase (HGD, E.C.1.12.11.5) (8), leading to increased 
homogentisic acid (HGA), a metabolite of tyrosine catabolism (Fig. 1). HGA 
accumulates in connective tissue, particularly cartilage, where it is deposited as a dark 
pigment, a process termed ochronosis. Ochronosis underlies a range of clinical 
features in AKU, the most debilitating of which is severe, early-onset osteoarthropathy 
that alters the physico-mechanical properties of cartilage (9,10). 
Nitisinone has emerged as a promising therapeutic agent in AKU because it reduces 
circulating HGA concentrations (11–15) by reversibly inhibiting hydroxyphenylpyruvic 
acid dioxygenase (E.C. 1.13.11.27). Nitisinone completely inhibits ochronosis in an 
HGD-/- mouse model of AKU (16). Although not currently licensed for AKU, nitisinone 
is being used to treat patients attending the National Alkaptonuria Centre (NAC) in the 
UK. One of the major metabolic consequences of nitisinone is hypertyrosinaemia 
(11,13–15,17–21) (Fig. 1). The objective of our study was to apply the developed 
profiling strategy to urine from patients with AKU and HGD-/- mice to understand the 
wider metabolic consequences of nitisinone treatment. 
 
Materials and Methods 
Metabolite standards library preparation 
619 standards (IROA Technology MS metabolite library of standards; molecular 
weight 45-1354 Da) were from Sigma-Aldrich (UK) in seven deepwell plates. Each 
compound was present at 5 µg/well (>95% purity). Plates were stored at -80°C. The 
standards covered a broad range of primary and intermediary metabolism, including 
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the following compound classes: carboxylic acids, amino acids, biogenic amines, 
polyamines, nucleotides, coenzymes, vitamins, carbohydrates, fatty acids, lipids, 
steroids and hormones (Supplemental Files 1 and 2).  
Prior to analysis, plates were thawed at ambient temperature (18˚C) and compounds 
reconstituted in 15 µL methanol (LC/MS grade, Sigma-Aldrich) followed by 285 µL 
deionized water (DIRECT-Q 3UV Millipore water purification system). Plates 1-5 were 
left to stand for 1 h following addition of water and methanol. Plates 6 and 7 (primarily 
non-polar compounds) were left to stand for 2 h at room temperature following addition 
of methanol to ensure solubilization; water was then added. Plates were agitated on a 
plate shaker (MTS 2/4m IKA, Germany) at 600 rpm for 10 min. Compounds were 
pooled across rows of each plate (12 wells/row). 20 µL was removed from each well 
and pooled into one well (12 compounds analyzed per injection). Fifty-six injections 
were performed in positive and negative polarity across all plates (112 injections for 
each LC-QTOF-MS method; Supplemental Fig. 1). The total volume of each pool was 
240 µL with each compound at 14 mg/dL (1-31 µmol/L). 
 
Evaluation of LC-QTOF-MS strategy and effect of nitisinone on the metabolome using 
AKU urine 
24 h urine was obtained from 25 patients with AKU attending the NAC (12 male, 
mean(±SD) age 51±15 y). Samples were collected before nitisinone then at 3 (2 mg 
every other day), 12 and 24 (2 mg daily) mo on nitisinone and stored at -80°C. Samples 
were diluted 1:3 with deionized water and stored at -80°C as three separate aliquots 
for analysis by methods 1-3. Metabolomic analysis was part of the diagnostic service 
to patients being seen at the NAC and with approval from the Royal Liverpool and 
Broadgreen University Hospital Trusts Audit Committee (audit no. ACO3836). 
Mouse urine was from 18 (9 male, mean age 27±12 wk) HGD-/- BALB/c mice (16) bred 
from laboratory stocks at the University of Liverpool. Samples were obtained on a 
single-collection basis before treatment then after 1 wk on nitisinone, administered in 
all drinking water (0.4 mg/dL), supplied ad libitum. Mouse urine was collected onto 
cling film, pipetted into sample tubes and stored at -80°C. Analysis was performed 
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following dilution of 1:9 with deionized water. Mouse breeding and dosing was 
authorized under the Animals (Scientific Procedures) Act, UK. 
Samples were pooled for quality assurance in profiling experiments. For each 
sampling time point, a representative pool was created by pooling 20 µL of each 
individual urine sample. An additional overall pool was created separately for human 
and mouse experiments by pooling equal proportions of the pooled urine groups 
detailed above. Pooled human and mouse samples were stored and treated as above 




Water for mobiles phases was purified as above. Methanol, acetonitrile, isopropanol 
(Sigma-Aldrich), formic acid (Biosolve, Netherlands) and ammonium formate (Fisher 
Scientific, Germany) were LC/MS grade. 
Equipment 
Sample analysis was performed on an Agilent 1290 Infinity LC coupled to an Agilent 
6550 QTOF-MS equipped with a dual AJS electrospray ionization source (Agilent, 
UK). 
Chromatographic conditions 
Three chromatographic methods were designed to separate different compound 
classes. Method 1: non-polar compounds. Method 2: a range of polar/non-polar 
compounds. Method 3: polar compounds. Metabolite standards were analyzed using 
all three LC-QTOF-MS techniques.  
Method 1 
A Zorbax Eclipse Plus C18 column (2.1x100 mm, 1.8 µm, Agilent) was maintained at 
60°C (flow rate 0.4 mL/min). Mobile phases were (A) water and (B) methanol both 
containing 31.6 mg/dL ammonium formate and 0.1% formic acid. The elution gradient 
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started at 5% B at 0-1 min increasing linearly to 100% by 12 min, held at 100% B until 
14 min, returning to 95% A for 5 min.  
Method 2 
Method 2 employed the same conditions and elution gradient as method 1, but with 
an Atlantis dC18 column (3x100 mm, 3 µm, Waters, UK). 
Method 3 
A BEH amide column (3x150 mm, 1.7 µm, Waters) was maintained at 40°C (flow rate 
0.6 mL/min). Mobile phases were (A) water and (B) acetonitrile (both containing 0.1% 
formic acid). The elution gradient started at 99% B decreasing linearly to 30% from 1-
12 min, held at 30% B until 12.6 min, returning to 99% B for 3.4 min. 
Sample injection volume was 1 µL for metabolite standards and human urine, and 2 
µL for mouse urine. The autosampler was maintained at 4°C and the needle was 
washed with a solution of water:methanol:isopropanol (45:45:10 v/v) between 
injections.  
 
Design of urine metabolic profiling experiments 
Human and mouse urine was analyzed separately. Human samples were analyzed 
batch-wise using all 3 methods, negative followed by positive polarity. Mouse samples 
were analyzed by method 2 only due to limited sample volumes, in one batch 
comprising both polarities.  
The analytical sequence of each profiling batch was designed according to published 
guidance (22). Each run commenced with 20 replicate injections of the overall pooled 
sample to condition the system. The order of individual samples was randomized 
computationally. Pooled samples were interspersed throughout the analytical 
sequence, every 10th injection. Injections of each sample group pool and the overall 





Data acquisition and processing 
Data acquisition and processing were performed using the MassHunter suite (Agilent). 
Data were acquired with Data Acquisition (build 06.00). Metabolite standards and urine 
samples were analyzed in both polarities, mass range 50-1700 (Supplemental File 3). 
Quality checks and processing of raw data were performed with Qualitative Analysis 
(build 07.00). Extracted ion chromatograms of reference masses were performed to 
check mass accuracy remained <5 ppm throughout the run. Binary pump pressure 
curves for injections across each analytical sequence were overlaid to check 
chromatographic reproducibility. 
Compound signals were extracted from the standards data in Qualitative Analysis 
(build 07.00) by molecular formula using the ‘find by formula’ algorithm; mass window 
of theoretical accurate mass (calculated from molecular formula) ±5 ppm. Allowed ion 
species were: H+ and Na+ and additionally NH4+ for methods 1 and 2 (positive polarity); 
and H- and additionally CHO2- for methods 1 and 2 (negative polarity). Charge state 
range was 1-2. Dimers were allowed. Separate AMRT databases were created for 
each method using PCDL Manager (build 08.00). Theoretical accurate mass, retention 
time (RT), molecular formula and METLIN chemical name were entered into each 
AMRT database for compounds that were retained and detected (databases publicly 
available via https://figshare.com/collections/_/4378235/0 (23)). 
Urine profiling data were mined for signals matching AMRT database compounds 
using ‘targeted feature extraction’ (Profinder, build 08.00). Targeted feature extraction 
uses the molecular formulae to extract and group spectral signals (i.e. adducts, 
multimers and isotopes), corresponding to individual database compounds. Feature 
extraction window; theoretical accurate mass ±10 ppm and database RT ±0.3 min. 
Allowed ion species were the same as specified above.  
  
Detection of non-AMRT database compounds in urine  
Urine data were also mined using Profinder for compounds not from generated AMRT 
databases but of interest for their predicted role in AKU/nitisinone metabolism. These 
compounds were associated with a) increased tyrosine: acetyl-L-tyrosine, γ-glutamyl-
L-tyrosine and tyramine-sulfate; b) ochronotic pigment: 2,5-dihydroxybenzaldehyde, 
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hipposudoric acid and norhipposudoric acid; or c) nitisinone metabolism: hydroxy-
nitisinone, nitisinone and 2-nitro-4-trifluoromethylbenzoic acid. For non-AMRT 
compounds, the same RT (range <0.3 min) was required across samples. Compound 
identifications were based on theoretical accurate mass ±10 ppm.  
 
Data quality control and statistical analyses 
Several quality control (QC) filters were applied to AMRT-matched entities from each 
profiling batch. First, entities were retained if observed in at least two samples per 
experimental group (i.e. sampling time point). Data files were then exported from 
Profinder and imported into Mass Profiler Professional (build 14.5). 24 h creatinine 
excretions (Roche Diagnostics, Germany) were used as external scalar for individual 
human urine samples (average values across each sampling time point used for 
pooled samples). Creatinine values were not available for mouse samples; the signal 
identified as creatinine by matched AMRT was used as external scalar for each 
sample using the peak area of the 13C [M+H]+ ion (13C because 12C creatinine signal 
was saturated) calculated in MassHunter Quantitative analysis (build 06.00). 
Entities were then further filtered in Mass Profiler Professional based on data from 
pooled samples from each experiment. Entities were retained if observed in 100% of 
replicate injections for at least one sample group pool, and with peak area coefficient 
of variation (CV) <25% across replicate injections of all sample group pools. 
Statistical analyses were performed in Mass Profiler Professional based on peak area. 
Human urine profiles were compared at 3, 12 and 24 mo on nitisinone with pre-
nitisinone by one-way repeated-measures ANOVA. Mouse urine profiles were 
compared pre-nitisinone vs 1 wk on nitisinone by paired t-test. Benjamini-Hochberg 
false-discovery rate adjustment was used in all statistical significance testing. Fold 
changes (FC’s) were calculated based on raw peak area. Principal component 







Analysis of metabolite standards 
Signals representing the chemical formulae for standards in each injection were 
extracted from the data by theoretical accurate mass ±5 ppm. Only standards with RT 
>0.3 min after the column void volume were considered. 519/619 (83.8%) of the 
standards were retained sufficiently to be detected by at least one method. 116/619 
(18.7%) and 226/619 (36.5%) of the compounds were retained sufficiently and 
detected by one or two methods only, respectively, demonstrating the utility of 
combining data from the three chromatographic methods (Figure 2A). RT, accurate 
mass and charge state were entered into an AMRT metabolite database for each 
method for matching unknowns against.  
Figure 2B-D shows the mass/RT distribution for compounds detected by each method. 
Figure 2B-D also highlights differences in selectivity for compounds from three 
example compound groups with different chemical properties: carbohydrates, amino 
acids and lipids (Supplemental File 4). Method 3 retained and separated highly polar 
compounds such as carbohydrates (20/26 detected, RT range 5-9.5 min). In methods 
1 and 2, the same carbohydrates were weakly retained; for method 1 all carbohydrates 
detected eluted within the initial column void (24/26 detected, RT range 0.58-0.68 min) 
and for method 2 all carbohydrates detected eluted close to the initial void (23/26 
detected, RT range 1.3-1.4 min). Method 1 showed some evidence of improved 
suitability for analysis of lipid-like compounds (11/11 detected, RT range 7.7-13.7 min) 
compared to methods 2 (8/11 detected, RT range 9.3-14.3 min) and 3 (7/11 detected, 
RT range 1.5-8.3 min), which detected fewer of these compounds within a narrower 
RT range overall. All three methods enabled detection of the amino acids, with method 
3 appearing to show the most useful chromatographic resolution and retention (19/21 
detected, RT range 5.4-8.1 min) compared to methods 1 (21/21 detected, RT range 






Identification of metabolites in pooled urine by AMRT 
Unknown chemical entities were matched against the respective AMRT database 
generated for each method: accurate mass ±10 ppm, RT ±0.3 min. For data presented 
here, analysis comprised two replicate injections of the overall pooled urine from 
patients with AKU from the start and end of each analytical run. Only unknowns 
obtained from both injections in positive or negative polarity and with single AMRT 
compound matches were retained in this analysis. Additional QC filters were then 
applied to ensure reproducibility across the run: CV <25% for peak area and RT 
between the two replicate injections. Table 1 summarizes matches retained for each 
method. No compounds were filtered out due to RT CV >25%. The maximum RT CV% 
change between the replicate injections across all analytical runs (each comprised 
205 injections) was 4.1%. 
Figure 3A shows that 203 unique compound matches were obtained from urine. 
Supplemental File 5 shows the matches obtained by methods 1-3. Fourteen AMRT 
matches were obtained by all three methods. An additional 61 AMRT matches were 
obtained by two methods, and 128 matches by only one of the methods, further 
supporting the increased coverage from the three methods in combination. Figure 3B-
D shows the mass/RT distribution of the AMRT matches. 
Table 1 and Supplemental Figure 2 show the number of AMRT matches obtained with 
narrower AMRT-matching windows. For each method, >50% of matches obtained with 
±10 ppm and ±0.3 min post-QC remained with ±5 ppm and ±0.15 min. 
 
Application of strategy to AKU: effect of nitisinone therapy on the urine metabolome 
Figure 4A,B shows the overall study design and a representative example of AMRT 
compound signals extracted from the data respectively. Representative principal 
components analysis plots (Figure 4C) show clear separation between the AMRT-
matched profiles of urine pre- vs post-nitisinone for human and mouse, showing that 
our strategy captured key metabolite changes. 
Thirty-five metabolites showed statistically significant changes (p<0.05, FC>2) in 
abundance after 3, 12 or 24 mo on nitisinone in humans or 1 wk on nitisinone in mice 
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(Figure 5). An FC >2 was chosen in order to limit false discovery and focus on clear 
changes. In patients with AKU, 13 metabolites increased and 14 decreased. In  
HGD-/- mice, 12 metabolites increased and 6 decreased. Ten metabolites changed in 
the same direction in humans and mice (Figure 5). Together, the majority of these 
metabolite changes could be categorized into three main metabolic pathways: those 
of tyrosine, tryptophan and purine. 
Interestingly, mouse data also showed clear separation by gender (principal 
component 1; x-axis Figure 4C). Histamine was the primary driver of this separation 
in positive polarity (principal component 1 loading; 0.42), which captured the effect of 
gender and explained 43% of the variation in the dataset. Histamine was significantly 
increased in female mice (p<0.0001, FC=16).  
 
Alterations to non-AMRT database compounds post-nitisinone 
Data showed alteration (p<0.05, FC>2) to metabolites with a predicted association to 
AKU/nitisinone metabolism that were not from AMRT databases (Supplemental Figure 
3). 2,5-dihydroxybenzaldehyde, probably associated with ochronotic pigment, was 
decreased post-nitisinone. The tyrosine metabolites acetyl-L-tyrosine and γ-glutamyl-
L-tyrosine and the nitisinone metabolite hydroxy-nitisinone were increased. These 
changes were observed in human and mouse urine.  
  
Discussion 
We have developed a strategy for comprehensive LC-QTOF-MS profiling with 
compound identification by three AMRT databases generated from metabolite 
standards. Application of this strategy enabled: a) identification of unknown chemical 
entities in complex biological matrix by AMRT; and b) identification of previously 
unreported changes to urinary metabolites and metabolic pathways following 
nitisinone treatment in AKU.  
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A limitation of LC-MS compound identification by public databases (24–28) is that data 
were acquired using different analytical techniques and parameters. The 
Metabolomics Standards Initiative has established levels of metabolite identification 
confidence (29,30). Only identification strategies, as reported here, that compared two 
or more orthogonal chemical properties (e.g. AMRT) with an authentic standard under 
identical analytical conditions achieved the highest identification confidence level. 
Identifications by public databases in which data were acquired under different 
analytical conditions can only achieve the second level of confidence (‘putative 
identification’), even with two matched orthogonal chemical properties. 
Combining data from three LC techniques enhanced the number of unique urine 
AMRT matches obtained, improving coverage of the metabolome. Methods 1 and 2 
showed some similarity in analyte retention (Figure 2B-D). Method 2 was used 
because the Atlantis dC18 column was previously shown to chromatographically 
resolve metabolites of the tyrosine pathway in patients with AKU (31-32). It also 
provided greater overall retention of polar metabolites compared to a standard C18 
column due to endcapping of bi-functionally bonded C18 stationary phase. Method 1 
was included here to improve peak capacity owing to the increased theoretical plates 
provided by the smaller 2.1 µm column particle size. Moreover, methods 1 and 2 
yielded 39 and 57 AMRT matches respectively that were exclusive to each method 
(Figure 3A). 
The congenital defect that causes AKU directly affects tyrosine catabolism. However, 
AKU is multi-systemic (9) and the wider metabolic consequences of the disease and 
nitisinone treatment have not been systematically studied. The strategy was applied 
to AKU, but given the range of primary and intermediary metabolism covered by the 
AMRT compounds, it could be applied to study metabolism in any disease. The data 
show that nitisinone alters tyrosine and tryptophan metabolism, and support alteration 
to the purine metabolic pathway. The changes observed comprise increased and 
decreased concentrations within the same pathways, suggesting that nitisinone has 
complex, wide-ranging effects on metabolism. Nitisinone is licensed to treat patients 
with hereditary tyrosinaemia type-1 (HT-1, OMIM 276700), another congenital disease 
of tyrosine metabolism, and is a promising HGA-reducing agent in AKU. In nitisinone-
treated HT-1 and AKU it is established that circulating tyrosine increases markedly 
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(11,13–15,17–21). Tyrosine is the precursor for catecholamines, thyroid hormones 
and melanin (Figure 1), suggesting that increased tyrosine substrate has potential to 
dysregulate these pathways. In HT-1 there are concerns that hypertyrosinaemia may 
contribute to neurodevelopmental delay (19,33-36). 
Application of our profiling strategy identified a number of previously unreported 
metabolite changes post-nitisinone. Increased 3-(4-hydroxyphenyl)lactic acid is 
probably directly related to elevated tyrosine and/or its clearance in urine. Changes a) 
homovanillic acid and the trace amine tyramine and b) L-tryptophan represent further 
alterations to dopamine and tryptophan-serotonin metabolism (respectively) than 
those previously reported. L-tryptophan is the precursor for serotonin, and a post-
nitisinone increase in the serotonin metabolite 5-hydroxyindoleacetic acid was 
previously reported in HT-1 cerebrospinal fluid (37) and AKU urine (20), although not 
observed here. Xanthurenic acid and L-kynurenine were increased and decreased 
respectively, indicating for the first time that the kynurenine pathway, originating from 
tryptophan, is altered by nitisinone. Also, indoxyl sulfate, a metabolite of the 
indolepyruvate pathway from tryptophan, was decreased. Alterations to 
indolepyruvate metabolism are previously reported in nitisinone-treated AKU plasma; 
carboxaldehyde, indole-lactate and indole-pyruvate increased, and in vitro studies 
indicated this as a direct consequence of increased 3-(4-hydroxyphenyl)pyruvic acid 
(38). This is the first report of alterations to purine metabolism following treatment with 
nitisinone. Decreased 3,5-cyclic-AMP and xanthosine were unexpected but replicated 
in mice. 
The remaining metabolite changes have been previously reported following nitisinone 
treatment; decreased HGA and increased tyrosine, acetyl-L-tyrosine, γ-glutamyl-
tyrosine, 3-(4-hydroxyphenyl)pyruvic acid and 3-methoxytyramine. Decreased HGA 
and increased tyrosine are well-known consequences of nitisinone, and observation 
of these changes in each analytical run (tyrosine in positive and HGA in negative 
polarity) supports the analysis, data extraction workflow, and validity of the data. 
Increased acetyl-L-tyrosine and γ-glutamyl-tyrosine have been previously reported in 
nitisinone-treated AKU and were proportional to tyrosine elevation (39). Increased 3-
methoxytyramine was previously reported in AKU urine (20); it is a metabolite of 
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dopamine metabolism and derived from tyrosine via decarboxylation of 
dihydroxyphenylalanine to dopamine.  
Ten AMRT-matched metabolite changes were observed in human and mouse: 4-
hydroxyphenylacetic acid, 3,(4-hydroxyphenyl)lactic acid, 3-(4-hydroxyphenyl)pyruvic 
acid, L-tyrosine, phenylacetic acid and tyramine increased post-nitisinone; 2-hydroxy-
4-(methylthio)butyric acid, 3,5-cyclic AMP, HGA and xanthosine decreased post-
nitisinone. The concordance between human and mouse data supports the approach 
and validity of the data. For mice, it was possible to control potentially confounding 
factors that could affect metabolism, such as diet and genetic diversity. This increases 
likelihood that observed changes are attributable to nitisinone. Reduced phenotypic 
variation could explain the prominent gender difference observed for mouse only; 
histamine was particularly elevated in urine from females, as previously reported in 
the literature for rats (40,41) but not mice to our knowledge. 
The limitations of this study are as follows. First is the relatively small sample size for 
a clinical metabolomics study (25 patients). However, AKU is a rare disease and the 
repeated-measures design enhanced statistical power. Second, data represent 
changes observed in urine not serum, which more closely reflects internal 
homeostasis. The urine metabolome is a composite of products from endogenous 
metabolism, diet, drugs and the gut microbiome. Urine does however give a valuable 
indication of the metabolic fate of the increased circulating tyrosine post-nitisinone. 
Further metabolomic analyses on fluids and tissues from other biological locations are 
required to achieve more detailed, compartment-specific data, for example 
cerebrospinal fluid to directly study the impact of nitisinone-induced tyrosinaemia on 
the central nervous system. Third, three chromatographic methods were used, 
however this may not always be feasible. For large-scale studies, it may be pragmatic 
to use two of the methods to reduce analytical and processing time. 
In conclusion, we have developed a targeted LC-QTOF-MS strategy for 
comprehensive coverage of the metabolome with compound structure identification 
using three AMRT databases, which are publicly available. Application of the approach 
to AKU has advanced our knowledge of the wider metabolic consequences of 
nitisinone, demonstrating the potential of our method as a metabolic phenotyping 
strategy more generally. 
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Table 1. Number of accurate mass retention time (AMRT) matches obtained by the three methods and retained following quality 
control filtering and decreasing AMRT window size during feature extraction. 
RT, retention time; Positive, positive ionization mode; Negative, negative ionization mode.
Feature extraction 
window 
Filtering step Number of urine AMRT matches 
    Method 1    Method 2    Method 3    
    Positive Negative Positive Negative Positive Negative 
 
Accurate mass 10 ppm,                  
RT 0.3 min 
None 274 153 248 105 111 74 
  
 
(1) Unique AMRT's only, 
manual curation 




(2) Abundance QC: peak 
area CV <25% between 
replicates 
75 36 107 35 59 30 
  
 
(3) RT shift QC: RT CV 
<25% between replicates   
75 36 107 35 59 30 
 
Accurate mass 5 ppm, 
RT 0.15 min 
Steps (1) - (3) 44 31 65 25 38 22 
 
Accurate mass 2.5 ppm,                 
RT 0.075 min 




Figure 1. Tyrosine catabolic pathway with reference to its defect in alkaptonuria 
and treatment with nitisinone. Lack of the enzyme homogentisate 1,2-dioxygenase 
increases concentrations of circulating homogentisic acid by preventing its conversion 
to maleylacetoacetic acid. It is previously established that nitisinone has the upstream 
consequence of increased concentrations of tyrosine, 3-(4-hydroxyphenyl)pyruvic acid 
and 3-(4-hydroxyphenyl)lactic acid as a result of the metabolic block induced by 
nitisinone. 
Figure 2. Summary of the data acquired from analysis of metabolite standards. 
A, Venn diagram summarizing the number of compounds retained and detected by 
methods 1-3, both alone (non-overlapping sections) and in combination (overlapping 
sections). B-D, Mass/RT scatter plots for metabolite standards detected with the three 
analytical methods, showing the different selectivities of the methods for compounds 
from different chemical classes. 
Figure 3. Summary of compounds identified from analysis of urine by accurate 
mass retention time (ARMT). A, Venn diagram summarizing the number of AMRT 
matches obtained for methods 1-3. B-D, Mass/RT scatter plots for AMRT compound 
matches obtained from analysis of urine by the three analytical methods.  
Figure 4. Application of the profiling strategy to alkaptonuria (AKU). A, Urine was 
obtained from patients with AKU and HGD-/- mice pre- then post-nitisinone therapy. B, 
Representative urine profiles (top) and extracted signals (bottom) for compounds 
identified by accurate mass retention time. C, Principle component analysis showing 
alteration to human (left) and mouse (right) urine metabolomes post-nitisinone. x, y 
and z axes represent components 1, 2 and 3 respectively. 
Figure 5. Urinary metabolite changes identified post-nitisinone in alkaptonuria 
by application of the profiling strategy. Red and blue indicate increases and 
decreases respectively. Fold changes (FC’s) are indicated in brackets and were 
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Background: The homogentisic acid-lowering therapy nitisinone is being evaluated 
for the treatment of Alkaptonuria (AKU) at the National Centre for AKU. Beyond 
hypertyrosinaemia the wider metabolic consequences of its use are largely unknown. 
The aim of this work was to evaluate the impact of nitisinone on the serum metabolome 
of patients with AKU after 12 and 24 months of treatment. 
Methods: Deproteinised serum from 25 patients with AKU (mean age(±SD) 
51.1±14.9y, 12 male) was analysed using the 1290 Infinity II LC system coupled to a 
6550 QTOF-MS (Agilent, UK). Raw data were processed using a batch targeted 
feature extraction algorithm and an accurate mass retention time database containing 
469 intermediary metabolites (mw 72-785). Matched entities (±10ppm theoretical 
accurate mass and ±0.3mins retention time window) were filtered based on their 
frequency and variability (<25% CV) in group QC samples, and repeated measures 
statistical significance analysis with Benjamini-Hochberg false discovery rate 
adjustment was used to assess changes in metabolite abundance.  
Results: Eight metabolites increased in abundance (log2 fold change 2.1-15.2, 
p<0.05); 7 of 8 entities were related to tyrosine metabolism, and 13 decreased in 
abundance (log2 fold change 1.5-15.5, p<0.05); including entities related to tyrosine 
(n=2); tryptophan (n=3); xanthine (n=2) and citric acid cycle metabolism (n=2).  
Conclusions: Evaluation of the serum metabolome of patients with AKU showed a 
significant difference in the abundance of several metabolites following treatment with 
nitisinone, including a number that have not been previously reported; several of these 
were not related to the tyrosine metabolic pathway. 
Take home message 
Nitisinone therapy has a significant impact on several metabolites beyond the tyrosine 
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Alkaptonuria (AKU, OMIM: 203500) is a rare autosomal recessive disorder of tyrosine 
metabolism resulting from a defect in homogentisate-1,2-dioxygenase (HGD, 
E.C.1.12.11.5), which leads to a marked increase in the circulating concentration of 
homogentisic acid (HGA) (Phornphutkul et al. 2002). The pathological hallmark of AKU 
is ‘ochronosis’, which is a consequence of the deposition of a dark pigment in 
connective tissue, mainly cartilage, which alters its physiomechanical properties. The 
exact composition and structure of this pigment is unknown, but is known to result 
from the accumulation of HGA (Figure S1) (Ranganath et al. 2013). 
 
Treatment options for AKU are conservative in large focusing on supportive and 
palliative measures (Ranganath et al. 2013). The HGA lowering agent nitisinone 
(Figure S1) has been shown to completely prevent ochronosis in AKU mice (Preston 
et al. 2014) and is being evaluated as a potential treatment in AKU patients 
(Phornphutkul et al. 2002; Suwannarat et al. 2005; Introne et al. 2011; Ranganath et 
al. 2016, 2018; Milan et al. 2017); it is however not without its own challenges as it is 
well documented to result in significant hypertyrosinaemia in AKU (Phornphutkul et al. 
2002; Suwannarat et al. 2005; Introne et al. 2011; Olsson et al. 2015; Ranganath et 
al. 2016, 2018; Milan et al. 2017; Davison et al. 2018a) and Hereditary Tyrosinaemia 
type 1 (HT1) (Lindstedt et al. 1992; Lock 2017; van Ginkel et al. 2017). The 
consequences of this are largely unknown in AKU; in HT1 it has been suggested this 
may contribute to the neurodevelopmental delay that is frequently observed in children 
treated with nitisinone (McKiernan et al. 2015). Several mechanisms have been 
proposed for this including altered metabolism of the monoamine neurotransmitters 
(Thimm et al. 2011). Davison et al.(2018b; 2018c) demonstrated in a cohort of AKU 
patients that nitisinone therapy resulted in altered urinary excretion of dopaminergic 
and serotoninergic neurotransmitter metabolites. However these findings are limited 
as they are not a direct reflection of neurotransmitter metabolism in the central nervous 
system. A recent study in an animal model of HT1 suggested that the disease itself 
and not treatment with nitisinone is likely to be responsible for slower learning and 
altered behavior in mice (Hillgartner et al. 2016). 
  
Recently, changes in the urine metabolome of an AKU mouse model and patients with 
AKU treated with nitisinone were reported (Norman et al. 2019). This study 
demonstrated novel changes in the tyrosine metabolic pathway, and unexpectedly in 
tryptophan and purine metabolism. While these changes in the urine metabolome 
provide insight into how nitisinone alters metabolism, one may postulate that changes 
observed in the serum are more relevant as they are a more direct reflection of internal 
homeostasis. Gertsman et al.(2015a) reported on the impact of nitisinone therapy on 
the serum metabolome of patients with AKU. In addition to the expected decrease in 
HGA and increase in tyrosine, significant increases in acetyl- and -glutamyltyrosine 
were also observed. In a separate publication (Gertsman et al. 2015b) in the same 




Herein for the first time we report the impact of nitisinone (2mg daily) therapy on the 
serum metabolome in the largest cohort of AKU patients to date over a two year period 
at the National AKU Centre (NAC) in the UK. 
  
Materials and methods 
Reagents 
Water for mobiles phases was purified in-house (DIRECT-Q 3UV Millipore water 
purification system). Methanol, acetonitrile and isopropanol were purchased from 
Sigma Aldrich (Dorset, UK). Formic acid and ammonium formate were obtained from 
Biosolve, (Netherlands) and Fisher Scientific (Germany), respectively. All reagents 
were LC-MS grade. Acetyl-tyrosine was purchased from Sigma Aldrich, UK. 
  
Patients and serum sample collection 
Ethical Approval 
Data collection and sample analyses at the NAC has approval from the Royal 
Liverpool and Broadgreen University Hospital Trusts Audit Committee (Audit no. 
ACO3836), this approval includes the use of patient data and biological material for 
metabolomics evaluation. As data and samples were collected as part of the clinical 
service, ethical approval was not required. Patients are informed verbally and through 
patient information leaflets about the clinical and research activities of the NAC and 




Serum samples (S-monovette, Sarstedt, Germany) were collected from patients after 
an overnight fast (≥8h). Patients’ dietary intake of protein was managed through a 7-
day food diary by a combination of lower protein in diet and phenylalanine/tyrosine-
free meal exchanges. Samples were centrifuged at 1500×g for 10 min at 4°C; and 
then deproteinised with perchloric acid (60% 5.8M; 1:10, perchloric acid:serum), 
vortexed and centrifuged at 1500×g for 10 min. Supernatant was stored at -20°C until 
analysis. 
  
Patient and quality control sample preparation 
Patient samples were prepared by diluting 150µL serum with 450µL deionized water 
(DIRECT-Q 3UV Millipore water purification system). Diluted samples were then 
transferred into a 96 well plate which was then agitated on a plate shaker (MTS 2/4m 
IKA, Germany) at 600rpm for 10 min. 
 
Patient group quality control (QC) samples were produced by adding 50µL of each 
patient sample into a single pool. In total four group QC pools were made [(i) baseline, 
(ii) 12-months, (iii) 24-months and (iv) overall – containing serum from all patients and 




The analytical sequence of samples was performed as per published guidance 
(Vorkas et al. 2015). Each run commenced with 20 replicate injections of the overall 
pooled sample to condition the system. The order of individual samples was 
randomised computationally. Pooled samples were interspersed throughout the 




Liquid chromatography (LC) was performed on an Agilent 1290 Infinity II LC system. 
An Atlantis dC18 column (3.0x100mm, 3µm, Waters, UK) was maintained at 60°C with 
a flow rate of 0.4mL/min. Mobile phases were (A) water and (B) methanol both 
containing 5mmol/L ammonium formate and 0.1% formic acid. The elution gradient 
started at 5% mobile phase B at 0-1 min increasing linearly to 100% B by 12 min, held 
at 100% B until 14 min, returning to 95% A for 5 min to recondition the column. Injection 
volume was 1µL. 
  
Quadrupole time-of-flight mass spectrometry (QTOF-MS) conditions 
An Agilent 6550 QTOF-MS equipped with a dual jet stream electrospray ionisation 
source was operated in 2GHz mode, over the mass range of 50-1700, in negative and 
positive polarities. A reference mass correction solution was continually infused at a 
flow rate of 0.5 mL/min via an external isocratic pump (Agilent, UK) for constant mass 
correction (see supplementary information 1 for additional details of QTOF-MS 
operating parameters and composition of reference ion solution). 
  
Metabolite identification, data quality control and statistical analyses 
Metabolite identification was carried out using an established accurate mass retention 
time (AMRT) database to match chemical entities (Norman et al. 2019). The database 
included theoretical accurate mass, measured retention time, and empirical formula. 
This was modified to include acetyl-tyrosine, -glutamyl-tyrosine and indole-3-lactate 
(I-3-L). AMRT data for acetyl-tyrosine were verified following the analysis of an 
analytical standard. AMRT data for -glutamyl-tyrosine and I-3-L were based on the 
elution time associated with theoretical monoisotopic mass of each compound and 
were not verified using an analytical standard. Data quality control and statistical 
analysis were performed using the MassHunter software suite (Agilent, UK). For 
additional details on data quality control and statistical analyses see supplementary 
information 1.  
 
Results 
Twenty-five patients [13 female, mean age (±standard deviation) 55.3(15.3) years 
(range 22-75); 12 male, mean age 44.2(15.8) years (range 22-70)] were included at 




Raw data from LC-QTOF-MS analysis showed that retention time and accurate mass 
ranges were 1.15-13.93min and 75.0318-730.5955Da, in positive and 1.03-14.67min 
and 75.0318-722.6247Da in negative polarity, respectively. Principal components 
analysis (Figure 1) showed clear separation between the AMRT matched profiles of 
AKU patients pre- vs. post-nitisinone therapy. 
 
 
Figure 1. Principal component analysis of raw data from LC-QTOF-MS profiling 
experiments of serum samples from patients at baseline (pre-nitisinone, brown circle), 
12-months (2mg daily nitisinone, red circle) and 24-months (2mg daily nitisinone, blue 
circle) x-axis – component 1, 22.09%; y-axis – component 2, 9.66%; z-axis – 
component 3, 7.78%. 
 
 
151/469 and 249/469 metabolites were aligned across all samples in positive and 
negative polarities (for matched compounds see Table S2), respectively at baseline, 
and after nitisinone treatment at 12- and 24-months. After filtering entities based on 
their frequency and variability across replicate injections of pooled QC samples from 
each experimental group 123 and 209 entities were retained from positive and 
negative polarity profiling experiments, respectively. Of these, 60 and 121 
respectively, were shown to be significantly different (p<0.05) following nitisinone 
therapy. Those with a log2 fold change (FC) >2 at 12 and or 24-months are 
summarised in Table 1. Applying this cut-off, eight (6.5%) entities were considered to 




Table 1. Serum metabolite changes identified post-nitisinone therapy at 12- and 24-months in patients with AKU using an in-house 
AMRT database. Regulation expressed as log2 FC compared to baseline (pre-nitisinone treatment). Log2 FC included if >2 at 12- 
and or 24-months. 
Compound  





12-months 24-months Down Up 
Glycocholate 12.7 12.7 <0.001   Bile acid 
Succinic acid 11.4 11.4 <0.001   Citric acid cycle 
-Ketoglutaric acid 10.0 10.0 <0.001   Citric acid cycle 
Trans-4-hydroxyproline 15.5 15.5 <0.001   Collagen 
Homoserine 12.5 12.5 <0.001   Methionine/Cysteine  
Mevalolactone 10.7 10.7 <0.001   Steroid 
L-Allothreonine 11.8 11.8 0.02   Threonine 
Trigonelline 12.8 12.8 <0.001   Tryptophan 
4-Quinolinecarboxylic acid 8.3 8.3 <0.001   Tryptophan 
Indole-3-lactate 2.1 2.3 <0.001   Tryptophan 
4-Hydroxyphenylacetate 4.2 5.4 <0.001   Tyrosine 
Benzaldehyde 6.9 6.9 <0.001   Tyrosine 
Homogentisate 4.0 5.0 <0.001   Tyrosine 
4-Hydroxybenzaldehyde 14.4 14.4 <0.001   Tyrosine 
L-N-Acetyl-Tyrosine 15.5 15.2 <0.001   Tyrosine 
-L-Glutamyl-L-tyrosine 3.2 3.0 <0.001   Tyrosine 
3-(4-Hydroxyphenyl)lactate 6.4 6.4 <0.001   Tyrosine 
L-Tyrosine 2.7 2.7 <0.001   Tyrosine 
Mandelic acid 12.6 12.0 <0.001   Tyrosine 
Inosine 10.8 10.8 <0.001   Purine 
Uridine 2.1 1.5 <0.001   Pyrimidine 
472 
 
Nine (43%) of the 21 metabolites that were affected following treatment with nitisinone 
relate to tyrosine metabolism. Many of the other metabolites that had altered regulation 
following nitisinone therapy did not follow a clear theme apart from tryptophan, citric 
acid cycle and purine/pyrimidine metabolism.  
 
Discussion 
Over the last two decades there have been several reports on the use of nitisinone to 
treat AKU. Its inhibition of HPPD (Figure S1) has been shown to dramatically reduce 
the circulating concentration of HGA (Phornphutkul et al. 2002; Suwannarat et al. 
2005; Introne et al. 2011; Ranganath et al. 2016, 2018; Milan et al. 2017), but leads to 
marked hypertyrosinaemia (Phornphutkul et al. 2002; Suwannarat et al. 2005; Introne 
et al. 2011; Olsson et al. 2015; Ranganath et al. 2016, 2018; Milan et al. 2017; Davison 
et al. 2018a). Beyond hypertyrosinaemia there is very little reported on the biochemical 
consequences of nitisinone therapy. Herein we report the impact of nitisinone therapy 
on the serum metabolome, using LC-QTOF-MS and a validated strategy to identify 
metabolites using an AMRT database developed in-house (Norman et al. 2019). This 
study is unique as it includes the largest cohort of patients with AKU to date, taking a 
2mg daily dose of nitisinone over 24-months. In addition as it is based on the analysis 
of serum it is a better reflection of the impact of nitisinone on internal homeostasis. 
 This study confirms previous reports that nitisinone treatment in AKU results in a 
marked reduction in serum HGA and increase in tyrosine. In addition, a significant 
increase in 3-(4-hydroxyphenyl)lactate (3-(4-HPLA) was observed. Unexpectedly 3-
(4-hydroxyphenyl)pyruvate (3-(4-HPPA), the metabolite immediately proximal to the 
site of action of nitisinone, was not increased (Figure S1). The marked increase in 
HPLA is an expected consequence of nitisinone therapy, but has not been reported in 
serum. There is an equilibrium between 3-(4-HPPA) and 3-(4-HPLA) (Figure S1) and 
it is likely that the reason for only observing significant increases in latter is that the 
sample pH shifted the equilibrium position to favour its formation. This pattern has 
been previously reported (Norman et al. 2019) in a study that reported on the urine 
metabolome of patients with AKU treated with nitisinone; a 84 and 16 fold (raw FC) 




Marked increases in the tyrosine conjugates acetyl-tyrosine and -glutamyl-tyrosine 
were also observed. The log2 FC observed was very similar for tyrosine and -
glutamyl-tyrosine, but that of acetyl-tyrosine was markedly higher. The latter suggests 
that an equilibrium shift between tyrosine and acetyl- tyrosine may exist, but not for 
tyrosine and -glutamyl-tyrosine. Norman et al.(2019) showed that urinary tyrosine 
was significantly higher than acetyl- and -glutamyltyrosine in a cohort of AKU patients 
on 2mg daily of nitisinone supporting that an equilibrium shift between tyrosine and 
tyrosine conjugates exists. In contrast, Gertsman et al.(2015a) reported a proportional 
increase in plasma tyrosine, acetyl- and -glutamyl-tyrosine following nitisinone 
suggesting there is no equilibrium shift. While direct comparisons between the 
magnitudes of FC cannot be made as herein we report log2 FC, the proportions of 
metabolites are clearly different between the two studies. This may be due to the small 
number of patients in the study reported by Gertsman et al (2015a) and that a 2mg 
dose was used only in our study. Nonetheless our findings support that non-traditional 
metabolic pathways are active in the face of tyrosine excess. 
  
The elevated -glutamyl-tyrosine suggests that glutathione metabolism and the redox 
state of cell (Griffith et al. 1979; Zhang and Forman 2009) are altered following 
treatment with nitisinone. This is of particular importance to AKU as elevated HGA is 
thought to lead to a pro-oxidant environment where ‘soluble melanins’ are formed 
(Davison et al. 2016). Increasing evidence to support HGA induced oxidative stress 
has been reported in vitro in serum (Braconi et al. 2011) and cellular models (Braconi 
et al. 2010), and in patients with AKU (Braconi et al. 2014). For a recent review on 
oxidative stress and its contribution to the mechanisms of the ochronotic process see 
Braconi et al 2015. One may postulate that treatment with nitisinone reduces the 
burden on the glutathione cycle improving glutathione availability. In turn this may 
enable transfer of the glutamyl moiety from glutathione to tyrosine, via the action of -
glutamyl-transpeptidase (Griffith et al. 1979; Zhang and Forman 2009) to form g-
glutamyl-tyrosine. Interestingly, this study also revealed a marked decrease in the 
citric acid cycle metabolites α-ketoglutaric and succinic acid, the keto-acids of α-
ketoglurarate and succinate, following nitisinone. In this study glutamine levels did not 
change, thus one may hypothesise that glutamate formed from glutamine is 
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preferentially converted to glutathione and not α-ketoglutaric and succinic acid (Figure 




Figure 2. Proposed mechanism for the formation of -glutamyl-tyrosine in AKU 
following nitisinone therapy. Entities in red and blue represent an increase and 
decrease in metabolite abundance, respectively. GR – glutathione reductase; GP – 
glutathione peroxidase; GT - -glutamyltranspeptidase 
 
The significance of increased acetyl-tyrosine is unknown, but has been reported in 
serum (Gertsman et al. 2015a) and urine (Norman et al. 2019) of AKU patients treated 
with nitisinone. It has also been observed in the urine of patients with Hereditary 
Tyrosinaemia type 2 (OMIM: 276600) (Macsai et al. 2001). One may postulate that 
acetyl tyrosine represents a more efficient way to eliminate the excess tyrosine from 
the body as it is more water soluble than tyrosine. Interestingly acetyl tyrosine has also 
been reported as an additive to foodstuffs given to patients on nutritional support 
(Hoffer et al. 2003). 
  
4-Hydroxyphenylacetic (HPA) and 4-hydroxybenzaldehyde (4-HBA) were increased 
and benzaldehyde decreased following treatment with nitisinone; these have not been 
previously reported in the serum metabolome of patients with AKU following nitisinone 
treatment. HPA has been reported in urine following treatment with nitisinone (Norman 
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et al. 2019a). 4-HPA is generated from gut microbiota (Liu et al. 2016); one may 
hypothesise that the increase observed herein resulted from less oxidative stress 
following nitisinone, which increased microbiotic metabolism. This is the first report in 
humans, but has been seen previously observed in a rat model of oxidative stress (Liu 
et al. 2016).  
 
 The increase in 4-HBA has been reported in the urine of patients with AKU following 
nitisinone (Norman et al. 2019), but the decrease in benzaldehyde has never been 
observed. The significance of both entities is uncertain. 4-HBA is a naturally occurring 
compound that originates from the saprophytic perennial Gastrodia elata (Kang et al. 
2017). Recent studies have reported the therapeutic effects of benzaldehydes in a 
number of areas including wound healing, cancer, vascular disease, and renal disease 
(Lee et al. 2010, 2014; Moon et al. 2012; Kong et al. 2014). In the context of AKU the 
significance of 4-HBA and benzaldehyde are unknown and require further 
investigation. One may speculate that they relate to the benzoquinones, proposed as 
intermediates in the formation of ochronotic pigment observed in AKU (Norman et al. 
2019). 
  
Mandelic acid was also increased following treatment with nitisinone, which has been 
reported previously (Norman et al. 2019). The significance of this is uncertain, but 
urinary elevation has previously been observed in patients with PKU on a 
phenylalanine restricted diet (Rampini et al. 1974). 
 
 The ‘off target effects’ of any drug are essential when considering its suitability in 
treating a patient (Lynch et al. 2017). Nitisinone therapy in AKU and HT1 have long 
been associated with altered tyrosine metabolism, and so can be considered a 
‘targeted effect’. More recently off targets effects of nitisinone have been reported due 
to its impact on tryptophan metabolism. A decrease in 5-hydroxyindoleacetic acid 
(serotonin metabolite) has been reported in the cerebral spinal fluid and urine of 
patients with HT1 (Thimm et al. 2011) and AKU (Davison et al. 2018b; 2018c), 
respectively. Serum tryptophan itself has been shown not to change following 
treatment with nitisinone (Davison et al. 2018a); in contrast urinary tryptophan has 
been shown to decrease (Norman et al. 2019). These differences may be explained 
by the fact that tryptophan is highly protein bound (~90-95%) (Cervenka et al. 2017) 
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and measurement in serum reflects total tryptophan and urinary tryptophan reflects 
free tryptophan. The biologically active fraction is the free fraction, which is not typically 
measured in serum, and the majority is metabolized via the kynurenine pathway 
(Cervenka et al. 2017). Herein I-3-L, 4-quinolinecarboxylic acid and trigonelline were 
the only tryptophan-related metabolites that were changed following nitisinone. The 
significance of the latter two metabolites is uncertain, but reinforces that downstream 
metabolism of kynurenine and niacin may be altered following nitisinone treatment. 
Gertsman et al (2015b) also demonstrated an increase in plasma I-3-L, but additionally 
indole-3-pyruvate (I-3-P). It has been proposed that the increased activity in the indole 
pyruvate pathway results from tryptophan aminotransferase having a higher affinity for 
tryptophan in the presence of keto-acids (e.g. 4-HPPA, 4-HPLA) (Lees and Weiner 
1973). The reason for not observing I-3-P is uncertain, however one may speculate 
that I-3-L and not I-3-P was increased due to reaction conditions favoring its formation. 
In addition, differences may in part be explained by different approaches to sample 
preparation, chromatographic and mass spectrometry conditions, patient cohorts and 
nitisinone doses used. In addition a separate study showed urinary xanthurenic acid, 
and L-kynurenine and indoxyl-sulfate were increased and decreased following 
nitisinone therapy, respectively (Norman et al. 2019) The significance of these 
changes are unknown. 
  
Beyond tryptophan metabolism there are limited reports on the off target effects of 
nitisinone on the metabolome. Herein we have shown that trans-4-hydroxyproline 
decreases significantly following treatment. This is of particular relevance to AKU as it 
suggests that there may be decreased collagen breakdown. This requires further 
investigation as previous authors (Taylor et al. 2017) have demonstrated a very low 
cartilage turnover state in AKU patients. In contrast, a different study reported that 
cartilage degradation, as well as bone resorption markers were elevated in AKU 
patients compared to controls (Genovese et al. 2015). 
  
In addition, significant decreases were observed in the purine and pyrimidine 
precursor’s inosine and uridine, respectively. In a previous study decreased excretion 
of the purine metabolites adenine and allantoin were reported in urine from AKU 
patients and an AKU mouse treated with nitisinone (Norman et al. 2019). Patients 
included in this study and previous (Norman et al. 2019) were not on uric acid-lowering 
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medication, however were on a protein-restricted diet which may contribute to this 
change. A plausible explanation for the observations in serum and in urine may also 
relate to changes in the oxidative state of the cell. Allantoin has previously been 
suggested as a marker of oxidative stress (Marrocco et al. 2017), one may postulate 
that the decreases observed in purine and pyrimidine metabolites are a reflection of 
reduced oxidation stress in the face of lower HGA concentrations (Marrocco et al. 
2017). 
  
Four unrelated entities were also shown to be decreased following nitisinone therapy; 
glycocholate, homoserine, mevalolactone and allothreonine. The reasons for this 
remain of unknown significance and requires further investigation. 
  
It is important to highlight several limitations in this study. Firstly, while the number of 
patients included in this study is the largest reported to date, metabolites identified 
need validating in a larger cohort or patients. Moreover, an untreated group of AKU 
patients would provide greater credibility that the findings presented herein are a 
consequence of nitisinone therapy.  In addition while we believe the AMRT database 
used in this study is comprehensive, the targeted evaluation of the serum metabolome 
precludes the identification of novel changes in metabolites. Furthermore, the use of 
non-selective sample preparation to gain broad coverage of the metabolome may 
have limited metabolite detection if present at a low concentration or if changes were 
not reproducible due to ion suppression.  
  
Conclusions 
Evaluation of the impact of nitisinone treatment on the serum metabolome of patients 
with AKU revealed a number of novel changes including a number that are not directly 
related to the tyrosine metabolic pathway. Some of these changes can be explained 
by the impact of nitisinone therapy on the cellular redox state and the wider impact of 
metabolites on enzyme activity. Further work is required to provide greater insight into 
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